| Title | Collaboration Type | HHS Participating Agencies | NIH Participating Institutes, Centers, and Offices | Description |
|---|---|---|---|---|
| 2024-2028 NIH-Wide Strategic Plan on Research on the Health of Women | Other | AHRQ, CDC, FDA, HRSA, OASH | CSR, FIC, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/All of Us, OD/DPCPSI/OAR, OD/DPCPSI/OBSSR, OD/DPCPSI/ODS, OD/DPCPSI/ODSS, OD/DPCPSI/OEPR, OD/DPCPSI/ONR, OD/DPCPSI/ORWH, OD/DPCPSI/SGMRO | ORWH is responsible for an NIH-wide strategic plan on research on the health of women that promotes allocation of NIH resources for conducting and supporting research efforts on the health of women across NIH Institutes and Centers. Recommendations made by the NIH Advisory Committee on Research on Women’s Health (ACRWH), NIH scientists and researchers, as well as recent scientific advances; new technologies; current health priorities; and feedback from a Request for Information were all considered in the development of the strategic plan to help guide future NIH research efforts to improve the health of all women throughout the entire life course. ORWH also ensured that HHS and VA were engaged in the development of the 2024-2028 NIH-Wide Strategic Plan on Research on the Health of Women, published in 2024. |
| 21st Century Cures Act Working Group | Committee, Work group, Advisory group, or Task Force | FDA | OD/OER | Federal subject matter experts carried out a review to identify inconsistent, overlapping, and unnecessarily duplicative regulations and policies and prepared a report of recommendations to reduce administrative burden on investigators while maintaining the integrity and credibility of research findings and protection of research animals. Implementation and evaluation is ongoing. |
| 21st Century Cures Implementation and Harmonization | Committee, Work group, Advisory group, or Task Force | FDA | OD/OER | Interagency meetings are held twice a year to review implementation of the 21st Century Cures Act Working Group recommendations and discuss ways to harmonize and continue burden reduction efforts |
| A nested case-control study of circulating per- and polyfluoroalkyl substances (PFAS) and uterine and ovarian cancers | Research Initiative | CDC | NCI | National Cancer Institute (NCI) and Centers for Disease Control and Prevention (CDC) are collaborating to measure serum levels of per- and polyfluoroalkyl substances (PFAS) for nested case-control studies of endometrial (uterine) and ovarian cancers in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. |
| A nested case-control study of serum PFAS and testicular cancer in military servicemen | Research Initiative | CDC | NCI | National Cancer Institute (NCI) is collaborating with Uniformed Services University of the Health Sciences (USUHS) and Centers for Disease Control and Prevention (CDC) on a nested case-control study measuring serum PFAS concentrations among military servicemen with samples in the Department of Defense Serum Repository. An initial study, focused on Air Force personnel, was completed. A follow-up study, involving personnel from other service branches, is underway. |
| A Study of Markers of Cosmic Radiation Exposure and Effect Among Flight Crews | Research Initiative | CDC | NCI | NCI and CDC are collaborating on a cross-sectional study of 83 airline pilots and 50 university faculty to assess the relation of stable chromosome translocations with cosmic radiation exposure. |
| A5418: Study of Tecovirimat for Human MPox Virus | Other | ASPR, CDC, FDA | NIAID | A5418 (STOMP) is a study of tecovirimat (also known as TPOXX) for the treatment of human monkeypox virus (HMPXV) disease. |
| Accelerating COVID-19 Therapeutic Interventions and Vaccines-6: Outpatient Repurposed Drugs (ACTIV-6) | Research Initiative | ASPR, CDC, FDA | NCATS, NHLBI, NIAID | The ACTIV public-private partnership has evaluated hundreds of available therapeutic agents with potential application for COVID-19, prioritized the most promising candidates, designed and harmonized adaptive master protocols for ACTIV clinical trials, and selected numerous NIH-supported networks to launch these clinical trials to test prioritized therapeutic candidates. ACTIV-6 is designed to test the effectiveness of repurposed drugs (drugs that are FDA-approved for non-COVID-19 indications and have known safety profiles) in reducing the duration and severity of symptoms associated with mild-to-moderate COVID-19. The large, randomized, placebo-controlled Phase 3 trial enrolled outpatient participants who are at least 30 years old, tested positive for SARS-CoV-2 infection and showed two or more mild-to-moderate symptoms of COVID-19 for no more than seven days. Results for ivermectin, fluvoxamine, fluticasone, montelukast, and metformin are available on medRxiv. Results for ivermectin and fluvoxamine have been published in JAMA. Results for montelukast were published in JAMA Network Open, and fluticasone results were published in the New England Journal of Medicine. |
| Accelerating Medicines Partnership® (AMP®) Autoimmune & Immune Mediated Diseases Program | Research Initiative | FDA | NEI, NIAID, NIAMS, NIDCR, OD/DPCPSI/ORWH | The National Eye Institute (NEI) is one of 5 NIH Institutes and Centers (ICs) that have partnered with the FDA, FNIH, pharmaceutical companies, and nonprofit organizations to create the Accelerating Medicines Partnership® (AMP®) Autoimmune & Immune Mediated Diseases Program (AMP AIM). The goals of the AIM are to dissect mechanisms of disease at the cellular level in affected tissues and blood in rheumatoid arthritis, lupus, Sjögren’s disease, and psoriatic spectrum diseases; create a spatial map of key molecular and cellular types and states to identify the pathways of crosstalk between cells that drive inflammation, abnormal immune function, and damage; compare mechanisms of autoimmune and immune-mediated diseases across tissues to facilitate the identification of shared and independent druggable pathways and targets and to create a dedicated Knowledge Portal to host clinical, cellular, and molecular datasets, standardized methods, and computational tools to allow rapid and efficient data sharing and interrogation by the research community. |
| Accelerating Medicines Partnership® Amyotrophic Lateral Sclerosis (ALS) | Resource Development | FDA | NINDS | AMP ALS aims to promote development of novel therapies for ALS, including by generating a comprehensive, centralized ALS dataset to facilitate ALS biomarker validation. |
| Accelerating Medicines Partnership® Schizophrenia | Research Initiative | FDA | NIMH | The Foundation for the National Institutes of Health (FNIH), together with National Institute of Mental Health (NIMH) and public and private partners, is leading the Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) as the first neuropsychiatric project within the AMP program. The public-private partnership will tackle the critical need for more effective treatments for people with schizophrenia. |
| AccessGUDID | Resource Development | FDA | NLM | The Global Unique Device Identification Database (GUDID) contains key device identification information submitted to the FDA about medical devices that have Unique Device Identifiers (UDI). The National Library of Medicine (NLM), in collaboration with the FDA, created the AccessGUDID portal to make device identification information in the GUDID available for everyone, including patients, caregivers, health care providers, hospitals, and industry. NLM provides technical and customer support for the system. As enhancements and changes are made to the system, NLM and FDA work collaboratively to provide user support and training. https://accessgudid.nlm.nih.gov |
| ACL Advisory Council on Grandparents Raising Grandchildren | Committee, Work group, Advisory group, or Task Force | ACF, ACL, ASPE, CDC, HRSA, ONC, SAMHSA | NIA | The mission of the Advisory Council to Support Grandparents Raising Grandchildren (SGRG) is to identify, promote, coordinate and disseminate information, resources, and best practices to help grandparents and older relative caregivers of children meet the health, educational, nutritional, and other needs of the children in their care, while maintaining their own physical, mental, and emotional well-being. As part of this vision, all recommendations will consider the needs of members of Native American tribes and families affected by the opioid crisis. |
| Action Collaborative on Disaster Research | Committee, Work group, Advisory group, or Task Force | ACF | NIAID, NICHD, NIEHS, OD/DPCPSI/OBSSR | The Action Collaborative, which is associated with the Forum on Medical and Public Health Preparedness for Disasters and Emergencies, provides a forum for exchange of ideas on development and integration of population, health care, clinical, environmental, and disaster research. Dr. Dixon is the Co-Chair. https://www.niehs.nih.gov/research/programs/disaster/community/index.cfm |
| Adaptive Optics Longitudinal Study | Research Initiative | FDA | NEI | In collaboration with the FDA (Dr. Daniel Hammer), we are conducting a longitudinal study to collect adaptive optics (AO) retinal images from human subjects with outer retinal diseases (diseases of the outer retina including photoreceptor, retinal pigment epithelium (RPE), basement membrane or choroidal pathologies) to develop new diagnostic methods, biomarkers, and clinical endpoints. We will enroll healthy volunteers without ocular disease and affected patients with any type of outer retinal diseases. We will investigate with multimodal AO retinal imaging systems that include high resolution optical coherence tomography (OCT) and scanning laser ophthalmoscopy (SLO). In general, videos of different retinal cellular structures will be acquired from several retinal locations using various imaging modes. These studies will help us understand the underlying mechanisms of diseases. |
| Adjuvant Working Group | Committee, Work group, Advisory group, or Task Force | BARDA, FDA | NIAID | Staff from all National Institute of Allergy and Infectious Diseases (NIAID) Divisions, program staff from the Biomedical Advanced Research and Development Authority (BARDA), and regulatory staff from the Food and Drug Administration (FDA) exchange information about ongoing programs related to novel adjuvants for infectious disease vaccines, identify high priority research areas (and gap areas), and discuss ideas to accelerate progress in adjuvant research through better access to information and resources. |
| Administration for Strategic Preparedness and Response | Other | ASPR, CDC, FDA | NIAID, OD/OM, OD/OM/OB | Congress requires the Administration for Strategic Preparedness and Response (ASPR) to submit an annual Multi-Year Budget (MYB) for the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE). ASPR works with OPDIVs including NIH (NIAID and OB) to develop the PHEMCE MYB forecasts the funding required to conduct basic research, advanced research and development, regulatory review, procurement, stockpiling, and replenishment of the USG’s civilian MCM products. |
| Adolescent Brain Cognitive Development (ABCD) Study | Research Initiative | CDC | NCI, NHLBI, NIAAA, NICHD, NIDA, NIMH, NIMHD, NINDS, OD/DPCPSI/OBSSR, OD/DPCPSI/ORWH | The Adolescent Brain Cognitive Development (ABCD) project, a landmark longitudinal study of brain development and child health, will increase our understanding of how diverse experiences during adolescence interact with changing biology to influence brain, cognitive, and social/emotional development of youth. In partnership with area public and private schools, researchers at twenty-one research sites across the country will recruit 10,000 children at age 9-10 from diverse races and ethnicities, education and income levels, and living environments and follow them through their teens and into early adulthood. Throughout this period, researchers will assess each child’s physical and mental health, substance use, sleep patterns, genetics, childhood experiences, and cultural/environmental influences, as well as track brain and cognitive development with non-invasive magnetic resonance imaging scans at regular intervals. To enrich the value of the study, ABCD will release anonymized data annually to the research community in an open science model to allow scientists from all over the world to conduct analyses and pool resources to rapidly expand the types of scientific questions that can be answered. The actionable information coming out of this study will enable education, substance use prevention, and other health promotion policies to ensure the wellbeing and success of the Nation’s children. |
| Adolescent HIV Prevention and Treatment Implementation Science Alliance (AHISA) | Committee, Work group, Advisory group, or Task Force | CDC, OS | FIC, NIAID, NICHD, NIMH, OD/DPCPSI/OAR | The Adolescent HIV Prevention and Treatment Implementation Science Alliance (AHISA) aims to enhance the effective use of evidence and help overcome implementation challenges related to prevention, screening and treatment of HIV among adolescents (ages 15 to 24) in sub-Saharan Africa by catalyzing collaboration and communication among researchers, program implementers, and policymakers. The Center for Global Health Studies at Fogarty is launching the initiative in collaboration with the Office of the Global AIDS Coordinator and other NIH Institutes and Centers. |
| Advanced Anticonvulsant System Interagency Product Team | Committee, Work group, Advisory group, or Task Force | FDA, OS | NINDS | The Advanced Anticonvulsant System Interagency Product Team is a Department of Defense-led effort to facilitate activities, both research and regulatory, related to the FDA approval of midazolam for use in treating nerve agent exposure. |
| Advancing American Kidney Health Initiative | Research Initiative | ASPE, ASPR, CDC, CMS, FDA, HRSA, IHS, OCR | NIDDK, NIEHS | This initiative aims to improve the lives of Americans suffering from kidney disease, expand options for American patients, and reduce healthcare costs. The initiative provides specific solutions to deliver on three goals: fewer patients developing kidney failure, fewer Americans receiving dialysis in dialysis centers, and more kidneys available for transplant. NIDDK promotes an integrated health system model of team-based clinical care based on the pragmatic experience of the IHS; Kidney Disease Program. NIDDK has developed new clinical tools and educational programs that improve the care of people with kidney disease in primary care settings. NIDDK works in collaboration with government, nonprofit, and health care organizations to raise awareness about screening for individuals at risk for kidney disease; educate individuals about how to manage their disease; provide information, training, and tools that help health care providers; and support important health systems changes. |
| Advising ARPA-H investigators of MASCOT regarding methods for growing and screening organoid cell cultures | Research Initiative | ARPA-H | NCI | The Biological Testing Branch (BTB) and other branches of NCI's Developmental Therapeutics Program (DTP) have extensive experience growing, culturing, drug testing/screening human patient derived organoid cell cultures as part of our lead involvement with the Patient Derived Models Repository (PDMR). In late 2024. Advanced Research Projects Agency for Health (ARPA-H) investigators approached our Division of Cancer Treatment and Diagnosis (DCTD) associate director asking for guidance regarding methods for growing and screening organoid cultures for their MASCOT (Manufacturing Agile and SCalable Organoid Tumor models) program. In 2025, DTP will gather involved parties for a series of meetings where NCI shares guidance, methodologies, Standard Operating Procedures (SOP), and our experience with robotic high throughput organoid screening. We will also discuss possible collaborative activities with ARPA-H to not waste time and resources duplicating efforts. |
| Advisory Commission on Childhood Vaccines (ACCV) | Committee, Work group, Advisory group, or Task Force | HRSA | NIAID | The ACCV provides advice and recommendations to theSecretary of Health and Human Services on the National Vaccine Injury Compensation Program (VICP or the Program), which provides compensation for certain vaccine-related injuries or deaths. |
| Advisory Committee for Organ Transplantation (ACOT) | Committee, Work group, Advisory group, or Task Force | HRSA, OASH | NIAID | The Advisory Committee on Organ Transplantation (ACOT) was established to assist the Department of Health and Human Services (HHS) Secretary in enhancing organ donation, ensuring that the system of organ transplantation is grounded in the best available medical science, and assuring the public that the system is as effective and equitable as possible, thereby increasing public confidence in the integrity and effectiveness of the transplantation system. |
| Advisory Committee on Heritable Disorders in Newborns and Children | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, HRSA | NCI, NHGRI, NHLBI, NICHD | The Advisory Committee on Heritable Disorders in Newborns and Children was established under the Public Health Service Act, Title XI, § 1109 (42 USC 300b-10), as amended by the Newborn Screening Saves Lives Reauthorization Act of 2014 (PL 113-240). The mission of the Advisory Committee on Heritable Disorders in Newborns and Children is to reduce morbidity and mortality in newborns and children who have or are at risk for heritable disorders. The Committee recommends that every newborn screening program include a Uniform Screening Panel that screens for 36 core disorders and 26 secondary disorders. The Committee advises the Secretary, US Department of Health and Human Services on the most appropriate application of universal newborn screening tests, technologies, policies, guidelines, and standards. Specifically, the committee provides to the Secretary, the following: Advice and recommendations concerning grants and projects authorized, awarded, or funded related to screening heritable disorders in newborns and children; technical information to develop Heritable Disorders Program policies and priorities that will enhance the ability of the state and local health agencies to provide screening; counseling and health care services for newborns and children who have or are at risk for heritable disorders, and recommendations; and advice and information to enhance, expand, or improve the ability of the Secretary to reduce mortality and morbidity from heritable disorders in newborns and children. The committee was chartered on May 7, 2015. |
| Advisory Committee on Immunization Practices (ACIP) | Committee, Work group, Advisory group, or Task Force | CDC | NIAID | The ACIP shall provide advice and guidance to the Director of the CDC regarding use of vaccines and related agents for effective control of vaccine-preventable diseases in the civilian population of the United States. Charter at: https://www.cdc.gov/vaccines/acip/committee/charter.html |
| Advisory Committee on Immunization Practices (ACIP) Working Group on Chickungunya vaccines | Committee, Work group, Advisory group, or Task Force | CDC | NIAID | This working group reviews data, and makes presentations to the larger ACIP on Chickungunya vaccines. |
| Advisory Committee on Immunization Practices (ACIP) Working Group on COVID-19 vaccines | Committee, Work group, Advisory group, or Task Force | CDC | NIAID | This working group reviews data, and makes presentations to the larger ACIP on COVID-19 vaccines. |
| Advisory Committee on Immunization Practices (ACIP) Working Group on Dengue vaccines | Committee, Work group, Advisory group, or Task Force | CDC | NIAID | This working group reviews data, and makes presentations to the larger ACIP on Dengue vaccines. |
| Advisory Committee on Immunization Practices (ACIP) Working Group on Influenza vaccines | Committee, Work group, Advisory group, or Task Force | CDC | NIAID | This working group reviews data, and makes presentations to the larger ACIP on Influenza vaccines. |
| Advisory Committee on Immunization Practices (ACIP) Working Group on Maternal/Pediatric RSV Vaccines | Committee, Work group, Advisory group, or Task Force | CDC, CMS, FDA, HRSA, IHS, OASH | NIAID | This group is focused on recommendation of RSV maternal immunizations. |
| Advisory Committee on Immunization Practices (ACIP) Working Group on Meningococcus vaccines | Committee, Work group, Advisory group, or Task Force | CDC | NIAID | This working group reviews data, and makes presentations to the larger ACIP on Meningococcus vaccines. |
| Advisory Committee on Immunization Practices (ACIP) Working Group on Pneumococcal vaccines | Committee, Work group, Advisory group, or Task Force | CDC | NIAID | This working group reviews data, and makes presentations to the larger ACIP on Pneumococcal vaccines. |
| Advisory Committee on Immunization Practices (ACIP) Working Group on RSV vaccines | Committee, Work group, Advisory group, or Task Force | CDC | NIAID | This working group reviews data, and makes presentations to the larger ACIP on RSV vaccines |
| Advisory Committee on Maternal/Pediatric RSV Vaccines | Committee, Work group, Advisory group, or Task Force | CDC, CMS, FDA, HRSA, IHS, OASH | NIAID | Group is focused on recommendation of RSV maternal immunization from Pfizer |
| Advisory Committee on RSV Vaccines in Older Adults | Committee, Work group, Advisory group, or Task Force | CDC | NIAID | Respiratory syncytial virus (RSV) is a major cause of lower respiratory illness, particularly among infants and children and among older adults and adults with chronic medical conditions. RSV vaccine development has progressed in the past decade with over 40 candidate vaccines currently in development. Target populations for whom these products are intended include infants and young children, pregnant women, older adults, and adults with chronic medical conditions.This Work Group will consider policy questions related to adult vaccination. The separate pediatric/maternal Work Group will consider policy topics related to vaccination of infants, young children, and pregnant women. |
| Advisory Council on Alzheimer's Research, Care, and Services | Committee, Work group, Advisory group, or Task Force | OS | NIA | The Advisory Council on Alzheimer's Research, Care, and Services was established to advise the Secretary for HHS on work conducted or needed regarding Alzheimer's disease and related dementias (AD/ADRD) and provide recommendations for the National Plan on a yearly basis. The Advisory Council meets officially every quarter for public meetings, and through subcommittees, members meet as often as necessary. |
| Agency Wide Selective Placement Program Coordinator Community of Practice (CoP) group | Meeting/ Workshop | IOS | OD/OM, OD/OM/OHR | By fostering cross-agency dialogue and engagement, they have significantly advanced efforts to enhance employment opportunities for individuals with disabilities, meriting recognition for their outstanding leadership and dedication. |
| Air Quality and Community Health Research Subcommittee (ACRS) | Committee, Work group, Advisory group, or Task Force | CDC | NIA, NIEHS | The objective of the Air Quality and Community Health Research Subcommittee (ACRS) is to advance and coordinate important research on air quality and associated community level health impacts and exposure disparities, with a focus on communities with environmental justice concerns. |
| Alaska Native Tumor Registry | Resource Development | CDC, IHS | NCI | In collaboration with CDC, IHS, and NCI, and with technical assistance from the Surveillance, Epidemiology, and End Results Program (SEER), the Alaska Native Tumor Registry collects information on cancer cases among Alaskan Native populations residing in Alaska. Other collaborative activities: disease registry |
| Alcohol Metabolism, Functional Consequences and Apoptosis Signaling Mechanism | Research Initiative | FDA | NIAAA | The overall goals of these lab projects are to perform basic research to investigate the molecular mechanisms of cell/organ damage and to conduct translational research to prevent tissue damage caused by ethanol (binge alcohol) in the absence or presence of other risk factors. Alcohol and many other potentially toxic compounds e.g., acetaminophen (APAP), carbon tetrachloride (CCl4), cisplatin, lipopolysaccharide (LPS), thioacetamide (TAA), Western-style high fat diet (HFD), fructose, nicotine, etc. are known to stimulate cell/organ injury through increased oxidative and nitrative (nitro-oxidative) stress. |
| Alzheimers.gov Collaborations with Federal Agencies | Public Education Campaign | ACL, CDC, FDA, HRSA, IHS | NIA | In the course of updating and maintaining the Alzheimers.gov website, NIA consults with the federal partners through the NAPA Federal Subgroup and direct outreach to federal partners, such as contacting them regarding resource updates and clearing content through them. |
| Analgesic Clinical Trial Translations, Innovations, Opportunities, and Networks | Research Initiative | FDA | NCATS, NCI, NIAAA, NINDS | The mission of the Analgesic Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership funded by the US Food and Drug Administration (FDA) is to identify, prioritize, sponsor, coordinate, and promote innovative activities — with a special interest in optimizing clinical trials — that will expedite the discovery and development of improved analgesic treatments for the benefit of the public health. |
| Annexes to the Playbook on Biological Incident Preparedness and Response - Clinical Research Response and Response Research Agenda | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NIAID | Will define the process by which the United States will implement clinical trials of vaccines, diagnostics, or medical countermeasures in affected foreign countries even when there is no pre-existing research platform. To rapidly assess what knowledge gaps exist around a particular pathogen, its transmission, ecology, or management, in order to create a prioritized research agenda to guide medium and long-term research activities |
| Antibody Interest Group (ABIG) | Committee, Work group, Advisory group, or Task Force | FDA | NCI, NHLBI, NIAID, NIDDK | The NIH ABIG promotes information exchange and interaction among NIH scientists who work on various aspects of antibody engineering and therapy. The success of antibody therapy requires a thorough understanding of biological systems in relation to molecular and cell biology, immunology, biochemistry, and microbiology, as well as diseases such as cancer, autoimmunity, and infectious diseases. Interest in antibody therapy crosses traditional biomedical disciplinary boundaries. ABIG provides an open forum for multidisciplinary discussion among colleagues who otherwise may have limited interaction. The principal ABIG activities are monthly meetings on current topics as well as an annual symposium on the NIH campus. The monthly ABIG meetings are open to everyone interested. These meetings are devoted to research seminars on numerous aspects of antibody engineering and therapy presented by both NIH scientists and outside speakers. |
| Antimicrobial Drugs Advisory Committee | Committee, Work group, Advisory group, or Task Force | FDA | NIAID | The Committee reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human drug products for use in the treatment of infectious diseases and disorders and makes appropriate recommendations to the Food and Drug Administration (FDA) Commissioner. |
| Antiretroviral Pregnancy Registry | Resource Development | CDC | NICHD | This is a registry of use of antiretroviral drugs in pregnancy that is sponsored by various pharmaceutical companies and has a committee of external experts and government staff from the National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), and Food and Drug Administration (FDA). The registry provides a resource for clinicians and researchers to improve the healthcare quality and patient safety for HIV infected mothers and their infants. http://www.apregistry.com/ |
| AoURP and Veterans Administration | Other | AoA | OD/All of Us | Enrollment award to support engagement, enrollment and retention across VA clinic locations to facilitate participation in AOURP among the veteran population. Collaboration Type: award to the VA for enrollment and retention of AOU participants |
| ARPA-H Biomedical Data Fabric Toolbox program partnership | Resource Development | ARPA-H | NCATS, NCI, NHLBI, NIBIB, NIEHS, OD/DPCPSI | To support both the mission of ARPA-H to “Accelerate better health outcomes for everyone by supporting the development of high-impact solutions to society's most challenging health problems,” and the NCI’s vision to “Maximize cancer data availability, usability, and utility through forward-thinking policies and processes”, NCI and ARPA-H are partnering to advance Biomedical Data Fabric research efforts for cancer and chronic conditions by integrating advanced capabilities from across DARPA and NIH Institutes and Centers. |
| ARPA-H Glide Program | Research Initiative | ARPA-H, CDC, FDA | NIA, NIAMS | Groundbreaking Lymphatic Interventions and Drug Exploration. https://arpa-h.gov/explore-funding/programs/glide |
| ASPR Filovirus Working Group | Committee, Work group, Advisory group, or Task Force | ASPR, CDC, FDA | NIAID | Working group focused on filoviruses. |
| ASPR H-Core for Vaccines and Therapeutics | Committee, Work group, Advisory group, or Task Force | ASPR, BARDA, CDC, FDA | OD/OM, OD/OM/ORS | The purpose of this work group/task force is to establish an HHS jurisdiction for procurement and distribution of vaccines and treatments for ongoing pandemics and outbreaks (e.g., COVID and Mpox) through the CDC. HHS and partnering agencies have essential critical infrastructure workforce staff, special patient populations, etc. that need to be treated for and/or vaccinated against dangerous pathogens and diseases. The NIH is coordinating on behalf of CDC and overseeing an independent, but collaborative, program for CDC to provide these vaccines and treatments directly to participating federal agencies for vaccination and treatment of their designated essential critical infrastructure workforce staff and special population groups such as patients enrolled in clinical trials. |
| ASPR Respiratory Protective Device (RPD) Working Group and ASPR Gowns/Gloves Workgroup | Committee, Work group, Advisory group, or Task Force | ASPR | OD/OM, OD/OM/ORS | These working groups will perform a validation process of existing and new PPE requirements in support of the upcoming MCM Preparedness Review due to Congress in 2023. This Review includes efforts historically referred to as the Strategic National Stockpile (SNS) Annual Review. |
| Assessing the Burden of Diabetes by Type in Children, Adolescents, and Young Adults Network | Resource Development | CDC | NIDDK | The primary goal of the DiCAYA network is to modernize diabetes surveillance efforts to capitalize on large-volume, electronic health record data streams and on recent advances in statistics and clinical informatics to provide accurate, timely, cost-effective, granular, and representative indicators of diabetes prevalence and incidence among children, adolescents and younger adults. The network aims to monitor overall trends as well as trends within subgroups (e.g., age, sex, diabetes type, socioeconomic status, urbanicity, geographic area). NIDDK is a DiCAYA research sponsor. |
| Assessment of Inhalation Exposures to Indoor and Occupational Aerosols | Research Initiative | CDC | NIEHS | The primary goal of this collaboration is to study inhalation exposures to indoor and occupational aerosols, with a current focus on characterizing the health hazards associated with exposure to common fungal contaminants. NIOSH uses a specially developed exposure system to conduct subchronic toxicology studies following repeated exposure to molds identified by the NTP as a public health concern. Subprojects under this IAA are examining the association of exposure to mycotoxins and health by analyzing indoor air samples, developing biomarkers of exposure and response, and using genomic sequencing methodologies to assess fungal diversity associated with the built environment. |
| Assessment of task-based exposures that may affect reproductive health in nail salon employees | Research Initiative | CDC | NIEHS | The goal of this study is to better understand a nail technician's exposure profile to select reproductive toxicants by evaluating the contributions of different tasks. |
| Bacteriophage Interest Group | Committee, Work group, Advisory group, or Task Force | FDA | NIAID | Scientific interest group discussing science and issues around bacteriophage as treatment. Includes members from FDA, BARDA, and DMID |
| BARDA ECMO Working Group | Committee, Work group, Advisory group, or Task Force | BARDA, FDA | NHLBI | Participate in scientific discussions that address challenges and opportunities for Extracorporeal Membrane Oxygenation (ECMO). |
| BARDA IL-6 and GM-CSF in Sepsis Committees | Committee, Work group, Advisory group, or Task Force | ASPR | NICHD | These meetings with BARDA and industry discuss studies being conducted on pediatric sepsis and multiple organ dysfunction. |
| BARDA-DRIVe | Research Initiative | ASPR | NIAID | BARDA DRIVe funds early stage companies for life saving innovation. Collaboration is on agnostic pathogen detection. |
| Bench to Bedside: Integrating Sex and Gender to Improve Human Health | Training Initiative | FDA | OD/DPCPSI/ORWH | Bench to Bedside: Integrating Sex and Gender to Improve Human Health was developed in partnership with the Food and Drug Administration (FDA) Office of Women’s Health (OWH). This online course gives users a thorough and up-to-date understanding of sex and gender influences on health and disease so users can apply this knowledge when conducting research and interpreting evidence for clinical practice. Course material showcases examples from basic science through clinical trials and translation into practice to ensure participants understand the importance of considering the influence of sex and gender throughout the research spectrum and beyond. Through its six modules, the course focuses on key health conditions on which sex and gender have an impact. The six modules that compose the course are Immunology, Cardiovascular disease, Pulmonary disease, Neurology, Endocrinology, and Mental Health. |
| Best Pharmaceuticals for Children Act (BPCA) Working Group | Committee, Work group, Advisory group, or Task Force | FDA | NICHD | The overarching goals of BPCA are to encourage the pharmaceutical industry to perform pediatric studies to improve labeling for patented drug products used in children by granting an additional 6 months of patent exclusivity and authorize NIH, through Section 409I, to prioritize needs in various therapeutic areas and sponsor clinical trials of off-patent drug products that need further study in children, as well as training and other research that addresses knowledge gaps in pediatric therapeutics. The Data Monitoring Committee subgroup provides safety oversight for all studies conducted under BPCA. The Research Oversight Committee provides programmatic support to project lead for the BPCA clinical program, which includes the oversight prioritization, concept developments, and study implementation for the Pediatric Trials Network. |
| BioCompute Object Project | Committee, Work group, Advisory group, or Task Force | FDA | NCI | The BioCompute Object (BCO) Project is a community-driven initiative to build a framework for standardizing and sharing computations and analyses generated from High-throughput sequencing (HTS -- also referred to as next-generation sequencing or massively parallel sequencing). The project has since been standardized as IEEE 2791-2020, and the project files are maintained in an open source repository. The July 22nd, 2020 edition of the Federal Register announced that the FDA now supports the use of BioCompute (officially known as IEEE 2791-2020) in regulatory submissions, and the inclusion of the standard in the Data Standards Catalog for the submission of HTS data in NDAs, ANDAs, BLAs, and INDs to CBER, CDER, and CFSAN. Originally started as a collaborative contract between the George Washington University and the Food and Drug Administration, the project has grown to include over 20 universities, biotechnology companies, public-private partnerships and pharmaceutical companies including Seven Bridges and Harvard Medical School. The BCO aims to ease the exchange of HTS workflows between various organizations, such as the FDA, pharmaceutical companies, contract research organizations, bioinformatic platform providers, and academic researchers. Due to the sensitive nature of regulatory filings, few direct references to material can be published. However, the project is currently funded to train FDA Reviewers and administrators to read and interpret BCOs, and currently has 4 publications either submitted or nearly submitted. |
| Biodosimetry Trans-NIH Working Group and Special Journal Issue | Committee, Work group, Advisory group, or Task Force | ASPA, BARDA, FDA | NIAID | This collaboration highlights regulatory and scientific approaches in research and advancement of biodosimetry tests in both NIAID and BARDA portfolios |
| Biomarkers of Exposure and Effect in Agriculture (BEEA) | Research Initiative | CDC | NCI | National Cancer Institute (NCI) and the Centers for Disease Control and Prevention (CDC) are collaborating to characterize exposure to glyphosate, permethrin, and other pesticides by measuring urinary metabolites among participants in the Biomarkers of Exposure and Effect in Agriculture (BEEA) study. |
| Biomarkers of Exposure and Effect in Agriculture (Water Contaminants) | Research Initiative | CDC | NCI | National Cancer Institute (NCI) and the Centers for Disease Control and Prevention (CDC) and the US Geological Survey (USGS) are collaborating on a study to characterize exposure to water contaminants by measuring urinary nitrate excretion, and drinking water concentrations of nitrate, pesticides, and other chemicals, as well as hormone activity among a subset of participants in the Biomarkers of Exposure and Effect in Agriculture (BEEA) study. |
| Biomedical Advanced Research Development Agency (BARDA) | Other | BARDA | OD, OD/OM | Provide Contract Property Support for R&D Contracts containing government furnished equipment |
| Biosafety and Biosecurity Innovation Initiative Working Group for the Executive Order on Strengthening the Bioeconomy | Committee, Work group, Advisory group, or Task Force | ASPR, CDC, FDA, ONS | OD/OM, OD/OM/ORS, OD/OSP | BBII-IWG is tasked with launching the Biosafety and Biosecurity Innovation Initiative which seeks to reduce biological risks associated with the Bioeconomy. BBII-IWG is tasked with writing a "plan for biosafety and biosecurity for the bioeconomy." |
| Biosafety in Biomedical and Microbiological Laboratories | Resource Development | CDC | OD/OM, OD/OM/ORS | The purpose is to update guidance for biosafety and biosecurity for biomedical laboratories, and update the BMBL. |
| Blood, Organ, and Tissue Senior Executive Council (BOTSEC) | Committee, Work group, Advisory group, or Task Force | OASH | NHLBI, NIAID | The Blood, Organ, and Tissue Senior Executive Council (BOTSEC) is an advisory forum for senior leadership from the Department of Health and Human Services (HHS) organizational components, as well as liaison representatives from Department of Defense and Veterans’ Health Administration, that are involved in blood, organ, and tissue safety and availability. The HHS Assistant Secretary for Health serves as the Council Chair, and the Office of the Assistant Secretary for Health (OASH) Senior Advisor for Blood and Tissue Policy serves as the BOTSEC Executive Director. |
| Board of Regents of the National Library of Medicine | Committee, Work group, Advisory group, or Task Force | CDC, OSG | NLM | The National Library of Medicine (NLM) Board of Regents (the Board) provides advice and recommendations on policy matters related to NLM. This includes guidance on the acquisition of materials, defining the scope, content, and organization of services, and establishing rules for the availability of NLM materials, publications, facilities, and services to different user groups. The Board may also make recommendations on research conducted at NLM, review and make recommendations about applications for grants, contracts, and cooperative agreements for support of medical library resources and systems, research in medical informatics and management of biotechnology information, training for research and the use of information management technology, biomedical publications, development and demonstration projects, educational technology, and related projects that show promise of making valuable contributions to NLM’s mission. The Board also advises on the development of a biomedical communications network through the support and maintenance of a national network of libraries of medicine. https://www.nlm.nih.gov/od/bor/bor.html |
| Board of Scientific Counselors (BSC) of the CDC's National Center for Injury Prevention and Control | Committee, Work group, Advisory group, or Task Force | CDC, ACF, ACL, AHRQ, HRSA, IHS, SAMHSA | NIA, NICHD, NIDA, NIMH | The BSC advises the Secretary, Department of Health and Human Services; the Director, Centers for Disease Control and Prevention (CDC); and the Director, National Center for Injury Prevention and Control (NCIPC) regarding surveillance, basic epidemiologic research, intervention research, and implementation, dissemination, and evaluation of promising and evidence-based strategies for the prevention of injury and violence. The Board makes recommendations regarding policies, strategies, objectives, projects, and priorities, and reviews progress toward injury and violence prevention. |
| Botanical Safety Consortium | Research Initiative | FDA | NCCIH, NIEHS | The Botanical Safety Consortium will provide a sound scientific basis for integrating existing botanical safety & toxicity information with the latest toxicological tools. This multi-partite, multi-stakeholder international effort will bring together key scientific experts to enhance the botanical safety toolkit and bring clarity to botanical dietary ingredient assessments. |
| Brain Attack Coalition | Committee, Work group, Advisory group, or Task Force | CDC | NINDS | The Brain Attack Coalition (BAC) is a group of public and private entities representing medical, scientific, advocacy, and government professionals from across the stroke continuum. The BAC is dedicated to setting direction, advancing knowledge, and communicating best practices to improve our ability to prevent and combat stroke. |
| Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative | Research Initiative | FDA | NCCIH, NEI, NIA, NIAAA, NIBIB, NICHD, NIDA, NIDCD, NIMH, NINDS, OD/DPCPSI/OBSSR | The Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is revolutionizing our understanding of the brain by developing and applying innovative technologies to study brain circuits and, ultimately, to develop new ways to treat brain disorders. Circuits of brain cells enable us to think, perceive our world, and act upon it, and disruption of these circuits underlies neurological, psychiatric, and substance misuse disorders. The BRAIN Initiative also facilitates collaborative neuroscience research partnerships, resource meetings, and working groups. |
| Brain Tumors in the United States Military | Research Initiative | USPHS | NCI | This research initiative focuses on gathering and disseminating epidemiologic data on primary benign and malignant brain and other CNS tumors in the United States Military Veterans population. |
| BRIDG Standard Development | Research Initiative | FDA | NCI | Developing and maintaining a conceptual data model that harmonize EMR data and protocol driven data *also a resource development collaboration type |
| Bridge to Artificial Intelligence | Research Initiative | FDA | FIC, NCATS, NCCIH, NCI, NEI, NHGRI, NIA, NIAID, NIAMS, NIBIB, NIDDK, NIGMS, NIMH, NIMHD, NINDS, NLM, OD/All of Us, OD/DPCPSI/OBSSR, OD/DPCPSI/ODSS, OD/DPCPSI/OSC | The Bridge to Artificial Intelligence (Bridge2AI) program seeks to propel biomedical research forward by setting the stage for widespread adoption of artificial intelligence (AI) and machine learning (ML) that tackles complex biomedical challenges beyond human intuition. Bridge2AI works with representatives from the Defense Advanced Research Projects Agency (DARPA), U.S. Department of Energy (DOE), National Science Foundation (NSF), National Institute of Standards and Technology (NIST), and U.S. Food and Drug Administration (FDA) in order to bring expertise from across the federal government to help develop this groundbreaking new program that aims to harness the power of AI/ML for human health. Bridge2AI is also collaborating with DOE Office of Science program in Advanced Scientific Computing Research to jointly address important issues and challenges in developing AI and machine learning methods for privacy-sensitive datasets. |
| Bulk Office Supply Support | Other | OASH | OD, OD/OM | IAA funding allocated by HHS - Office of the Assistant Secretary for Health (OASH) for bulk (i.e. copier paper, notebooks) office supplies for their programs, to be used throughout FY25 as needed. |
| Burden of Disease U.S. Health Disparities Working Group | Committee, Work group, Advisory group, or Task Force | CDC | NCI, NHLBI, NIA, NIAMS, NIMHD, OD/DPCPSI/OBSSR, OD/DPCPSI/ODP | Through this project, the U.S. Burden of Health Disparities Working Group at NIH aims to generate a landmark and comprehensive report and public platform with data on U.S. Burden of Health Disparities by Race/Ethnicity, Sex, Age, Socioeconomic Status and Geography. The project entails producing detailed county-level estimates of disease burden stratified by race/ethnicity, socioeconomic status (SES), age, and sex for a vast array of diseases, injuries, and risk factors. The report would include a broad set of measures of the burden of disease (e.g., disability-adjusted life years and healthy life expectancy). This project would result in a platform for downloadable, publicly available data review and visualization tools for extracting information on these stratified analyses at the county-level for every U.S. County. CDC/NCVS is providing guidance on vital statistics data, algorithms and procedures used to generate life expectancy estimates, etc., by race and ethnicity. |
| CADCA Federal Partners Planning | Committee, Work group, Advisory group, or Task Force | SAMHSA | NIDA | CADCA, or Community Anti-Drug Coalitions of America, engages in strategic planning and partnerships with several federal agencies to advance its mission of reducing substance misuse in communities across the nation. This collaboration was for the purpose of meeting to discuss NIDA's efforts for the yearly National Meeting in February. |
| Canadian-U.S. Dietary Reference Intakes Working Group | Committee, Work group, Advisory group, or Task Force | OASH, AHRQ, CDC, FDA | NIDDK, OD/DPCPSI/ODS, OD/DPCPSI/ONR | The US and Canadian governments have each established Federal DRI Committees that work collaboratively to identify DRI needs and to coordinate government sponsorship of DRI reviews and related activities. The DRIs — which reflect nutrient reference values essential to national nutrition policies and to professionals working in the field of nutrition and health — have been developed under the auspices of the Institute of Medicine with funding from the US and Canadian governments. |
| Cancer Cabinet Prevention and Screening Task Force Nutrition Subgroup | Committee, Work group, Advisory group, or Task Force | CDC, FDA, IHS | NCCIH, NCI, NIA, NINR, OD/DPCPSI/ODP | The Cancer Cabinet was convened by the White House, bringing together cabinet agencies and relevant departments, including multiple White House components to address progress against cancer in five priority actions.(1) close the screening gap, (2) understand and address environmental exposure, (3) decrease the impact of preventable cancers, (4) bring cutting edge research through the pipeline to patients and communities, and (5) support patients and caregivers. This is an interagency group for developing and disseminating evidence based talking points for federal staff, and compiling resources for public facing purposes and around screening for dietary and nutrition risk factors. |
| Capturing the full trajectory of patient-centered cancer care via enhanced data linkages | Resource Development | ASPE | NCATS, NCI | This 3-year, $1.8 million project is funded by the Office of Secretary's Patient Centered Outcomes Trust Funds. NCI and NCATS are collaborating to establish linkages between cancer registry data and EHR data to create patient cohorts for two common and two rare cancers. This project shall use the N3C data platform of NCATS to create a new cancer tenant within N3C. One objective is to assess the feasibility of extracting data on cancer treatments and patient-centered outcomes within each cancer cohort. Another objective is to characterize cancer treatment variations. This project is exploring a partnership with NIDDK, which is creating renal and diabetes tenants using the same N3C platform. |
| Cardio-Oncology Working Group | Committee, Work group, Advisory group, or Task Force | FDA | NCI, NHLBI | A working group aiming at stimulating interest in cardio-oncology, a growing research area due to advancements in cancer therapies, unfortunately associated with significant cardiovascular toxicity. By leveraging a strong partnership between NHLBI, NCI, and the FDA, the group seeks to identify gaps in research, emerging areas, new screening tools, and novel strategies for early detection, prevention, and management of cardiovascular toxicity related to cancer treatment, to improve cancer patients outcomes. |
| CCDI Molecular Targets Platform | Resource Development | FDA | NCI | The CCDI Molecular Targets Platform allows users to browse and identify associations between molecular targets, diseases, and drugs.The RACE Act requires evaluation of new molecularly targeted drugs and biologics “intended for the treatment of adult cancers and directed at a molecular target substantially relevant to the growth or progression of a pediatric cancer.” This act also eliminates the orphan exemption for pediatric studies of cancer drugs directed at relevant molecular targets. In accordance with the RACE Act, the FDA, in collaboration with NCI and the pediatric cancer research community, developed a Relevant Molecular Target List (RMTL) to provide guidance to industry in planning for new drug and biologic submissions. NCI converted this RMTL list into a computer-readable format with gene-level granularity and all targets mapped and hyperlinked to additional resources and identifiers; integrated this list into Molecular Targets Platform. |
| CDC Acute Flaccid Myelitis (AFM) Task Force | Committee, Work group, Advisory group, or Task Force | CDC | NIAID, NINDS | The AFM Task Force was established to aid in the ongoing investigation to define the cause of, and improve treatment and outcomes for, patients with AFM. The Task Force functions as a work group of the CDC Board of Scientific Counselors, Deputy Director for Infectious Diseases.https://www.cdc.gov/ddid/bsc/afm-task-force.html |
| CDC Advanced Molecular Detection Platform & NGS Quality Committee | Committee, Work group, Advisory group, or Task Force | CDC, CDC | NLM | The CDC-led Technical Coordinating Committee for Advanced Molecular Detection Platform and Next-Generation Sequencing Quality (TANQ) coordinates information sharing and collaboration between CDC and state public health laboratories. Focusing on bacteria and viruses, TANQ prioritizes key activities, provides feedback, and supports the development of bioinformatics capacity and a CDC bioinformatics platform to meet public health needs. Its meetings primarily include representatives from state public health labs, CDC employees, and some academic partners. |
| CDC COVID-19 Testing Coordination Committee | Committee, Work group, Advisory group, or Task Force | CDC, OASH | NICHD | This Committee shares COVID-19 testing updates for activities in school settings to share progress and coordinate amongst different federal agencies. |
| CDC Integration with GrantSolutions | Resource Development | CDC, ACF | OD/OER | Collaboration with GrantSolutions to allow the Centers for Disease Control and Prevention (CDC) Research programs to seamlessly use electronic Research Administration (eRA) research grant support services, including the eRA Commons grantee portal and the eRA Peer Review suite while having grants management staff process awards within GrantSolutions. |
| CDC National Health and Nutrition Examination Survey (NHANES) Dietary Supplements and Selected Nutritional Biomarkers | Health Survey | CDC | OD/DPCPSI/ODS | NHANES is a major program of the National Center for Health Statistics (NCHS) - part of the Centers for Disease Control and Prevention (CDC) - and is a program of studies designed to assess the health and nutritional status of adults and children in the United States. The NIH Office of Dietary Supplements has provided funding for several biomarkers over the years and most recently biomarkers for folate status, iodine status and magnesium. |
| CDC National Health and Nutrition Examination Survey team | Health Survey | CDC | NHLBI, NIAID, NIEHS | The CDC National Health and Nutrition Examination Survey Team (CDC, NIAID, NIEHS, NHLBI and others) are collaborating to develop and generate survey questions on asthma and allergic diseases . Additionally, NIAID and CDC will conduct serum IgE measurements covering aeroallergens and food allergens. |
| CDC Treatment Guidelines for Tularemia | Committee, Work group, Advisory group, or Task Force | CDC, BARDA | NIAID | The focus of the working group is to develop clinical treatment guidelines for tularemia. |
| CDC-NCHS-NHANES Audiometry Component | Health Survey | CDC | NIDCD | This interagency collaborative project will provide support to the National Center for Health Statistics (NCHS), CDC for implementation of nationally representative hearing health examinations and interview survey questions for assessment of hearing thresholds and risk factors for hearing loss and related conditions such as hyperacusis and tinnitus in both children and adults. |
| CDC-NCHS-NHIS Inclusion of Whole Person Health Index Questions | Health Survey | CDC | NCCIH | Development and validation of brief survey item (Whole Person Health Index) and inclusion in the 2025 National Health Interview Survey (NHIS) |
| CDC-NCHS-NHIS Taste & Smell Questionnaire Supplement | Health Survey | CDC | NIDCD | To provide support to the National Center for Health Statistics (NCHS), CDC for implementation of a nationally representative health interview survey questions inquiring about taste & smell and communication disorders and disabilities of voice, swallowing, speech, and language in both childhood and adults. Communication disabilities, including voice, swallowing, speech, and language disabilities, can profoundly affect a person’s life and health; impacting the ability to work, interact socially and engage during health care encounters. Adults with communication disabilities are at risk for decreased quality of life, health status, and health care services received. Targeted interventions delivered in a community or medical setting, including speech-language pathology services, and occupational support can potentially mitigate these risks. Few current epidemiological studies have explored the prevalence of communication disorders and their associated etiologies in the United States.While voice, swallowing, speech, and language disorders are distinct disabilities with different biological mechanisms, they can all cause a person to have difficulty communicating and thus are collectively referred to as communication disorders. Multiple national surveys, including the American Community Survey (ACS), the Current Population Survey – Annual Social and Economic Supplement (CPS-ASEC), and the Decennial Census of Population and Housing, collect information on the prevalence of disability in the United States, but these surveys do not specifically identify or distinguish between voice, swallowing, speech, and language disorders.Persons with voice, swallowing, speech, and language disorders represent about 10 percent of the US population.1-3 Adults with communication disorders have about a two-fold increased risk of also having chronic diseases (hypertension, cardiovascular disease, stroke, emphysema, asthma, cancer, diabetes, and arthritis). They are also much more likely to report their general health status as “fair/poor” compared to adults without communication disorders. While adults with communication disorders more frequently use healthcare, they have greater difficulty accessing healthcare than those without communication disorders.4Communication disorders are treated by speech-language therapists or pathologists, who are specialists trained and licensed to diagnose and treat communication disorders. Because physical, neurological, or psychological conditions are frequently either responsible for or are related to these disorders, the therapist often works as a member of a health care team. Communication disorders caused by disease, injury, or malformation will normally require the services of a physician or surgeon. After medical problems are treated, the speech-language therapist is responsible for helping the patient improve communications ability. Speech-language pathologists (SLPs) provide screening, assessment, treatment, consultation and education for voice, speech, language, or swallowing problems in adults. SLPs also treat children who have difficulty understanding or using language, producing speech sounds correctly, feeding/ swallowing, stuttering or voice problems. About 1 in 12 children aged 3 to 17 years in the United States have had voice, speech, and language disorders during the past year.3,5,6 These disorders are often linked to problems with behavior or development. Early evaluation by a speech-language pathologist can help families identify these disorders and get the right treatment for their child. To function in our society, we must be able to communicate effectively. Despite valuable scientific and technological advances, many aspects of modern life remain profoundly difficult for an individual with a voice, swallowing, speech, or language disorder. These disorders often affect a person's emotional and social life and can compromise educational and job or employment opportunities. Taste and Smell - Sample AdultSponsor: National Institute on Deafness and Other Communication DisordersConcepts to be Measured• Past 12 months, have you had difficulty with sense of smell or ability to detect odors (SMELLDF_A)• Compared to when you were (25 years old / 5 years younger), ability to smell (better, worse, no change)( SMELLCOMP_A)• Past 12 months, smell an unpleasant, bad, metallic, or burning odor when nothing is there (SMELLPHT_A)• Past 12 months, difficulty with your ability to taste sweet, sour, salty, or bitter foods and drinks (TASTEDF_A)• Compared to when you were (25 years old / 5 years younger), ability to taste sweet, sour, salty, or bitter foods and drinks (better, worse, no change) (TASTECOMP_A) • Compared to when you were (25 years old / 5 years younger), ability to taste flavors such as chocolate, vanilla, or strawberry (better, worse, no change) (TASTEFLAV_A)• Past 12 months had an unwanted taste or other sensation in mouth that does not go away (TASTEUNW_A)• Ever discussed any problem with, or a change in your ability to taste or smell, with a doctor or other health professional (TSTSMHP_A)o When was the last time discussed any problem with ability to taste or smell with a doctor or other health professional (TSTSMLAST_A)• Past 12 months, had any of the following o … a head cold or flu for longer than a month (COLDFLU12M_A)o … persistent dry mouth (DRYMOUTH12M_A)For those with positive coronavirus diagnosis• Had coronavirus symptoms include losing sense of smell, having distortions, or smelling odors that were not there? (CVDSYMSM_A)o Has your sense of smell fully or partially recovered? (CVDSMREC_A)• Had coronavirus symptoms include losing ability to taste or having unwanted tastes or sensations in your mouth that did not go away (CVDSYMTST_A)o Has ability to taste fully or partially recovered? (CVDTSTREC_A) |
| CDC-NCHS-NHIS Voice, Swallowing, Speech, and Language Components | Health Survey | CDC | NIDCD | This interagency collaborative project will provide support to the National Center for Health Statistics (NCHS), CDC for implementation of nationally representative health interview survey questions inquiring about communication disorders of voice, swallowing, speech, and language in both childhood and adults. This survey obtains information about communication disabilities, including voice, swallowing, speech, and language disabilities, and asks about the impact on a person’s life and health, ability to work or go to school, interact socially and engage during health care encounters. Adults with communication disabilities are at risk for decreased quality of life, health status, and health care services received. Targeted interventions delivered in a community or medical setting, including speech-language pathology services and occupational support, can potentially mitigate these risks. Few current epidemiological studies have explored the prevalence of communication disorders and associated factors in the United States.While voice, swallowing, speech, and language disorders are distinct disabilities with different biological mechanisms, they can all cause a person to have difficulty communicating and thus are collectively referred to as communication disorders. Multiple national surveys, including the American Community Survey (ACS), the Current Population Survey – Annual Social and Economic Supplement (CPS-ASEC), and the Decennial Census of Population and Housing, collect information on the prevalence of disability in the United States, but these surveys do not specifically identify or distinguish between voice, swallowing, speech, and language disorders. |
| CDC-NIH Lyme Disease Serum Sample Repository | Resource Development | CDC, OS | NIAID | Initiated in 2008, this resource was made available to the scientific community on a broad basis in late 2011. Lyme disease and related serum samples are available upon request for testing and comparison of new and current diagnostic tests with a common serum sample set for standardization. Samples are distributed by the Centers for Disease Control and Prevention (CDC). CDC and National Institutes of Health (NIH) both provided support to acquire the samples and continue to work together to ensure the scientific community has access to samples needed for Lyme disease diagnostic test development. |
| CDC/NIH Quarterly Check-ins | Other | CDC | NIAID, NIMH, OD/DPCPSI/OAR | This is an informal information sharing group. Regularly scheduled calls between CDC and NIH to share high level information, administrative updates, and upcoming initiatives related to the HIV response, including programmatic, surveillance, and research activities. |
| CDER Controlled Substances Program | Committee, Work group, Advisory group, or Task Force | FDA | NIDA | Representatives from DTMC/NIDA/NIH hold a quarterly call with the Controlled Substances Staff/CSP/CDER/FDA to exchange information about respective projects, programs, and funding opportunities, enhancing collaboration between the two agencies. |
| CEIRR Risk Assessment Pipeline Working Groups | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NIAID | Working groups to coordinate CEIRR investigators and select external partners to discuss and plan for CEIRR's pipeline and process on studying, characterizing, and responding to new influenza strains and outbreaks. The four standing working groups consist of Wild Animal Surveillance, Domestic Animal Surveillance, Phenotypic Characterization, and Phylodynamics and Computational Modeling. There are ad hoc working groups as well for specific topics, such as the Bovine H5 Outbreak working group as well. Members are mostly academic researchers funded by CEIRR, but also includes USDA, CDC, and FDA representatives, as well as NIAID staff not affiliated with CEIRR. |
| Center for Preparedness and Response (CPR) Board of Scientific Counselors (BSC) | Committee, Work group, Advisory group, or Task Force | CDC | NIAID | The Board of Scientific Counselors (BSC) is an advisory committee chartered under the Federal Advisory Committee Act. This advisory group comes together to provide advice and guidance about the public health preparedness and response activities conducted by CDC. The BSC is charged with: Advising the Secretary of Health and Human Services, the Assistant Secretary for Health, the CDC Director concerning strategies and goals for preparedness programs and research; Conducting peer-review of scientific programs; Performing secondary reviews of research proposals; and monitoring overall strategic direction and focus.The BSC is managed by the Office of Science and Public Health Practice. |
| Central Brain Tumor Registry of the United States | Research Initiative | CDC | NCI | CBTRUS is a resource for gathering and disseminating epidemiologic data on primary benign and malignant brain and other CNS tumors. Dr. Barnholtz-Sloan and her research team work with the CBTRUS team on a variety of research topics related to the epidemiology of brain tumors. |
| CEPI Interagency Meeting | Committee, Work group, Advisory group, or Task Force | ASPR, CDC, FDA, OGA | NIAID | Group convened to advise USAID in their role as CEPI funder and member of CEPI Investor Council and Board. Group meets quarterly, in advance of each CEPI board meeting, to discuss USG positions on CEPI's investment proposals that will come before the board, as well as any other issues that require collaboration. |
| CEPI-NIAID Collaboration for the development of broadly protective coronavirus vaccines | Other | BARDA, BARDA | NIAID | The purpose of the collaboration is to convene experts within and funded by the organizations to establish consensus vaccine research and development goals, coordinate resources that enable vaccine development, and to address challenges along the development path of promising BPCV candidates. |
| Cervical screening guidelines | Resource Development | CDC, FDA, HRSA | NCI | The National Cancer Institute (NCI) is generating risk estimates that inform cervical screening and management guidelines. NCI is working with CDC, HRSA, and FDA to collect study populations, conduct risk estimation, and disseminate guidelines. |
| CFAR Diversity, Equity, Inclusion Pipeline Initiative | Research Initiative | OASH | FIC, NCI, NHLBI, NIA, NIAID, NIDDK, NIMH, NINR, OD/DPCPSI/OAR | The overarching goal of the NIH-supported CFAR Diversity, Equity, and Inclusion Pipeline Initiative (CDEIPI) is to support a diverse pool of trainees who are engaged in HIV science at the high school, undergraduate, graduate (masters, doctoral or medical) and post-doctoral levels, including trainees from underrepresented racial and ethnic groups. CDEIPI seeks to develop pathways for these "CFAR Scholars" to successful careers in science and medicine. OASH provided key information and advice in the development of this initiative. |
| Characterize Emerging HIV Strains from Blood Donors and Patients | Resource Development | FDA | NIAID | This initiative will continue research to develop a well characterized, dynamic repository of diverse HIV strains for diagnostics, drug, and vaccine studies. To accomplish this, FDA and NIAID will collaborate in the work of characterizing these diverse strains and using a subset of viruses and plasma to develop globally diverse panels for evaluating performance of HIV diagnostic assays. In the era of early ART and PrEP, the performance of HIV diagnostic assays in persons on these regimens may be compromised. By developing reference materials, it will enable cross-comparison of different assays using the same reagents. |
| Chemical Hazards Emergency Medical Management (CHEMM) Working Group | Committee, Work group, Advisory group, or Task Force | OS | NINDS | The goal of CHEMM is to provide a comprehensive, user-friendly resource to help enable first responders and other healthcare providers to plan for, respond to, recover from, and mitigate the effects of mass-casualty incidents involving chemicals.https://chemm.hhs.gov/ |
| Chronic Kidney Disease Surveillance System | Health Survey | CDC | NIDDK | The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) assists the Centers for Disease Control and Prevention (CDC) in its surveillance program of chronic kidney disease, including taking part in an Advisory Group to provide feedback on the program. |
| Circulating Estrogens, Androgens, and Progestogens and Risk of Breast Cancer in the PLCO Cohort | Research Initiative | CDC | NCI | In a stratified cohort study of breast cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO), restricted to postmenopausal women not on menopausal hormone therapy, we are using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay recently developed by CDC to assess prediagnostic circulating levels of the endogenous steroid hormones believed to be involved in breast cancer etiology. Although it is known that endogenous hormones play a critical role in the etiology of breast cancer, the interrelationships among estrogens, androgens, and progesterone in determining risk are not well understood. |
| CISA: Clinical Immunization Safety Assessment Network | Committee, Work group, Advisory group, or Task Force | CDC | NHLBI, NIAID | DAIT leadership and Allergy, Asthma and Airway Biology Branch personnel discussing with CDC findings from a recent CDC-funded study suggetive of an association between the amount of aluminum in infant vaccines and the incidence of asthma |
| ClinGen-FDA Recognized Human Variant Database | Resource Development | FDA | NCI, NEI, NHGRI, NICHD, NINDS | In April 2018, the FDA announced the initiation of a Public Human Genetic Variant Database program to support the agency’s precision medicine initiatives. A primary aim of the program is to foster innovation among test developers and advances in patient care through access to valid sources of accurate human variant interpretation data. Data and assertions within the database are considered to be valid scientific evidence that can be used to streamline the test development and validation processes. The NIH-funded Clinical Genome Resource (ClinGen) become the first FDA recognized database with a scope focused on germline variants in hereditary disease with a high likelihood the condition will manifest. ClinGen is currently working with the FDA to maintain this recognition. |
| Clinical and Translational Serology Task Force | Resource Development | ASPR, CDC, FDA | NCI, NIAID | The National Cancer Institute established a taskforce to catalyze translation of research findings into public health changes. The task force brings together government, academia and industry to provide relevant tools and information related to serology testing to help decisionmakers manage the current and future status of the SARS-CoV-2 pandemic. The task force includes scientists from several disciplines, clinicians, regulatory and public policy experts, and patient advocates. |
| Clinical Research Using Medicare Data from the Virtual Research Data Center (VRDC) | Research Initiative | CMS | NLM | The National Library of Medicine (NLM) and other Institutes and Centers at NIH work with the Centers for Medicare & Medicaid Services (CMS) to demonstrate the value of the CMS Virtual Research Data Center (VRDC) as a data source for research. NLM's health information standards and discovery research leverage the VRDC to answer important epidemiologic and clinical questions, particularly regarding drug benefits and possible harms. https://resdac.org/ |
| Clinical Trials Innovation Unit | Other | FDA | NCI | The NCI Clinical Trials Innovation Unit (CTIU) was launched in February 2023 to advance innovative science, trial designs, and operational efficiencies for high-priority clinical research needs. It includes experts from NCI, the Food and Drug Administration (FDA), and the extramural cancer clinical research community. |
| Clinical Trials of Biodefense Vaccines (Dengue) | Research Initiative | CDC | NIAID | Clinical Trials of Biodefense Vaccines (Dengue) |
| Clinical Trials Transformation Initiative | Committee, Work group, Advisory group, or Task Force | FDA | NIAID | Working group developing a pandemic preparedness clinical trial framework. |
| Clinical Vocabulary and Standards Development for Meaningful Use of Electronic Medical Records | Resource Development | OS, CDC, CMS, FDA, ONC | NLM | The National Library of Medicine (NLM) collaborates with the HHS Assistant Secretary for Technology Policy/Office of the National Coordinator for Health Information Technology (ASTP/ONC) to develop, maintain, and disseminate clinical terminologies and codes related to health information technology, electronic health records, and messaging. http://www.nlm.nih.gov/healthit.html |
| CMS Alliance to Modernize Healthcare Federally Funded Research & DevelopmentCenter (Health FFRDC) | Committee, Work group, Advisory group, or Task Force | CMS, ACF, AHRQ, ASA, ASFR, ASPE, ASPR, CDC, CMS, FDA, HRSA, IHS, OASH, OCIIO, OGA, OIG, ONC, OS, SAMHSA | CC, NCATS, NCI, NHLBI, NIA, NIAID, NLM | As a Federally Funded Research and Development Center (FFRDC), the Alliance To Modernize Healthcare a.k.a. "Health FFRDC" provides unique access to unbiased strategic insights, analyses, and best practices to accelerate and optimize business transformation. Formally established under Federal Acquisition Regulation (FAR) Part 35.017, FFRDCs meet special, long-term research and development needs integral to the mission of the sponsoring agency. FFRDCs operate in the public interest, free from conflicts of interest, and are managed and/or administered by not-for-profit organizations, universities, or industrial firms as separate operating units.More information at https://www.cms.gov/data-research/research/alliance-modernize-healthcar… |
| CMS Caregiver Workgroup | Committee, Work group, Advisory group, or Task Force | CMS, ACL, CDC, HRSA | NIA | Cross-section of organizations such as caregiver organizations, aging network organizations, federal agencies, disease specific organizations, employers and CMS. |
| CMS-Medicare Current Beneficiary Survey - Dietary Supplements, Measures of Malnutrition and Frailty | Health Survey | CMS | OD/DPCPSI/ODS | The National Institutes of Health's, Office of Dietary Supplements works with the Centers of Medicare and Medicaid Service to collect data on dietary supplement use, malnutrition and measures of frailty in the Medicare Current Beneficiary Study (MCBS). MCBS is a continuous, in-person, longitudinal survey of a representative national sample of the Medicare population. |
| CMS-NIH Emergency Department Subgroup | Committee, Work group, Advisory group, or Task Force | CMS | NIDA | With focused participation from both the Centers for Medicare and Medicaid Services (CMS) and experts across the National Institutes of Health (NIH), the CMS-NIH Emergency Department (ED) Subgroup is designed to accelerate collaboration between these two HHS Operating Divisions around issues involving SUD treatment initiation among people who present to the ED. |
| CMS-NIH Joint Leadership Council | Committee, Work group, Advisory group, or Task Force | CMS | NCCIH, NCI, NHLBI, NIA, NIDA, NIDDK, NIMHD, NINR, OD/DPCPSI, OD/IMOD, OD/OER, OD/OSP | Facilitates leadership-level development of mutual priorities between both Department of Health and Human Services (HHS) operating divisions. |
| CMS-NIH Joint Leadership Council Evidence Generation Working Group (EGWG) | Committee, Work group, Advisory group, or Task Force | CMS | NCI, NIA, NIDDK, NIMH | Organized in January 2018 for the purpose of developing a framework to enable the agencies to jointly address high-cost conditions; to consider the applicability of clinical trial results to Medicare, Medicaid, and Children’s Health Insurance Program beneficiaries; and to collaboratively identify evidentiary and policy issues of high mutual interest. |
| CMS-NIH Opioid Working Group Subgroup on Evidence for Nonpharmacological Treatments for Pain | Committee, Work group, Advisory group, or Task Force | CMS | NCATS, NCCIH, NIAMS, NIDA, NINDS, NINR | Discusses NIH/CMS partnerships in discussing nonpharmacological pain treatments and bridging research/policy gaps. |
| CMS-NIH Sickle Cell Disease Working Group | Committee, Work group, Advisory group, or Task Force | CMS | NHGRI, NHLBI | Working group that meets to explore what is required to implement CMS coverage for curative therapies in SCD. |
| Code Map Services for Interoperability of Common Data Models and Data Standards (CDMH III) | Resource Development | ASPE, FDA, ONC | NCATS, NCI | Code Map Services facilitate the use of open, consensus-based standards, consistent with HHS’s recognition of the need for greater interoperability of data and sharing of resources. The goal of this project is to facilitate Common Data Model (CDM) network interoperability, thereby expanding researchers’ access to clinical data that can be used for addressing new questions across a range of populations and settings. Specific objectives of the research include developing CDM interoperability services, improving quality and efficiency of model-to-model mappings, and extending the functionality of CDMs to allow submissions of clinical trials data. |
| Collaboration with the New York Lung Cancer Foundation | Committee, Work group, Advisory group, or Task Force | FDA | NCI | Dr. Peter Ujhazy has actively participated in the New York Lung Cancer Foundation Summit “Call to Action” on March 3-4, 2023 by co-chairing two sessions: 1. "Small cell lung cancer: Needs and future clinical trials" session, and 2. "What are we missing in lung cancer research?" session. The meeting lead to a white paper manuscript (see attached), which is now published. Peter Ujhazy contributed to the manuscript and is one of the co-authors. The paper addresses the most recent developments in lung cancer research and lists priorities and future opportunities in lung cancer clinical research. The manuscript is registered in the NIH MRS and Dr. Ujhazy's participation has been approved by DCTD leadership. The manuscript has the PMID39002176.In 2024 the same group met again in New York, NY on March 15-16. Dr. Ujhazy participated in the meeting too having similar responsibilities as in the 2023 meeting. While he contributed to the new white paper manuscript from this meeting, he is not listed as a co-author, rather than a contributor in the Acknowledgments because of the NCI restrictions on authorship. The paper was published in 2024 and has the PMID39413875. |
| Collaborative Community on Ophthalmic Imaging (CCOI) | Committee, Work group, Advisory group, or Task Force | FDA | NEI | CCOI held its fourth international meeting in January 2024 entitled “Expanding Datasets for Digitally Enhanced Management of Eye Diseases: Patient-Generated Data, Generative AI, 4D Imaging, and other Alternate Data Streams,” the meeting gathered experts from around the world and across academia, government institutions, patient groups, and the private sector to discuss the opportunities and challenges of utilizing various datasets in AI and ophthalmic imaging for the diagnosis and treatment of eye disease, with a special emphasis on issues of AI implementation in the real world. |
| Collaborative on Healthy Parenting in Primary Care | Public Education Campaign | CDC, HRSA, SAMHSA | The Collaborative on Healthy Parenting in Primary Care recognizes the accumulated evidence of the effectiveness of family-focused prevention programs that promote the physical and behavioral health and emotional well-being of children from before their birth through adolescence. Members of the Collaborative have united around an initiative to support the integration of effective programs that promote healthy parenting into primary care settings in order to achieve optimal health for children. | |
| Combating Antibiotic Resistant Bacteria (CARB) | Resource Development | CDC, FDA | NIAID, NLM | The National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB) is a multi-agency initiative to address urgent and serious drug-resistant threats that affect people in the U.S. and around the world. NLM contributes to several aspects of the plan to strengthen public health surveillance and data reporting while also advancing research to better understand environmental factors that contribute to antibiotic resistance. NLM's National Center for Biotechnology Information contributes to Sub-Objectives 2.1, 2.2, 2.4, 4.1, and 4.5 of the National Action Plan for Combating Antibiotic Resistant Bacteria https://obamawhitehouse.archives.gov/sites/default/files/docs/national_… |
| Commissioned Corps of the U.S. Public Health Service (USPHS) Oral Health Coordinating Committee (OHCC) | Committee, Work group, Advisory group, or Task Force | USPHS, ACF, ACL, AHRQ, ASPE, CDC, CMS, FDA, HRSA, OASH, SAMHSA | NIDCR | The United States Public Health Service (USPHS) Oral Health Coordinating Committee (OHCC), with representatives from HHS and other federal agencies, directs and coordinates a broad range of oral health policy, research, and programs within the USPHS, across federal agencies, and between the public and private sectors. The OHCC contributed to the HHS Oral Health Strategic Framework, 2014-2017 and the update is currently under publication review. |
| Community Preventive Services Task Force SDOH Coordination Team | Committee, Work group, Advisory group, or Task Force | CDC | NIMHD | The Community Preventive Services Task Force is conducting a systematic review on Paid Parental Leave |
| Comparison of Immunoassays Designed to Measure Immune Response to HPV Vaccination: The Serology Methods Study, Phase II (SMS-II) | Research Initiative | CDC | NCI | This work serves as an expansion to the original serology methods study (SMS I) that evaluated the validity and reproducibility of measures of the vaccine induced HPV16/18 antibody response by several HPV serologic assays. Now, with the investigation of single-dose regimens of the nonavalent HPV vaccine (9vHPV), it is necessary to expand this assessment to the additional seven genotypes included in the 9vHPV vaccine formulation. Further, as most of the assays evaluated in the first study were single-plex assays, performance characteristics for the HPV 16 and 18 antibody detection in multiplex assays testing of nine HPV types will be confirmed. The second phase of the methods work, the SMS II, continues to focus on single-dose HPV vaccine recipients as they have, on average, lower antibody levels compared to people who receive multi-dose regimens. |
| Complement Animal Research In Experimentation (Complement-ARIE) | Research Initiative | FDA, BARDA | NCATS, NCCIH, NCI, NEI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIMH, NINDS, NLM, OD/DPCPSI/ODSS, OD/DPCPSI/ORIP, OD/DPCPSI/ORWH, OD/DPCPSI/OSC, OD/OSP | The NIH Common Fund’s Complement Animal Research In Experimentation (Complement-ARIE) program will speed the development, standardization, validation, and use of human-based New Approach Methodologies (NAMs). NAMs are lab or computer-based research approaches intended to more accurately model human biology, and complement, or in some cases, replace traditional research models. The Complement-ARIE program will build upon ongoing efforts related to NAMs, while identifying opportunities for innovation and coordination. Complement-ARIE will significantly advance understanding of human health and disease by providing a range of ready and standardized biomedical research models. Developing these models will require expertise in disease research, personalized medicine, and in screening therapeutics for safety and effectiveness. |
| Computational Toxicology Analysis | Committee, Work group, Advisory group, or Task Force | FDA | NIDA | The Center for Drug Evaluation and Research at the Food and Drug Administration evaluates molecular structures for potential toxicities provided by NIDA using software platforms developed for this purpose. This interagency agreement stimulates the development of predictive software models that benefit drug discovery programs at both agencies. |
| Consumer Product Chemical Exposures in Pregnancy and Their Cumulative Impact on Disorders of Fetal Growth | Research Initiative | CDC | NIEHS | The purpose of this collaboration is to characterize exposure to organophosphate (OP) flame retardants and pesticides among pregnant women by measuring OP flame retardants and dialkyl phosphate metabolites (DAPs) in urine samples from 3 visits in pregnancy. We will examine associations between these markers and fetal growth as well as inflammation biomarkers. |
| Coordinated Sentinel Surveillance and Discovery Program for Emerging Human Pathogens | Committee, Work group, Advisory group, or Task Force | CDC | OD/DPCPSI/OSC | Ongoing detection and discovery (Khoj in Hindi) for surveillance of emerging and reemerging human pathogens are central to public health preparedness and outbreak detection and response at a regional, national, and international level. This surveillance is dependent on microbiological diagnoses from individual patients and, based on the type of infection, up to 60% of patients with serious infections may not have a pathogen identified even after extensive testing in the microbiology laboratory. There is no nationwide threat-agnostic surveillance system for emerging or reemerging human pathogens. Developing a coordinated sentinel surveillance system to apply advanced molecular methods (e.g., “shotgun metagenomics”) to clinical specimens from people with severe illness and who are negative by commercially available diagnostic assays would provide a foundation for systematic emerging pathogen discovery at an unprecedented scale, and significantly strengthen proactive preparedness and response capabilities. An interagency steering committee is in place to facilitate internal and external partnerships to conduct the project activities and establish a foundation of leadership and strategy for a national, coordinated sentinel surveillance system for emerging and reemerging human pathogens. Project activities that this steering committee will inform include: 1) developing the approach and scope of a targeted landscape analysis to identify existing activities and gaps in coordination; 2) establishing an information sharing mechanism to increase collaboration; 3) piloting receipt of specimens for external laboratories and analysis with shotgun metagenomic sequencing; and 4) examining the feasibility of accessing CDC resources to setup control panels. RTI International (RTI) will support advancing the Bio- Khoj project with CDC and the steering committee. |
| Coordinating Council on Access and Mobility | Committee, Work group, Advisory group, or Task Force | ACF, ACL, CDC, CMS, HRSA, IHS, OASH, SAMHSA | NIA | The Coordinating Council on Access and Mobility (CCAM) is a Federal interagency council that works to coordinate funding and provide expertise on human services transportation for three targeted populations: people with disabilities, older adults, and individuals of low income. |
| Coordination for Multi-Cancer Detection Tests | Committee, Work group, Advisory group, or Task Force | FDA | NCI | Coordination of development of multi-cancer detection (MDC) tests for clinical research use |
| Council of Federal Executive Secretariats | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC, CMS, FDA, HRSA, IHS, IOS, OIG | OD/IMOD/ES | Representatives from Executive Secretariats across government meet monthly for information exchange, knowledge sharing, and to receive updates from the White House Office of Presidential Correspondence Office. |
| Country Work in Cancer Research and Cancer Control Planning Strengthening: Kenya | Resource Development | CDC | FIC, NCI, NIAID | Kenya has an estimated population of approximately 53 million (World Bank). Cancer ranks third as a cause of death after infectious and cardiovascular diseases. It estimated that over 18,000 Kenyans die of cancer annually. The most common types of cancer in Kenya are cancers of the cervix, breast, esophagus, and prostate. The Ministry of Health released a National Cancer Control Strategy (2010-2015) and a National Cervical Cancer Prevention Program Strategic Plan (2012-2015). NCI looks to build upon those efforts in coordination with the many US government and non-governmental partners (NGOs) working in the country. US government agencies, including the National Cancer Institute (NCI), the National Institute of Allergy and Infectious Disease (NIAID), the Fogarty International Center (FIC), the Centers for Disease Control (CDC), and the US Agency for International Development (USAID) have significant presence in Kenya. Between FY2010 and FY2012, there were 121 NIH or CDC awards totaling $160.1M, and USAID invested $700 million in Kenya in FY2011. At least six NCI-designated cancer centers have activities in Kenya ranging from capacity building for cancer screening and treatment to studies of cancers associated with chronic infection, including HPV. Notably, Moi University has hosted the Academic Model Providing Access to Healthcare (AMPATH) partnership, along with Indiana University (IU), since 2001. The AMPATH-Moi-IU partnership has created the largest clinical research data enterprises in the developing world and includes 18 HIV clinics in western Kenya with 2,000 new patients enrolling per month as of 2012. |
| COVID antibody testing | Research Initiative | ASPR | NIAID | Testing of candidate therapeutic antibodies for neutralization against SARS-CoV-2 variants |
| Covid Serology Research and Results Tracker (SeroHub) | Resource Development | CDC | NCI, NIAID | The Covid-19 Serology Research Tracking System and Dasboard serves as a research resource to the NCI/NIAID/CDC and to the broader research community to monitor seroprevalence. Project is slated to end in August 2024. DCEG contact is Dr. Stephen Chanock. |
| COVID-19 and Influenza Scenario Modeling Hubs | Research Initiative | CDC | FIC | Collaboration between NIH, CDC and academia for disease projections. From weather to infectious diseases, it has been shown that synergizing results from multiple models gives more reliable projections than any one model alone. The COVID-19 Scenario Modeling Hub is a collaborative effort between multiple government agencies and academic institutions to harmonize COVID-19 projections in the United States and facilitate planning and decision making at a 3-12 month time scale. Since December 2020, the COVID19 scenario modeling hub has released 12 rounds of projections on issues as varied as the impact of the vaccination program, non-pharmaceutical interventions, waning immunity, and new variants on the trajectory of cases, hospitalizations and deaths across the US. The most recent set of projections addresses the impact of Omicron. In each round of projections, a set of 4 scenarios are identified to allow alignment of model projections for collective insights. Scenarios are designed in consultation with academic modeling teams, NIH and the CDC. Between 6 and 10 models have contributed to each round. All projections are made publicly available via the COVID-19 scenario modeling hub github and website. After each round, a report summarizing key results is shared with decision-makers and public health stakeholders. There has been substantial media coverage on this effort and results have been used by CDC/ACIP to guide COVID19 vaccine recommendations. The hub expanded in 2022 to generate influenza projections. This study builds on long-standing efforts led by the Fogarty International Center's in-house research division to develop computational approaches to mitigate pandemic risk and foster collaborative network in disease modeling. This effort extends a prior collaboration titled the Multinational Influenza Seasonal Mortality Study (MISMS) to assess the epidemiology, ecology, and evolutionary dynamics of influenza and other rapidly transmissible respiratory viruses. Multinational and bilateral collaborations developed through MISMS collect, analyze, and disseminate research findings through scientific publications, training workshops, and communication tools for investigators and decision-makers. These research findings inform numerous national governments, multilateral organizations, and research stakeholders on interventions for both pandemic and seasonal influenza. To date, data have been acquired from more than 40 countries (representing ~3.2 billion people), resulting in over 220 publications. |
| COVID-19 Scientific Interest Group | Committee, Work group, Advisory group, or Task Force | FDA | NCCIH, NCI, NEI, NHGRI, NHLBI, NIAID, NIAMS, NIEHS, NIMHD, NINDS | Scientific interest group discussing science, clinical, epidemiology, and social issues around SARS-CoV-2 and COVID-19. Includes members from FDA. Organizes seminars, workshops, websites, and originally cataloging research and reagents at NIH and FDA intramural programs. |
| COVID-19 Therapeutics Resistance Task Team (for SIG) | Committee, Work group, Advisory group, or Task Force | ASPR, CDC, FDA | NIAID | To share updates on the wide range of COVID therapeutics efforts that are progressing across the agencies, with a focus on emerging variants and possible drug resistance |
| COVID-RADx-UP Working Group | Committee, Work group, Advisory group, or Task Force | FDA | NCATS, NEI, NIBIB | The overarching goal of the RADx-UP initiative is to understand the factors associated with disparities in COVID-19 morbidity and mortality and to lay the foundation to reduce disparities for those underserved and vulnerable populations who are disproportionately affected by, have the highest infection rates of, and/or are most at risk for complications or poor outcomes from the COVID-19 pandemic. |
| CRIMM Biorepository PCT | Committee, Work group, Advisory group, or Task Force | BARDA | NIAID | The focus of the working group is to advise on the CRIMM Biorepository. |
| Critical Path for Rare Neurodegenerative Diseases | Research Initiative | FDA | NINDS | Critical Path for Rare Neurodegenerative Diseases is a public-private partnership aimed at advancing the understanding of neurodegenerative diseases and supporting the development and regulatory review of treatments for amyotrophic lateral sclerosis (ALS) and other rare neurodegenerative diseases. |
| Cross Federal Workgroup on Telehealth | Committee, Work group, Advisory group, or Task Force | HRSA, AHRQ, CDC, CMS, FDA, HRSA, IHS | NIDA | The goal of this work group is to develop a coordinated view of what the Federal government is undertaking in telehealth, in an effort to identify possible collaboration mechanisms and share lessons learned across multiple agencies. |
| Cross HHS Primary Care Research Workgroup Meeting | Committee, Work group, Advisory group, or Task Force | AHRQ, ACF, AHRQ, ASPR, CDC, CMS, HRSA, IHS, OS | NINR, OD/DPCPSI | Supporting collaboration/coordination of primary care research efforts across HHS |
| CTAC Ad hoc Strategic Planning Working Group | Committee, Work group, Advisory group, or Task Force | CMS, FDA | NCI | The CTAC SPWG was charged to re-assess NCI’s strategic vision for its clinical trials system for 2030 and beyond. The Working Group will review and address the capabilities of the clinical trials infrastructure necessary for achieving this vision as well as consider recommendations for relevant future CTAC activities. |
| CTAC ad hoc Working Group on Streamlining Clinical Trials | Committee, Work group, Advisory group, or Task Force | FDA | NCI | The CTAC Streamlining Clinical Trials Working Group will address the implementation of the CTAC Strategic Planning Working Group’s recommendations around streamlining NCI’s clinical trials. The Working Group will advise NCI on ways to limit data collection in clinical trials as well as optimize the utilization of Electronic Health Records (EHRs) to support clinical trials.*The working group released its interim report in FY2023. |
| CURE ID | Research Initiative | FDA | NCATS | CURE ID is a public repository that reports novel uses of existing drugs for difficult-to-treat diseases through a website, a smartphone or other mobile device. The platform enables the crowdsourcing of medical information from health care providers, patients and care partners to help facilitate the development of new treatments for diseases that lack approved therapies. CURE ID is a collaboration between the FDA and the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH). FDA and NIH are also collaborating with academic, medical societies and patient organizations to optimize the entry of information into CURE ID as well as provide the information on novel uses of existing drugs back to the public. |
| Cytokine Interest Group | Committee, Work group, Advisory group, or Task Force | FDA | NCI, NEI, NHGRI, NIA, NIAID, NIAMS, NIDCD | The Cytokine Interest Group brings together NIH and FDA scientists from many different areas working with cytokines as mediators of immune processes. It provides a platform for establishing networks for the exchange of ideas and reagents. Its activities comprise multiple minisymposia throughout the year and an award for the best paper in cytokine research for postdoctoral fellows working at the NIH or FDA. |
| DailyMed | Resource Development | FDA | NLM | DailyMed is an online database maintained by the National Library of Medicine (NLM) that provides high-quality information on marketed drugs, including FDA labeling information (package inserts). DailyMed provides health care providers, information professionals, researchers, and the public with a standard, comprehensive, up-to-date resource for accessing and downloading medication content and labeling as found in medication package inserts. http://www.dailymed.nlm.nih.gov |
| Data-Sharing Meeting | Committee, Work group, Advisory group, or Task Force | FDA | NIDA | Collaboration description: This meeting between NIDA, FDA, and DEA convenes three times per year to discuss emerging abuse-liability data relevant to the scheduling of psychoactive substances. NIDA DTMC’s Addiction Treatment Discovery Program often shares drug discrimination and locomotor activity data collected on these substances (presented by Carol Hubner). These data are used to inform scheduling decisions and are at times included in Eight Factor Analyses. |
| Department of Health and Human Services (DHHS) Medical Claims Review Panel | Committee, Work group, Advisory group, or Task Force | OS, AHRQ, CDC, CMS, FDA, HRSA, IHS, SAMHSA | CC | The Medical Claims Review Panel (MCRP) assists the Department of Health and Human Services (DHHS) in meeting its responsibility to provide quality health care in its facilities and by its practitioners. The MCRP reviews paid claims against DHHS facilities and providers to determine if the care provided met the standard of care and makes quality improvement recommendations to health care facilities and individual providers. The Panel meets monthly and includes two National Institutes Health (NIH) representatives; the current Chair of the Panel is an NIH physician. |
| DHHS Behavioral Health Coordinating Council Suicide Prevention Crisis Care 988 Workgroup | Committee, Work group, Advisory group, or Task Force | SAMHSA, ASPE, CDC, CMS | NIMH | This working group is developing and implementing strategies to achieve objectives associated with the 988 Suicide & Crisis Lifeline. |
| Diabetes Mellitus Interagency Coordinating Committee (DMICC) | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA | NEI, NHGRI, NHLBI, NIA, NIAID, NIDCR, NIDDK, NINR | Originally mandated by Public Law 93-354 and established in 1974, the Diabetes Mellitus Interagency Coordinating Committee (DMICC) is chaired by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and includes other members of the Department of Health and Human Services and other federal agencies that support diabetes-related activities. The DMICC facilitates cooperation, communication, and collaboration on diabetes among these government entities. DMICC meetings, held several times a year, help members identify emerging issues and opportunities and develop ways in which different government components can work together and build upon each other’s expertise and resources. This approach helps ensure that federal diabetes activities are coordinated and not duplicated, as well as stimulates collaborations where appropriate. |
| Diabetes Prevention Program Outcomes Study | Research Initiative | CDC | NCI, NEI, NHLBI, NIA, NIDDK | The Diabetes Prevention Program (DPP) showed that lifestyle change or the drug metformin delay the development of type 2 diabetes. The Diabetes Prevention Program Outcomes Study is studying the long-term effect of diet and exercise and the diabetes medication, metformin, on the delay of type 2 diabetes in participants of the DPP. |
| Diabetic Eye Disease Information Dissemination | Public Education Campaign | FDA, CDC | NEI | The Centers for Disease Control and Prevention (CDC's) National Diabetes Education Program is part of the National Eye Health Education Program Partnership. The National Eye Institute (NEI) continues to collaborate with CDC and other stakeholders to share information about diabetic eye disease with various communities. |
| Diet Induced Hypomethylation in Preneoplastic Liver | Research Initiative | FDA | NCI | The Food and Drug Administration (FDA)'s the National Center for Toxicological Research, and the National Cancer Institute (NCI)'s Division of Cancer Prevention, Nutritional Sciences Research Group are collaborating on an Interagency Agreement in which NCI will provide funds to examine the role of epigenetic mechanisms as factors that determine susceptibility to the development of hepatocellular carcinoma and to examine epigenetic alterations which may be used as markers of susceptibility to disease development, and whether correction of those epigenetic abnormalities during hepatocarcinogenesis may be a crucial decisive factor in cancer prevention strategies. 2022 publication update: Non-alcoholic fatty liver disease-associated DNA methylation and gene expression alterations in the livers of Collaborative Cross mice fed an obesogenic high-fat and high-sucrose diet.Tryndyak VP, Willett RA, Avigan MI, Sanyal AJ, Beland FA, Rusyn I, Pogribny IP. Epigenetics. 2022 Nov;17(11):1462-1476. doi: 10.1080/15592294.2022.2043590. Epub 2022 Mar 24.PMID: 35324388 |
| Dietary Guidelines for Americans Public Engagement and Communications Subcommittee (ICHNR) | Committee, Work group, Advisory group, or Task Force | IOS/ODPHP, FDA | OD/DPCPSI/ONR | The goal for this subcommittee of the Interagency Committee on Human Nutrition Research (ICHNR) is to identify ways to engage with the public regarding the Dietary Guidelines for Americans. The subcommittee will host public meetings in July 2024, collate that input in August 2024, and start drafting a report by September 2024. Recommendations will be included in a report, which will be provided to the USDA Under Secretary for Research, Education and Economics/Chief Scientist, and the HHS Assistant Secretary for Health. The report will also be released publicly around the end of December 2024. |
| Dietary Supplement Research Coordinating Committee | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NINR, NLM, OD/DPCPSI/OBSSR, OD/DPCPSI/ODS, OD/DPCPSI/ONR, OD/DPCPSI/ORWH | The National Institutes of Health's, Office of Dietary Supplement Dietary Supplement Research Coordinating Committee (DSRCC) was established in 2022 by the Office of Dietary Supplements (ODS) to increase collaboration among NIH Institutes, Centers, and Offices and federal agency partners whose programs include work that focuses on dietary supplements and the intersection of dietary supplement, natural product, and nutrition research. The DSRCC provides research coordination through the exchange of programmatic and scientific information, collaborative planning, and the implementation of relevant activities and initiatives. |
| Dietary Supplement Special Interest Databases | Resource Development | CDC, FDA | NCI, OD/DPCPSI/ODS | NIH ODS leads the development of publicly accessible database resources to expand knowledge of the composition of dietary supplements and to support research on dietary supplement use by different populations across the lifespan and investigations of their health effects. The Dietary Supplement Ingredient Database (DSID) and the Dietary Supplement Label Database (DSLD) contain information on the composition of many dietary supplements sold in the United States and, together with food composition databases, enable more accurate estimates the total daily intakes of nutrients and other bioactive substances from dietary intake. Databases of dietary supplement and food composition for certain specific nutrients, such as iodine, purines, and nitrates/nitrites, provide tools for epidemiologic research characterizing the nutrient status of diverse populations. |
| Digestive Diseases Interagency Coordinating Committee (DDICC) | Committee, Work group, Advisory group, or Task Force | CDC, CMS, FDA | NCI, NIBIB, NIDDK | The Digestive Diseases Interagency Coordinating Committee, chaired by NIDDK, is charged with facilitating cooperation and collaboration in research efforts in digestive diseases among NIH Institutes and other relevant Federal health agencies to provide a structure for coordinated efforts to combat digestive diseases. The Committee also prepares reports on the status of digestive disease research funding as well as needs for future research in specific areas of digestive diseases. The Committee meets to encourage exchange of information among member organizations and develop common initiatives. |
| Digital Health R&D (DHRD) Interagency Working Group | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, ONC | NCATS, NCI, NHLBI, NIA, NIBIB, NICHD, NIMH, OD/DPCPSI/OBSSR, OD/OSP | The Digital Health R&D (DHRD) Interagency Working Group was formed in 2010 as the Health Information Technology R&D IWG to coordinate Federal R&D for improving medical, functional, and public health outcomes across 15 participating agencies. Guided by the four fundamental challenges described in the Federal Health Information Technology Research & Development Strategic Framework, the IWG advances R&D by coordinating agency plans and activities, promoting collaborations, and providing a forum for exchanging information and articulating R&D needs to policy-makers and decision-makers.Digital health, as defined by the FDA, includes a wide range of R&D areas, such as mobile health (mHealth), wearable devices, telehealth, and personalized medicine, as well as computing platforms, connectivity, software, sensors to collect data, and AI/ML to analyze health-related data.Strategic PrioritiesAccelerate the R&D and implementation of next-generation health IT tools and services to reduce administrative burden, enable a new bio economy, and serve the full community of users.Leverage the power of data, computing, and AI to promote infrastructure and standards for accessible, interoperable, reusable health data, devices, and related applications.Develop privacy-preserving and secure methods, standards, testing, certification, and data transfer strategies to make systems and repositories more robust and accessible for research collaboration.Provide education and training opportunities to build the diverse, highly skilled, and interdisciplinary health IT workforce of the future. |
| Disaster Research Response Network (DR2) | Committee, Work group, Advisory group, or Task Force | CDC | FIC, NCI, NIA, NIAID, NIEHS, NINDS | The DR2 Program provides training, funding, and a Resources Portal of tools to empower human health research in response to disasters and public health emergencies. |
| DOD Congressionally Directed Medical Research Programs (CDMRP) Autism Research Programmatic Panel | Committee, Work group, Advisory group, or Task Force | CDC | NINDS | The CDMRP Autism Research Programmatic Panel aims to advance the understanding, diagnosis, and treatment of Autism through its award mechanisms, programs, and funding recommendations. |
| DRCR Retina Network | Research Initiative | OS | NEI, NIDDK | The DRCR Retina Network (formerly known as the Diabetic Retinopathy Clinical Research Network) (DRCR.net) is a collaborative network dedicated to facilitating multicenter clinical research of diabetic retinopathy, diabetic macular edema, and associated conditions. The DRCR.net supports the identification, design, and implementation of multicenter clinical research initiatives focused on diabetes-induced retinal disorders. Principal emphasis is placed on clinical trials, but epidemiologic outcomes and other research may be supported as well. The network is funded by the National Eye Institute (NEI), and co-funded by the Office of the Secretary (OS), through National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), with the Special Funding Program for Type 1 Diabetes Research. |
| Drug Development Interest Group | Committee, Work group, Advisory group, or Task Force | ASPR | NHLBI, NIAID | DDIG is a NIAID team that promotes knowledge sharing and discussions on drug development, technological platforms and models for the discovery and development of antiinfectives having different chemical structures and modalities (e.g. small molecule-, peptide-, natural product-based inhibitors, antibodies, targeted degradation, live microbes). The team aims to identify gaps and opportunities to advance translational and clinical research for treatment of bacterial, viral, fungal and parasitic infections, particularly those cause by antibiotic resistant pathogens and viruses of pandemic potential |
| Drug Induced Liver Injury Network | Resource Development | FDA | NCI, NIDDK | Both a prospective and retrospective database containing cases of drug-induced liver disease, the Drug-Induced Liver Injury Network (DILIN) is funded by a cooperative agreement and includes eight clinical centers and a central data coordinating center. Established by NIDDK, one of the goals of the DILIN is to establish a database of well-characterized cases of drug-induced liver injury along with serum, DNA, and tissue samples that will facilitate research on the mechanisms of hepatic injury due to drugs. Cases of liver injury due to herbal medications are also included. The DILIN will develop standardized definitions of drug-induced liver disease and standardization of scoring systems for causality. Employees of the Food and Drug Administration (FDA) serve as ad hoc members on the committee overseeing the network activities. |
| DURC/PEPP Policy Implementation Working Group | Health Survey | ASPR, CDC, FDA | OD/OSP | Interagecy Working Group to develop processes and guidance and oversee effective and consistent USG-wide implementation of the U.S. Government Policy for Oversight of Dual Use Research of Concern (DURC) and Pathogens with Enhanced Pandemic Potential (PEPP). |
| Early Hearing Detection and Intervention Working Group | Committee, Work group, Advisory group, or Task Force | HRSA, CDC | NIDCD | HRSA-led intra-agency collaborative focused on oversight and implemetation of the federal EHDI program |
| Ebola Clinical Research Response in Democratic Republic of the Congo | Research Initiative | ASPR, CDC | NIAID | Multi-lateral collaborative partnerships including, but not limited to National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), and host countries Ministries of Health. Research focus includes Ebola and other emerging and re-emerging infectious diseases. These programs are capable of rapidly mounting a clinical research response. |
| Ebola Research Agenda Working Group | Committee, Work group, Advisory group, or Task Force | ASPR, CDC, FDA | NIAID | Working group to establish a research agenda for Ebola virus. |
| ECHO Institute and Project ECHO for Cancer Research and Control | Other | CDC | NCI | The mission of Project ECHO (Extension for Community Healthcare Outcomes) at the University of New Mexico Health Sciences Center (UNMHSC) is to demonopolize knowledge and amplify the capacity to provide best practice care for underserved people all over the world. In pursuit of this mission, Project ECHO® faculty, staff and partners have dedicated themselves to de-monopolizing knowledge in order to expand access to best-practice medical care across the United States and globally. The ECHO model utilizes a technology-enabled case-based knowledge exchange approach. The NCI/CGH through partnership with the ECHO Institute utilizes the ECHO model to convene global cancer research and control networks to exchange knowledge to advance the uptake of evidence-based interventions to advance cancer control and build research partnerships. Project Extension for Community Healthcare Outcomes (ECHO) is a collaborative medical education model that aims to build workforce and knowledge capacity, through use of online videoconferencing to allow for knowledge exchange across interdisciplinary teams on relevant medical, healthcare, and health systems related topics. The National Cancer Institute (NCI) Center for Global Health (CGH) Project Echo Cancer Control Planning Program will link participants active in cancer control planning in low- and middle-income country settings with researchers, regional colleagues, and relevant technical experts, through monthly ECHO sessions that will provide virtual didactic instruction, case study learning, and knowledge exchange on relevant evidence-based cancer control planning principles. These sessions will relay evidence-based, general cancer control principals and related to cervical cancer screening. The CGH Project ECHO program’s primary goals are to increase participant knowledge of the aforementioned topics, improve the application of knowledge, including evidence-based practices and policies, and to increase collaboration among participants and experts who are active in cancer control planning in the participating countries. |
| Emergency Preparedness, Medical Countermeasures | Other | ASPR, CDC | NCI | NCI provides expertise in radiation biology, radiation oncology and disaster preparedness and response to ASPR for radiological and nuclear incidents. Collaboration Type: Subject matter expertise |
| Enabling Technologies for Photonic Chips-based Optical Coherence Tomography (PIC-OCT) | Research Initiative | ARPA-H | NEI | ARPA-H aims to produce OCT technology for eye screening that is more affordable and widely accessible. NEI representatives are serving as project oversight on this project. |
| End-Stage Renal Disease Collaboration | Committee, Work group, Advisory group, or Task Force | CMS, FDA | NIBIB, NIDDK | Participating agencies, including NIDDK, and patient and physician groups are collaborating to help the medical product development community to understand the challenges and milestones needed to achieve the goal of a successful alternative to dialysis. Research, regulatory, and reimbursement needs for such a product are discussed in phone calls and structured meetings. |
| Ending the HIV Epidemic in the U.S. (EHE) Principal Operational Leadership Team | Committee, Work group, Advisory group, or Task Force | OIDP, CDC, HRSA, IHS, SAMHSA | NIAID, NIMH, OD/DPCPSI/OAR | This committee meets regularly with senior leadership from different agencies for critical thinking and in-depth discussions on EHE progress, and opportunities to optimize coordination for effective EHE program outcomes. |
| Ending the HIV Epidemic in the US administrative supplement announcement for NIH Centers for AIDS Research and NIMH AIDS Research Centers | Research Initiative | CDC, HRSA | NIAID, NIMH, OD/DPCPSI/OAR | The NIH CFAR and NIMH ARC EHE administrative supplements support implementation research by addressing the four key pillars of the EHE initiative (Diagnose, Treat, Prevent, and Respond). Specifically, the NIH will support CFAR/ARC investigators to conduct research in collaboration with local partners funded by the participating HHS agencies to support local EHE plans. CDC and HRSA provided key support in the development of the research topics. |
| Endocrinologic and Metabolic Drugs Advisory Committee | Committee, Work group, Advisory group, or Task Force | FDA | NICHD | The Endocrinologic and Metabolic Drugs Advisory Committee (the Committee) advises the Commissioner or designee in discharging responsibilities as they relate to helping to ensure safe and effective drugs for human use and, as required, any other product for which the Food and Drug Administration (FDA) has regulatory responsibility. https://www.fda.gov/advisory-committees/endocrinologic-and-metabolic-dr… |
| Enhanced Federal Collaborations in Implementation Science and Research of HIV Prevention and Treatment | Other | CDC, HRSA | NIAID, NIMH | This paper describes federal collaborations that have supported this increased focus on implementation from the perspective of NIH, CDC, and HRSA, resulting in improved communication and coordination of efforts in the shaping and alignment of priorities in research and service delivery, increased implementation research conducted in real-world community and clinical settings. |
| Enhancing Public Access to the Results of Research Supported by the Department of Health and Human Services - A Workshop | Meeting/ Workshop | ACF, ACL, FDA | OD/OSP | Public workshop, sponsored by the National Institutes of Health (NIH), which provided a venue for invested parties to discuss steps that HHS agencies, including the NIH, Administration for Children and Families, Administration for Community Living, and the Food and Drug Administration, could consider to help ensure changes to public access policies promote equity in publication opportunities for investigators. |
| Enhancing Scientific Collaboration between US and Colombia | Committee, Work group, Advisory group, or Task Force | OGA | FIC, NIA, NIAID | The Office of the Americas of the HHS has formed a group consisting of representatives from NIAID, FIC, and NIA to foster communication with the goal of enhancing scientific collaboration between US and Colombia. |
| Environmental Microbiome Next-Generation Sequencing Community of Interest | Committee, Work group, Advisory group, or Task Force | ASPR, BARDA, CDC | NLM | The environmental microbiome next-generation sequencing (NGS) community of interest aims to share information on NGS, with a focus on environmental biodetection for biodefense and biosurveillance. It explores novel and evolving technologies that may provide breakthroughs relevant to environmental microbiome characterization, including sampling methods, processing techniques, sequencing platforms, data analysis, AI/ML utilization, decision-making support, and review of agent-agnostic sentinel surveillance environmental biodetection capabilities. |
| Environmental Phthalate Exposures In Pregnancy in Relation to Fetal and Placental Development | Research Initiative | CDC | NIEHS | The purpose of this collaboration is to characterize exposure to phthalates and phthalate alternatives in pregnant women by measuring phthalate and phthalate alternative metabolites in urine samples from 8 visits in pregnancy. We will examine associations between these markers and fetal growth as well as ultrasound measures of placental development. |
| eRA Federal Shared Services | Resource Development | ARPA-H, AHRQ, ASFR, FDA, SAMHSA | OD/OER | Grants Quality Service Management Office (Grants QSMO) Marketplace solution provider. Collaboration with other HHS agencies and federal agencies to provide electronic Research Administration (eRA) grants management services and support across the full grants life cycle. |
| Establishment of representative examination and dose repository for patients undergoing interventional fluoroscopic procedures | Research Initiative | FDA | NCI | NCI and FDA investigators are collaborating to establish representative examination and organ doses for fluoroscopically-guided interventional procedures by collecting anonymized patient data from multiple US clinical institutions. |
| Estrogen Metabolism Pathways in Pregnancy and Maternal Breast Cancer Risk: A Prospective Follow-up Study | Research Initiative | FDA | NCI | In the years following pregnancy, breast cancer risk is elevated, particularly for hormone receptor negative (HR-) tumors. Exposure to high maternal circulating estrogens, when the breast is vastly remodeling in structure and morphology, has been associated with risk, particularly for HR- tumors. Estrogen metabolite profiles in nonpregnant women, notably the ratio of 2:16 hydroxylation (OH) pathway metabolites, are associated with postmenopausal breast cancer development; whether estrogen metabolism during pregnancy influences subsequent HR- breast cancer risk is unknown. DCEG is collaborating with FDA on this project. |
| Evaluation of Oropharyngeal responses to SARS-CoV-2 | Research Initiative | FDA | NIAID | Evaluation of Oropharyngeal responses to SARS-CoV-2 |
| Evidence-based Cancer Control Programs | Resource Development | CDC | NCI | The Evidence-based Cancer Control Programs website is a searchable database of cancer control interventions and program materials and is designed to provide program planners and public health practitioners easy and immediate access to research-tested materials. |
| Executive Committee for Acquisitions | Committee, Work group, Advisory group, or Task Force | ASFR, CDC, FDA, HRSA | OD/OM, OD/OM/OALM | The Executive Committee for Acquisitions meets under the leadership of the HHS Senior Procurement Executive (SPE) and includes all the Heads of Contracting Activities from the various HHS Operating Divisions. The purpose is to receive policy updates and collaborate on acqusiition related issues. |
| Exploring T Cell functional dynamics following low-dose radiation exposure: insights into metabolic and other regulatory alterations using a multi-omics systems biology approach | Research Initiative | FDA | NCATS | Low-dose radiation studies studies are challenging because molecular responses can be modest at best, so choice of in vivo model systems is critical. The planned studies on T cells in mice and humanized mice are highly significant since we have already documented clear measurable responses in DOE’s preferred dose range. In the case of relevance to exposed populations, both shorter- and long-term immune effects impact human health, as documented in human population studies after LDR. As will be discussed, a critical component of immune responses is dependent on T cell subsets and metabolic programming is a central component for T cell activation and differentiation. Thus, this proposal will focus on T-cell perturbations after LDR with emphasis on elucidating signaling and metabolic pathways involved and robustly evaluating associations between responses at the different omic levels. To enable reuse and enhance utility of the comprehensive multi-omic datasets produced, we will provide public access to LDR-specific molecular responses from in our models and thus readily enable integration of our data with complementary data from other programs, such as the Low-dose Understanding, Cellular Insights, and Molecular Discoveries (LUCID) program. All data and code will be made publicly available to ensure reproducibility and reuse of the data by the broader radiation community. |
| FDA Center for Drug Evaluation (CDER)/NIDA Division of Therapeutics and Medical Consequences (DTMC) | Committee, Work group, Advisory group, or Task Force | FDA | NIDA | Collaboration between the FDA Center for Drug Evaluation (CDER)/NIDA Division of Therapeutics and Medical Consequences (DTMC). |
| FDA Device Workgroup | Committee, Work group, Advisory group, or Task Force | FDA | NIMH | This workgroup provides ongoing dialogue with the Food and Drug Administration (FDA) related to devices and mHealth. |
| FDA Dispute Resolution Panel | Committee, Work group, Advisory group, or Task Force | FDA | NIAID | This Committee provides expertise in the evaluation of evidence submitted by pharmaceutical companies to the Food and Drug Administration (FDA) for drug approval. |
| FDA Endocrinologic and Metabolic Drug Advisory Committee | Committee, Work group, Advisory group, or Task Force | FDA | NIAID | This Committee provides expertise in the evaluation of evidence submitted by pharmaceutical companies to the Food and Drug Administration (FDA) for drug approval. |
| FDA Medical Imaging Drugs Advisory Committee | Committee, Work group, Advisory group, or Task Force | FDA | CC, NCI | The Committee reviews and evaluates data concerning the safety and effectiveness of marketed and investigational human drug products for use in diagnostic and therapeutic procedures using radioactive pharmaceuticals and contrast media used in diagnostic radiology and makes appropriate recommendations to the Commissioner of Food and Drugs. https://www.fda.gov/advisory-committees/human-drug-advisory-committees/… |
| FDA Microbiology Devices Panel of the Medical Devices Advisory Committee | Committee, Work group, Advisory group, or Task Force | FDA | NIAID | This Committee provides expertise in the evaluation of evidence submitted by pharmaceutical companies to the Food and Drug Administration (FDA) for drug approval. |
| FDA Oncologic Advisory Committee | Committee, Work group, Advisory group, or Task Force | FDA | NIAID | This Committee provides expertise in the evaluation of evidence submitted by pharmaceutical companies to the Food and Drug Administration (FDA) for drug approval. |
| FDA Peripheral and Central Nervous System Advisory Committee | Committee, Work group, Advisory group, or Task Force | FDA | NIAID | This Committee provides expertise in the evaluation of evidence submitted by pharmaceutical companies to the Food and Drug Administration (FDA) for drug approval. |
| FDA-NCI Monthly Meeting | Meeting/ Workshop | FDA | NCI | These monthly meetings enhance communication between NCI DCTD/CTEP and FDA, thereby expediting the development of new anti-cancer agents. General topics discussed include patient safety, clinical efficacy, clinical and statistical trial design, and regulatory pathways to licensure, as well as an understanding of the operations of the sister agencies. Since NCI DCTD/CTEP acts as the official regulatory sponsor of IND studies performed in the ETCTN, and selected studies in the NCTN, PBTC, and PEP-CTN, these monthly meetings are important to ensure NCI DCTD/CTEP is performing its regulatory responsibilities in compliance with regulations and the dialogue with the FDA also helps in exploring new ways to enhance patient safety and clinical trial monitoring in a risk-based approach. New areas of discussion include the use of decentralized elements, streamlined data collection, and incorporation of real-world data components in IND studies to facilitate clinical trial conduct and ensure trial results are generalization to the patient population that suffer from the specific cancers under study in trials.The monthly meeting dates each year are discussed and scheduled in consultation with the FDA depending on the availability of appropriate FDA staff for the particular issue that will be discussed. NCI and FDA staff also have pre-meeting discussions to decide on topics that will be discussed at the monthly meetings to ensure new areas of research and design, as well as trial operational issues are incorporated into meeting agenda in a timely manner. |
| FDA-NIA collaboration on FDA's Medical Device Development Tool program | Research Initiative | FDA | NIA | The objective of this collaboration is to stimulate the participation of small businesses in the FDA's Medical Device Development Tools (MDDT) program. This collaboration led to developing a contract topic entitled DIGITIAL TECHNOLOGIES AS TOOLS TO DIAGNOSE AND MONITOR ALZHEIMER’S DISEASE (AD) AND RELATED DEMENTIAS (ADRD). This contract topic was recently approved in the May National Advisory Council on Aging meeting. The goal of this topic is to develop and demonstrate the utility of digital technologies as a measure of AD/ADRD screening and monitoring as qualified MDDTs to assess medical devices subject to regulation by FDA's Center for Devices and Radiological Health. |
| FDA-NIH Clinical Research Working Group | Committee, Work group, Advisory group, or Task Force | FDA | NCI, NLM | The use of clinical research terminology describing innovative designs and operational approaches has been inconsistent and ambiguous. Work Group activities include 1) analyzing current clinical design characteristics 2) defining a taxonomy of clinical research design characteristics 3) defining terms in acompanion glossary |
| FDA-NIH Interagency Clinical Outcome Assessments Working Group (ICOAWG) | Committee, Work group, Advisory group, or Task Force | FDA, FDA | NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAMS, NICHD, NIDA, NIDCD, NIDDK, NIEHS, NIMH, NIMHD, NINDS, NLM, OD/DPCPSI, OD/DPCPSI/OBSSR, OD/DPCPSI/ODP, OD/DPCPSI/SGMRO | The Interagency Clinical Outcome Assessments Working Group (ICOA WG) works to foster the development, evaluation, and qualification of Clinical Outcomes Assessments (COAs) for use in both medical product development and clinical research. Leveraging the unique strengths, knowledge, and resources at both the US Food and Drug Administration (FDA) and the National Institutes of Health (NIH), the objectives of the ICOA WG are: (1) To increase communication between the relevant groups at FDA and the many separate efforts at NIH to advance measurement science by exchanging information about specific COA projects of common interest, thereby improving the knowledge base for COA development; (2) To clarify and disseminate information about the regulatory processes for evaluation of medical product development tools; (3) To foster appropriate interagency scientific efforts to generate evidence toward the development and potential qualification of novel COAs; and (4) To leverage public and private efforts toward consensus and standards development in this area. The ICOA WG is composed of representatives and selected senior staff of each agency |
| FDA-NIH Joint Agency Nutrition Working Group (JAN) | Committee, Work group, Advisory group, or Task Force | FDA | NCI, NINR, OD/DPCPSI/ONR | The FDA-NIH Joint Agency on Nutrition (JAN) Working Group was formed in 2016 by the FDA-NIH Joint Leadership Council to facilitate high-quality nutrition research to improve public health outcomes across the lifespan in order to: 1) reduce the risk factors for and incidence of nutrition-related chronic disease; and 2) to inform nutrition-related regulatory decision-making and consumer outreach/education related to nutrition, including addressing gaps and opportunities in the areas of dietary supplements and nutrition research related to pregnant women and children. The JAN Working Group reports to the NIH-FDA Joint Leadership Council and is co-chaired by the Director of the NIDDK Office of Nutrition Research and the Director of the FDA‘s Center for Food Safety and Applied Nutrition). Members of the NIH Nutrition Research Task Force also participate in this Working Group. |
| FDA-NIH Joint Leadership Council | Committee, Work group, Advisory group, or Task Force | FDA | NCI, NEI, NHLBI, NIDA, NIMH, NINDS, NLM, OD/DPCPSI, OD/IMOD, OD/OER, OD/OSP | The FDA-NIH Joint Leadership Council (JLC) is a collaborative committee to identify and address clinical trial policy issues, programs, and research initiatives of mutual interest. |
| FDA-NIMH Points of Contact Working Group Meeting - Drugs | Committee, Work group, Advisory group, or Task Force | FDA | NIMH | Food and Drug Administration (FDA) and National Institute of Mental Health (NIMH) representatives meet quarterly to discuss issues of mutual interest related to the development and clinical trials of pharmacologic therapeutic interventions. |
| FDA/CDC-NIH Tobacco Update Call | Research Initiative | CDC | NIDA | Communicate on tobacco related initiatives. |
| Federal Administration for Strategic Preparedness and Response - Botulism Work Group | Committee, Work group, Advisory group, or Task Force | ASPR | NIAID | The objective of this Botulism Working Group is to develop the annual Medical Countermeasures Preparedness Review (MCMPR) – i.e., the annual SNS review, for the PHEMCE Division. The group drafts a modeling report produced by our modeling partners based on the work group’s chosen scenarios. This details casualty counts based on each scenario and impacts to the casualty count based on existing countermeasures held in the SNS (HBAT and ventilators). This will help inform the national quantitative requirement needs for the Botulism Requirement. |
| Federal Cervical Cancer Collaborative | Committee, Work group, Advisory group, or Task Force | HRSA, CDC, CMS, FDA, OASH | NCI, OD/DPCPSI/ORWH | The FCCC is a collaboration between HRSA, NCI, CDC, and NIH Office of Women's Health to improve access to cervical cancer services and accelerate uptake of new cervical screening and management recommendations and HPV vaccination. The FCCC is hosting roundtable discussions with several groups in 2022 and will develop toolkits, particularly to support safety-net settings of care. |
| Federal Committee on Statistical Methodology (FCSM) Sexual Orientation, Gender Identity, and Sex Characteristics (SOGI) Interest Group | Research Initiative | CDC, CMS, HRSA, IHS, SAMHSA | OD/DPCPSI/SGMRO | The Sexual Orientation, Gender Identity, and Sex Characteristics (SOGISC) Interest Group provides ongoing opportunities for federal employees interested in statistical methods or data quality related to measuring sexual orientation, gender identity, and sex characteristics (SOGISC) to interact, exchange information, and explore issues related to this topic. |
| Federal Committee on Statistical Methodology (FCSM) Sexual Orientation, Gender Identity, and Sex Characteristics (SOGISC) Subcommittee | Committee, Work group, Advisory group, or Task Force | CDC | OD/DPCPSI/SGMRO | The Sexual Orientation, Gender Identity, and Sex Characteristics (SOGISC) Subcommittee promotes coordination between federal agencies on issues relating to measuring sexual orientation and gender identity in federal data collections. The SOGISC Subcommittee advises the FCSM and the Interagency Council on Statistical Policy (ICSP) on SOGISC measurement issues, provides technical assistance as needed across Federal agencies on SOGISC measurement issues, and oversees meetings of the FCSM Sexual Orientation, Gender Identity, and Sex Characteristics (SOGISC) Interest Group. |
| Federal Data Consortium on Pregnancy and Birth to 24 Months (P/B-24) | Committee, Work group, Advisory group, or Task Force | OASH, CDC, FDA | NCI, NHLBI, NIAID, NICHD, NIEHS, NIGMS, NIMHD, OD/DPCPSI/ODS, OD/DPCPSI/ONR, OD/ECHO | The Federal Data Consortium on Pregnancy and Birth to 24 Months (P/B-24, Data Consortium) is a federal forum for sharing information and finding solutions to resolve crucial needs for data on pregnancy and early childhood populations to inform public health initiatives. The collaboration is open to any U.S. federal employee and currently spans 185 federal staff and leaders from 30 agencies in five Departments (HHS, USDA, USAID, EPA, and DoD). The Data Consortium is co-led by representatives of ODPHP, CDC, NIH, and FDA of HHS and ARS and FNS of USDA. The Data Consortium arose out of work by ODPHP/ OASH in 2016 to coordinate requests for “special studies” from CDC’s National Health and Nutrition Examination Survey (NHANES) to fill crucial needs for data on P/B24 populations to support future Dietary Guidelines for Americans (DGA) in providing science-based food-based recommendations to help promote health and prevent chronic disease. However, 4 APPENDIX — National Institutes of Health: 2020–2030 Strategic Plan for NIH Nutrition Research as the Data Consortium has demonstrated, the essentiality for these data goes beyond the needs of the DGA; over a dozen Federal agencies have funded projects coordinated by the Data Consortium and focused on filling critical gaps in scientific knowledge to support evidence-based programs, policies, and educational initiatives across the government and non-government sectors. The work of the Federal Data Consortium on P/B24, supported by NIH and other Agencies, has resulted in several current initiatives including, but not limited to: • New B-24 questionnaire content in the NHANES Diet and Behavior Questionnaire • A pilot study to determine the feasibility of collecting venous blood samples from children under 1 year of age in NHANES, currently only collected from ages 1 year and older. |
| Federal Dietary Reference Intakes Steering Committee | Committee, Work group, Advisory group, or Task Force | OASH, ACL, AHRQ, CDC, FDA, IOS/ODPHP | NHLBI, NIDDK, OD/DPCPSI/ONR | This Dietary Reference Intakes subcommittee reports to the Interagency Committee on Human Nutrition Research (ICHRN) to provide oversight on the process used to establish the Dietary Reference Intakes. These values serve as a basis for many federal nutrition programs and policies. |
| Federal Fleet Management (Vehicles) | Other | ASPR, CDC, FDA, IHS, PSC | OD/OM, OD/OM/OALM | Support and advise on agency-owned and leased fleet vehicle assets relating to services, customer support, logistics, acquisitions, data analysis, data analytics, contract drafting, documentation management to conduct business-related services and correspondences pertaining to fleet management services. |
| Federal Health Information Technology Coordinating Council | Committee, Work group, Advisory group, or Task Force | ONC, ACF, AHRQ, ASA, CDC, CMS, FDA, HRSA, IHS, OASH | NHGRI, NLM | The Assistant Secretary for Technology Policy/Office of the National Coordinator for Health Information Technology (ASTP/ONC) promotes improved federal coordination through the Federal Health IT Coordinating Council, a voluntary group of 25 agencies actively implementing the national health IT agenda. Among the topics addressed at coordination meetings include implementation of the 21st Century Cures Act, the MyHealthEData Initiative, Digital Health, HIPAA Audits, and HIPAA Access Rights. Priority collaborations between ASTP/ONC and the Centers for Medicare & Medicaid Services (CMS) have brought greater focus to interoperability in CMS policies and programs. |
| Federal HIV Implementation Science Workgroup | Committee, Work group, Advisory group, or Task Force | CDC, HRSA, SAMHSA | NIAID, NIDA, NIMH, NINR, OD/DPCPSI/OAR | Representatives from the Centers for Disease Control and Prevention (CDC, Division of HIV/AIDS Prevention), the Health Resources and Services Administration (HRSA, HIV/AIDS Bureau), and the National Institutes of Health (NIH) continued to convene a workgroup to focus on implementation science. The membership of the workgroup expanded to include the National Institutes of Health (NIH) Office of AIDS Research and the National Institute on Drug Abuse (NIDA), as well as the Substance Abuse and Mental Health Services Administration (SAMHSA). The overall goal of the workgroup is to increase collaborative efforts and decrease duplication of efforts related to the implementation of HIV prevention and treatment interventions. To achieve this goal, the workgroup agrees to pursue a number of broad actions, including: 1) clearly define implementation science for the purpose of the workgroup; 2) understand current implementation science activities and interests within each agency and in the HIV prevention field; 3) identify and define current implementation science successes and challenges within each agency; 4) identify shared priorities and individual priorities for each agency and how future activities could address identified challenges; 5) within the workgroup, share lessons learned and successful strategies for program implementation and how using implementation science might advance implementation efforts; 6) advance the broader dissemination and adoption of key result and evidence-based, evidence-informed, or novel implementation strategies to programmatic and research partners; 7) align technical assistance efforts to support programs to integrate evidence-based, evidence-informed, and novel implementation strategies; and 8) support the advancement of implementation science as a field. |
| Federal HIV/AIDS Web Council (FHAWC) | Committee, Work group, Advisory group, or Task Force | OIDP, AoA, ASPA, CDC, CMS, FDA, HRSA, IHS, OASH, OCR, OGA, OS, SAMHSA | NIAID, NIDA, OD/DPCPSI/OAR | The Council includes web, subject matter experts (content), and communications leads from over twenty programs, agencies and offices, representing HIV programs across the U.S. Government. Members plan and implement Federal new media efforts around HIV. In addition, the Council promotes coordination and collaboration to improve delivery of HIV/AIDS prevention, testing, and treatment messages and services via new media. The HIV.gov team convenes the Council's monthly conference calls and coordinates an annual in-person meeting. |
| Federal Indian Boarding School Healing Summit | Meeting/ Workshop | ACF, AHRQ, IHS, OASH, SAMHSA | NCATS, NCCIH, NCI, NHGRI, NHLBI, NIA, NIAAA, NIAMS, NIDA, NIGMS, NIMH, NIMHD, NINDS, NINR, OD/All of Us, OD/DPCPSI/OAR, OD/DPCPSI/OBSSR, OD/DPCPSI/ONR, OD/DPCPSI/THRO | The NIH Tribal Health Research Office (THRO) in collaboration with the National Native American Boarding School Healing Coalition and with assistance and participation from multiple NIH ICOs, and federal agencies, held the Federal Indian Boarding School Healing Summit on the main NIH campus from December 18-20, 2024. THRO conducted the summit to develop cross-cutting initiatives aimed to address the intergenerational harms perpetuated by the Indian Civilization Act and boarding school policies on American Indian, Alaska Native, and Native Hawaiian communities. This summit brought together boarding school survivors, community practitioners, and scientific leaders in intergenerational trauma research and intervention development with NIH leaders and representatives from 18 NIH institutes, centers, and offices, and federal agencies, including DOI, OASH, SAMHSA, IHS, VA, ACF and AHRQ. The goal was to identify gaps in knowledge and align priorities for developing initiatives within and across communities, NIH, and federal agencies to ensure a whole-of-government and community-informed approach in synchronizing responses to address boarding school and intergenerational trauma healing at individual, familial, community, and population levels. |
| Federal Interagency Forum for Child and Family Statistics | Other | ACF, AHRQ, ASPE, OASH, SAMHSA | NICHD, NIDA, NIMH | The Federal Interagency Forum on Child and Family Statistics (Forum) is a collection of 23 Federal government agencies involved in research and activities related to children and families. The Forum was founded in 1994 and formally established in April 1997 under Executive Order No. 13045. The mission of the Forum is to foster coordination and collaboration and to enhance and improve consistency in the collection and reporting of Federal data on children and families. The Forum also aims to improve the reporting and dissemination of information on the status of children and families. |
| Federal Interagency Forum on Aging Related Statistics | Committee, Work group, Advisory group, or Task Force | ACL, AHRQ, ASPE, CMS, SAMHSA | NIA | This Interagency Forum was formed with the goal of bringing together Federal agencies that share a common interest in improving aging-related data. The specific goals of the Forum are to improve both the quality and use of data on the aging population. |
| Federal Interagency Refugee and Migrant Mental Health Working Group | Committee, Work group, Advisory group, or Task Force | SAMHSA | NICHD | Ensuring that the behavioral health needs of refugees and unaccompanied children are integrated into key federal programs utilizing an approach that is developmentally appropriate, interdisciplinary, culturally informed, collaborative, equitable, trauma-informed and builds the capacity of federal programs and the national mental health workforce to address the behavioral health needs of these populations. |
| Federal Interagency Workgroup on Autism (FIWA) | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, ASPE, ASPR, CDC, CMS, FDA, HRSA, IHS, SAMHSA | NIA, NICHD, NIMH | The Federal Interagency Workgroup on Autism Spectrum Disorders (FIWA) is composed of representatives from departments and agencies across the U.S. Government, who voluntarily meet to coordinate research, services, and support activities related to autism spectrum disorder (ASD). The FIWA was first convened as an interagency workgroup to address requirements of the Autism Collaboration, Accountability, Research, Education, and Support (CARES) Act of 2014 (PL 113-157). The Autism Cares Act of 2014 required that the Secretary of Health and Human Services (HHS) designate a National Autism Coordinator to oversee national ASD research, service, and support activities, and prevent unnecessary duplication of effort, in consultation with the Secretaries of Defense and Education. The Autism Cares Act of 2014 also required that this coordination of activities take into account the Strategic Plan developed by the Interagency Autism Coordinating Committee (IACC), and requested a Report to Congress concerning young adults with ASD and the challenges related to the transition from existing school-based services to those services available during adulthood. |
| Federal Interagency Workgroup on Child Abuse and Neglect (FEDIAWG) | Committee, Work group, Advisory group, or Task Force | ACF | NIAAA, NICHD, NIMH | The Federal Interagency Workgroup on Child Abuse and Neglect meets to provide a forum through which staff from relevant federal agencies can communicate and exchange ideas concerning the prevention of child maltreatment and other related issues. |
| Federal Interagency Workgroup on Improving Diagnostic Safety and Quality in Healthcare | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, HRSA, IHS, OASH, ONC, SAMHSA | CC, NCATS, NCI, NIBIB, NLM | Federal Interagency Workgroup on Improving Diagnostic Safety and Quality in Healthcare was established in response to the Senate Report 115-150, which requested that AHRQ convene a cross-agency work group to address the lack of dedicated research into improving medical diagnosis and in particular, diagnostic failures that lead to patient harm. The Senate language was in response to the 2015 National Academies of Sciences, Engineering, and Medicine "Improving Diagnosis in Health Care." This report was a continuation of two previously published reports from the Institute of Medicine: To Err Is Human: Building a Safer Health System (2000) and Crossing the Quality Chasm: A New Health System for the 21st Century (2001). These reports bring attention to the specific problem of diagnostic errors and their effect on the quality and safety of healthcare. https://ahrq.gov/topics/diagnostic-safety-and-quality.html |
| Federal Interagency Workgroup on Intellectual Disabilities/Developmental Disabilities Administrative Data | Committee, Work group, Advisory group, or Task Force | ACL, AHRQ, ASPE, CDC, CMS, HRSA, SAMHSA | NICHD, NIMH | Launched in early 2020, the purpose of the FIW IAD is to establish greater coordination and collaboration of existing and newly developing federal activities related to ID/DD administrative data, terminology and definition concerns, data collection and related methodologies. We are committed to identifying and prioritizing opportunities to maximize the reach of federal efforts using IDD administrative data to understand and improve the lives of people with IDD. |
| Federal Interagency Working Group on Measuring Sexual Orientation and Gender Identity | Committee, Work group, Advisory group, or Task Force | ACF, ACL, CMS, SAMHSA | NICHD, OD/DPCPSI/SGMRO | This working group explores measurement of sexual orientation and gender identity (SOGI), considering multiple different dimensions of sex, gender, and sexuality. The Working Group examines variability in measurement by age, race, ethnicity, and cultural group. It prepares recommendations to the Office of Management and Budget (OMB) and other Federal agencies for the development, testing, and usage of SOGI measures to more accurately describe LGBT populations. |
| Federal Interagency Workshop: Nonhuman Primate Resources and Needs for Biomedical Research | Meeting/ Workshop | BARDA | OD/DPCPSI/ORIP | This Federal Interagency Workshop was hosted by the NIH-Wide Nonhuman Primate Resource Planning Working Group. The meeting was held March 22, 2022, in response to a recommendation of the Expert Panel forum, entitled; Challenges in Assessing Nonhuman Primate Needs and Resources for Biomedical Research, held August 23-24, 2018. A non-public Final Report of the 2022 Federal Interagency Workshop was also developed. |
| Federal Partners in Bullying Prevention | Committee, Work group, Advisory group, or Task Force | ACF, CDC, HRSA, IHS, SAMHSA | NIAAA, NICHD, NIMH | The mission of the Federal Partners in Bullying Prevention is to provide information from a broad array of government agencies on the identification and prevention of and ways to respond to bullying and cyberbullying, as well as individuals most at risk to experience it. https://www.stopbullying.gov/about-us |
| Federal Partners in Transition (FPT) | Committee, Work group, Advisory group, or Task Force | ACF, ACL, HRSA | NIMH | The Federal Partners in Transition (FPT) is a voluntary interdepartmental/interagency working group that consists of representatives from several federal agencies, including the Departments of Education, Health and Human Services, and Labor, as well as the Social Security Administration, which are involved in promoting inclusive service delivery for transitioning youth with disabilities from school into postsecondary education, the workforce, and independent living. |
| Federal Physical Activity Networking Group | Committee, Work group, Advisory group, or Task Force | CDC, HRSA, SAMHSA | NIA, NICHD | The networking group provides an example of coordinating with partners in other sectors to promote physical activity. |
| Federal Plan for Equitable Long-Term Recovery and Resilience | Committee, Work group, Advisory group, or Task Force | OASH, ATSDR, CDC, FDA, HRSA, SAMHSA | OD/DPCPSI/ODS | The Federal Plan for Equitable Long-Term Recovery and Resilience (Federal Plan for ELTRR) was developed by the ELTRR Interagency Workgroup with active, sustained, and consistent engagement. The interagency body was formed in early 2020 in response to a specific objective in the federal government’s joint COVID-19 response.Senior career professionals from over 35 federal departments and agencies collaborated to develop the Plan. The number of departments and agencies engaged in the workgroup continues to grow. |
| Federal Privacy Council (FPC) | Committee, Work group, Advisory group, or Task Force | ACF, ASPE | OD/OM, OD/OM/OMA | This committee supports Senior Agency Officials for Privacy in hiring, retaining, training, and developing an effective and efficient workforce of privacy professionals that enables agency mission success. |
| Federal Substance-Exposed Pregnancies Working Group | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, ASPE, CMS, FDA, HRSA, IHS, OASH, OS | NIDA | Keep up to date with federal efforts related to Neonatal Abstinence Syndrome (NAS) and Neonatal Opioid Withdrawal Syndrome (NOWS). |
| Federal Supply and Demand of Isotopes | Committee, Work group, Advisory group, or Task Force | FDA | NCI, NIBIB | A workshop on Isotope Federal Supply and Demand is held annually. The workgroup that organizes this workshop consists of representatives of federal agencies with the aim of providing a forum for interaction between agencies, departments, and medical societies to communicate about potential shortages of isotopes that are of strategic importance to the nation including the availability of medical isotopes. Also, a report of isotope supply and demand and whether needs are commercially available is compiled by the National Institutes of Health (NIH) and submitted to DOE annually. The report includes demand for NIH intramural research programs and NIH extramural projects (grantees). Not included in this report are NIH intramural research needs that are supplied by its cyclotron or isotope needs to be met by commercial suppliers. NIH collects data from ICs and submits annual reports as required. On January 12, 2021, DOE, NIH, and the members of the Isotope Needs Program held the 7th Workshop on Isotope Federal Supply and Demand. The meeting reviewed the Program’s ongoing activities and reported that the newly evolving use of electron- and alpha-emitting isotopes are seeing increased need (based on FDA’s approval for medical applications); the DOE is developing a plan to meet the current and foreseen increased use of these isotopes for cancer therapy. In support of these efforts, NIBIB conducted an August 16-17, 2021, workshop that focused on instrumentation development to directly image these new electron- and alpha-emitting isotopes for enhancing cancer therapy outcomes. |
| Federal Tobacco Cessation Workgroup | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, OASH, SAMHSA | NCI, NIDA, NIMHD | Monthly meeting of Federal staff who have a focus on and interest in tobacco cessation efforts. Discusses tobacco cessation strategies, opportunities for collaborations among HHS agencies, and the newest evidence around tobacco cessation research. |
| Federal Tuberculosis Task Force | Committee, Work group, Advisory group, or Task Force | CDC, AHRQ, CMS, FDA, HRSA, IHS, OS | NIAID, NICHD | The Federal Tuberculosis (TB) Task Force is a coalition composed of the federal agencies involved in U.S. TB research and control efforts. Established in 1991, it facilitates coordination of activities among these federal agencies. |
| Federal Web Archiving Interest Group | Committee, Work group, Advisory group, or Task Force | ASPA | NLM | The Federal Web Archiving Interest Group shares strategies, workflows, and best practices for collecting, preserving, and providing access to archived web content of interest to U.S. federal agencies. As needed, smaller working groups may form to advance joint projects. The main goal of this interest group is to serve as a forum for discussing current and future web archiving projects, fostering collaboration, and providing mutual support across the federal government, while also minimizing unnecessary duplication of efforts. https://siarchives.si.edu/about/partnerships/fedweb |
| Federal Working Group on Bone Diseases (FWGBD) | Committee, Work group, Advisory group, or Task Force | CDC, CMS, FDA | NIA, NIAMS, NICHD, NIDCR, NIDDK, OD/DPCPSI/ORWH | An interagency committee focusing on osteoporosis and other bone disorders. It offers a forum for sharing information, learning from each other and invited speakers, and facilitating the development, early in the planning stages, of collaborative research activities based on each agency's mission. |
| Federated learning across Health Information Exchanges (HIE) | Committee, Work group, Advisory group, or Task Force | ONC | NCI | In cooperation with the Nebraska Health Information Initiative (NEHII) and the National Cancer Institute (NCI), NIH launched a pilot program earlier this year that uses a machine learning concept known as federated learning that could leverage existing HIE data while ensuring privacy. Federated learning is a machine learning technique that shares an analytical model between different groups, allowing them to analyze their own data – and share those results – without needing to share the actual raw data.The pilot aimed to expand clinical insights regarding COVID-19 using the existing ways health data are stored and protected in the US. In our pilot, each organization connected to a central cloud ecosystem known as the Multi-state Federated Architecture for Shared Analytics, better known as MuFASA. |
| Federated Linked Data System Working Group | Committee, Work group, Advisory group, or Task Force | CDC, CMS, FDA, OS | NCI | Provide feedback and guidance for the legal and governance framework of a federated linked data system |
| Fellowship in Genomic Science and Health Equity | Training Initiative | FDA | NHGRI | The FDA's Office of Minority Health and Health Equity and the NHGRI jointly sponsor a fellowship program for masters and postdoctoral level scholars to provide training in genetic, genomic, and pharmacogenomic approaches to advance minority health and health equity. Working closely with mentors at both the FDA and NIH, this program helps fellows learn to bridge research, development and review processes, advance their knowledge of health disparities, and build awareness of regulatory sciences. |
| Filovirus Animal Non-Clinical Group (FANG) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NIAID | The Filovirus Animal Non-Clinical Group (FANG) focuses on the advanced development of Filovirus medical countermeasures (MCM), both vaccines and therapeutics. The FANG focuses on the product development tools and other interagency product development issues relevant to FDA approval of filovirus MCM. A standing interagency working group, the Portfolio Advisory Committee, oversees the FANG. The FANG will develop strategies to address broadly applicable and interagency product development issues relevant to licensure of filovirus MCM. The FANG will develop consensus recommendations to facilitate standardization of reagents, methods, and procedures across multiple agencies and laboratories. |
| Flow Cytometry Interest Group | Committee, Work group, Advisory group, or Task Force | FDA | NCI, NEI, NHLBI, NIAID, NIAMS, NIDCR | The NIH Flow Cytometry Interest Group, an NIH-affiliated scientific interest group supported by the NIH Office of the Director, provides central information for basic and clinical investigators doing flow and image cytometry at NIH. The group sponsors two meetings a year on the science and technology of cytometry, and is a central clearinghouse for cytometry resources at NIH. |
| FNIH Advanced Medicines Partnership® - Bespoke Gene Therapy Consortium (FNIH AMP BGTC) | Research Initiative | FDA | NCATS, NEI, NIAMS | The BGTC is a public–private partnership, where NIH is working with the Food and Drug Administration (FDA), industry and nonprofit partners with experience in designing, developing and manufacturing AAV-based gene therapies. It was formed to address the challenge of developing adeno-associated virus (AAV) gene therapies for rare monogenic diseases. The BGTC’s objectives are to streamline and accelerate clinical development, support first-in-human clinical trials for several rare diseases, and to increase knowledge about AAV transduction, production and gene expression through grants that support research. By reducing the cost and challenges for the development of AAV gene therapies, BGTC’s efforts may change what diseases are of commercial interest, with rare diseases becoming more mainstream for investment by the pharmaceutical industry and other stakeholders. The goal of the BGTC is to optimize and streamline the gene therapy development process to help fill the unmet medical needs of people with rare diseases, in particular those diseases that are too rare to be of commercial interest. The BGTC aims to advance the understanding of adeno‑associated virus (AAV) biology, improve and accelerate gene and vector manufacturing and production processes, standardize and streamline clinical and regulatory processes for gene therapies. |
| FNIH Biomarkers Consortium | Research Initiative | CMS, FDA | NCI, NHLBI, NIA, NIAMS, NIBIB, NICHD, NIDCD, NIDDK, NIEHS, NIMH, NINDS | The Biomarkers Consortium is a major public-private biomedical research partnership managed by the Foundation for the National Institutes of Health (FNIH) with broad participation from members of government, industry, patients and patient advocacy groups, and not-for-profit organizations. In addition to the FNIH, founding members include the National Institutes of Health (NIH), Food and Drug Administration (FDA), and the Pharmaceutical Research and Manufacturers of America. The Biomarkers Consortium brings together the expertise and resources of various partners to rapidly identify, develop, and qualify potential high-impact biomarkers to enable improvements in drug development, clinical care, and regulatory decision-making. |
| FNIH Biomarkers Consortium Neuroscience Steering Committee | Research Initiative | CMS, FDA | NIA, NIAAA, NIMH, NINDS | The Biomarkers Consortium is a major public-private biomedical research partnership managed by the Foundation for the National Institutes of Health (FNIH) with broad participation from members of government, industry, academia, patients and patient advocacy groups , and not-for-profit organizations. In addition to the FNIH, founding members include the National Institutes of Health (NIH), Food and Drug Administration (FDA), and the Pharmaceutical Research and Manufacturers of America. The Biomarkers Consortium brings together the expertise and resources of various partners to rapidly identify, develop, and qualify potential high-impact biomarkers to enable improvements in drug development, clinical care, and regulatory decision-making. The Neuroscience Steering Committee is responsible for identifying and moving forward promising pre-competitive biomarkers projects for implementation by the Biomarkers Consortium, as well as overseeing each individual project under its purview. The members of the Steering Committee represent a variety of sectors, including academia, government, industry and not-for-profit/advocacy organizations, and are led by two co-chairs representing two of the following three sectors: academia, government or industry. |
| FNIH Partnership for Accelerating Cancer Therapies (RFA-CA-22-038) | Committee, Work group, Advisory group, or Task Force | FDA | NCI | The Partnership for Accelerating Cancer Therapies (PACT) is a five-year public-private research collaboration totaling $215 million launched by the National Institutes of Health, the FNIH (Foundation for the NIH) and 11 leading pharmaceutical companies as part of the Cancer Moonshot. PACT is initially focused on efforts to identify, develop and validate robust biomarkers — standardized biological markers of disease and treatment response — to advance new immunotherapy treatments that harness the immune system to attack cancer. The partnership is managed by the FNIH, with the Food and Drug Administration serving in an advisory role. |
| Focus on Aging: Federal Partners Webinar Series | Meeting/ Workshop | ACL, AHRQ, ASPE, CDC, CMS, HRSA, IHS | NIA | The Focus on Aging: Federal Partners Webinar Sereies addresses important topics for public health and health care professionals, aging services organizations, the research community, and other stakeholders in aging. The series is a joint project of nine of the federal agencies that support the health and wellness of older adults in the U.S.: the Administration for Community Living, the Agency for Healthcare Research and Quality, the Office of the Assistant Secretary for Planning and Evaluation, the Centers for Disease Control and Prevention, the Centers for Medicare and Medicaid Services, the Health Resources and Services Administration, the Indian Health Service, the National Institute on Aging, and the Department of Veterans Affairs. In addition to general topics of interest for older adults and those who work with them, each webinar includes information specific to individuals living with Alzheimer’s disease and other types of dementia, as well as their caregivers. |
| Food is Medicine Federal Agencies Working Group | Committee, Work group, Advisory group, or Task Force | IOS/ODPHP, ACF, ACL, AHRQ, CDC, CMS, FDA, HRSA, IHS, IOS, OASH | OD/DPCPSI/ONR | The White House Conference on Hunger, Nutrition, and Health — held in September 2022 — renewed national attention and issued a call to action to end hunger and reduce the prevalence of chronic disease in the United States by 2030. Food is Medicine approaches that focus on integrating consistent access to diet- and nutrition- related resources are a critical component to achieve this goal. The approaches are increasingly present across many communities and systems. There’s also increasing federal investment and action to support Food is Medicine approaches in a variety of settings. Building on this collective energy, the Department of Health and Human Services (HHS) developed a Food is Medicine initiative in response to a congressionally funded initiative. This link is external to health.gov. in fiscal year 2023. This congressional action directed the Secretary of HHS, in consultation with other federal agencies, to develop and implement a federal strategy to reduce nutrition-related chronic diseases and food insecurity to improve health and racial equity in the United States. This includes diet-related research and programmatic efforts that will increase access to Food is Medicine initiatives. Access to nutritious food is critical to health and resilience. Food is Medicine is a concept that reaffirms this connection, recognizing that access to high-quality nourishment is essential for well-being. By supporting the production of and facilitating access to nutritious food across a health continuum and range of settings, approaches to Food is Medicine support immediate and long-term resources for people, communities, and systems. This HHS Office of Disease Prevention and Health Promotion (ODPHP)-led working group is focused on working collaboratively with federal partners and external organizations and communities to develop resources that can be used to advance Food is Medicine approaches across the country. |
| FoodData Central (FDC) Meeting | Committee, Work group, Advisory group, or Task Force | FDA, CDC, IHS | NCI, NEI, NHLBI, NIA, NIDCR, NIDDK, OD/DPCPSI/ODS | The National Food and Nutrient Analysis Program (NFNAP), now known as FoodData Central (FDC) Meeting, is a dynamic research program that aims to achieve long-sought improvements in the nutrient values for foods in the National Nutrient Databank System (NDBS) as well as support initiatives in development of dietary supplement databases. NFNAP is a collaboration between the US Department of Agriculture (USDA) and multiple groups including the Department of Health and Human Services (HHS) and other federal agencies. Analytical data generated through the NFNAP are compiled and released in annual updates of the USDA National Nutrient Database for Standard Reference (SR). They are also used to calculate estimates for related foods not analyzed, to assess nutrient variability, and to evaluate methods for estimating the nutrient content of multi-ingredient foods. |
| Foundations for Digital Twins programmatic working group | Committee, Work group, Advisory group, or Task Force | FDA | OD/DPCPSI/ODSS | Programmatic oversight and collaboration to support research on Foundations for Digital Twins as Catalyzers of Biomedical Technological Innovation (FDT-BioTech) https://new.nsf.gov/funding/opportunities/foundations-digital-twins-cat… |
| Framework for a Federated Linked Federal Data Ecosystem Work Group | Committee, Work group, Advisory group, or Task Force | CDC, CMS, FDA, IOS | NCI | This PCOR Trust Fund supported project seeks to develop a federated linked data system governance framework that will enable secure linkage of data across agencies and care settings and therefore improve researchers’ access to comprehensive and longitudinal patient-level data. Specifically, the framework will address data access/use governance, security/privacy controls, and a sustainable operating model for a federated linked data system to facilitate the linking of administrative and clinical data for cancer patients while preserving PII/PHI. An Executive Steering Committee has been established and is led by the HHS Office of the Chief Information Officer (OCIO) with representation from ARPA-H, NIH/NCI, CDC, FDA, CMS, Office of General Counsel (OGC), Assistant Secretary of Planning and Evaluation (ASPE), and HHS Immediate Office of the Secretary (IOS). Expected products include a landscape analysis, a final report, and an interactive dashboard for navigating project documents. |
| Full-text health-related documents at NLM (includes HSTAT) Bookshelf | Resource Development | AHRQ, ASPE, ATSDR, CDC, CMS, FDA, HRSA, IHS, ONC, OPHS, SAMHSA | NLM | NLM manages and maintains Bookshelf, a free web-based resource of full-text documents that provide evidence-based information related to health-care decision making. Content in Bookshelf is made available through NLM Literature Archive agreements and clauses in Interagency Public Access agreements to make the full text of various federal government grey literature—such as systematic reviews, clinical guidelines, assessments, and technical reports—publicly available. Bookshelf also manages the Health Services/Technology Assessment Texts (HSTAT) collection of health services research documents and serves as the point of contact for federal agencies to make their new and updated documents publicly accessible. https://www.ncbi.nlm.nih.gov/books/?term=(%22Agency+for+Health+Care+Pol… |
| Funding Opportunity Announcement Module (FOAM) | Resource Development | ACF, ACL, AHRQ, CDC, CMS, FDA | CIT, CSR, FIC, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/OER | The Funding Opportunity Announcement Module (FOAM) allows National Institutes of Health (NIH) Institutes and Centers and Department of Health and Human Services (HHS) Operating Divisions to develop content for and perform the needed approvals to publish funding opportunity announcements. The system has a flexible configuration to meet all of the needs for HHS Operating Divisions. In addition FOAM serves as a Federal Shared Service in collaboration with Grant Solutions supporting other agencies including Department of the Interior, Department of Housing and Urban Development, and Department of Homeland Security. FOAM achieves economies of scale by preventing the need for individual agencies to develop duplicate systems at a cost much greater than that of developing a unified system. |
| FY 22 Ending the HIV Epidemic in the US Funding Opportunity Announcement | Research Initiative | CDC, HRSA | NIAID, NIDA, NIMH | Three NIH EHE RFAs supports locally defined and culturally sensitive research projects that address the four key pillars of the EHE initiative (Diagnose, Treat, Prevent, and Respond). Specifically the NIH supports investigators in one of the 57 priority jurisdictions to work with implementing partners to develop and test locally defined and culturally sensitive solutions that align with jurisdictional EHE plans. CDC and HRSA provided key support in the development of the research topics. |
| Genetic Epidemiology of Diabetes and Obesity | Research Initiative | IHS | NIDDK | Genetic Epidemiology of Diabetes and Obesity |
| Genetic Epidemiology of Diabetic Complications | Research Initiative | IHS | NIDDK | Genetic Epidemiology of Diabetic Complications |
| Genetic Studies in the National Birth Defects Prevention Study (NBDPS) | Research Initiative | CDC | NHGRI | This study is a collaboration between The Centers for Disease Control and Prevention (CDC) and the National Human Genome Research Institute (NHGRI) to carry out DNA sequencing and genotyping on samples collected as part of the National Birth Defects Prevention Study. |
| Genital Herpes Workshop | Committee, Work group, Advisory group, or Task Force | CDC | NIAID | This workshop was co-sponsored by NIAID and CDC to review the status of research, product development, and education on genital herpes. |
| Genitourinary Cancers Steering Committee (GUSC) Clinical Trials Planning Meeting on ‘Defining the next generation of clinical trials with combination therapies in non-muscle invasive bladder cancer’ | Meeting/ Workshop | FDA | NCI | The purpose of this meeting was to accelerate further advances in clinical trials for patients with high-risk non-muscle invasive bladder cancer (NMIBC). The meeting focused on the evaluation of strategies incorporating intravesical therapy, systemic therapy, trimodal therapy (incorporating radiation therapy), and combination therapies toward a goal of improving bladder preservation rates and survival outcomes for patients with high risk including BCG-unresponsive NMIBC. |
| Genome in a Bottle Consortium | Resource Development | CDC, FDA | NCI, NHGRI, NLM | The Genome in a Bottle (GIAB) Consortium, hosted by the National Institute of Standards and Technology, is a public-private-academic consortium to develop the technical infrastructure (reference standards, reference methods, and reference data) to enable translation of whole human genome sequencing to clinical practice and innovations in technologies. The priority of GIAB is authoritative characterization of human genomes for use in benchmarking, including analytical validation and technology development, optimization, and demonstration. NLM/NCBI provides data portal (Data Coordination Center) and data management and contributes data analysis to GIAB. https://www.nist.gov/programs-projects/genome-bottle ; https://ftp.ncbi.nlm.nih.gov/ReferenceSamples/giab/ |
| Genomic and genetic determinants of the susceptibility to non alcoholic fatty liver disease (NAFLD) and NAFLD-related liver cancer | Research Initiative | FDA | NCI | The Food and Drug Administration (FDA)'s the National Center for Toxicological Research, and the National Cancer Institute (NCI)'s Division of Cancer Prevention, Nutritional Sciences Research Group are collaborating on an Interagency Agreement in which NCI will provide funds to examine the role of epigenetic mechanisms as factors that determine susceptibility to the development of hepatocellular carcinoma and to examine epigenetic alterations which may be used as markers of susceptibility to disease development, and whether correction of those epigenetic abnormalities during hepatocarcinogenesis may be a crucial decisive factor in cancer prevention strategies. |
| Genomic epidemiology of norovirus GII.4 globally | Research Initiative | FDA | FIC | Collaboration with Dr. Gabriel Parra's team at FDA. His group has compiled a global genomic dataset of thousands of norovirus GII.4 genomic sequences spanning 37 years of sampling. Dr. Nidia Trovao's team at the NIH/FIC will employ molecular epidemiology concepts and phylodynamic modeling to shed light on the viral evolutionary history and transmission dynamics. We will also gain insight into the viral diversity circulating across countries/regions, how the viral effective population size changes over time, and identify source-to-sink patterns in norovirus GII.4 spread. This will be important to inform control strategies and the development of therapeutics and vaccines. |
| Glaucoma Outcomes Survey Structured Data Capture | Resource Development | FDA | NEI | In a recent publication, A Health-Related Quality of Life Measure for Patients Who Undergo Minimally Invasive Glaucoma Surgery, the FDA and their collaborators developed a patient-reported outcome measure to assess the impact of glaucoma and treatment, including minimally invasive glaucoma surgery MIGS). The NEI Office of Data Science and Health Informatics is developing a Fast-Healthcare Interoperability Resources (FHIR), Structured Data Capture (SDC) representation of the quality-of-life survey instrument. This will ensure that the tool can be represented in standardized file formats that ensure scalability and fidelity across systems and that data collected using the instruments will be consistently collected. |
| Global Change Research Program | Committee, Work group, Advisory group, or Task Force | CDC | FIC, OD/DPCPSI/ONR | The U.S. Global Change Research Program (USGCRP) was established by Congress in 1990 to coordinate federal research and investments in understanding the forces shaping the global environment, both human and natural, and their impacts on society. USGCRP facilitates collaboration and cooperation across 15 federal member agencies to advance understanding of the changing Earth system. Research supported by USGCRP informs the Nation in navigating the challenges of a changing environment and identifying opportunities for a more resilient future. Together, USGCRP and its member agencies provide a gateway to authoritative science, tools, and resources to help people and organizations across the country manage risks and respond to changing environmental conditions. |
| Global Initiative for Cancer Registry Development | Committee, Work group, Advisory group, or Task Force | CDC | NCI | Cancer incidence and mortality are rising rapidly worldwide, particularly in low- and middle-income countries. There is overwhelming need for countries to adopt and implement cancer control actions, yet only one in five low- and middle-income countries have the necessary data to inform policy and research in order to reduce the cancer burden. Such data are necessary to measure progress toward achieving targets set for the global cancer initiatives. The Global Initiative for Cancer Registry Development (GICR) is a coordinated, multi-partner approach to deliver the required change. Its objective is to make cancer data count, particularly in lower resource settings, through providing training and technical support to countries in population-based cancer registration and research. GICR is needed to ensure data are available to estimate the global cancer burden as presented on the Global Cancer Observatory. |
| GlycoBiology Scientific Interest Group | Committee, Work group, Advisory group, or Task Force | FDA | NCI, NHGRI, NHLBI, NIAID, NIDCR, NIDDK | A core group of laboratories representing several institutes and the FDA, form the postdoctoral training laboratories of the Glycobiology SIG. Laboratory training is augmented with a “Special Topics in Glycobiology Course,” a seminar series and an annual NIH FDA Glycosciences Research Day held each spring that highlights work being done locally in the glycosciences. A Steering Committee composed of both intra and extramural NIH, FDA, NIST and DOE scientists organize the SIGs activities. |
| Government-University-Industry Research Roundtable | Committee, Work group, Advisory group, or Task Force | FDA | NCATS | The National Academies of Sciences, Engineering, and Medicine Government-University-Industry Research Roundtable is charged with improving the research enterprise of the United States by successfully resolving the cross-sectoral issues that prevent the U.S. research enterprise from reaching its full potential. This mission is achieved by convening senior-most representatives from government, universities, and industry to frame the critical issues, followed – when appropriate – by the execution of activities designed to address specific cross-sectoral impediments to achieving a healthy, vibrant research enterprise. GUIRR provides a unique forum for dialogue among top government, university and industry leaders of the national science and technology enterprise. |
| GSRS | Research Initiative | FDA | NCATS, OD/OIR | GGSRS is a public software and web application that supports the registration and documentation of substances found in medicinal products. Importantly, the definition of substances is based on a global and consistent definition (ISO 11238 standard). The software has been heavily utilized at the FDA since 2016, and has also been adopted by other regulatory agencies and pharma around the world, such as EMA (European Medicines Agency), BfArM (Federal Institute for Drugs and Medical Devices), WHO-UMC, Glaxo-Smith Kline and the United States Pharmacopeia. NCATS provides access to a public instance of the software, publicly available data on substance definitions and properties as provided by the FDA, and also provides detailed documentation on how to install and use the system. Together, these public resources are widely used by the broader translational research community. |
| H-CORE Immune Assay CoP Team | Committee, Work group, Advisory group, or Task Force | ASPR, BARDA | NIAID | A continuation of the OWS SARS-CoV-2 Immune Assays Subteam_Assay Working Group but with a more narrow focus on immune correlates of protection. |
| HDPulse Dissemination and Adaptation Working Group | Resource Development | OASH | NIMHD | This working group was established to promote the dissemination of the NIMHD HDPulse interventions portal and its adaptation to include the HHS Office of Minority Health’s (OMH) evidence-informed practices. Building on OMH’s efforts to disseminate and spread evidence-informed practices and NIMHD’s development and maintenance of HDPulse, this working group is expected to achieve the following outcomes:Identification and dissemination of health equity-promoting evidence-informed practices, particularly those focused on addressing racial and ethnic health disparities, through HDPulseIncreased awareness and utilization of HDPulse, including health equity-promoting interventions in the Interventions Portal, by government agencies, organizations, and practitioners serving racial and ethnic minority populations. |
| Health and Housing Group | Committee, Work group, Advisory group, or Task Force | CDC | NCI, NHLBI, NIA, NICHD, NIDDK, NIEHS, NIMH, NINR, OD/DPCPSI/IMOD, OD/DPCPSI/OBSSR, OD/DPCPSI/ODP | The Health and Housing Group is made up of representatives from across the NIH, the U.S. Department of Housing and Urban Development, and the Centers for Disease Control and Prevention. Members share their agencies’ work at the intersection of health and housing, interests in health and housing research, and data and resources. The group also works together to identify health and housing research gaps, and explores opportunities to collaborate to advance health and housing research. The Health and Housing Group is open to federal staff only. |
| Health and Retirement Study | Health Survey | CDC, CMS | NIA | This study follows more than 20,000 men and women over 50, offering insight into the changing lives of the older US population. Launched in 1992, this multidisciplinary, longitudinal study has become known as the Nation’s leading resource for data on the combined health and economic conditions of older Americans. SSA co-funds the HRS via a JFCA with NIA and participates in a monitoring committee managed by NIA. |
| Health Information National Trends Survey (HINTS) | Health Survey | ONC | NCI | NCI's Health Information National Trends Survey (HINTS) was first fielded in 2003 with the goal of detecting changes and trends in communication and technology, identifying and tracking health information support needs in the population, documenting disparities and communication inequalities, and identifying opportunities for applied communication interventions. HINTS has partnered with the HHS Office of the National Coordinator for Health Information Technology (ONC), now called the Assistant Secretary for Technology Policy (ASTP), since 2017 to field items related to implementation of the Affordable Care Act and the widespread adoption of electronic health records. This co-funding partnership continued in FY24 and is biennial in nature, to coincide with the survey's biennial fielding. Over the years, other federal agencies and offices have been engaged with the HINTS program in various capacities (as co-funders, item champions, data users, etc.). Past partners have included the Food and Drug Administration (FDA), the Federal Communications Commission (FCC), the Centers for Disease Control and Prevention (CDC), and the Office of Disease Prevention and Health Promotion (ODPHP)—which uses HINTS to track national progress toward six Healthy People 2030 targets related to health communication and health information technology objectives. |
| Health Information Technology Advisory Committee (HITAC) | Committee, Work group, Advisory group, or Task Force | ONC | NEI, NIAID, NIAMS, NIEHS, NIGMS, NINDS | The Health Information Technology Advisory Committee (HITAC) was established by the 21st Century Cures Act (P.L. 114-255) and is governed by the provisions of the Federal Advisory Committee Act (FACA), P.L. 92-463, as amended, 5 U.S.C. App. 2, which sets forth standards for the formation and use of federal advisory committees. The HITAC will recommend to the National Coordinator for Health Information Technology policies, standards, implementation specifications, and certification criteria relating to the implementation of a health information technology infrastructure, nationally and locally, that advances the electronic access, exchange, and use of health information. HITAC unifies the roles of, and replaces, the Health Information Technology Policy Committee and the Health Information Technology Standards Committee that were in existence before the date of the enactment of the 21st Century Cures Act. HITAC replaced the Content Standards Workgroup of the Health Information Technology (HIT) Standards Committee, which was part of the Federal Advisory Committee that was charged with making recommendations to ONC on standards, implementation specifications, and certification criteria for the electronic exchange and use of health information. |
| Health Promotion Activity to Recognize National Minority Health Month | Other | OASH | NIMHD | NIMHD collaborates with the HHS Office of Minority Health each year to develop and promote activities for National Minority Health Month. CAPT Tarsha Cavanaugh, Ph.D., Principal Director, Office of Minority Health provided the April 2024 keynote address. |
| Healthcare Infection Control Practices Advisory Committee (HICPAC) | Committee, Work group, Advisory group, or Task Force | CDC, AHRQ, CMS, FDA, HRSA, IHS | CC | This committee serves as the major policy advisory committee in the nation for healthcare epidemiology. https://www.cdc.gov/hicpac/php/about/index.html |
| Healthy Hearts Network | Meeting/ Workshop | CDC, FDA, IHS, IOS/ODPHP, OASH | NHLBI, NIA | Community of federal employees who share resources and updates on heart health-related content. |
| Healthy People 2030 Federal Interagency Working Group | Committee, Work group, Advisory group, or Task Force | OASH, CDC, HRSA, IHS | NCI, NEI, NHLBI, NIAAA, NICHD, NIDA, NIDCR, NIMH, NIMHD, NINDS, OD/DPCPSI/OBSSR, OD/ECHO | The Federal Interagency Workgroup (FIW) leads the development and implementation of the Healthy People initiative along with individual workgroups of federal subject matter experts representing more than 20 federal agencies. It also helps review data and resources associated with the objectives and provides ongoing science-based and expert consultation to the Assistant Secretary for Health throughout the decade. |
| Healthy People 2030 LGBT Health Workgroup | Committee, Work group, Advisory group, or Task Force | HRSA, ACF, CDC, FDA, OASH | OD/DPCPSI/SGMRO | This working group was originally established for the Healthy People (HP) 2020 LGBT Health topic area and continued on for HP2030. This group provides support and recommendations to the Healthy People program regarding objectives, data collection, and Healthy People webinars and other products. |
| Healthy People 2030 Nutrition and Weight Status Working Group | Committee, Work group, Advisory group, or Task Force | OASH, CDC, FDA, IOS/ODPHP | NIDDK, OD/DPCPSI/ONR | The Nutrition and Weight Status group develops goals based on strong science supporting the health benefits of eating a healthful diet and maintaining a healthy body weight. The objectives also emphasize that efforts to change diet and weight should address individual behaviors, as well as the policies and environments that support these behaviors in settings such as schools, worksites, health care organizations, and communities. |
| Healthy People 2030 Oral Health Workgroup | Committee, Work group, Advisory group, or Task Force | OASH, CDC, HRSA, IHS | NIDCR | The Healthy People 2030 Oral Health Workgroup develops objectives related to oral health and tracks progress toward achieving these objectives throughout the decade. Members of the workgroup have expertise in areas including oral health surveillance, evidence-based dentistry, access to health care services, workforce development, and health education. |
| Healthy People 2030, Chronic Kidney Disease Workgroup | Committee, Work group, Advisory group, or Task Force | OS | NIDDK | The Office of the Secretary of Department of Health and Human Services (HHS) leads the Healthy People 2030 initiative. The lead agency for most data activities is the Centers for Disease Control and Prevention (CDC). However, for the kidney area, most of the information is provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) through the US Renal Data System. |
| Healthy People 2030, Chronic Pain Working Group | Committee, Work group, Advisory group, or Task Force | OASH | NINDS | The goal of the Healthy People 2030 Chronic Pain Workgroup is to reduce the prevalence and impact of high-impact chronic pain and improve pain self-management.https://health.gov/healthypeople/about/workgroups/chronic-pain-workgroup |
| Healthy People 2030, Dementia Including Alzheimer's Disease Workgroup | Committee, Work group, Advisory group, or Task Force | OASH, ACL, CDC, IOS/ODPHP | NIA | Healthy People 2030 sets data-driven national objectives to improve Americans' health and well-being over the next decade. The Dementia Including Alzheimer's Disease Workgroup develops and tracks progress on Healthy People objectives related to the health and quality of life of people living with Alzheimer's disease and other dementias, as well as their caregivers. |
| Healthy People 2030, Disability and Health Work Group | Committee, Work group, Advisory group, or Task Force | ACL, CDC | NICHD | Healthy People is a national effort that sets goals and objectives to improve the health and well-being of people in the United States. Every decade, the Healthy People initiative develops a new set of science-based, 10-year national objectives with the goal of improving the health of all Americans. Healthy People 2030 is the fifth edition of Healthy People. It aims at new challenges and builds on lessons learned from its first 4 decades. The development of Healthy People 2030 includes establishing a framework for the initiative—the vision, mission, foundational principles, plan of action, and overarching goals—and identifying new objectives. The development of Healthy People 2030 is a multiyear process with input from a diverse group of subject matter experts, organizations, and members of the public. The framework explains the central ideas and function of the Healthy People 2030 initiative and it will guide the selection and prioritization of 2030 objectives. https://www.healthypeople.gov/2020/About-Healthy-People/Development-Hea… |
| Healthy People 2030, Health Communication/Health Information Technology Working Group | Committee, Work group, Advisory group, or Task Force | OASH | NCI | This committee decides on Healthy People 2030 objectives in the area of health communication and health information technology, including the relevant objective, how to measure progress and the data source. |
| Healthy People 2030, Heart Disease and Stroke Federal Working Group | Committee, Work group, Advisory group, or Task Force | OASH | NHLBI, NINDS | The Healthy People Initiative sets science-based, national objectives with 10-year targets to improve the health of the nation. The HP2030 Heart Disease and Stroke Federal Work Group is responsible for creation, refinement, and tracking of HP2030 goals related to heart disease and stroke related prevention and health promotion.https://health.gov/healthypeople/about/workgroups/heart-disease-and-str… |
| Healthy People 2030, Older Adults Workgroup | Committee, Work group, Advisory group, or Task Force | OASH, ACL, CDC, IOS/ODPHP | NIA | Healthy People 2030 sets data-driven national objectives to improve Americans' health and well-being over the next decade. The Older Adults Workgroup develops and tracks progress on Healthy People objectives related to older adults' health, functioning, and quality of life. |
| Healthy People 2030, Social Determinants Working Group | Committee, Work group, Advisory group, or Task Force | OASH | NCI, NIA, NIAAA, NIMHD, NINR | Within the Federal Government, the Federal Interagency Workgroup (FIW) led the Healthy People 2030 development effort. FIW members include representatives from U.S. Department of Health and Human Services agencies and offices as well as other federal departments. The overarching goals for Healthy People 2030 incorporate a focus on social determinants of health as well as on health outcomes and risk factors. The Working Group intends to develop objectives for the social determinants and methods to ensure their integration across all Healthy People 2030 objectives. |
| Healthy People 2030, Substance Use Workgroup | Committee, Work group, Advisory group, or Task Force | OS | NIAAA | Healthy People 2030 has added several objectives, including developmental objectives, designed to monitor trends in opioid use, overdose deaths, and opioid use disorder treatment. Core objectives selected by the Substance Use Workgroup aim to improve public understanding of the risks of substance use, improve access to treatment for substance use disorders, and expand the use of evidence-based practices for the prevention and treatment of substance use disorders. Wherever possible, objectives track disparities among racial/ethnic groups. |
| Healthy People 2030, Substance Use Working Group | Committee, Work group, Advisory group, or Task Force | IOS/ODPHP, CDC, SAMHSA | NIDA | Members of the Substance Use (SU) Workgroup have expertise in areas including biostatistics, epidemiology, addiction neuroscience, substance use prevention and treatment, alcohol and drug policy, and health disparities. They developed the objectives related to substance use and substance use disorders, and they’ll provide data to track progress toward achieving these objectives throughout the decade. |
| Healthy People Initiative: Vision Health | Health Survey | CDC, AHRQ | NEI | Healthy People Initiative is a collaboration with the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Agency for Healthcare Research and Quality (AHRQ) to survey and measure public health outcomes for a variety of common diseases over the current decade. The National Eye Institute's (NEI) goal for this program is to Improve the visual health of the Nation through prevention, early detection, timely treatment, and rehabilitation. |
| Healthy Vision Month | Public Education Campaign | CDC | NEI | Each May the National Eye Institute (NEI) sponsors Healthy Vision Month (HVM), which is a national observance designed to elevate eye health as a priority for Americans. The National Institutes of Health (NIH) has worked with the Centers for Disease Control and Prevention (CDC) and recently with the Office of the Surgeon General to spotlight on the connection between eye health and overall health. |
| Heart Valve Collaboratory | Committee, Work group, Advisory group, or Task Force | FDA | NHLBI | Promote scientific meetings, workshops, and education on the heart valves. |
| Helicobacter pylori Genome Project | Research Initiative | CDC | NCI, NLM | Investigators in the Infections and Immunoepidemiology Branch and the Metabolic Epidemiology Branch of DCEG are undertaking a joint effort to catalog comprehensively bacterial genetic and epigenetic variation potentially related to long-term outcomes of infection. Isolates from patients with gastric cancer or advanced premalignant lesions are compared to controls with benign infection (superficial gastritis) from the same geographic area. The study goal is to sequence 1000 strains representing both high and low gastric cancer risk populations worldwide, with over 300 isolates from 16 different countries completed to date. An international team of experts is collaborating on analyses of these complex data to identify associations with the gastric carcinogenesis cascade. |
| Hematopoietic Stem Cell Transplantation (HSCT) Workgroup | Committee, Work group, Advisory group, or Task Force | HRSA, CDC, FDA | CC, NCI, NHLBI, NIAID | Interagency workgroup to discuss hematopoietic cell therapy advances and challenges across the federal workspace. Chair: Shelley Grant, Supervisory Public Health Analyst, HRSA’s Division of Transplantation. Background: The HSCT Workgroup is comprised of various government agencies and was created to share and collaborate on matters pertaining to hematopoietic blood stem cell transplantation and donation. The HSCT WG is chaired by HRSA and meets twice per year. The workgroup includes representatives: from Centers for Disease Control and Prevention, Centers for Medicare and Medicaid Services, Food and Drug Administration, National Institutes of Health, Office of Assistant Secretary for Health, Office of Assistance Secretary for Preparedness and Response, the U.S. Department of Defense – Navy, and the Department of Veterans Affairs. |
| Hemp cigarette product testing | Research Initiative | CDC | NCI | In collaboration with CDC, NCI is conducting product testing of hemp cigarettes in order to determine the potential carcinogenicity of hemp smoke. |
| Hepatitis B Research Network | Research Initiative | CDC | NCI, NIDDK | The Hepatitis B Research Network (HBRN), supported by NIDDK, was established in 2008 to advance understanding of disease processes and natural history of chronic hepatitis B, as well as to develop effective approaches to treatment with currently available therapies. The Network brought together clinical centers from throughout the US and Canada. This multi-center Network enrolled patients in multiple clinical trials in both adults and children with hepatitis B. The Network is currently completing and publishing analyses from these trials. |
| HHS Action Plan for Cessation Committee | Committee, Work group, Advisory group, or Task Force | OASH | NCI | Group convened to lead the development of an action plan to support and accelerate smoking cessation. |
| HHS Agency Priority Goals Maternal Health | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, ASPE, CDC, CMS, FDA, HRSA, OASH, OGA | NICHD, OD/DPCPSI/OEPR | HHS-wide group to set an impact statement and priority goals regarding maternal morbidity and mortality. |
| HHS AI Task Force Working Groups | Committee, Work group, Advisory group, or Task Force | OS, ACF, AHRQ, ASPR, CDC, CMS, FDA, HRSA, IHS, IOS, OCIIO, OGC, ONC, SAMHSA | NHLBI, NIBIB, NIGMS, OD/DPCPSI/ODSS, OD/EO, OD/OER, OD/OM/OMA | The HHS AI Task Force was established in response to the rapid expansion of artificial intelligence (AI) capabilities and Executive Order 14110 on Safe, Secure, and Trustworthy Development and Use of Artificial Intelligence. Workgroups: Participation from over 200 individuals across the eight workgroups: 1) Research and Discovery, 2) Drug and Device, 3) Healthcare and Human Service Delivery, 4) Public Health, 5) Ethical and Responsible Use, 6) Critical Infrastructure and Cybersecurity, 7) Biosafety and Biosecurity, and 8) Internal Operations. |
| HHS Artificial Intelligence Task Force | Committee, Work group, Advisory group, or Task Force | OS, ACF, AHRQ, ASPR, CDC, CMS, FDA, OASH, OGC, ONC | NCATS, NCI, NHLBI, NIAID, NIAMS, NIBIB, NLM, OD/DPCPSI/ODSS, OD/OSP | The HHS AI Task Force provides directional guidance (e.g., steering, strategy) and operational accountability to HHS on responsible use of AI in the HHS sector, in line with direction from HHS senior leaders; inform HHS senior leader decision-making on major resource allocations or other significant decisions. It is composed of a Program Management Office, Steering Committee, and the following Working Groups: Biosafety & Biosecurity, Critical Infrastructure & Cybersecurity, Drug & Device, HHS Service & Delivery, Internal Operations, Public Health, and Research & Discovery. Language requiring HHS to stand up the task force came from EO 14110 (AI EO): The Secretary of HHS shall, in consultation with the Secretary of Defense and the Secretary of Veterans Affairs, establish an HHS AI Task Force that shall, within 365 days of its creation, develop a strategic plan that includes policies and frameworks—possibly including regulatory action, as appropriate—on responsible deployment and use of AI and AI-enabled technologies in the health and human services sector (including research and discovery, drug and device safety, healthcare delivery and financing, and public health). |
| HHS Artificial Intelligence Task Force (AI TF): Research and Discovery Working Group (R&D WG) | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC, FDA, HRSA, OCR, OGC, SAMHSA | NIAID, NLM | In response to the President’s EO on Safe, Secure, and Trustworthy Development and Use of AI, HHS is developing an AI Strategy, including a portion that will focus on Research & Discovery. Section 5 of the EO outlines efforts related to support responsible AI development and use. This Working Group has been established to coordinate actions in support of this EO. |
| HHS Artificial Intelligence Task Force: Ethical and Responsible Use WG | Committee, Work group, Advisory group, or Task Force | ASPE, AHRQ, CDC, CMS, FDA, ONC | OD/OSP | Working group to examine the ethical and responsible use of AI in the context of health care delivery, public health, and drug and device development. Key policy concerns included ethics and scientific integrity, accountability and responsibility, disclosure and transparency, privacy, fairness and equity, and safety and reliability. Input from WG informed the HHS Strategic Plan on AI. |
| HHS Behavioral Health Coordinating Council (BHCC) | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, ASPE, CDC, CMS, FDA, OASH, OS, SAMHSA | NIDA, OD/IMOD | The BHCC is tasked with coordinating all federal government resources to address inequities and gaps within the mental health and substance use disorder system. |
| HHS Behavioral Health Coordinating Council (BHCC), Behavioral Health Integration Subcommittee | Committee, Work group, Advisory group, or Task Force | ACL, AHRQ, CDC, CMS, HRSA, IHS, SAMHSA | NIAAA, NIDA, NIMH | The Behavioral Health/Primary Care Integration Subcommittee addresses the need to improve the integration of mental health and primary care services. This group convenes bi-monthly to share agency initiatives in this area and collaborate on new initiatives to promote this integration. |
| HHS Behavioral Health Coordinating Council (BHCC), Buprenorphine Availability Subcommittee | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, ASPE, CDC, CMS, FDA, OASH, OS, SAMHSA | NIAAA, NIDA, NIMH | The BHCC is tasked with coordinating all federal government resources to address inequities and gaps within the mental health and substance use disorder system. |
| HHS Behavioral Health Coordinating Council (BHCC), Children and Youth Behavioral Health Subcommittee | Committee, Work group, Advisory group, or Task Force | CMS, FDA, HRSA, OASH, SAMHSA | NICHD, NIDA, NIMH | The BHCC is tasked with coordinating all federal government resources to address inequities and gaps within the mental health and substance use disorder system. |
| HHS Behavioral Health Coordinating Council (BHCC), Children and Youth Subcommittee | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, ASPE, CDC, CMS, FDA, HRSA, IHS, OASH, OSG, SAMHSA | NICHD, NIDA, NIMH, NIMHD | Subcommittee of HHS Behavioral Health Coordinating Council (BHCC), addressing these high level priorities: • Ensure children, youth, and caregivers have access to appropriate behavioral health prevention resources, screening, referral, and treatments in their communities, schools, and early education settings.• Address behavioral health needs resulting from the COVID-19 pandemic. • Advance health equity by addressing the health needs of underserved communities. • Support the behavioral health workforce that serves children and youth. |
| HHS Behavioral Health Coordinating Council (BHCC), Contingency Management Subcommittee | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, ASPE, CDC, CMS, FDA, OASH, OS, SAMHSA | NIAAA, NIDA, NIMH | The BHCC is tasked with coordinating all federal government resources to address inequities and gaps within the mental health and substance use disorder system. |
| HHS Behavioral Health Coordinating Council (BHCC), Expanding Access to Naloxone Subcommittee | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, ASPE, CDC, CMS, FDA, OASH, OS, SAMHSA | NIAAA, NIDA, NIMH | The National Institutes of Health (National Institute on Drug Abuse; NIDA) Serves as Co-Chair with the Food and Drug Administration (FDA) on this inter-agency subcommittee addressing drug overdose. NIDA participates on its constituent working groups whose topics include: drafting and implementation of the HHS Overdose Prevention Strategy; expanding access to contingency management; addressing pharmacy availability of buprenorphine; expanding access to naloxone; and determining the public health impact of kratom scheduling; and improving clinician education on controlled substance prescribing. |
| HHS Behavioral Health Coordinating Council (BHCC), High Dose Buprenorphine Subcommittee | Committee, Work group, Advisory group, or Task Force | FDA | NIDA | The National Institutes of Health (National Institute on Drug Abuse; NIDA) Serves as Co-Chair with the Food and Drug Administration (FDA) on this inter-agency subcommittee addressing drug overdose. NIDA participates on its constituent working groups whose topics include: drafting and implementation of the HHS Overdose Prevention Strategy; expanding access to contingency management; addressing pharmacy availability of buprenorphine; expanding access to naloxone; assessing the landscape of prescription stimulant use and misuse; and improving clinician education on controlled substance prescribing. |
| HHS Behavioral Health Coordinating Council (BHCC), Overdose Prevention Strategy Primary Prevention Metrics Subcommittee | Committee, Work group, Advisory group, or Task Force | FDA | NIDA | The National Institutes of Health (National Institute on Drug Abuse; NIDA) Serves as Co-Chair with the Food and Drug Administration (FDA) on this inter-agency subcommittee addressing drug overdose. NIDA participates on its constituent working groups whose topics include: drafting and implementation of the HHS Overdose Prevention Strategy; expanding access to contingency management; addressing pharmacy availability of buprenorphine; expanding access to naloxone; assessing the landscape of prescription stimulant use and misuse; and improving clinician education on controlled substance prescribing. |
| HHS Behavioral Health Coordinating Council (BHCC), Overdose Prevention Strategy Subcommittee | Committee, Work group, Advisory group, or Task Force | FDA, AHRQ, ASPE, CDC, CMS, HRSA, IHS, OASH, SAMHSA | NIAAA, NICHD, NIDA, NIMH | The National Institutes of Health (National Institute on Drug Abuse; NIDA) Serves as Co-Chair with the Food and Drug Administration (FDA) on this inter-agency subcommittee addressing drug overdose. NIDA participates on its constituent working groups whose topics include: drafting and implementation of the HHS Overdose Prevention Strategy; expanding access to contingency management; addressing pharmacy availability of buprenorphine; expanding access to naloxone; assessing the landscape of prescription stimulant use and misuse; and improving clinician education on controlled substance prescribing. |
| HHS Behavioral Health Coordinating Council (BHCC), Performance Measures, Data, and Evaluation Subcommittee | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, ASPE, CDC, CMS, FDA, OASH, OS, SAMHSA | NIAAA, NIDA, NIMH | The BHCC is tasked with coordinating all federal government resources to address inequities and gaps within the mental health and substance use disorder system. |
| HHS Biannual Dual Use Research of Concern (DURC) Inventory | Other | ASPR, CDC, FDA | FIC, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI, OD/OSP | Develops the HHS Biannual Dual Use Research of Concern (DURC) inventory report, as required by the United States Government (USG) Policy for Oversight of Dual Use Research of Concern. |
| HHS Biosafety and Biosecurity Coordinating Committee | Committee, Work group, Advisory group, or Task Force | ASPR, ASPA, ASPE, CDC, FDA, HRSA, IHS, OGC, OGA, OS | OD/OM, OD/OM/ORS, OD/OSP | High-level and formal mechanism for coordinating and collaborating on biosafety and biosecurity issues across the Department of Health and Human Services. |
| HHS Border Health Intraagency Working Group | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC, FDA, HRSA, OS | NIA, NIAID, NICHD, NIMH, NIMHD | This intra-agency workgroup allows for the exchange of information and cooperation among the Department of Health and Human Services (HHS) agencies on issues related to border health. The purpose of this group is to convene HHS components that have a vested interest in US-Mexico border health issues to provide a platform for discussion, coordinate efforts, and potentially identify mutual areas of collaboration to improve the health and quality of life for border residents. |
| HHS Cancer Moonshot Data Strategy: CMS-NIH Data Sharing Workgroup | Committee, Work group, Advisory group, or Task Force | CMS, ASPE, OGC, ONC | NCATS, NCCIH, NCI, NIA, NIAAA, NIDA, NIDCD, NIDDK, NIMH, NINDS | CMS and NIH established a trans-agency workgroup to streamline access to linked clinical and administrative data for research purposes. |
| HHS Cancer Moonshot Data Strategy: Federated Data System Working Group | Committee, Work group, Advisory group, or Task Force | IOS, ARPA-H, ASPE, CDC, CMS, FDA, OCIIO, ONC | NCATS, NCI, NHLBI | The U.S. Department of Health and Human Services released its Data Strategy, which seeks to further realize the Department’s mission by advancing its management and use of data to improve human health outcomes. It envisions data that is available, accessible, timely, equitable, meaningfully usable, and protected–and can be effectively used by HHS, its partners, and the public. In support of President Biden’s Unity Agenda, the strategy promotes greater access to data to advance cancer research and improve patient outcomes and advance the goal of the Biden Cancer Moonshot to cut the cancer death rate in half over the next 25 years on our way to ending cancer as we know it. The strategy contains 5 priorities for improving data infrastructure and capabilities department-wide, and a series of near-term initiatives for each. This WG focuses on federal data systems. |
| HHS Cancer Moonshot Data Strategy: Interoperability and Data Standards Working Group | Committee, Work group, Advisory group, or Task Force | CMS, ONC | NCI | The U.S. Department of Health and Human Services released its Data Strategy, which seeks to further realize the Department’s mission by advancing its management and use of data to improve human health outcomes. It envisions data that is available, accessible, timely, equitable, meaningfully usable, and protected–and can be effectively used by HHS, its partners, and the public. In support of President Biden’s Unity Agenda, the strategy promotes greater access to data to advance cancer research and improve patient outcomes and advance the goal of the Biden Cancer Moonshot to cut the cancer death rate in half over the next 25 years on our way to ending cancer as we know it. The strategy contains 5 priorities for improving data infrastructure and capabilities department-wide, and a series of near-term initiatives for each. This WG focuses on interoperability and data standards. |
| HHS Cancer Moonshot Data Working Group | Committee, Work group, Advisory group, or Task Force | IOS, ARPA-H, AHRQ, ASPE, CDC, CMS, FDA, IHS, OASH, OCIIO, ONC, OS | NCI | This WG is focused on the new HHS Data Strategy goals and is an advisory group for the Cancer Moonshot. |
| HHS Chief Grants Management Officers Council | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, AoA, ASA, ASFR, ASPA, ASPE, ASPR, ATSDR, BARDA, CFBNP, CDC, CMS, CTO, DAB, FDA, GDM, HRSA, IEA, IHS, IOS, IOS/ODPHP, OASH, OCIIO, OCR, OGC, OGA, OIDP, OIG, OMHA, ONC, ONS, OPHS, ORAC, OS, OSG, OSTP, PHSSEF, PSC, SAMHSA, USPHS | OD/OER | A forum for consistent executive levelcommunication and collaboration for responding to financial assistance initiatives and emerging issues. |
| HHS CIO Council | Committee, Work group, Advisory group, or Task Force | OS, ASFR, CDC, CMS, FDA, HRSA, IHS, SAMHSA | OD/OCIO | HHS meets monthly with all OpDivs CIOs to discuss IT issues of strategic importance. |
| HHS CISO Council | Committee, Work group, Advisory group, or Task Force | OS, ASFR, CDC, FDA, HRSA, IHS, SAMHSA | OD/OCIO | HHS meets monthly with all OpDivs CISOs to discuss IT issues of strategic importance. |
| HHS Cloud Security Working Group | Committee, Work group, Advisory group, or Task Force | OS, AHRQ, CDC, CMS, FDA, IHS, SAMHSA | OD/OCIO | Working Group to Facilitate HHS Cloud Security efforts across all OpDivs - largely attended to CISOs and their delegate |
| HHS Community Health Partnership, The Center for Faith and Opportunity Initiatives | Other | IEA | NIDA | Quarterly calls with DHHS department's efforts to build and support partnerships with faith-based and community organizations in order to better serve individuals, families and communities in need. |
| HHS Community of Practice (Early Career Talent and Pathways Programs) | Meeting/ Workshop | IOS | OD/OM, OD/OM/OHR | Pathways discussions on implementation and best practices across HHS. |
| HHS Continuous Monitoring Working Group | Committee, Work group, Advisory group, or Task Force | OS, AHRQ, CDC, CMS, FDA, HRSA, IHS, SAMHSA | OD/OCIO | Working Group to Facilitate Continuous Monitoring under the NIST Risk Management Framework efforts across all OpDivs - largely attended to CISOs and their delegate |
| HHS Coordinating Committee on Women's Health | Committee, Work group, Advisory group, or Task Force | OASH, AHRQ, CDC, FDA, HRSA, IHS, SAMHSA | NHLBI, NICHD, OD/DPCPSI/ORWH | The HHS Coordinating Committee on Women’s Health (CCWH) was established in 1984 to advise the Assistant Secretary for Health (and, in 1993, the Deputy Assistant Secretary for Health – Women’s Health) on activities across HHS that would safeguard and improve the physical and mental health of all women in the United States. The coordinating committee is chaired by the OWH Director, and members include senior-level representatives from each of the federal agencies and offices within HHS. |
| HHS Coordination Operations and Response Element (previously Operation Warp Speed) | Committee, Work group, Advisory group, or Task Force | ASPR | NIAID | A program designed to coordinate and respond to the public health emergency by expediting the development of vaccines, treatments, testing and other measures as needed. |
| HHS Corporate Recruitment Program (CRP) Community of Practice (CoP) Monthly Meeting | Meeting/ Workshop | ASA | OD/OM, OD/OM/OHR | HHS OPDIV meeting to share best practices in outreach and recruitment. |
| HHS CPIC Meetings | Meeting/ Workshop | OS | OD/OCIO | HHS OCIO meets at least monthly with all OpDivs to discuss CPIC topics. |
| HHS Customer Experience Initiative | Committee, Work group, Advisory group, or Task Force | ASFR | OD/OM, OD/OM/ORS, OD/OM/OSPMO | OSPMO coordinates with project leads to compile quarterly data on key milestones and accomplishments related to projects aimed at improving the NIH Visitor Experience. This is in response to the HHS Customer Experience Initiative. |
| HHS DATA Act Compliance | Committee, Work group, Advisory group, or Task Force | ASFR | OD/OER, OD/OM/NBS | The HHS Assistant Secretary for Financial Resources (ASFR) coordinates OPDIV activities including communications, implementation, and compliance with the DATA Act. |
| HHS Data Council | Committee, Work group, Advisory group, or Task Force | ASPE, OASH, ACF, ACL, AHRQ, ASA, ASPR, CDC, CMS, FDA, HRSA, IHS | NIGMS, NLM, OD/DPCPSI/ODSS, OD/DPCPSI/SGMRO, OD/OER, OD/OSP | The Department of Health and Human Services (HHS) Data Council is the principal internal advisory body to the Secretary on health and human services data policy. The Council coordinates data policy activities in HHS, including the development and implementation of an HHS data strategy. The Council consists of senior level officials and staff designated by their operating and staff division leadership. |
| HHS Data Council: Data Modernization Workgroup | Committee, Work group, Advisory group, or Task Force | ASPE, ARPA-H, ACL, AHRQ, ASPR, CDC, CMS, HRSA, IHS | OD/DPCPSI/OEPR | The main function of the HHS Data Council is to guide and inform health and human services data policy in HHS, including the development and implementation of an HHS data strategy, data standards, and privacy policy. The Council operates by developing consensus on data policy issues. This work is often accomplished through the topic-specific Workgroups. Data modernization is one of three topics currently prioritized by the HHS Data Council via a topic-specific Workgroup. The FY2024 goals of the Data Modernization Work Group are to: 1) Inform and/or propose data policies that support implementation of HHS Data Strategy; 2) Recommend sound approaches for meeting HHS Data Strategy Focus Area 2, Objective 5; and 3) Identify gaps and opportunities for data modernization at HHS. |
| HHS Data Governance Board | Committee, Work group, Advisory group, or Task Force | OS | OD/DPCPSI/ODSS, OD/OSP | The purpose of the DGB is to serve as the Department’s principal data governance forum and decision-making body for managing HHS’ data as a strategic asset to support HHS in meeting its mission and agency priorities, including implementation of the Evidence Act.In accordance with OMB M-19-23, the DGB will:• Support agency priorities, such as those identified in strategic plans and learning agendas, by informing strategic information resources management plans for the agency and identifying resources to implement those priorities; • Coordinate and support implementation of data management responsibilities with agency data-management actors to strengthen strategic plans and learning agendas;• Set agency data policy in a manner that complements, but does not supplant the statutory authority of established positions; and • Coordinate implementation of the Federal Data Strategy by assessing data maturity, risks, and capabilities to recommend related data investment priorities.In accordance with the Geospatial Data Act, the DGB will:• Ensure that HHS and its components fully implement the covered agency responsibilities found in GDA section 759(a). (299-908-10-1 OS)• Maintain an inventory of all geospatial data assets, per section 759(b) of the GDA. (299-908-10-2 OS) |
| HHS DEIA Operations Council | Committee, Work group, Advisory group, or Task Force | OS | OD/IMOD | HHS DEIA Operations Council |
| HHS DEIA Partnership and Recruitment Workstream (Subgroup) | Meeting/ Workshop | ASA | OD/OM, OD/OM/OHR | HHS OPDIV meeting to organize a way to hire individuals who were incarcerated. |
| HHS Dietary Guidance Review Committee | Committee, Work group, Advisory group, or Task Force | IOS/ODPHP, OASH, ACF, CDC, FDA, HRSA, IHS | NIDDK, OD/DPCPSI/ONR | This committee reviews draft nutrition materials developed by all federal agencies and fulfills the legislative mandate (1990 NNMRRA) to ensure that Federal dietary guidance is consistent with the Dietary Guidelines for Americans and is scientifically accurate. |
| HHS Digital Council | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, SAMHSA | OD/OCPL | HHS manages its digital communications activities through a Digital Council, led by ASPA Digital, and comprising of representatives of HHS Operating and Staff Divisions. ASPA Digital works with the HHS Digital Council to develop Department digital communications policies, standards, and guidance. The Council exchanges best practices and lessons learned to ensure quality, efficiency, and a focus on users in communications and operations. |
| HHS Disability Collaborative | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, ASA, ASFR, ASPA, ASPE, ASPR, CDC, CMS, FDA, HRSA, IHS, OASH, OCR, OIG, ONC, SAMHSA | NIA | The HHS Collaborative is for OpDivs and StaffDivs to work in partnership on issues that impact person with disabilities. This group will address emerging issues, funding announcements, research and evaluation, pre-clearance conversations, special events, announcements, and rollouts. Anticipated results includes enhanced communication across agencies, elevated focus on key disability issues, improved awareness and coordinated messaging, alignments of budgets and policy proposal, and enhanced knowledge transfer across HHS. This is not a governing body. The lead organizations are ACL and ASPE. |
| HHS EA Policy Re-Write Working Group | Committee, Work group, Advisory group, or Task Force | OS, AHRQ, CDC, CMS, FDA, IHS, SAMHSA | OD/OCIO | eets weekly with EA reps from OpDivs to create new HHS EA Policy |
| HHS EA Tool Working Group | Committee, Work group, Advisory group, or Task Force | OS, AHRQ, CDC, CMS, FDA, IHS, SAMHSA | OD/OCIO | Meets weekly with EA reps from OpDivs to define requirements for across HHS EA tool |
| HHS EARB | Committee, Work group, Advisory group, or Task Force | OS, AHRQ, CDC, CMS, FDA, HRSA, IHS, SAMHSA | OD/OCIO | Meets montly to discuss EA concerns across the HHS |
| HHS Ebola Medical Countermeasures Scientific Working Group | Committee, Work group, Advisory group, or Task Force | ASPR | NIAID | Focuses on supporting ASPR and NSC on scientific issues related to Ebola MCMs in response and development |
| HHS Environmental Justice Working Group | Committee, Work group, Advisory group, or Task Force | OASH, ACF, ACL, AHRQ, ASPE, ASPR, ATSDR, CDC, CMS, FDA, HRSA, IHS, OCR, PSC, SAMHSA | NCI, NIEHS, NIMHD, NINR, OD/DPCPSI/OSC | Convened to ensure a cross-departmental approach to advancing environmental justice and assist with the development and implementation of a comprehensive HHS Environmental Justice Strategy that outlines a framework for addressing the concerns and needs of communities. The National Institutes of Health (NIH) Environmental Justice (EJ) Working Group, in support of the Department of Health and Human Services’ (HHS) EJ Strategic Plan, is developing a new EJ training Program for communities, workers, researchers, health care and public health professionals, and policy makers. The program aims to building capacity of community residents and community-based organizations; Train researchers to work in partnership with communities to address EJ issues; Train healthcare professionals, public health professionals, and policy makers to build their understanding of EJ and the connection it has to health and well-being. The two focus areas are (1) Researchers and Staff Training Program: Train NIH staff and researchers on the fundamentals of environmental justice, health disparities, community engaged and participatory research, and citizen science. (2) Community Training Program: Build the capacity of at-risk communities to address current and emerging environmental threats through customized and tailored trainings on environmental health data access and use, and evidence-based research design." |
| HHS Equity Technical Assistance Center (ETAC) Engagement | Resource Development | ASPE | OD/DPCPSI/OSC | The National Institutes of Health (NIH) Office of Strategic Coordination (OSC) seeks support from the HHS Equity Technical Assistance Center (ETAC) to conduct a rapid equity assessment (REA) of the Common Fund Data Ecosystem’s (CFDE) human subjects’ data reporting processes across its participating Common Fund programs. The goal of this REA is to develop a set of recommendations to improve the data reporting process to ensure the CFDE search platform can support equity-related research. By data reporting, we are referring to the process by which metadata from data sets generated through individual Common Fund programs are incorporated into the broad CFDE search platform. We have adapted ETAC’s six-step REA process to help NIH OSC understand participating Common Fund programs’ past and present data reporting processes for human studies to identify opportunities for integrating data equity principles across Common Fund program activities. ETAC will also coordinate with NIH OSC to facilitate a discussion with NIH OSC staff to increase their understanding of data equity for their outward-facing programs and program management practices. |
| HHS Evaluation & Evidence Policy Council | Committee, Work group, Advisory group, or Task Force | ASPE | OD/DPCPSI/OEPR | The HHS Evaluation & Evidence Policy Council is a Department-wide group that help develops evaluation capacity by sharing best practices and promising new approaches across HHS. In addition, it assists HHS in implementing Title I requirements of the Foundations for Evidence-Based Policymaking Act of 2018. |
| HHS Evidence and Evaluation Council, Capacity Assessment Survey Work Group | Committee, Work group, Advisory group, or Task Force | ASPE, ACF, CDC, SAMHSA | OD/DPCPSI/OEPR | This Work Group was convened to design and deploy the FY2026 HHS Capacity Assessment Survey to assess the evidence and evaluation needs of HHS Operating and Staff Divisions. |
| HHS FAC Bi-Monthly Meeting | Meeting/ Workshop | ACF, CDC, CMS, FDA, HRSA | OD/OM, OD/OM/OALM | The HHS FAC bi-weekly meetings occur under the leadership of the HHS Acquisition Career Manager (ACM) and includes the Bureau Acquisition Career Managers from each Operating Division. The purpose is to receive policy and guidance updates and discuss issues with current SOPs and guidance. |
| HHS FDA NIDA Working Group on Cannabis Scheduling | Committee, Work group, Advisory group, or Task Force | FDA | NIDA | Per request by President Biden for consideration of rescheduling cannabis, this group worked on the information submitted by HHS to DOJ regarding proposed rescheduling |
| HHS Federal Working Group on Suicide Prevention | Committee, Work group, Advisory group, or Task Force | SAMHSA, ACF, ACL, AHRQ, ASPE, CDC, HRSA, IHS | NIAAA, NIDA, NIMH | The Federal Work Group on Suicide Prevention, led by the Substance Abuse and Mental Health Services Administration (SAMHSA), brings together multiple agencies within HHS and across agencies (e.g., Veterans Affairs, Department of Transportation, Department of Justice) to meet and discuss suicide prevention initiatives within the federal government on a quarterly basis. Meeting topics range from SAMHSA updates on the 988 implementation and other initiatives to a round robin which provides a forum for federal agencies to share various suicide prevention initiatives they are leading or are involved in. |
| HHS FISMA Working Group | Committee, Work group, Advisory group, or Task Force | OS, AHRQ, CDC, CMS, FDA, HRSA, IHS, SAMHSA | OD/OCIO | Working Group to Facilitate HHS FISMA scorecard development and compliance with all OpDivs |
| HHS Food is Medicine Working Group | Committee, Work group, Advisory group, or Task Force | IOS/ODPHP, ACF, ACL, AHRQ, CDC, CMS, FDA, HRSA, IHS, OASH | OD/DPCPSI/ONR | The White House Conference on Hunger, Nutrition, and Health — held in September 2022 — renewed national attention and issued a call to action to end hunger and reduce the prevalence of chronic disease in the United States by 2030. Food is Medicine approaches that focus on integrating consistent access to diet- and nutrition- related resources are a critical component to achieve this goal. The approaches are increasingly present across many communities and systems. There’s also increasing federal investment and action to support Food is Medicine approaches in a variety of settings. Building on this collective energy, the Department of Health and Human Services (HHS) developed a Food is Medicine initiative in response to a congressionally funded initiative in fiscal year 2023. This congressional action directed the Secretary of HHS, in consultation with other federal agencies, to develop and implement a federal strategy to reduce nutrition-related chronic diseases and food insecurity to improve health and racial equity in the United States. This includes diet-related research and programmatic efforts that will increase access to Food is Medicine initiatives. Access to nutritious food is critical to health and resilience. Food is Medicine is a concept that reaffirms this connection, recognizing that access to high-quality nourishment is essential for well-being. By supporting the production of and facilitating access to nutritious food across a health continuum and range of settings, approaches to Food is Medicine support immediate and long-term resources for people, communities, and systems. This HHS Office of Disease Prevention and Health Promotion (ODPHP)-led working group is focused on working collaboratively with federal partners and external organizations and communities to develop resources that can be used to advance Food is Medicine approaches across the country. |
| HHS Future of Work Coordinating Committee | Committee, Work group, Advisory group, or Task Force | OS | OD/OM, OD/OM/ORS | The Coordinating Committee (Committee) for the HHS Future of Work (FOW) Initiative shapes, advises, and supports implementation of the Department’s approach to FOW activities. The Committee brings together leaders from across the Department to make data-driven recommendations on best practices to enable the HHS workforce to achieve mission outcomes. The Committee guides and advises FOW Working Groups as they seek to achieve the following: Assess current practices, programs, and policies, including gaps and inconsistencies. Identify and promote of best practices.Formulate recommendations designed to promote fairness and equity, efficient use of Department resources, and mission delivery |
| HHS Grants Closeout Initiative (GCI) | Committee, Work group, Advisory group, or Task Force | OS, ACF, ACL, AHRQ, ASPR, ATSDR, BARDA, CDC, CMS, FDA, HRSA, IHS, SAMHSA | OD/OER | HHS Working Group to actively monitor the grants backlog and recommend integrated solutions that streamline and optimize the grant closeout process, reduce manual intervention, and improve overall efficiency.https://hhsgov.sharepoint.com/sites/CBPRCommunicationsCenter?xsdata=MDV… |
| HHS Grants Systems Team (GST) | Committee, Work group, Advisory group, or Task Force | OS, ACF, ACL, AHRQ, ASPR, ATSDR, BARDA, CDC, CMS, FDA, HRSA, IHS, SAMHSA | OD/OER | HHS Working Group to manage system implementation of HHS initiatives and policies. |
| HHS Health Disparities Council | Committee, Work group, Advisory group, or Task Force | OS | NIMHD, OD/IMOD | The Council serves as the venue to share information, leverage HHS investments, and coordinate HHS activities, reduce program duplication, and track progress on the strategies and actions of the HHS Disparities Action Plan. |
| HHS Health Literacy Workgroup | Committee, Work group, Advisory group, or Task Force | OASH, ACF, AHRQ, CDC, CMS, FDA, HRSA, IHS, IOS, OASH, ONC, SAMHSA | NLM, OD/OCPL | The Department of Health and Human Services (HHS) Health Literacy Workgroup is comprised of all operating and most staff divisions under HHS, and has met regularly since 2003. ODPHP founded, hosts, and supports the efforts of the Health Literacy Workgroup and currently runs the Workgroup in coordination with the Agency for Healthcare Research and Quality (AHRQ).The workgroup collaborates to ensure that improving health literacy remains a priority for HHS. The workgroup strives to:Create understandable and actionable health informationSupport and facilitate engaged and activated health consumersRefresh the health literacy science base on a regular basis |
| HHS Health Literacy Working Group | Committee, Work group, Advisory group, or Task Force | IOS/ODPHP, ACF, AHRQ, CDC, CMS, FDA, HRSA, IHS, IOS, OASH, ONC, SAMHSA | NCATS, NIA, NIAID, NIAMS, NIDA, NINR | The Department of Health and Human Services (HHS) Health Literacy Workgroup is comprised of all operating and most staff divisions under HHS, and has met regularly since 2003. ODPHP founded, hosts, and supports the efforts of the Health Literacy Workgroup and currently runs the Workgroup in coordination with the Agency for Healthcare Research and Quality (AHRQ). |
| HHS HIV Bidirectional Technical Planning Committee | Committee, Work group, Advisory group, or Task Force | OGA, CDC, FDA, HRSA, IHS, OASH, SAMHSA | NIAID, NIMH, OD/DPCPSI/OAR | Committee planning meetings of the HHS global and domestic policy and program leaders to share successful strategies and lessons learned, and to discuss potential adaptations to enable the transfer/implementation of proven strategies among new environments. |
| HHS Interagency PEPFAR working group | Committee, Work group, Advisory group, or Task Force | OGA, FDA, HRSA | OD/DPCPSI/OAR | Meeting of the HHS implementing agencies to discuss relevant PEPFAR-related updates/activities. Topics included: PEPFAR strategies, guidance for Country Operational Plans, agencies submissions of Headquarters Operational Plans activities and progress reports, annual PEPFAR meeting activities, plans and updates regarding conference and other convenings. |
| HHS Internal Advisory Group (HIAG) of the Children's Interagency Coordinating Council | Committee, Work group, Advisory group, or Task Force | ASPE, ACF, ACL, CDC, CMS, HRSA, IHS, SAMHSA | NICHD, NIDA | The Office of the Assistant Secretary for Planning and Evaluation (ASPE) has been tasked with setting up a new Children’s Interagency Coordinating Council (CICC). in December 2022, Congress charged HHS with chairing and establishing the CICC. Congress also indicated that the CICC should foster greater coordination and transparency on child policy across federal agencies and examine and periodically report on a broad array of cross-cutting issues affecting child well-being. HHS is forming the CICC with a structure that promotes interagency engagement at multiple levels of leadership from 10 departments and agencies (including HHS) by creating both a Leadership Team with senior appointees and a Coordinating Committee of senior career leaders from each department/agency. To support and coordinate the efforts of the HHS representatives on the CICC in these interagency discussions, the HHS Internal Advisory Group (HIAG) will inform and advise, as well as serve as a liaison between NICHD and the CICC. |
| HHS ISCM Working Group | Committee, Work group, Advisory group, or Task Force | OS, AHRQ, CDC, CMS, FDA, IHS, SAMHSA | OD/OCIO | Working Group to Facilitate HHS ZTA efforts across all OpDivs - largely attended to CISOs and their delegate |
| HHS IT Strategic Plan | Committee, Work group, Advisory group, or Task Force | OS, AHRQ, CDC, CMS, FDA, IHS, SAMHSA | OD/OCIO | Meets to get OpDiv input for the HHS IT strategic plan |
| HHS ITAM Working Group | Committee, Work group, Advisory group, or Task Force | OS, AHRQ, CDC, CMS, FDA, HRSA, IHS, SAMHSA | OD/OCIO | Meets to discuss ITAM concerns and policy |
| HHS LGBTQI+ Coordinating Committee | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, ASA, ASPR, CDC, CMS, DAB, FDA, HRSA, IHS, IOS, OASH, OCR, OGC, OGA, OIG, OMHA, SAMHSA | NIAID, OD/DPCPSI/SGMRO | The HHS LGBTQI+ Coordinating Committee is a venue for establishing and strengthening collaboration and communication across the department in the context of SGM health, human services, policy, research, and other relevant emerging issues. |
| HHS Liaison to NASA | Other | FDA | NCATS | As HHS Liaison to NASA, Dr. Rutter and her team at NCATS coordinate interactions and expertise sharing among components of HHS to explore joint areas of interest. In January 2021, HHS appointed staff members to centralize the partnership and ensure continuity between administrations. NCATS remains as a leader in these efforts, working alongside NASA and HHS staff to coordinate activities, such as the Tissues Chips in Space Program. |
| HHS Maternal Health Working Group | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, SAMHSA | NHLBI, NICHD, NIMHD, OD/DPCPSI/ORWH | This internal Department of Health and Human Services (HHS) group was formed in June 2019, with the goal of developing a trans-HHS Action Plan aimed at making the U.S. the safest place in the world to give birth. |
| HHS Maternal Morbidity and Mortality Steering Committee | Committee, Work group, Advisory group, or Task Force | OASH | OD/DPCPSI/ORWH | Dr. Clayton has been a member of this committee since 2018. |
| HHS Minority Health Offices Directors Committee | Committee, Work group, Advisory group, or Task Force | OS | NIMHD | The directors of the HHS Offices of Minority Health meet monthly to discuss issues for coordination/collaboration related to minority health and health disparities in their respective agencies to leverage partnerships, foster cross-agency collaborations and share updates. |
| HHS NASEM Cannabis Science Policy Study Update Meetings | Resource Development | CDC | NCCIH, NCI, NIDA | NASEM is funded by CDC and NIH to develop report on impact of different state legalization policies for cannabis, including research priorities. |
| HHS NASEM Prevention Infrastructure Study Update Meeting | Resource Development | CDC, SAMHSA | NIDA | NASEM Prevention infrastructure study |
| HHS National CLAS Standards Work Group | Meeting/ Workshop | IHS | NIMHD | The work group includes subject matter experts in health disparities and health equity who are responsible for advising the development of a business case for the National Standards for Culturally and Linguistically Appropriate Services (CLAS) in Health and Health Care. that will present a compelling evidence base for implementation of the National CLAS Standards in health systems. Its target audience will be health care policymakers, administrators, and other decision-makers, who can leverage its findings to advocate for the implementation of the National CLAS Standards at their organization. Ultimately, the business case can empower health systems to take action toward implementation of the National CLAS Standards. |
| HHS National Women's Health Week | Public Education Campaign | AHRQ, CDC, FDA, HRSA, IHS, OASH, SAMHSA | NHLBI, NICHD, OD/DPCPSI/ORWH | In 2024, ORWH supported HHS's National Women's Health Week by releasing NIH-Wide Strategic Plan for Research on the Health of Women 2024-2028, NIH Fact Sheets on Women’s Health Research, Health of Women of U3 (Underrepresented, Underserved, and Underreported in biomedical research) Populations Data Book, Annual Vivian W. Pinn Symposium, Future Directions in Menopause Research: Optimizing Midlife Health of Women Roundtable |
| HHS Noise-Induced Hearing Loss Federal Partner Working Group | Committee, Work group, Advisory group, or Task Force | CDC | NIDCD | Work group to coordinate and collaborate HHS activities and messages related to noise-induced hearing loss. Federal partners include NIH (National Institute on Deafness and Other Communication Disorders) and CDC (National Center for Environmental Health and National Institute for Occupational Safety and Health). |
| HHS Nurse Council (HHSNC) | Committee, Work group, Advisory group, or Task Force | USPHS, ACF, ACL, AHRQ, ASPR, ATSDR, CDC, CMS, FDA, HRSA | CC, NINR | The purpose of the HHSNC is to provide a forum for nurse leaders within the 12 operating divisions of the Department of Health and Human Services (HHS) to inform and collaborate on projects and initiatives that advance the health and well-being of the nation. The HHSNC complements existing groups across HHS, including the National Advisory Council on Nurse Education and Practice, serves as the unifiedvoice of federal civilian and USPHS Commissioned Corps nurses, and advises on current topics that are relevant to HHS nurses and the national and global nursing communities. |
| HHS Nutrition Working Group | Committee, Work group, Advisory group, or Task Force | OASH | NCI, NHLBI, NIDCR, OD/DPCPSI/ONR, OD/ECHO | This HHS interagency group meets frequently to discuss topics and issues that are pertinent to the implementation of the Biden-Harris National Strategy on Hunger, Nutrition, and Health. This group also helped develop the framework for the White House Conference on Hunger, Nutrition, and Health. Since the Biden-Harris Administration hosted the White House Conference on Hunger, Nutrition, and Health and released its National Strategy in September 2022, agencies across the federal government have made progress toward the actions and priorities laid out in the National Strategy. These milestones span the National Strategy's 5 pillars:Pillar 1: Improve food access and affordabilityPillar 2: Integrate nutrition and healthPillar 3: Empower all consumers to make and have access to healthy foodPillar 4: Support physical activity for allPillar 5: Enhance nutrition and food security research |
| HHS OASH Initiative to Strengthen Primary Care | Committee, Work group, Advisory group, or Task Force | OASH | NINR | HHS recently launched the Strengthen Primary Health Care Initiative led by OASH. The goal of this initiative is to foster the provision of high-quality and accessible primary care. The initial task is to develop an HHS plan for strengthening primary health care. |
| HHS Office on Women's Health, Section on Pregnancy and Newborn Care | Committee, Work group, Advisory group, or Task Force | OS, SAMHSA | NICHD, NIMH | The National Institutes of Health (NIH) scientists work together with other Department of Health and Human Services (HHS) experts to develop and review content for HHS public-facing websites, including the womenshealth.gov website. |
| HHS Performance Officers | Committee, Work group, Advisory group, or Task Force | ASFR, ACF, ACL, ASA, ASPE, ASPR, CDC, CMS, FDA, HRSA, IHS, OASH, OCR, OIG, OMHA, ONC, SAMHSA | OD/DPCPSI/OEPR | This committee was established to facilitate communication and information sharing between ASFR and OpDiv/StaffDiv Performance Officers. |
| HHS Physical Activity Networking Group | Committee, Work group, Advisory group, or Task Force | OASH, CDC, HRSA, IHS | NCCIH, NIA, OD/DPCPSI/ODP | The purpose of this group is to foster a space where connections are formed, ideas are shared, and federal work related to physical activity is amplified. |
| HHS Privacy Committee | Committee, Work group, Advisory group, or Task Force | ASPE | OD/OM, OD/OM/OMA | Coordination of Privacy related activities. HHS recognizes the importance of protecting the personally identifiable information (PII) entrusted to us by millions of members of public and employees alike, and has built a robust privacy program to safeguard this information and ensure that HHS upholds Americans' privacy rights. |
| HHS Privacy Compliance Working Group | Committee, Work group, Advisory group, or Task Force | OS, AHRQ, CDC, CMS, FDA, HRSA, IHS, SAMHSA | OD/OCIO | Working Group to Facilitate HHS Privacy compliance with all OpDivs |
| HHS Quality Service Management Organizations (QSMO) on Federal Grants | Committee, Work group, Advisory group, or Task Force | OS | OD/OER | In September 2022, the Grants Quality Service Management Office (Grants QSMO) launched its public-facing Marketplace of validated Federal Shared Solutions/Services for use by all Federal Awarding Agencies that award grants and/or cooperative agreements. This Grants QSMO Marketplace provides Federal Awarding Agency customers with information to support and inform decisions regarding adoption of shared solutions/services across the entire grants lifecycle. Federal Awarding Agencies that have identified a requirement for grants IT for any part of the grants lifecycle will consult this Marketplace, the Grants QSMO team, and the respective Shared Service Providers to determine if Marketplace offerings can meet their grants IT requirements. |
| HHS Reproductive Healthcare Access Task Force | Committee, Work group, Advisory group, or Task Force | OS, AHRQ, ASPE, CDC, HRSA, IHS, OASH, OCR | NICHD, OD/IMOD | More must be done to protect and bolster sexual and reproductive health. To that end, Secretary Becerra has launched an HHS-wide Task Force to address these critical priorities. The Task Force on Reproductive Healthcare Access (Task Force) is composed of senior-level HHS officials who have been designated by their respective agencies to identify and coordinate activities across the Department to protect and bolster access to essential sexual and reproductive health care, including implementation of activities identified in the White House National Strategy on Gender Equity and Equality - PDF. The working group activities are focused on advancing quality, access, and equity for reproductive health, rights, and justice and include coordinating federal interagency policymaking, program development, and outreach efforts to address barriers impacting individuals and communities seeking reproductive health care. |
| HHS SARS-CoV-2 Immune Assay Correlates of Protection Group | Committee, Work group, Advisory group, or Task Force | ASPR, BARDA, CDC, FDA | NIAID | Coordination of Correlates of Protection Advisory Group of HHS Coordination Operations and Response Element (H-CORE) performers in H-CORE Assays |
| HHS SARS-CoV-2 Immune Assay Testing of Ph3 clinical samples- Task Order | Resource Development | ASPR | NIAID | Coordination of testing of Phase 3 clinical samples from HHS Coordination Operations and Response Element (H-CORE) performers in H-CORE Assays (Microneutralization assay) |
| HHS Secretary's Budget Council | Committee, Work group, Advisory group, or Task Force | OS | OD/IMOD | HHS Secretary's Budget Council |
| HHS Secretary's Challenge Winners Working Group | Committee, Work group, Advisory group, or Task Force | OS, ACF, CDC, CMS, HRSA, ONC | OD/DPCPSI/SGMRO | The HHS Secretary's Office offered a challenge program to which federal agencies could apply. This working group helps to coordinate relevant HHS-wide efforts for the winning topic/project. |
| HHS Secretary's Implementation Council on Behavioral Health | Committee, Work group, Advisory group, or Task Force | OS | OD/IMOD | The HHS Secretary's Implementation Council on Behavioral Health, related to the Behavioral Health Coordinating Council (BHCC), was established by the Department of Health and Human Services (HHS) to oversee and coordinate behavioral health efforts across the department. This council plays a crucial role in implementing policies and strategies related to mental health and substance use disorders. |
| HHS Section 508 Operations Board | Committee, Work group, Advisory group, or Task Force | OS, CDC, CMS, FDA, HRSA, IHS, SAMHSA | OD/OCIO | Meeting for oversight, planning, collaboration, governance for Section 508 |
| HHS Social Determinants of Health (SDOH) Workgroup | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, ASA, ASFR, ASPE, ASPR, CDC, CMS, HRSA, OASH, OCR, ONC, OS, SAMHSA | NIA, NIAID, NICHD, NIMHD, NINR, OD/DPCPSI/IMOD | The HHS SDoH Workgroup has developed a strategic vision to make health outcomes more equitable by improving the delivery of, and integration between healthcare and social services with a particular focus on individuals and populations in government health and human service programs at high risk for adverse outcomes. The SDoH workgroup identifies how HHS can address SDoH and work with other federal, state, local, tribal, and private sector partners to both ascertain and achieve shared objectives. |
| HHS SPD-15 Action Plan Advisory Group | Committee, Work group, Advisory group, or Task Force | ASPE, ACF, ACL, AHRQ, ASA, ASPR, CDC, CMS, FDA, HRSA, IHS, OASH, OCIIO, OGA, SAMHSA, USPHS | NIMHD | Develop an action plan to implement the revised SPD-15 across HHS. |
| HHS Strategic Plan FY 2022-2026: Subcommittee for Objective 3.4 | Committee, Work group, Advisory group, or Task Force | ACF, ACL, ASFR, ASPE, HRSA, SAMHSA | NICHD, NIMH | This subcommittee shares knowledge and expertise about HHS priorities and programs that will lead to the strategies at the heart of the HHS Strategic Plan Objective 3.4 to increase safeguards to empower families and communities to prevent and respond to neglect, abuse and violence, while supporting those who have experienced trauma or violence. https://www.hhs.gov/draft-strategic-plan |
| HHS Supervisor Mentoring Circle | Committee, Work group, Advisory group, or Task Force | OS | NIDDK | At the request of HHS, established and launched the HHS Supervisor Mentoring Circle as part of the Inspire Supervisory Excellence Program (ISEP) and in alignment with the Workforce Engagement Strategic Plan (WESP). The inaugural mentoring circle consists of GS 13-15 supervisors from 7 different OpDivs and 3 different job series. |
| HHS Syndemic Steering Committee | Committee, Work group, Advisory group, or Task Force | OIDP, ACL, AHRQ, CDC, CMS, FDA, HRSA, IHS, OASH, SAMHSA | OD/DPCPSI/OAR | The Federal Syndemic Steering Committee is composed of federal leadership with a stake in the intersections of HIV, STIs, viral hepatitis, substance use disorders, mental health, and the social and structural determinants of health that facilitate the clustering of these conditions and is charged with identifying opportunities for cross-departmental collaboration to address these syndemics. |
| HHS Task Force to Prevent Human Trafficking | Committee, Work group, Advisory group, or Task Force | OS | NICHD, OD/DPCPSI/OBSSR | The U.S. Department of Health and Human Services (HHS) has a critical role in the U.S. Government’s comprehensive response to prevent and combat human trafficking. The HHS Task Force to Prevent Human Trafficking coordinates and collaborates on the implementation of the National Action Plan to Combat Human Trafficking and anti-trafficking efforts in related national strategies. The strategic objective is to Implement the National Action Plan to Combat Human Trafficking and other relevant strategic plan actions; report on accomplishments to the President’s Interagency Task Force. https://www.acf.hhs.gov/archive/otip/fact-sheet/hhs-task-force-prevent-… |
| HHS Tobacco Cessation Workgroup | Committee, Work group, Advisory group, or Task Force | OS | NIDA | The committee coordinates and initiates tobacco control activities across HHS agencies. The Committee meets monthly to promote information exchange and collaboration across HHS on a wide array of tobacco prevention and control issues, and to update members on the latest relevant research findings. |
| HHS Tobacco Control Steering Committee | Committee, Work group, Advisory group, or Task Force | OASH | NCI, NIDA, NIMHD | The committee coordinates and initiates tobacco control activities across HHS agencies. The Committee meets monthly to promote information exchange and collaboration across HHS on a wide array of tobacco prevention and control issues, and to update members on the latest relevant research findings. |
| HHS Tribal Affairs Operating Divisions Committee (HHS op-divs) | Committee, Work group, Advisory group, or Task Force | IEA, ACF, ACL, AHRQ, ASFR, ASPR, CDC, CMS, FDA, HRSA, IHS, IOS, OGC, SAMHSA | OD/DPCPSI/THRO | The HHS Tribal op-divs committee consists of representatives from HHS divisions who administer and oversee various health and human service programs involving Tribal communities and Native Americans. HHS op-divs committee works to coordinate and ensure effective service delivery and to foster advances in science and technology between federal agencies and Tribal governments and Native Americans. The HHS IEA op-divs committee supports HHS IEA as they serve as a crucial link between HHS and state, local, and Tribal governments, facilitating communication and coordination on key issues, including the Secretary's Tribal Advisory Committee and formal HHS Tribal consultation. |
| HHS Ultra-processed Foods Working Group | Committee, Work group, Advisory group, or Task Force | IOS, IOS/ODPHP, CDC, FDA | OD/DPCPSI/ODP, OD/DPCPSI/ONR | The HHS Ultra-processed Foods Working Group was formed to coordinate and discuss work towards understanding health impacts of UPFs. |
| HHS Veteran Employment Program Managers and Military Spouses | Meeting/ Workshop | IOS | OD/OM, OD/OM/OHR | HHS meeting to discuss recruiting Veterans, write a newsletter, and other various activities. |
| HHS Violence Against Women Steering Committee | Committee, Work group, Advisory group, or Task Force | OASH | NIA, NIAAA, NIMH, OD/DPCPSI/OAR, OD/DPCPSI/OBSSR, OD/DPCPSI/ORWH | The DHHS Violence Against Women Act (VAWA) committee has the responsibility for coordinating the Department of Health and Human Services (DHHS) response to issues related to violence against women and their children, and also coordinates DHHS violence-related activities with those of other Federal agencies. The members of the committee establish links with professional societies in the health and social service fields to increase attention to women’s health and violence issues. The members of the committee also serve as resource experts for the National Advisory Committee on VAW, which is chaired by the HHS Secretary and the DOJ Attorney General. |
| HHS Viral Hepatitis Implementation Working Group | Committee, Work group, Advisory group, or Task Force | OASH | NIAID, NIDA, NIDDK, OD/DPCPSI/OAR | The Department of Health and Human Services (HHS) Viral Hepatitis Interagency Working Group was created by the Office of the Assistant Secretary for Health to address a report sponsored by the Institute of Medicine entitled Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. The group meets to discuss collaborations and activities directed at achieving the goals for viral hepatitis research and control highlighted in the IOM report. (Although the National Institute of Allergy and Infectious Diseases (NIH Lead), the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute on Drug Abuse, and the NIH Office of AIDS Research represent the National Institutes of Health as Working Group members, other NIH Institutes/Centers/Offices also provide input to the VHIG through their participation in the Trans-NIH Committee on Viral Hepatitis.) The working group helped develop the 2021-2025 Viral Hepatitis National Strategic Plan. |
| HHS VMO Enterprise Software Collaboration | Committee, Work group, Advisory group, or Task Force | OS, AHRQ, CDC, CMS, FDA, HRSA, IHS, SAMHSA | NCI, OD/OCIO | Discussing Department-wide IT licensing procurement, coordinate on large software packages for users across the entire HHS Enterprise, and establish HHS-wide BPAs to maximize cost savings and administrative efficiencies. |
| HHS Workgroup on Cannabis Impaired Driving | Committee, Work group, Advisory group, or Task Force | FDA | NIDA | Provide input to NHTSA on cannabis driving impairment with current products and on improved detection of impairment for Congressionally mandated report. |
| HHS Zero Trust Working Group | Committee, Work group, Advisory group, or Task Force | OS, AHRQ, CDC, CMS, FDA, IHS, SAMHSA | OD/OCIO | Working Group to Facilitate HHS ZTA efforts across all OpDivs - largely attended to CISOs and their delegate |
| HHS-DoD Nonhuman Primate Discussion Group | Committee, Work group, Advisory group, or Task Force | OS | OD/DPCPSI/ORIP | Share information, coordinate activities, and identify opportunities for potential collaboration among HHS and DoD personnel to address nonhuman primate (NHP) topics including, but not limited to, considering supply issues, improving efficiency and rigor of NHP use, and minimizing the need for NHPs through the development and application of alternative animal models and new approach methods (NAMs). |
| HHS-Interagency Testing Coordination Group (TCG) | Committee, Work group, Advisory group, or Task Force | ASPR, BARDA, CDC, FDA | NIBIB | Coordinates federal response to COVID-19 testing. |
| HHS/NIH Small Business Town Hall | Meeting/ Workshop | CDC, FDA | OD/DPCPSI/ORIP, OD/OER | HHS/NIH Small Business Town Hall meetings organized by the Small Business Education and Entrepreneurial Development (SEED) at OER, OD. Attendance includes all Small Business Representatives (HHS Small Business Program Managers) of the NIH-ICOs, CDC and FDA. Meetings are three to four times a year and are organized to inform about news, updates, program reauthorization, directives changes/interpretation, budgets and initiatives (NOFOs) related to the Small Business program. |
| HHS/OGA Global Gender Equality and Reproductive Rights | Committee, Work group, Advisory group, or Task Force | OGA | This group meets monthly and reviews policies on gender equality and reproductive rights that have a global impact. | |
| HHS: Continuity Management Council | Committee, Work group, Advisory group, or Task Force | OS, CDC, CMS, FDA, IHS | OD/OM, OD/OM/ORS | This is a monthly meeting led by the HHS Administration for Strategic Preparedness and Response (ASPR) that brings together all HHS operating divisions to coordinate and discuss continuity plans and exercises. |
| HIV Clinical Guidelines Working Groups of OARAC | Committee, Work group, Advisory group, or Task Force | CDC, FDA, HRSA | NIAID, NICHD, NLM, OD/DPCPSI, OD/DPCPSI/OAR | There are five Office of AIDS Research Advisory Council (OARAC) Working Groups to maintain updated federally approved clinical practice guidelines for HIV. The five working groups are the 1) Panel on Antiretroviral Guidelines for Adults and Adolescents, 2) Panel on Opportunistic Infections in Adults and Adolescents with HIV, 3) Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV, 4) Panel for the Prevention and Treatment of Opportunistic Infections in Children with and Exposed to HIV, and 5) Panel on Treatment of HIV in Pregnancy and Prevention of Perinatal Transmission. The HIV Clinical Guidelines Panels update guidelines for HIV/AIDS care providers with the most current information on combination antiretroviral therapy, treatment and prevention of opportunistic infections for people with HIV; the prevention of perinatal HIV transmission; and the safety and efficacy of HIV therapies. |
| HIV/AIDS Cancer Match Study | Research Initiative | CDC | NCI | A study linking HIV and cancer registries in multiple US regions to evaluate the spectrum of cancer risk and outcomes in people living with HIV |
| Home and Community-Based Services Federal Opportunities Regarding Workforce and Research Data (HCBS FORWARD) Committee | Committee, Work group, Advisory group, or Task Force | ASPE, CMS | NIA | The Home and Community-Based Services Federal Opportunities Regarding Workforce and Research Data (HCBS FORWARD) Committee identifies, and makes recommendations on, key policy questions on the HCBS workforce to establish data priorities, analyze existing data sources on this workforce, and identify ways to fill critical gaps in knowledge. |
| HOPE Act NPRM Working Group | Committee, Work group, Advisory group, or Task Force | CDC, HRSA, OASH | NIAID | HOPE Act NPRM Working Group meets at least biweekly to develop new policy rule making for the HOPE Act (2013) for the Secretary |
| HRIT Modernization IPT | Committee, Work group, Advisory group, or Task Force | OS | OD/OCIO | HHS is working with NIH HR Stakeholders and NIH EA to rationalize NIH HR applications to HHS HR application |
| Human Milk Composition Initiative | Committee, Work group, Advisory group, or Task Force | FDA, OASH | NIEHS, OD/DPCPSI/ODS, OD/ECHO | The Human Milk Composition Initiative is a U.S.-Canada collaboration with subject matter experts from HHS, the U.S. Department of Agriculture, and other U.S. and Canadian agencies that coordinates across many entities to share information on human milk composition data availability for use by programs focused on maternal and child health. |
| IAA with FDA - Using big data to compare SARS-CoV-2 infection and therapeutic efficacy between human lung on a chip and animal model testing | Other | FDA | NIAID | This collaboration will allow the development of in vitro organ on a chip technology for modeling of SARS-CoV-2 infection, identification of biomarkers and transcriptomic and tissue expression imaging by MIBI/CODEX. The data collected from the organ on a chip systems will then be compared to ongoing analysis of human clinical samples and parallel testing in animal models of COVID. |
| ICCFASD SBI Working Group for Pregnant and Postpartum People (ISBI-WG) | Committee, Work group, Advisory group, or Task Force | AHRQ, ASPE, CDC, CMS, HRSA, IHS, SAMHSA | NIAAA | This is a special interest working group formed and led by the ICCFASD. The objectives of the ISBI working group are to exchange information and resources, identify gaps and opportunities for improved implementation and research, and expand collaboration and partnerships between federal agencies. The group includes representatives from the ICCFASD and other federal agencies. |
| ICCFASD Strategic Planning Working Group | Committee, Work group, Advisory group, or Task Force | FDA | NIAAA | The ICCFASD Strategic Planning Working Group was formed to review the ICCFASD Strategic Plan and make recommendations to the ICCFASD on ICCFASD strategic planning to make the most impact in the next several years. The ICCFASD Strategic Planning Working Group includes representatives from a variety of ICCFASD member agencies. Continued engagement with communities is essential to the ICCFASD. Input has been sought from a range of community partners (e.g., researchers, practitioners, individuals with lived experiences) to ensure that the ICCFASD collaborative partnership and its priorities and objectives address the needs of persons affected by Fetal Alcohol Spectrum Disorders (FASD) and their families and prevention of prenatal alcohol exposure in children. |
| IEEE Reporting Standards for In Vivo Neural Interface Research Working Group | Committee, Work group, Advisory group, or Task Force | FDA | NINDS | The Institute of Electrical and Electronics Engineers (IEEE) Reporting Standards for In Vivo Neural Interface Research Working Group aims to improve the transparency, interpretability, reproducibility of in vivo research studies involving neural interface technology and establish rigorous standard experimental methodologies and outcome measures. |
| ImmuneChip+ Area of Interest (AOI) | Committee, Work group, Advisory group, or Task Force | ASPR | NCATS, NIAID | This working group began with BARDA DRIVe and NCATS who developed an Microphsyiological Systems (MPS) AOI resulting in BAA contracts in 2021 for immune chip development. Continuation of these interests include refining more complex MPS that incorporate the ability to study immune responses across multiple tissues. Focus includes medical counter measures against biological, radiological and chemical threats while fostering the development of interoperable systems, biosensor incorporation (TEER etc.) and MPS standardizations. |
| Immunology Interest Group | Meeting/ Workshop | FDA | CC, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAMS, NIDA, NIDCD, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, OD/OIR | The NIH Immunology Interest Group brings together immunologists from across all NIH institutes as well as the FDA. The two major activities of the IG are a Wednesday afternoon lecture series highlighting world-class immunologists and intramural immunologists and an annual workshop where up to 350 NIH/FDA immunologists get together to present their work to the community. |
| IMPAACT 2046 - Understanding Parental Lactation and Infant Feeding Decisions Tailored to People with HIV (UPLIFT) | Research Initiative | CDC | NIAID, NICHD | This project is a collaboration with the CDC as lead agency to co-fund the IMPAACT 2046/UPLIFT study, which is a multi-site, mixed-methods, observational cohort study to explore infant feeding preferences, practices, and outcomes among mothers with HIV and their families in the United States. |
| IMPACT Collaboratory: Transforming Dementia Care | Research Initiative | CDC | NIA | "The mission of the IMbedded Pragmatic Alzheimer's disease (AD) and AD Related Dementias (AD/ADRD) Clinical Trials (IMPACT) Collaboratory is to build the nation’s capacity to conduct pragmatic clinical trials of interventions embedded within health care systems for people living with dementia and their care partners. The IMPACT Collaboratory accomplishes this mission by developing and disseminating best practice research methods; supporting the design and conduct of pragmatic trials, including pilot studies; building investigator capacity through training and knowledge generation; catalyzing collaboration among stakeholders, healthcare providers, and investigators; and ensuring the research includes culturally tailored interventions and people from diverse and under-represented backgrounds." |
| Implementation Research in HRSA Ryan White Sites: Screening and Treatment for Mental and Substance Use Disorders to Further the National "Ending the HIV Epidemic" (EHE) Goals | Research Initiative | HRSA | NIDA, NIMH | The National Institute of Mental Health (NIMH) and National Institute on Drug Abuse (NIDA) collaborated with the Health Resources and Services Administration (HRSA) HIV/AIDS Bureau to develop a research funding opportunity (RFA-MH-20-520 and RFA-MH-20-521) on methods to enhance screening and treatment for mental and substance use disorders in HRSA Ryan White HIV/AIDS Program funded sites through implementation research, in order to advance the goals of the Ending the HIV Epidemic in the U.S. initiative. The research initiative seeks to strengthen the research/service delivery collaboration between NIH grantees and HRSA-funded HIV care sites, with the goal of increasing retention in HIV care and viral suppression through implementation of evidence-based mental disorder and substance use screening, prevention, and treatment. The research initiative was published in 2020. Eight grants were funded through this initiative (6 NIMH grants and 2 NIDA grants). The NIMH maintains ongoing communication with HRSA to discuss progress and outcomes. |
| Improving Genomics/Omics Technical Standards and Molecular Tools for Prebiotic Probiotic Research and Development Working Group | Research Initiative | CDC, FDA | NCCIH, NCI, NHGRI, NHLBI, NIA, NIDDK, NIEHS, NINDS, OD/DPCPSI/ODS | The overarching workgroup effort is to enhance research initiatives/resource development as an Interagency Agreement (IAA) workgroup members committed to sustain and accelerate translatability of validation analytics and reference datasets using omics and other multi-omics substitutable [SMART] tools, devices, and HL-7 Fast Healthcare Interoperability Resources (FHIR) technologies to support rapid and efficient interoperability with electronic health records and clinical decision support systems. A second goal is to coordinate and plan trans-NIH and Inter-agency meetings, workshops and initiatives with greater efficiency of Institute and Center Operations (ICO) resources and expertise between agencies. Innovative technologies like HL-7 SMART on FHIR have been demonstrated to enhance health information exchange, affordably and accurately. Novel device monitoring using reference standards including, Food and Drug Administration (FDA) Precision and National Institute of Standards and Technology (NIST) nanofabrication, multi-omics and modeling strategies can be integrated to improve validation and standards biosafety, risk monitoring of adverse drug events, food safety, overuse and resistance to antibiotics, and emerging infection. The intent originated in April 2016 with an Initiative planning meeting that is now ongoing for IAA partnered with the Patient-Centered Outcomes Research Institute (PCORI); other IAA collaboratives in progress. |
| In Vitro Assessment of Dermal Hypersensitivity: Using Alternative Methods to Predict Skin Sensitization | Research Initiative | CDC, FDA | NIEHS | The primary goal of these efforts is to assess the utility of non-animal test methods for predicting human skin sensitization hazard in an expanded chemical space |
| In Vitro Assessment of Respiratory Hypersensitivity: Using Alternative Methods to Predict Respiratory Sensitization | Research Initiative | FDA | NIEHS | The primary goal of these efforts is to assess the utility of non-animal test methods for predicting human respiratory sensitization hazard in an expanded chemical space. |
| Industrywide exposure assessment study of workers exposed to graphene and other two-dimensional nanomaterials | Research Initiative | CDC | NIEHS | There have been relatively few studies evaluating the toxicity of 2D nanomaterials and even fewer data are available regarding workplace exposures in the United States. This project will provide real-world exposure data along with important material characteristic information for the interpretation of current and future toxicity and risk assessment studies. |
| Influenza (Flu) Risk Management Meeting (FRMM) (aka HHS Pandemic and Seasonal Influenza Risk Management Meeting) | Committee, Work group, Advisory group, or Task Force | ASPR | NIAID | The Influenza (Flu) Risk Management Meeting (FRMM) is a senior-level forum for decision makers from stakeholder agencies to identify and address risk management issues related to the development, acquisition, deployment, and use of medical and public health countermeasures for influenza. Meetings provide members with a venue to discuss issues relating to the U.S. Department of Health and Human Services (HHS) response to pandemic influenza. Subjects for discussion include but are not limited to considerations of vaccine and antiviral stockpiles and clinical trial response to influenza outbreaks such as H7N9 and H3N2v. HHS Agency Collaborators on this activity include CDC, FDA, and OS. |
| Informal U.S. Government Nanoplastics Interest Group | Committee, Work group, Advisory group, or Task Force | ATSDR, CDC, FDA | NIEHS | Formed in 2019 with the encouragement of the Nanoscale Science, Engineering, and Technology (NSET) Subcommittee of the National Science and Technology Council Staff support from the National Nanotechnology Coordination Office (NNCO). Purposes include:Share information, Enhance collaborations and coordinate research, Minimize redundancies, leverage resources and capabilities, Understand knowledge gaps. Thrust areas: Collection & Characterization , Hazard, Exposure, & Risk Assessment, Reduction & Mitigation. |
| Innovation Equity Forum (IEF) Women's Health R&D | Other | CDC, FDA | FIC, NCATS, NCI, NHLBI, NIA, NIBIB, NIMH, NIMHD, NINDS, OD/DPCPSI/ODP, OD/DPCPSI/ORWH, OD/DPCPSI/SGMRO | The Innovation Equity Forum, convened by NIH and the Bill & Melinda Gates Foundation, consists of over 250 experts and community partners-representing over 50 countries and diverse perspectives in women's health. Forum members have developed an opportunity map to promote innovation that substantially impacts women's health within the next 15 years. |
| Innovation Equity Forum Steering Committee | Research Initiative | BARDA, FDA | FIC, NCATS, NCCIH, NHLBI, NIA, NINDS, OD/DPCPSI/ORWH | Purpose:1.Convene a global community of key stakeholders and gatekeepers of health innovation around women’s health R&D (e.g., funders, researchers, and community partners) 2. Mobilize and accelerate innovations to improve women’s health through shared understanding of critical women’s health R&D priorities (where possible based on existing blueprints) 3. Foster cross-sector multinational partnerships to advance R&D efforts in women’s health innovation through enhanced coordination and collaboration |
| Inter-Agency Working Group for Bayh-Dole | Committee, Work group, Advisory group, or Task Force | ACL, AHRQ, CDC, FDA | OD/OER, OD/OSP | The Interagency Working Group for Bayh-Dole: Manages extramural research activities within the field of tech transfer and works to create consensus and policy across agencies, in consultation with the National Institutes of Health. |
| Inter-Agency Working Group on Technology Transfer | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NCI, NIAID, NINDS, OD/OER, OD/OSP, OD/OTT | The Interagency Working Group for Technology Transfer: Identifies and disseminates creative approaches to technology transfer from Federal laboratories through an inter-agency task force. |
| Inter-Society Coordinating Committee for Practitioner Education in Genomics (ISCC-PEG) | Committee, Work group, Advisory group, or Task Force | CDC, HRSA | CSR, NCATS, NCI, NEI, NHGRI, NIA, NIAAA, NLM | This education collaborative facilitates sharing interactions among professional societies, agencies, and health systems. It intends to enhance the accrual of knowledge and skill among practitioners applying genomic results to clinical care. In its start-up phase, the ISCC-PEG focused primarily on physicians and dentists. It has since expanded to engage and collaborate with allied practitioner groups such as nurse practitioners, physician assistants, pharmacists, genetic counselors, and nurses comprising integrated health care teams. It will continue to add other relevant professions and add to the reviewed and searchable educational resources on its website. |
| Interagency Adult Literacy Research Group | Committee, Work group, Advisory group, or Task Force | ACF | NICHD | This is an intra-government, trans-agency group shares updates on research relevant to adults with lower literacy skills (i.e., reading and writing) as well as practices and programs that are being implemented to assist these learners in various agencies. The goal is for staff and corresponding agencies to be informed of broader efforts occurring around adult literacy within the federal government and to keep abreast of research and promising programs that might inform their work. |
| Interagency advisory group - immune assay variant updates for Project NextGen | Committee, Work group, Advisory group, or Task Force | ASPR, BARDA, CDC, FDA | NIAID | Advisory group to provide expert recommendation regarding the need to develop new assays for variants supporting development of candidate vaccines in the project next gen portfolio and assessment of their correlates of protection |
| Interagency Agreement between NIH OLAW and ASPR Biomedical Advanced Research and Development Authority (BARDA) | Other | BARDA | OD/OER | OLAW technical and administrative services provided to ensure compliance with the Public Health Service Policy on Humane Care and Use of Laboratory Animals (PHS Policy) for BARDA awards involving research with live vertebrate animals. |
| Interagency Agreement between NIH OLAW and Centers for Disease Control and Prevention (CDC) | Other | CDC | OD/OER | OLAW technical and administrative services provided to ensure compliance with the Public Health Service Policy on Humane Care and Use of Laboratory Animals (PHS Policy) for CDC awards involving research with live vertebrate animals. |
| Interagency Agreement between NIH OLAW and Food & Drug Administration (FDA) | Other | FDA | OD/OER | OLAW technical and administrative services provided to ensure compliance with the Public Health Service Policy on Humane Care and Use of Laboratory Animals (PHS Policy) for FDA awards involving research with live vertebrate animals. |
| Interagency Agreement NTP/NIEHS and NCTR/FDA | Other | FDA | NIEHS | Collaborative working relationship between NTP/NIEHS and NCTR/FDA |
| Interagency Artificial Pancreas Working Group | Committee, Work group, Advisory group, or Task Force | FDA | NIBIB, NIDDK | The Interagency Artificial Pancreas Working Group is a group of multi-disciplined scientists and clinicians from the Food and Drug Administration (FDA) and the National Institutes of Health (NIH) to support the Artificial Pancreas Initiative. The goals of this initiative are to provide infrastructure for narrowing the gap between basic biomedical knowledge and clinical application of novel technologies, and to cross-fertilize and partner with stakeholders in order to identify and overcome the clinical and scientific challenges to the development of an artificial pancreas. Through collaborative efforts, such as workshops, the group strives to develop innovative strategies to achieve their goals. |
| Interagency Autism Coordinating Committee (IACC) | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, CDC, CMS, FDA, HRSA, IHS, SAMHSA | NICHD, NIDCD, NIEHS, NIMH, NINDS, OD/DPCPSI/OBSSR | The Interagency Autism Coordinating Committee (IACC) is a federal advisory committee charged with coordinating federal activities concerning autism spectrum disorder (ASD) and providing advice to the Secretary of Health and Human Services on issues related to autism. Membership of the Committee includes a wide array of federal departments and agencies involved in ASD research and services, as well as public stakeholders, including self-advocates, family members of children and adults with ASD, advocates, service providers, and researchers, who represent a variety of perspectives from within the autism community. The Committee members provide a wide range of expertise and experiences and allow the IACC to address the breadth of issues and challenges faced by individuals and families affected by autism. The IACC was reauthorized under the Autism Collaboration, Accountability, Research, Education, and Support (CARES) Act of 2019. In fiscal year 2024, the IACC held four full committee meetings on: October 11, 2023; January 24, 2024; April 17, 2024; and July 10, 2024. The IACC also held an IACC Strategic Plan Update Meeting on September 23, 2024. The IACC is currently authorized under the Autism CARES Act of 2024. |
| Interagency Cancer Diagnostic Devices (CD2) Task Force for Near-Patient Use | Committee, Work group, Advisory group, or Task Force | FDA, HRSA | NCI | The NCI, FDA, Health Resources and Services Administration (HRSA) and CMS partnered in late 2019 to establish the Interagency Cancer Diagnostic Devices (CD2) Task Force for Near-Patient Use. Near-patient diagnostics generally refers to a system whereby a sample is analyzed, and the results are delivered in the same location and while the patient is being evaluated. Near-patient diagnostics are often offered at point-of-care settings where at-home tests may be available with a prescription or purchased over-the-counter. CD2 is a collaborative effort among four federal partners working together within and across their respective missions to bring more soluctions to: detect and diagnose cancer earlier; enhance identification of patients at high risk of developing cancer and surveillance of those at risk of cancer recurrence; improve monitoring of patient response during cancer treatment; and reduce the effect of health disparities and equitably extend the benefits of health care to all populations. The primary goal of this initiative is to develop opportunities that accelerate the pace by which point of care diagnostic devices get to patients for the earlier detection and screening of cancer. The Task Force and Initiative will address cancer types for geographically isolated, medically underserved, and otherwise vulnerable communities, with emphasis to: 1) Cancer types with clear, existing need and highly prevalent, for example cervical cancer; and 2) Cancer types that have evidence of future need from emerging at-risk populations, for example liver cancers derived from nonalcoholic steatohepatitis (NASH). On Friday, September 17, 2021, leadership from the National Cancer Institute (NCI), Food and Drug Administration (FDA), and Health Resources and Services Administration (HRSA) signed a Memorandum of Understanding (MOU) to support solutions for early cancer detection and diagnosis to improve patient outcomes, quality of life, and reduce health disparities among medically underserved, geographically isolated, and otherwise vulnerable populations through the interagency CD2 task force. |
| Interagency Collaborative Animal Research Education (ICARE) Training Project | Training Initiative | ASPR, BARDA, FDA | OD/OER | The Interagency Collaborative Animal Research Education (ICARE) Academies and Train the Trainer Institutes use active learning to train participants to meet their responsibilities for animal welfare oversight. The program empowers accountability for facts and conceptual understanding of Federal standards through the study of realistic problems encountered in animal care and use programs. Faculty includes subject matter experts from biomedical research institutions and federal agencies, including National Institutes of Health (NIH) and United States Department of Agriculture (USDA). Institutional Animal Care and Use Committee members, staff, institutional officials, veterinarians, animal facility personnel, administrators, consultants, as well as compliance and regulatory personnel involved in the humane use of animals in research all may participate in the ICARE program |
| Interagency Collaborative to Advance Research in Epilepsy (ICARE) | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, HRSA | FIC, NCATS, NHGRI, NHLBI, NIA, NIAAA, NIAMS, NICHD, NIMH, NINDS | The Interagency Collaborative to Advance Research in Epilepsy (ICARE) is an interagency epilepsy working group that includes broad representation across the National Institutes of Health (NIH) institutes and centers (ICs) involved in epilepsy-related research, as well as across the Department of Health and Human Services other Federal agencies multiple epilepsy research organizations, and patient advocacy groups with a primary focus on biomedical research. The purpose of this group, which is led by the National Institute of Neurological Disorders and Stroke, is to increase communication among institutes and agencies sponsoring epilepsy-related research and to explore opportunities for increased coordination. The group’s annual meetings provide a forum for sharing information about ongoing and planned epilepsy research activities, highlighting advances, discussing needs and opportunities, and promoting increased collaboration toward common research goals. https://www.ninds.nih.gov/Current-Research/Focus-Research/Focus-Epileps… |
| Interagency Committee on Disability Research (ICDR) | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, ATSDR, CDC, CMS, FDA, HRSA, IHS, OS, OSG, SAMHSA | NHLBI, NIA, NIAID, NICHD, NIDCD, NIMH, NINDS | The ICDR's mission is to promote coordination and cooperation among federal deparments and agencies conducting disability, independent living, and rehabilitation research programs--including those that relate to assistive technology research, and research that incorporates the principles of universal design. |
| Interagency Committee on Drug Control (ICDC) | Committee, Work group, Advisory group, or Task Force | FDA, SAMHSA | NIDA | The Interagency Committee on Drug Control (ICDC) meets three times per year and is a collaboration between NIDA, DEA, FDA, ONDCP, SAMHSA, and the State Department (Chaired by Drew Townsend for 2024). Members share news on new initiates, U.S. Scheduling Actions, International Scheduling issues, upcoming Legislation initiatives, and other new business. This exchange of information and related documents are collated into minutes and circulated with the group. |
| Interagency Committee on Human Nutrition Research (ICHNR) | Committee, Work group, Advisory group, or Task Force | OASH, CDC, FDA | NCI, NHLBI, OD/DPCPSI/ODS, OD/DPCPSI/ONR | The Interagency Committee on Human Nutrition Research (ICHRN) is charged with improving the planning, coordination, and communication among federal agencies engaged in nutrition research. |
| Interagency Committee on Smoking and Health | Committee, Work group, Advisory group, or Task Force | CDC, OS | NCI, NIDA | The Committee was chartered in 1985 and advises the Secretary, Department of Health and Human Services (DHHS), the Assistant Secretary for Health, and the Centers for Disease Control and Prevention on coordination of research, educational programs, and other activities within the Department that relate to the effect of smoking on human health, and on coordination of these activities with other Federal, State, local, and private agencies. The Committee established and maintains a liaison with appropriate private entities, other Federal agencies, and State and local public agencies respecting activities relating to the effect of cigarette smoking on human health. |
| Interagency Committee on the American Community Survey (ACS) | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC, CMS, HRSA, OS | NICHD, OD/DPCPSI/SGMRO | OMB in conjunction with the Census Bureau co-chairs this Federal Interagency Committee on the ACS (the Committee) established by the Interagency Committee on Statistical Policy’s Subcommittee on the ACS (ICSP-SACS). The Committee will exist to participate in reviews of the ACS content and tests of new and/or revised content for the ACS. The Committee will make recommendations on any additions, revisions, or deletions of questions on the ACS to the ICSP-SACS in its capacities of advising the Chief Statistician at OMB and the Director of the Census Bureau. |
| Interagency Comparative Genomics Working Group | Committee, Work group, Advisory group, or Task Force | CDC | NCATS, NCCIH, NCI, NHGRI, NIAID, NIBIB, NICHD, NIDCR, NIGMS | The comparative genomics program officers working group (previously animal genomics WG) was created to bridge the scientific engagement across diverse species biomedical models (NIH), agricultural models (USDA, USAID), and other non-model or research organisms (NSF, DOE) in the area of genomics. NHGRI co-leads the Inter-Agency Comparative Genomics working group with the USDA. It aims to have representatives across the government including: multiple NIH institutes, multiple divisions within the National Science Foundation, multiple USDA institutes, the United States Agency for International Development, and the Foundation for Food and Agriculture Research. |
| Interagency Coordinating Committee for Newborn Screening | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, HRSA | NICHD | This committee makes recommendations for screening certain disorders, developing a system to adjudicate newborn screening expansion, and assist states in implementing programs to test for the recommended conditions. |
| Interagency Coordinating Committee on Fetal Alcohol Spectrum Disorder (ICCFASD) | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC, CMS, HRSA, IHS, SAMHSA | NIAAA, NICHD, NIDA | The Interagency Coordinating Committee on Fetal Alcohol Spectrum Disorders (ICCFASD) fosters improved communication, cooperation, and collaboration among disciplines and federal agencies that address issues related to prenatal alcohol exposure. ICCFASD is sponsored and chaired by the National Institute on Alcohol Abuse and Alcoholism (NIAAA). https://www.niaaa.nih.gov/interagency-coordinating-committee-fetal-alco… |
| Interagency Coordinating Committee on Healthy Aging and Age-Friendly Communities | Committee, Work group, Advisory group, or Task Force | AHRQ, ASPE, CDC, CMS, HRSA, OASH, SAMHSA | NIA | The Interagency Coordinating Committee on Healthy Aging and Age-Friendly Communities, authorized by the Older Americans Act, supports federal coordination on aging-related priorities. This coordination will contribute to an America that values older adults, embraces aging, and recognizes that all people have the right to live with dignity, make their own choices, and participate fully in society. |
| Interagency Coordinating Committee on Human Growth Hormone and Creutzfeldt-Jakob Disease | Committee, Work group, Advisory group, or Task Force | OASH, CDC, FDA | NIDDK, NINDS | The Public Health Service Interagency Coordinating Committee on Human Growth Hormone (hGH) and Creutzfeldt-Jakob Disease (CJD) was established in 1985 by the Assistant Secretary for Health, the Department of Health and Human Services (HHS) to review information relevant to patients who received pituitary-derived hGH that was distributed through the NIH-funded National Hormone and Pituitary Program (NHPP). The Committee analyzes this information to determine the extent of the problem of transmission of CJD (a rare, incurable brain disease) through contaminated pituitary hGH, and to inform physicians and patients who received pituitary hGH about the health risks associated with pituitary hGH. Although NHPP’s distribution of hGH ceased when its potential to transmit CJD was discovered in 1985—and today, recombinant growth hormone that is not susceptible to CJD contamination is exclusively used for treatment—the Committee continues to maintain oversight of this issue because CJD may take years or decades to develop. The Committee includes representatives from the National Institutes of Health (NIH), the Food and Drug Administration (FDA), and the Centers for Disease Control and Prevention (CDC), and is chaired by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Director. |
| Interagency Coordinating Committee on the Prevention of Underage Drinking (ICCPUD) | Committee, Work group, Advisory group, or Task Force | CDC, SAMHSA | NIAAA, NIDA | ICCPUD provides national leadership in federal policy and programming to support state and community activities that prevent and reduce underage drinking. ICCPUD develops the Comprehensive Plan for preventing and reducing underage drinking. |
| Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NCATS, NCI, NIEHS, NLM, OD/DPCPSI/ORIP | The ICCVAM Authorization Act outlines the following purposes of ICCVAM: Increase the efficiency and effectiveness of U.S. federal agency test method review.Eliminate unnecessary duplication of effort and share experience among U.S. federal regulatory agencies.Optimize utilization of scientific expertise outside the U.S. federal government.Ensure that new and revised test methods are validated to meet the needs of U.S. federal agencies.Reduce, refine, or replace the use of animals in testing where feasible. |
| Interagency Coordination on Firearm Violence and Community Violence | Committee, Work group, Advisory group, or Task Force | CDC | NINR, OD/DPCPSI/OBSSR | N/A |
| Interagency Elder Justice Working Group | Committee, Work group, Advisory group, or Task Force | ACL, ASPE, CDC, HRSA, OASH | NIA | The Elder Justice Interagency Working Group (EJWG) provides continuous input and support to the Elder Justice Coordinating Council (EJCC), which was established in response to the Elder Justice Act. The EJWG is comprised of federal officials responsible for carrying out elder justice activities, including elder abuse prevention, research, grant and program funding, and prosecution. Since 2012, members have met regularly to discuss emerging issues, promising practices, and ways to coordinate their efforts. |
| Interagency Group for Development of Lung Infection Models for P. aeruginosa and A.baumannii | Committee, Work group, Advisory group, or Task Force | BARDA, CDC, FDA | NIAID | This interagency working group meets quarterly to discuss the development of various lung infection animal models. |
| Interagency Group on Alzheimer's Disease and Related Dementias for implementation of the National Alzheimer's Project Act | Committee, Work group, Advisory group, or Task Force | ACL, AHRQ, AoA, ASPE, CDC, CMS, HRSA, IHS, OASH, SAMHSA | NIA | This interagency group was established by Department of Health and Human Services (HHS) in response to the Congressional directive to address Alzheimer disease. The group works to carry out the National Alzheimer’s Project Act’s charges to coordinate research and services across agencies, accelerate the development of AD/ADRD treatments, improve early diagnosis and coordination of care, reduce ethnic and racial disparities in rates of AD/ADRD, and coordinate with international efforts to fight these conditions. |
| Interagency Hazard Communication Working Group | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NCI, OD/DPCPSI/OBSSR | This group coordinates hazard communication research and implementation needs across the Federal government, and is co-led by DCCPS Senior Scientist Paul Han. |
| Interagency High Containment Laboratory Working Group | Committee, Work group, Advisory group, or Task Force | ASPR, CDC, FDA | OD/OM, OD/OM/ORS | The purpose is to fulfill strategies for the Interim Strategy for Federal High Containment Laboratories. |
| Interagency Modeling and Analysis Group (IMAG) | Committee, Work group, Advisory group, or Task Force | AHRQ, BARDA, CDC, FDA | CSR, FIC, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, OD/DPCPSI/OBSSR, OD/DPCPSI/ODS | The purpose of the IMAG is to provide an open forum for communication among government representatives to share updates on individual programs from the various IMAG agencies, and to plan trans-agency activities that will have a broad impact on the communities served by the IMAG. https://www.imagwiki.nibib.nih.gov/content/msm-participants |
| Interagency Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Working Group | Committee, Work group, Advisory group, or Task Force | CDC | NIAID, NINDS | The Interagency ME/CFS Working Group consists of multiple government agencies and patient ME/CFS patient advocacy organizations interested in research and care issues related to ME/CFS. The working group was established to help coordinate ME/CFS-related efforts across the federal agencies to enhance research efforts, improve treatment options and patient outcomes, promote public outreach, and strengthen workforce development. The working group, which is co-led by NINDS and CDC, met for the first time in August 2020, and will continue to meet regularly to provide updates, discuss issues relevant to ME/CFS research, and identify and foster communication and collaboration across the federal agencies and with ME/CFS stakeholders. |
| Interagency Nonhuman Primate Repurposing Working Group | Committee, Work group, Advisory group, or Task Force | CDC | OD/DPCPSI/ORIP | This working group is exploring possible ways to efficiently re-use research animals. |
| Interagency Oncology Task Force Fellowship: Tracks 3 and 4 | Training Initiative | FDA | NCI | The objective of the Interagency Oncology Taskforce Fellowship Program is to train a cadre of scientists in research and research-related regulatory review, policies, and regulations so that they develop a skill set bridging the two disparate processes. Track 3 will train postdocs in the aspects of research and review of medical product development process to facilitate the movement of drugs, biologics, and devices from the bench to the bedside. Fellows will receive formal training and mentoring in the relevant federal statutes, regulations, principles, and practices of FDA medical product review, including issues related to product development, e.g., manufacturing processes, production, purification, characterization, testing, quality control, and quality assurance, understanding the biology, chemistry, pharmacoepidemiology, manufacturing, postmarketing surveillance, and mechanism of action/pathogenesis of disease. Track 4 of this fellowship will provide training in cancer prevention (e.g., chemoprevention, vaccination, and early detection). Individuals will be trained in the drug, biologic, or device development and approval processes and their application to study populations (including healthy subjects) to facilitate the movement of novel approaches from the bench to the community. Combining training in public health, cancer prevention research, and research-related regulatory overview will allow individuals to develop expertise across these disciplines. |
| Interagency Oncology Taskforce Fellowship: Track 1 | Research Initiative | FDA | NCI | Also Training Initiative.The Interagency Oncology Task Force Fellowship (IOTF) program trains scientists in research and research-related regulatory review, policies, and regulations to develop a skill set that bridges the two disparate processes. This track will train physicians currently participating in the NIH Hematology Oncology Fellowship in aspects of clinical trials methodology and analysis, epidemiology, clinical aspects of medical product development, and regulation, as it relates to clinical research to facilitate the movement of drugs, biologics, and devices from the basic bench science to commercialization.Multilateral Benefit in a Joint Program to Recruit Combined FDA and NCI/CCR Clinical Investigators: the FDA gains an academic oncologist with disease-specific expertise who is actively involved and understands critical nuances of the field; NCI gains a clinical investigator and leader who understands regulatory considerations in drug development; and the oncologic community gains a regulator/academic who will provide a leadership voice to help design trials with regulatory endpoints in mind. |
| Interagency Pain Research Coordinating Committee (IPRCC) | Committee, Work group, Advisory group, or Task Force | AHRQ, FDA | NCCIH, NIDA, NIDCR, NINDS, NINR | The Interagency Pain Research Coordinating Committee (IPRCC) is a Federal advisory committee created by the Department of Health and Human Services to enhance pain research efforts and promote collaboration across the government, with the ultimate goals of advancing the fundamental understanding of pain and improving pain-related treatment strategies. |
| Interagency Pediatric Surge Working Group | Committee, Work group, Advisory group, or Task Force | ASPR, CDC, HRSA | NICHD | The interagency working group meets weekly to discuss pressing surges and opportunities as it relates to addressing pediatric healthcare capacity, delivery and science. |
| Interagency Policy Committee on Social Determinants of Health (SDOH) | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, CDC, CMS, HRSA, SAMHSA | NIAMS, NINR | Convened by the White House Domestic Policy Council and the Office of Science and Technology Policy - the SDOH-IPC purpose is to support a Federal framework for a Coordinated Care Delivery Model to Address SDOH; Develop a White House Action Plan sharing guidance and potential policy levers to address Social Determinants of Health through data accessibility, integration and blending and braiding of funds. |
| Interagency Policy Council on Nutrition | Committee, Work group, Advisory group, or Task Force | CDC, HRSA | NCI, NHLBI, NIDCR, NIDDK, OD/DPCPSI/ONR | This working group is convened by the White House Domestic Policy Council (DPC) was charged with organizing the White House Conference on Hunger, Nutrition, and Health and developed and is implementing the Biden-Harris Administration National Strategy on Hunger, Nutrition, and Health. |
| Interagency Rehabilitation and Disability Research Portfolio | Resource Development | ACL, CDC | NICHD | IRAD is a searchable database of government funded research projects in the areas of disaiblity, independent living and rehabilitation research. The purpose of IRAD is to provide a publicly available resource that enables analysis of the federal research portfolio in disability, independent living, and rehabilitation research. This will aid in collaboration and coordination of research activities across federal agencies, as well as increase transparency and visibility for the public and legislative stakeholders. |
| Interagency Select Agent Review Group (ISARG) | Committee, Work group, Advisory group, or Task Force | BARDA, CDC | NIAID, OD/OM, OD/OM/ORS, OD/OSP | The Interagency Select Agent Review Group (ISARG), composed of members from the Centers for Disease Control and Prevention (CDC), the Department of Justice, the Department of State, the NIH-OD and BARDA, advises the National Institute of Allergy and Infectious Diseases (NIAID) on whether facilities and procedures at NIAID-funded foreign research sites are comparable to those required by the Select Agent Regulations for domestic institutions before Select Agent work at the foreign site may proceed. |
| Interagency Task Force for Trauma-Informed Care | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, ASPE, CDC, CMS, FDA, HRSA, IHS, OCR, OMHA, SAMHSA | NICHD, NIMH | The Center for Mental Health Services (CMHS) leads the leads the Interagency Task to develop best practices for trauma-informed identification, referral, and support. The Interagency Task Force on Trauma-Informed Care (TIC Task Force) was established on October 13th, 2018, with the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act of 2018 (Public Law 115-271). The TIC Task Force is charged with identifying, evaluating, and making recommendations regarding: (1) best practices with respect to children and youth, and their families as appropriate, who have experienced or are at risk of experiencing trauma; and (2) ways in which federal agencies can better coordinate to improve the federal response to families impacted by substance use disorders and other forms of trauma. |
| Interagency Task Force on the Arts and Human Development | Committee, Work group, Advisory group, or Task Force | ACF, CDC, SAMHSA | NCCIH, NCI, NIA, NICHD, NIMH, OD/DPCPSI/OBSSR | Beginning in 2011, the National Endowment for the Arts (NEA) has convened a Federal Interagency Task Force on the Arts and Human Development to encourage more and better research on how the arts can help people reach their full potential at all stages of life. https://www.arts.gov/national-initiatives/task-force/members |
| Interagency Well-being Workgroup | Committee, Work group, Advisory group, or Task Force | CDC, OASH, ACL, HRSA, SAMHSA | NIA | The Interagency Well-being Workgroup coordinates efforts across the federal government to promote well-being as a public health priority. |
| Interagency Working Group (IWG) | Committee, Work group, Advisory group, or Task Force | SAMHSA, ARPA-H, CDC, FDA, HRSA | OD/OM, OD/OM/OALM | White House Interagency Working Group for Historically Black Colleges and Universities. Including all federal agencies and senior leadership from HHS. |
| Interagency Working Group - Harmful Algal Blooms and Hypoxia Research Control Act (IWG HABHRCA) | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NIEHS | This group coordinates and convenes Federal agencies to discuss HAB and hypoxia events in the United States, and to develop action plans, reports, and assessments of these situations. This group was mandated and formed following the HABRCA legislation in 2014. |
| Interagency Working Group on Biological Data Sharing | Committee, Work group, Advisory group, or Task Force | FDA | NCI | The working group will identify the diverse types of biological and clinical data, define specific needs and best practices for storing, managing, curating, archiving, and maintaining the confidentiality and integrity of these data, and define agency roles and responsibilities for addressing research and policy (exclusive of regulatory) priority gaps to enable data sharing. The working group will develop a road map to enable robust sharing and maximize reuse of data, identifying opportunities for interagency coordination, and academic, industrial, and international partnerships. |
| Interagency Working Group on Communicating Hazard Information and Other Types of Uncertainty, NSTC Subcommittee on Social and Behavioral Sciences | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NCATS, NCI, NIMHD, NINR | The primary goal of the SBS is to focus on the ways in which social and behavioral research can be created and mobilized to support the U.S. government in making evidence-based decisions. This subgroup of the SBS aims to increase USG’s effective and equitable communication of hazard information and various types of uncertainty in a variety of domains to the American public. It may explore topics including health communication (e.g., regarding COVID-19 and other public health crises), environmental hazard communication, and climate crisis communication, among others. It will emphasize how approaches informed by social and behavioral sciences can increase the likelihood that diverse subpopulations of the U.S. public will receive the information they need in ways that enable responses consistent with individuals’ overall health and well-being, no matter where they live or how they identify. |
| Interagency Working Group on Historically Black Colleges and Universities, Tribal Colleges and Universities, and Minority-Serving Institutions (IWG-MSI) | Committee, Work group, Advisory group, or Task Force | FDA | OD/SWD | The Interagency Working Group on Historically Black Colleges and Universities, Tribal Colleges and Universities, and Minority-Serving Institutions is a working group of CoSTEM, focused on addressing the need for a coordinated Federal approach to carry out a sustained program of outreach activities to increase clarity, transparency, and accountability for Federal research agency investments in STEM education and research activities at HBCUs, TCUs, and MSIs, including such institutions in rural areas. This will be done by identifying and determining the use of existing policies, confirming best practices across agencies, identifying and collecting barriers to performance and implementation, and recommending opportunities for improvement, uniformity, and consistency across agencies. |
| Interagency Working Group on Research and Data Standards | Committee, Work group, Advisory group, or Task Force | AHRQ, ASPE, CMS, FDA, HRSA, IOS, SAMHSA | OD/DPCPSI/ORWH | The Working group integrates women's health across federal research portfolios to develop and strengthen research and data standards on women’s health across all relevant research and funding opportunities. |
| Interagency Working Group on Scientific Collections | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NCI, NLM, OD/OSP | The Interagency Working Group on Scientific Collections (IWGSC) was established by the White House National Science and Technology Council (NSTC) in June 2006. IWGSC currently operates as a subcommittee under the Committee on Science and Technology Enterprise. IWGSC is co-chaired by U.S. Department of Agriculture and the Smithsonian and originally reported to the NSTC Committee on Science. IWGSC’s mission was to assess the status and needs of the scientific collections owned, managed, and/or supported by the U.S. Federal Government, and to recommend ways to improve their management, effectiveness and impact.The IWGSC is currently implementing the three recommendations which:• Formalize each Department’s and Agency’s policies toward scientific collections;• Establish appropriate budgeting guidelines and procedures that ensure proper stewardship for scientific collections, which are considered government assets; and• Create a public clearinghouse for information on the scientific collections that are owned, managed and supported by the Federal Government. |
| Interagency Working Group on the National Healthcare Quality and Disparities Report | Committee, Work group, Advisory group, or Task Force | AHRQ, ACF, ASPE, CDC, CMS, FDA, HRSA, IHS, OS | NCATS, NCI, NHLBI, NIDA, NIMHD, NINR, OD/DPCPSI | Provide expert scientific guidance for the National Healthcare Quality and Disparities Report. These annual reports measure trends in effectiveness of care, patient safety, timeliness of care, patient centeredness, and efficiency of care. The reports present, in chart form, the latest available findings on quality of and access to health care. |
| Interdepartmental Federal Cannabis Partners | Committee, Work group, Advisory group, or Task Force | CDC, FDA, SAMHSA | NCI, NIDA | The Federal Cannabis Partners working group meets quarterly to discuss issues of interest related to cannabis and public health and to foster collaborations across HHS and other agencies. |
| Interdepartmental Health Equity Collaborative (IHEC) | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, SAMHSA | NCATS, NCI, NEI, NHLBI, NIA, NIAAA, NIAID, NICHD, NIDDK, NIEHS, NIMH, NIMHD, NINDS, NINR, OD/DPCPSI/ODP | The Interdepartmental Health Equity Collaborative (IHEC), formerly known as Federal Interagency Health Equity Team (FIHET), is a trans-federal working group to address health equity in the US health systems. The mission of theis to convene federal leaders to end health disparities by building capacity for equitable policies and programs, cultivating strategic partnerships, and sharing relevant models for action. IHEC goals are to: 1) collaborate with diverse federal agencies to define linkages and implement coordinated approaches between their missions and health equity; 2) identify, develop, and integrate strategies with measurable outcomes to advance health equity in/through federal policies, programs, and activities; 3) leverage assets, influence, and experiences of federal agencies, partners, and communities to advance health equity; 4) generate, facilitate, and translate research, data, and emerging knowledge about health equity into practice and policy; and 5) educate and mentor leader and peers to develop equity champions within all federal agencies. https://minorityhealth.hhs.gov/npa/ |
| Interdepartmental Serious Mental Illness Coordinating Committee | Committee, Work group, Advisory group, or Task Force | SAMHSA, ACL, CMS | NIMH | In December 2016, the 21st Century Cures Act was signed into law (Public Law 114-255). Through this Act, the Interdepartmental Serious Mental Illness Coordinating Committee (ISMICC) was established to address the needs of adults with serious mental illness (SMI) and children and youth with serious emotional disturbance (SED) and their families so that Americans with SMI and SED are able to improve their lives and receive the highest possible standard of care-care that is deeply informed by knowledge of science and medicine. The ISMICC includes representatives from eight federal departments that support programs that address the needs of people with SMI and SED and is informed and strengthened by the participation of non-federal members, including national experts on health care research, mental health providers, advocates, people with living with mental health conditions, and their families and caregivers. This cross-sector, public-private partnership provides a unique opportunity to share and generate solutions to the problems facing the mental health system. The ISMICC seeks to support a system where individuals with SMI or SED are able to engage effectively with a range of treatment and recovery support services that promote opportunities for people to live well in their communities. A central charge of this committee is to submit two reports to Congress, the first no later than one year after the enactment of the Act, and the second five years following enactment. The ISMICC has five priority areas and corresponding workgroups for these priority areas. Representatives from the National Institute of Mental Health (NIMH) sit on each of these workgroups. |
| International Cancer Control Partnership | Other | CDC | NCI | The National Cancer Institute and the Union for International Cancer Control convened global partners including the Centers for Disease Control and Prevention (CDC) to cooperate in assisting countries to develop and implement quality cancer plans linked to Non-communicable Disease (NCD) control. This International Cancer Control Partnership, ICCP, believes that prioritizing cancer is critical to reaching the “25x25” goal for NCD control. ICCP partners will assist countries by: (1) Creating and maintaining a searchable database of current cancer control plans from around the globe; (2) Performing analysis of gaps and highlighting priority areas for inclusion in plans; (3) Providing technical assistance to countries working to develop plans with targets and evaluation strategies; (4) Providing planners with relevant existing materials and tools; and (5) Coordinating an online community of practice (through partnership with the University of New Mexico's Project ECHO) for dissemination and utilization of scientific knowledge for National Cancer Control Plan implementation. ICCP partners will use their collective state, country, and regional-level planning experience to guide plan development and implementation and will ensure planners utilize effective, evidence-based strategies to help meet the global NCD targets. |
| International Cancer Screening Network (ICSN) | Committee, Work group, Advisory group, or Task Force | CDC | NCI | The International Cancer Screening Network (ICSN) is a voluntary consortium of screening practitioners who work in countries that are planning for or implemented population-based cancer screening programs with the mission of reducing the burden of cancer by promoting dialogue and collaborative cancer screening research, evaluation and dialogue regarding the effectiveness of context-specific evidence-based cancer screening programs, including promotion, recruitment and follow-up among other relevant topics. ICSN goals include:1. To provide global leadership in cancer screening research and evaluation by organizing scientific studies, biennial conferences, consultations, mentorship, training, and by publishing collaborative papers.2. To create a community of screening practitioners (researchers, evaluators, implementers and screening program staff) to exchange data, evidence, ideas and experiences that advance the field of cancer screening.3. To assist in the design of studies to evaluate the process and effectiveness of cancer screening programs; to evaluate and promote innovation in cancer screening through new technologies; to enhance the screening process for treatment of screen-detected lesions, among other topics.4. To be a source of education and dialogue about basic aspects of cancer screening as well as advanced and emerging concepts and technology.5. To include membership who conducts cancer screening research, develop infrastructure for cancer screening, and establish programs whose goal is to deliver the highest quality health care while producing the maximum benefit to the population and minimizing its harms. Other collaborative activities: health survey, meeting/workshop |
| International Lead Working Group | Committee, Work group, Advisory group, or Task Force | CDC, CDC, FDA | FIC, NIEHS | Working group to share lessons learned in the field of Pb from research to policy to regulation. |
| International Medical Countermeasure (MCM) Interagency Technical Working Groups | Committee, Work group, Advisory group, or Task Force | OGA, ASPR, CDC, FDA, OS | NIAID | The purpose of these Technical Working Groups is to establish a process to facilitate interagency technical discussions to: (1) advance a U.S. Government proposal for a global coordination hub which convenes and facilitates information sharing to help coordinate the implementation platforms and partners and improve equity and equitable access to MCMs (e.g., personal protective equipment, diagnostics, vaccines, therapeutics, etc.) during health emergencies; (2) ensure that any U.S. Government proposal will be credible internationally and can be effectively operationalized; and (3) inform the development and reexamination of U.S. Government policy positions relevant to longer-term solutions within and beyond the potential outcomes of the G20 process and other multilateral efforts including at the WHO and in the Working Group on Amendments to the International Health Regulations (2005) (WGIHR) IHR and Intergovernmental Negotiating Body (INB) negotiations. |
| International Neonatal Consortium | Meeting/ Workshop | FDA | NICHD | Launched on May 19, 2015, INC is C-Path’s ninth consortium – a global collaboration formed to forge a predictable regulatory path for evaluating the safety and effectiveness of therapies for neonates. “By uniting stakeholders from research institutions, drug developers, regulatory agencies, patient advocacy and other organizations,” said Janet Woodcock, Director of the U.S. Food and Drug Administration’s Center for Drug Evaluation and Research (FDA/CDER), “INC can develop practical tools that can be incorporated into clinical trials for neonates, which will then lead to more successful, efficient trials and provide this population with better treatments.” |
| International Working Group | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NIAID, NICHD, NIDDK | This working group brings scientists from multiple Federal agencies together to discuss and present research regarding the various clinical research topics like human subjects protection and regulations governing clinical research. |
| Intragovernmental Select Agents and Toxins Technical Advisory Committee (ISATTAC) | Committee, Work group, Advisory group, or Task Force | CDC, ASPR, FDA | NIAID, OD/OM, OD/OM/ORS, OD/OSP | The ISATTAC is a working group of subject matter experts from the Federal Government formed by the Centers for Disease Control and Prevention (CDC) Director to provide recommendations to the CDC's Division of Regulatory Science and Compliance in three technical areas: 1) review requests for exclusion of attenuated strains, 2) review requests to conduct restricted experiments, and 3) review select agents and toxins. The Committee conducts a biannual review, required by the Select Agent Rule, of the Select Agents and Toxins list for HHS. |
| Invent It Here; Make It Here IPC | Committee, Work group, Advisory group, or Task Force | ASPE, ASPR, FDA, IOS, OGC, OGA | OD/OER, OD/OSP, OD/OTT | Implementing Executive Order on Federal Research and Development in Support of Domestic Manufacturing and United States Jobs (also known as “Invent It Here, Make It Here”) |
| Iodine Initiative | Resource Development | FDA | OD/DPCPSI/ODS | The NIH Office of Dietary Supplement's Iodine Initiative past and present activities include convening state of the science workshops and symposia, development of databases that characterize the iodine content of foods and dietary supplements, and supporting the improvement of analytical measurements, assessments of U.S. population-level iodine intake and iodine status. |
| Its a Noisy Planet. Protect Their Hearing® Public Education campaign | Public Education Campaign | CDC | NIDCD | The National Institute on Deafness and Other Communication Disorders (NIDCD) sponsors It’s a Noisy Planet Protect Their Hearing®, a national public education campaign to increase awareness among parents of children ages 8 to 12 about noise-induced hearing loss (NIHL) and how to prevent it. The campaign disseminates messages through print and digital materials, social media, community events, and other methods. The CDC’s National Center for Environmental Health and National Institute for Occupational Safety and Health (NIOSH) have actively collaborated with the NIDCD for this campaign. |
| Joint Agency Microbiome Working Group | Committee, Work group, Advisory group, or Task Force | FDA | NCI, NIA | JAM is an inter-agency group that helps to promote trans-agency collaborations advancing microbiome-related research and to coordinate symposia and workshops to share research advances, identify scientific/technical knowledge gaps, support development of standards/resources, and update related regulatory activities/needs. |
| Joint External Evaluation Working Group (JEEWG) | Committee, Work group, Advisory group, or Task Force | OS, CDC, FDA, OS | NCI, NIAID, NIEHS, NINDS, OD/OM/ORS, OD/OSP | Supports the Global Health Security Agenda activities related to International Health Regulations implementation to include internal and external joint evaluations, draft a National Action Plan (NAP) to address recommendations, and periodically review and report the status of the NAP. |
| Joint Subcommittee on Environment, Innovation and Public Health (JEEP) | Committee, Work group, Advisory group, or Task Force | OSTP, ASPR, CDC, FDA | NIEHS | The purpose of the JEEP is to promote Federal cross-disciplinary research, development, and solutions to evolving and immediate environmental and public health concerns. The JEEP will address areas that cut across disciplines and federal initiatives and are fundamentally linked by their associated public health impacts to detect, address, and mitigate these concerns. Such areas include ones that are congressionally mandated (e.g. contaminants of emerging concern, PFAS, sustainable chemistry, toxic exposures), and other topics that would benefit from the cross-disciplinary, cross-Agency approach of the JEEP. The scope of the JEEP includes landscape and gap analysis to understand the Federal research and development portfolio, strategic planning to ensure a robust research and development infrastructure, coordination of Federal research and development efforts, and drafting policy to address gaps in Federal response to environmental and public health concerns. |
| Kaposi Sarcoma and HHV8 in Sickle Cell and Other Ugandan Populations | Research Initiative | CDC | NCI | Epidemiological studies are being conducted to assess small-area variation of Kaposi's sarcoma-associated herpesvirus (HHV8) and to learn about socio-demographical and environmental risk factors for HHV8 and Kaposi sarcoma in Uganda. |
| Kidney Innovation Accelerator | Research Initiative | OSTP, ASPR, FDA, OASH | NCATS, NIBIB, NIDDK | KidneyX, also called the Kidney Innovation Accelerator, is a public-private partnership between the U.S. Department of Health and Human Services (HHS) and the American Society of Nephrology (ASN). Established in April 2018, KidneyX aims to use prize competitions to accelerate the development of innovative solutions that can prevent, diagnose, and/or treat kidney diseases. KidneyX aims to promote collaboration between patients, health professionals, innovators, industry, and government with the ultimate goal of improving quality of life for people living with kidney diseases. |
| Kidney, Urologic, and Hematologic Diseases Interagency Coordinating Committee | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, HRSA | NCCIH, NCI, NHLBI, NIA, NICHD, NIDDK, NINDS | The Kidney, Urologic, and Hematologic Diseases Interagency Coordinating Committee (KUHICC), chaired by NIDDK, encourages cooperation, communication, and collaboration among all Federal agencies involved in kidney, urology, and hematology research and other activities. Section 429 of Public Law 99-158 created the KUHICC in 1987. The committee met for the first time in 1988, and has the following subcommittees: Kidney Interagency Coordinating Committee, Urology Subcommittee, and Hematology Subcommittee. Meetings focus on interagency collaboration to elicit ideas from meeting participants to enhance current research directions within the National Institutes of Health and to form partnerships among agencies. |
| Know Stroke | Public Education Campaign | CDC | NINDS | The goal of the Know Stroke campaign is to help educate the public about the symptoms of stroke and the importance of timely access to medical care. The campaign includes outreach to consumers and health care professionals using mass media, partnerships, and community education. |
| Lab-2-Market Subcommittee | Committee, Work group, Advisory group, or Task Force | FDA | OD/OTT | The Lab-to-Market (L2M) Subcommittee is an interagency community convened by OSTP to strengthen the Nation’s ability to transition federally funded innovations from the laboratory to the commercial or government marketplace. Maximizing the real world impact of research and development (R&D) to improve lives—regardless whether the research was done at a Federal lab, a university, or a private company—has been a long standing priority of the U.S. Government across multiple Administrations. |
| Leprosy Research Support in Armadillos (Dasypus novemcinctus) | Other | HRSA | NIAID | The Leprosy Research Support and Maintenance of an Armadillo Colony – Post Genome Era interagency agreement provides standardized research reagents to investigators worldwide to assist in the development of skin test antigens used to detect leprosy. This agreement supports collaborative research to continuously improve biochemical, microbiological, and immunological models for leprosy research in an effort to provide the most up-to-date resource and expertise for mycobacterial researchers. |
| Leveraging Implementation Science to End the HIV Epidemic in the U.S.: Progress and Opportunities for Federal Agencies | Research Initiative | CDC, HRSA | NIAID | Development of manuscript. |
| Library of Congress Demographic Group Terms (LCDGT) Advisory Board | Committee, Work group, Advisory group, or Task Force | SAMHSA | NLM | Members of the Library of Congress Demographic Group Terms Advisory Board are appointed for a minimum of two years. Duties include reviewing proposals for new or changed demographic group terms and voting on whether to approve each one. The Advisory Board also discusses and votes on broader topics and policies affecting the development and maintenance of the vocabulary. https://www.loc.gov/aba/publications/FreeLCDGT/freelcdgt.html |
| Linkage of Surveillance, Epidemiology, End Results data to Centers for Medicare and Medicaid data | Resource Development | CMS | NCI | SEER registry data (e.g., cancer diagnosis date, site, histology) are individually linked to CMS data (e.g., enrollment, claims, assessments and surveys) using personally identifiable information. The data on the matching cancer cases are pulled together with CMS data on non-cancer controls (e.g., individuals not known to have a cancer diagnosis who reside in a SEER area) to create four research data resources: SEER-Medicare, SEER-Medicare Health Outcomes Survey (SEER-MHOS), SEER-Consumer Assessment of Healthcare Providers and Systems (SEER-CAHPS) and SEER-Medicaid. |
| Linkage of Surveillance, Epidemiology, End Results- Medicare to Dept of Housing and Urban Development (HUD) data | Resource Development | CMS | NCI | SEER registry data (e.g., cancer diagnosis date, site, histology) that are individually linked to CMS Medicare data (e.g., enrollment, claims, assessments and surveys) are then indivdiually linked to HUD housing assistance data. The linkage of these data allows for the examination of the associations between housing assistance status with cancer presentation, treatment, and outcomes. |
| Liquid Biopsy Working Group | Committee, Work group, Advisory group, or Task Force | CMS, FDA | NCI | This transagency work group meets monthly to review progress in liquid biopsy toward early detection of cancer. Members from several NCI Divisions and Offices, CMS and FDA participate in the meeting. As part of this committee, experts from the extramural community are invited to speak about latest progress in liquid biopsy. |
| Logical Observation Identifiers Names and Codes | Resource Development | AHRQ, CDC, CMS, HRSA, IHS, IOS | NLM | This activity supports the maintenance, distribution, and continued development of LOINC® (Logical Observation Identifiers Names and Codes), a set of universal codes and names to identify laboratory and other clinical observations and facilitate the exchange and pooling of clinical results for clinical care, outcomes management, public health, and research. NLM collaborates with other federal agencies such as the Agency for Healthcare Research and Quality, CDC, Centers for Medicare and Medicaid Services, Health Resources and Services Administration, Indian Health Service, and the HHS Immediate Office of the Secretary to ensure that LOINC is reviewed and enhanced in ways that meet their needs. http://www.nlm.nih.gov/research/umls/loinc_main.html |
| Long-Term Impact of Military-Relevant Brain Injury (LIMBIC) Consortium/Chronic Effects of Neurotrauma Consortium (GENC) Government Steering Committee | Committee, Work group, Advisory group, or Task Force | ACL | NINDS | The goals of LIMBIC-CENC are to examine the immediate effects of concussion on the brain as well as those later in life (e.g. risk for dementia), to identify the best treatments for concussion. and to disseminate this information to service members and relevant stakeholders. |
| Lower Limb Prosthetics Research Standards Working Group | Committee, Work group, Advisory group, or Task Force | ACL, AHRQ, CMS, FDA | NICHD | This working group helps to determine research standards for lower limb prosthetics. |
| Lupus Federal Working Group (LFWG) | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, HRSA | NCCIH, NEI, NHLBI, NIAID, NIAMS, NIDCR, NIDDK, NIEHS, NIMHD, NINDS, OD/DPCPSI/ORWH | The Lupus Federal Working Group, established on behalf of the Department of Health and Human Services (HHS) Secretary by the National Institutes of Health (NIH), facilitates collaboration among NIH components, other Federal agencies, voluntary and professional organizations, and industry groups with an interest in lupus. https://www.niams.nih.gov/about/working-groups/lupus-federal |
| Lyme and Tick-borne Diseases Work Group | Committee, Work group, Advisory group, or Task Force | CDC, CMS, FDA, OS | NIAID | This workgroup involves members from agencies including the Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), and the National Institutes of Health (NIH) with the purpose of continued coordination and communication of activities, policy updates, events, agency highlights, and other shared interests relating to Lyme disease and other tick-borne diseases. |
| Making Medicaid Data More Accessible Through Common Data Models and FHIR APIs | Resource Development | ASPE, FDA | NLM | This joint agency project involving the FDA and NIH's National Library of Medicine (NLM) aims to develop and publish open-source code to format Transformed Medicaid Statistical Information System (T-MSIS) Research Identifiable Files (RIFs) to the FDA's Sentinel Common Data Model in tandem with NLM's formatting of the T-MSIS RIFs to the Observational Medical Outcomes Partnership Common Data Model. Data quality will be characterized using a harmonized Data Quality Assessment Framework for electronic healthcare data developed in a previously funded Office of the Secretary Patient-Centered Outcomes Research Trust Fund (OS-PCORTF) project. This project will assess the feasibility of using Fast Healthcare Interoperability Resources (FHIR) Application Programming Interfaces (APIs) to link T-MSIS data with electronic health records. |
| Mapping of the Systematized Nomenclature of Medicine-Clinical Terms (SNOMED CT) and International Classification of Disease (ICD) Clinical Terminology | Resource Development | CDC | NLM | NLM supports the HHS goal for the nationwide implementation of an interoperable health information technology infrastructure to improve the quality and efficiency of health care. Achieving this goal requires that key clinical data elements are captured or recorded in a detailed, standardized form (using standard vocabularies, codes, and formats) as close to their original sources (e.g., patients, health care providers, laboratories, diagnostic devices) as possible. If these standardized clinical data can also be used to generate HIPAA-compliant billing transactions automatically, this will provide another incentive for the adoption of clinical data standards. For the automated generation of bills from clinical data to become a reality, robust mappings from standard clinical terminologies to the HIPAA code sets must be created. To support the transition to ICD-10-CM (International Classification of Diseases, Tenth Revision. Clinical Modification), a map from SNOMED CT to ICD-10-CM is being created. The ICD-10-CM is a system used by physicians and other health care providers to classify and code all diagnoses, symptoms, and procedures recorded in conjunction with hospital care in the United States. https://www.nlm.nih.gov/research/umls/mapping_projects/snomedct_to_icd1… |
| Maternal Health Leadership Team | Committee, Work group, Advisory group, or Task Force | ASPE, ACF, ACL, AHRQ, CDC, CMS, HRSA, IEA, IHS, OASH, OCR, SAMHSA | NICHD | This is an HHS-wide leadership team that meets monthly to discuss ongoing and planned maternal health activities in response to the White House Blueprint for Maternal Health and the HHS Action Plan for Maternal Health. NIH reports out on ongoing maternal health activities and coordinates and collaborates with other HHS agencies as possible. |
| Medical Devices Epidemiology Network (MDEpiNet) TMJ Patient-led RoundTable Working Group - Steering Committee | Meeting/ Workshop | FDA, AHRQ, CMS | NIDCR | The Medical Devices Epidemiology Network (MDEpiNet) TMJ Patient-Led RoundTable comprises key stakeholders as partners including patients, the FDA, NIDCR, the Agency for Health Care Research and Quality (AHRQ), the American Association of Oral and Maxillofacial Surgeons (AAOMS), TMJ implant manufacturers, clinicians, scientists, advocacy organizations, and other experts, all under the auspices of Medical Devices Epidemiology Network (MDEpiNet). |
| Medical Expenditure Panel Survey (MEPS): Experiences with Cancer Survivorship Supplement | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC | NCI, OD/DPCPSI/OBSSR | The Medical Expenditure Panel Survey (MEPS) is a national household survey administered by AHRQ to collects data on health care utilization and expenditures. The National Cancer Institute (NCI) has collaborated with CDC, AHRQ, and OBSSR to provide supplemental funding for the MEPS Experiences with Cancer Survivorship Supplement (also known as the MEPS Cancer Self-Administered Questionnaire or CSAQ). Using responses to the National Health Interview Survey (NHIS) question about ever receiving a cancer diagnoses, cancer survivors were asked to complete the MEPS Cancer Supplement in 2011, 2016, and 2017. Responses from this sample of cancer survivors was used to improve the quality of data for estimating the cancer survivorship burden in the United States. Data from the MEPS Cancer Supplement are publicly available without charge and are used to further understand the burden of cancer, its treatment and impact on access to health care, the ability to work and participate in usual activities, health insurance, and quality of care. The collaborative MEPS Cancer Supplement working group, led by NCI, developed an updated version of this questionnaire, with additional questions on employment impacts of cancer, social isolation, survivorship care, and social determinants of health, which will be administered by AHRQ (with the core MEPS survey) in FY2025. |
| Medical Imaging & Data Resource Center | Research Initiative | ARPA-H, FDA | NCATS, NCI, NHLBI, NIBIB, NLM | MIDRC curates medical images and develops AI-ready data and AI/ML algorithms for helping with the clinical management of COVID-19 patients and the pandemic in general. As of this date, over 105,000 highly curated AI-ready COVID image-sets are already available for public access and investigation, about 200,000 more image-sets are in the pipeline, and 24 algorithms are under development. MIDRC-sponsored challenges have enhanced algorithm development. The contract was extended to a third year (ongoing) to include & study patients who have suffered from longer-term symptoms of COVID. MIDRC has expanded interoperability with other NIH ICs (e.g., NCATS, NHBLI) and Argonne National Lab (DOE). An internal NIH advisory board monitors MIDRC progress along with NIBIB. MIDRC is now a national resource of curated medical images of COVID patients, ready to be used to develop clinically useful AI applications. Medical facilities in 24 US states contribute information and interact with MIDRC through the American Association of Medical Physicists, the American College of Radiology, and the Radiological Association of America. |
| Memorandum of Understanding (MoU) between FDA/Center for Drug Evaluation and Research (CDER) and NIH/NINDS | Other | FDA | NINDS | This MoU provides a mechanism for addressing cross-cutting issues related to drug evaluation and research for neurological disorders, from bench science to clinical studies and the Food and Drug Administration (FDA) approval. |
| Memorandum of understanding (MOU) between NIDA and the FDA Center for Devices and Radiological Health | Other | FDA | NIDA | Will Aklin leads a memorandum of understanding (MOU) between NIDA and the FDA Center for Devices and Radiological Health which was established in 2019 and reissued in 2024. The MOU allows regular interaction and sharing of information regarding digital therapeutics and device-based treatments. MOU goals also include developing guidance to grant applicants to help navigate the FDA submission and authorization process and accelerate the progression of these technologies through the regulatory pathway. |
| Memorandum of Understanding (MOU) between the FDA Center for Devices and Radiological Health and NIH/NINDS | Other | FDA | NINDS | This MOU provides a mechanism for addressing cross-cutting issues related to the development of devices for neurological disorders, from bench science to clinical studies and the Food and Drug Administration (FDA) approval. |
| Memorandum of Understanding (MOU) between the FDA/Center for Biologics Evaluation and Research (FDA/CBER) and NIH/NINDS | Other | FDA | NINDS | This MoU provides a mechanism for addressing cross-cutting issues related to therapy development for neurological disorders, from bench science to clinical trials and the Food and Drug Administration (FDA) approval and licensure. |
| Memorandum of Understanding Between the FDA Center for Biologics Evaluation and Research and the NIH National Heart, Lung, and Blood Institute | Meeting/ Workshop | FDA | NHLBI | Promote scientific discussion between the FDA Center for Biologics Evaluation and Research and the National Heart, Lung, and Blood Institute. |
| Mental Health Multi-Disciplinary Team Consultation | Committee, Work group, Advisory group, or Task Force | ACF, CDC, SAMHSA | NIMH | The Quarterly Mental Health Meeting is the proactive prong of the Mental Health Multi-Disciplinary Team Consultation (MDTC) that brings together federal experts and national resettlement agencies into a crisis planning and system-reflection space to identify strengths and areas for improvement in mental health practice, policy, training, and data collection. |
| Metabolic responses in human induced pluripotent stem cells upon flavivirus infection | Research Initiative | FDA | NCATS | Transmission of flaviviruses is well documented through human cells and tissues, even in cases where the individual was no longer viremic. Cord blood (a rich source of stem cells) samples when associated with Zika travel risk are deemed ineligible for stem cell collection, which is essential for research and clinical purposes, and an FDA-approved Zika detection assay for cord blood is unavailable. Variability exists among individual flaviviruses concerning tissue tropism, their ability to evade or counteract host immunity, and the detection and presentation of disease. Moreover, expanding insect vector populations due to rising global temperature have led to a surge in flavivirus diseases. So, a rapid, sensitive, and specific pan-flaviviral detection tool may prove useful to the detection of cells/tissues that may be contaminated and able to transmit disease to recipients. Metabolomics is a precise analytical method to acquire detailed insights into the myriad metabolites generated within biological systems. Metabolomics can identify distinctive cellular metabolites produced during pathogen invasion, serving as markers for detecting pathogens. In this project, the Parties initially aim at studying the metabolite dynamics in human induced pluripotent stem cells (hiPSCs) upon ZIKV and DENV (Dengue virus) infection. The long-term goal of this project is to identify metabolite markers that can be used for detection of flaviviruses in human stem cells. |
| Microphysiological Systems for Drug Efficacy and Toxicity Testing (Tissue Chip for Drug Screening) | Research Initiative | ASPR, BARDA, FDA | NCATS, NCI, NEI, NHLBI, NIAID, NIAMS, NIBIB, NIDCR, NIDDK, NIEHS, NIGMS, NINDS, NINR, OD/DPCPSI/ORWH, OD/DPCPSI/OSC | The Microphysiological systems (MPS) initiative aims to develop 3-D human tissue chips that accurately model the structure and function of human organs, such as the lung, liver, and heart. Researchers are currently using these models to predict whether a candidate drug, vaccine, or biologic agent is safe or toxic in humans in a faster and more cost-effective way than current methods. More than 30 percent of promising medications have failed in human clinical trials because they are determined to be toxic despite promising pre-clinical studies in animal models. These organs-on-chips will also enable scientists to predict more accurately how effective a therapeutic candidate would be in clinical studies. To help streamline the therapeutic development pipeline, NIH, in collaboration with the US Food and Drug Administration (FDA) and the Innovation and Quality (IQ) Consortium of pharmaceutical companies, is leading this initiative to improve the process for predicting whether drugs will be safe and effective in humans. In an effort to overcome some clinical trial challenges, Clinical Trials on a Chip is supporting the development of tissue chips to inform clinical trial design for both common and rare diseases; support the planning and execution of clinical trials; assist in patient stratification; help identify reliable clinical trial endpoints; and ultimately develop tools for more informative and efficient clinical trials for both common and rare diseases. Another program, the Tissue Chips in Space initiative, is creating tissue- and organ-on-chip platforms that can be sent to the ISS National Lab so that scientists can better understand the role of microgravity on human health and diseases and translate those findings to improve human health on Earth. Current efforts aim to bring tissue chips towards FDA regulatory qualification as drug development tools by establishing Translational Centers for MPS. |
| Mind Your Risks | Public Education Campaign | CDC, CMS | NHLBI, NIA, NINDS | The Mind Your Risks campaign is designed to create awareness and action about the fact that risk factors for stroke, particularly hypertension, may be linked to cognitive impairment and dementia. |
| Mine Safety and Health Research Advisory Committee | Committee, Work group, Advisory group, or Task Force | CDC | NIEHS | The Mine Safety and Health Research Advisory Committee shall advise the Secretary, HHS; the Director, Centers for Disease Control and Prevention (CDC); and the Director, National Institute for Occupational Safety and Health (NIOSH), CDC, on the conduct of mine health research, including making of grants and entering into contracts for such research (30 U.S.C. §812(b)(2), [Section 1 02(b )(2) of Public Law 91-173]). The committee shall also provide advice on the conduct of mine safety research. The committee shall evaluate the degree to which: 1) the mine research activities of NIOSH conform to those standards of scientific excellence appropriate to Federal scientific instructions in accomplishing objectives in mine safety and health; 2) the mine research activities, alone or in conjunction with other known activities inside and outside of NIOSH, address currently relevant needs in the field of mine safety and health; and 3) the research activities produce intended results in addressing important research questions in mine safety and health, both in terms of applicability of the research findings and translation of the findings. |
| Molecular Approaches To Antiviral Development For Viral Hepatitis and Other Viral Diseases | Research Initiative | IHS | NIDDK | Molecular Approaches To Antiviral Development For Viral Hepatitis and Other Viral Diseases |
| Molecular Profiling of Diabetes and its Complications | Research Initiative | IHS | NIDDK | Molecular Profiling of Diabetes and its Complications |
| Morphine Milligram Equivalents (MME) Interagency Meeting | Committee, Work group, Advisory group, or Task Force | FDA, CDC, IHS | NIDA | Trans-agency workgroup to identify gaps in calculating daily morphine milligram equivalents (MMEs). |
| MOU among USDA/FDA/NIH | Other | FDA | OD/OER | Agreement for reciprocal cooperation to assist each agency in meeting its responsibilities in promoting proper laboratory animal care and welfare |
| Move Your Way Steering Committee | Committee, Work group, Advisory group, or Task Force | OASH | NIA | This committee assists in the planning and review of activities to disseminate and educate the public about the National Physical Activity Guidelines. |
| Multi-Agency Tissue Engineering Science (MATES) Interagency Working Group | Committee, Work group, Advisory group, or Task Force | FDA | NCI, NHLBI, NIA, NIAMS, NIBIB, NIDCD, NIDCR, NINDS | The Multi-Agency Tissue Engineering Sciences (MATES) is an ad hoc interagency working group that provides a platform where federal agencies can interact efficiently and effectively to exchange information on tissue engineering and regenerative medicine. MATES members coordinate efforts related to cell therapy, gene therapy, biomaterials, tissue engineering, regenerative medicine and organ on a chip from research and development to commercialization. MATES holds monthly meetings to exchange information. |
| Multiagency Data Initiatives to Build Data Capacity for Patient-Centered Outcomes Research for COVID-19 | Resource Development | ASPE, AHRQ | NCATS, NIDDK | NIH is working with the HHS Office of the Assistant Secretary for Preparedness and Evaluation on several initiatives related to building data capacity for patient-centered outcomes research for COVID-19. The “Understanding COVID-19 Trajectory and Outcomes in the Context of MCC Through e-Care Plan Development” project (a collaboration between AHRQ, NIDDK, and ASPE) works to expand standards-based e-Care plan tools to facilitate aggregation and sharing of person-centered-planning data, including health concerns, social determinants of health, complex constellations of COVID 19 sequelae, and behavioral health concerns, across disparate systems for people living with multiple chronic conditions, their caregivers, and their care teams. The “National COVID-19 Longitudinal Research Database Linked to CMS Data” project (a collaboration between ASPE, NIDDK, and NCATS) works to evaluate disparities by looking at community characteristics using geocoding approaches and information on air quality and housing. It also seeks to capture care and outcomes of vulnerable populations such as patients on dialysis, nursing home residents, and low-income individuals. |
| Multiple Chronic Conditions eCare Plan Project | Resource Development | AHRQ, ASPE | NIDDK | The goal of this initiative is to build data capacity for conducting pragmatic, patient-centered outcomes research (PCOR) by developing an interoperable electronic care (eCare) plan to facilitate aggregation and sharing of critical patient-centered data across home, community, clinic and research-based settings by extracting data from point-of-care health systems and allowing transfer of that data cross settings. This is a joint initiative between the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the Agency for Healthcare Research and Quality (AHRQ), and the Assistant Secretary for Planning and Evaluation (ASPE). |
| Muscular Dystrophy Coordinating Committee (MDCC) | Committee, Work group, Advisory group, or Task Force | ACL, CDC, FDA, HRSA | NHLBI, NIAMS, NICHD, NINDS | This Federal Advisory Committee coordinates activities relevant to the various forms of muscular dystrophy across the National Institutes of Health (NIH) and other federal agencies. The committee also includes members from patient organizations. Strategic planning efforts by the coordinating committee led to the development of an Action Plan for the Muscular Dystrophies, which contains specific research objectives appropriate to the missions of all committee member agencies and organizations, and thus serves as a central focus for research coordination. The plan is available at the MDCC web site. https://www.mdcc.nih.gov/ |
| MyHealthfinder Steering Committee | Committee, Work group, Advisory group, or Task Force | OASH, AHRQ, CDC, CMS, FDA, HRSA, SAMHSA | NCI, NIA, NLM | The MyHealthfinder Steering Committee, comprised of federal partners from across HHS, provides insight into how MyHealthfinder (an online prevention and wellness resource from the HHS Office of Disease Prevention and Health Promotion) can be more useful to public health professionals and the clients they serve. The MyHealthfinder Steering Committee was formed in December 2020 and meets quarterly. |
| N3C Privacy-Preserving Record Linkage | Resource Development | ASPE, CMS | NCATS | Privacy-preserving record linkage (PPRL) significantly expands the scope of secure patient-level data for N3C and unlocks exciting new opportunities for clinicians, rearchers, and patients to better understand COVID-19. Users sign A Linkage Honest Broker Agreement (LHBA) and use de-identified tokens to get information from N3C. PPRL protects patient privacy, enhances accuracy, and enables diverse insights. |
| Nanotechnology Characterization Laboratory | Resource Development | FDA | NCI | Collaboration Type: Also Research Initiative The Nanotechnology Characterization Laboratory (NCL) performs and standardizes the preclinical characterization of nanomaterials intended for cancer therapeutics and diagnostics developed by researchers from academia, government, and industry. The NCL serves as a national resource and knowledge base for cancer researchers and facilitates the development and translation of nanoscale particles and devices for clinical applications. |
| Nanotechnology Environmental and Health Implications (NEHI) Working Group | Committee, Work group, Advisory group, or Task Force | ATSDR, CDC, FDA | NIEHS | Nanoscale Science, Engineering, and Technology (NSET) subcommittee of the National Science and Technology Council charged NEHI with supporting Federal activities to protect public health and the environment. The NSET Subcommittee’s NEHI Working Group provides a forum for focused interagency collaborations on nanotechnology EHS and leadership in establishing the national nanotechnology EHS research agenda, in addition to communicating EHS information among NNI agencies and to the public. Specifically 1) Providing for information exchange among Federal agencies that support nanotechnology research and Federal agencies responsible for regulation and guidelines related to nanomaterials and products containing nanomaterials; 2) Facilitating the identification, prioritization, and implementation of research and other activities required for the responsible research necessary to develop, use, and oversee nanotechnology; 3) Promoting communication of information related to research on environmental, health, and safety implications of nanotechnology; 4) Adaptively managing (i.e., coordinating, reviewing, and revising) the interagency EHS research strategy (EHS Strategy Document); 5) Assisting in developing information and strategies as a basis for drafting guidance in the safe handling and use of nanomaterials and products; 6) With input from NSET and other interagency groups, supporting the development of tools and methods to identify, prioritize, and manage strategies for specific research to enable risk analysis and regulatory decision-making for nanomaterials and products incorporating nanomaterials; 7) Supporting developed of nanotechnology standards, including nomenclature and terminology, by consensus-based Nanotechnology Standards; and 8) Working with international organizations and governments to share information on and to develop strategies for nanotechnology environmental, health, and safety research. |
| NAPA Clinical Care Subcommittee | Committee, Work group, Advisory group, or Task Force | ASPE, ACL, AHRQ, CDC, CMS, HRSA | NIA, NINDS | Subcommittee of the Advisory Council on Alzheimer's Research, Care, and Services, focused on clinical care |
| NAPA Federal Subgroup | Committee, Work group, Advisory group, or Task Force | ACL, AHRQ, ASPE, CDC, CMS, FDA, HRSA, IHS | NIA, NINDS | This informal group of federal staff meets quarterly, in advance of the meetings of the Alzheimer’s Council for Alzheimer’s Research, Care, and Services, to exchange information on federal activities in the Alzheimer’s disease space and foster collaborations across agencies. From 2014-2021, NIA facilitated these meetings and set the focus on research opportunities; starting in 2022, HHS/ASPE will coordinate these meetings and promote discussion across all NAPA goals, including those related to research, care, supports, and risk reduction. |
| NAPA Long-term Supports and Services (LTSS) Subcommitee | Committee, Work group, Advisory group, or Task Force | ASPE, ACL, AHRQ, CDC, CMS, FDA, HRSA, IHS | NIA, NINDS | Subcommittee of the Advisory Council on Alzheimer's Research, Care, and Services, focused on LTSS |
| NAPA Research Subcommittee | Committee, Work group, Advisory group, or Task Force | ASPE, AHRQ, CDC, CMS, FDA | NIA, NINDS | Subcommittee of the Advisory Council on Alzheimer's Research, Care, and Services, focused on research advances |
| NAPA Risk Reduction Subcommittee | Committee, Work group, Advisory group, or Task Force | ASPE, ACL, AHRQ, CDC, CMS, FDA, HRSA, IHS | NIA, NINDS | Subcommittee of the Advisory Council on Alzheimer's Research, Care, and Services, focused on risk reduction |
| NASA-NIH Scientific Potential/Actual Collaborative Efforts (SPACE) Group | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OASH | NCATS, NCI, NEI, NHGRI, NHLBI, NIA, NIAID, NIAMS, NIBIB, NICHD, NIDCD, NIDCR, NIDDK, NIMH, NINDS, NLM | The NIH-NASA Scientific Potential/Actual Collaborative Efforts (SPACE) Group is an integral part of the NIH-NASA collaboration that meets quarterly to discuss, share and brainstorm biomedical research activities that are of relevance to human and astronaut heath. Its goals are to explore areas of potential synergy for biomedical scientific research that fulfills the mandates of both NIH and NASA, facilitate communications among researchers to instigate and support collaborative efforts, and explore possibilities for joint efforts between NIH and NASA to support research into synergistic biomedical interest areas and implement appropriate joint exercises. |
| NASA/NIH/BARDA/FDA Microphysiological systems (MPS) Initiative Advisory Group | Research Initiative | BARDA, FDA | NCATS, NCI, NIAID | Contracts in this multi-agency collaboration will extend tissue viability and physiological function to a minimum of 6 months using automated engineering capabilities for real-time online readouts in complex human in vitro models, such as tissue chips or microphysiological systems. |
| NASEM Forum on Aging, Disability, and Independence | Committee, Work group, Advisory group, or Task Force | ACL | NIA | The National Academies of Sciences, Engineering, and Medicine have formed the Forum on Aging, Disability, and Independence to foster dialogue and address issues of mutual interest and concern related to aging and disability. |
| NASEM Forum on Drug Discovery, Development, and Translation | Committee, Work group, Advisory group, or Task Force | ASPR, FDA | NCATS, NCI, NIAID, NIMH, NINDS, OD/OSP | The Forum on Drug Discovery, Development, and Translation provides a neutral venue for stakeholders in government, academia, industry – including pharmaceutical, biotechnology, and digital health companies, foundations, and disease and patient advocacy to highlight critical issues, spur cross-sector collaboration, and inspire action towards improving the system of drug discovery, development, and translation. Forum-hosted public workshops, action collaboratives, and meetings focus on critical issues and practical approaches for advancing a clinical trials enterprise that is more efficient, effective, patient-centered, and integrated into the health delivery system. |
| NASEM Forum on Neuroscience and Nervous System Disorders | Committee, Work group, Advisory group, or Task Force | FDA | NCCIH, NIA, NIAAA, NIDA, NIEHS, NIMH, NINDS | The National Academies of Sciences, Engineering, and Medicine (NASEM) Forum on Neuroscience and Nervous System Disorders was established to bring together leaders from government, industry, academia, and disease advocacy organizations to examine issues concerning scientific needs and policies related to neuroscience and nervous system disorders research and the development and use of interventions for the nervous system. The Forum also sponsors workshops for its members and the public on key challenges and issues in the field. |
| NASEM Forum on Traumatic Brain Injury | Committee, Work group, Advisory group, or Task Force | ACL, CDC | NIA, NICHD, NINDS | The National Academies of Sciences, Engineering, and Medicine (NASEM) Forum on Traumatic Brain Injury provides a setting for experts to discuss how to advance the prevention, treatment, and care for people with brain injuries. The TBI Forum addresses topics relating to critical research gaps, TBI treatment and rehabilitation, and other related needs and challenges. |
| NASEM Roundtable on Genomics and Precision Health | Committee, Work group, Advisory group, or Task Force | CDC, FDA, HRSA | NCI, NHGRI, NIA, NIMH | This roundtable brings together diverse voices to encourage innovation and actions that foster the wide adoption of and equitable access to the benefits of genomics and precision health. |
| NASEM Roundtable on Obesity Solutions | Committee, Work group, Advisory group, or Task Force | CDC | NIDDK | This Working Group includes representatives from the NIH, CDC, Academia, NGOs, and Industry. |
| National Academy of Medicine Committee on Emerging Science, Technology, and Innovation in Health and Medicine | Committee, Work group, Advisory group, or Task Force | FDA | NIMH | The National Academy of Medicine Committee on Emerging Science, Technology, and Innovation in health and medicine brings together experts in a range of fields to assess the landscape of emerging scientific advances and technologies in health and medicine and address the potential societal, ethical, legal, and workforce implications of such technologies. The goal of the Committee is to develop a multi-sectoral governance policy framework. The Committee plans to examine examples of emerging technologies and their implications for society, through a multi-sectoral lens. The first point of focus will be on neurotechnology, specifically transcranial direct current stimulation. |
| National Action Alliance for Suicide Prevention (NAASP) | Committee, Work group, Advisory group, or Task Force | ACL, CDC, HRSA, IHS, OS, OSG, SAMHSA | NIAAA, NIMH, OD/DPCPSI/OBSSR | Founded in September 2010, the National Action Alliance for Suicide Prevention (NAASP) is a public-private partnership designed to advance the National Strategy for Suicide Prevention in the United States. The NAASP's Research Prioritization Task Force (RPTF) was charged with developing a process to prioritize suicide prevention research efforts and consider ways to integrate science and service to ensure that suicide deaths decrease significantly within the next decade. The RPTF released the Nation's first suicide research agenda, A Prioritized Research Agenda for Suicide Prevention: An Action Plan to Save Lives. The research agenda includes an overarching goal to advance suicide prevention research more rapidly, seeking ways to reduce suicide deaths and attempts by 20 percent in five years and by 40 percent or greater in ten years. In 2015, the RPTF produced the "U.S. National Suicide Prevention Research Efforts: 2008-2013 Portfolio Analyses." The analyses revealed that investments in suicide research are severely lagging, but there is a growing knowledge base of intervention research. NIMH participates in a number of NAASP activities related to identifying research needs for improving risk identification and suicide preventive care within healthcare systems, justice, and school settings. |
| National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB) 2020-2025 | Committee, Work group, Advisory group, or Task Force | AHRQ, BARDA, CDC, CMS, FDA | NIAID | The National Action Plan for Combating Antibiotic-resistant Bacteria, 2020-2025, was developed through the CARB Task Force, now reporting coordinated, strategic actions that the U.S. government takes to reduce the impact of antibiotic and antimicrobial resistance on the nation. |
| National Advisory Board for Medical Rehabilitation Research | Committee, Work group, Advisory group, or Task Force | ACL, CDC | NHLBI, NIA, NIAMS, NICHD, NIDCD, NINDS | The Director of the National Institutes of Health (NIH) was mandated in P.L. 101-613 to establish the National Advisory Board on Medical Rehabilitation Research. The Board advises the directors of the NIH, the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and NICHD's National Center for Medical Rehabilitation Research (NCMRR) on matters and policies relating to the NCMRR's programs. The Board is comprised of 12 members representing health and scientific disciplines related to medical rehabilitation and six members representing persons with disabilities. |
| National Advisory Committee on Seniors and Disasters | Committee, Work group, Advisory group, or Task Force | ASPR, ACL, BARDA, CDC, CMS | NIA | The National Advisory Committee on Seniors and Disasters (NACSD) will evaluate issues and programs and provide findings, advice, and recommendations to the Secretary of Health and Human Services to support and enhance all-hazards public health and medical preparedness, response, and recovery activities related to meeting the unique needs of older adults. |
| National ALS Registry | Research Initiative | CDC | NIA | Collaborative research project focused on understanding and treating amyotrophic lateral sclerosis, a neurodegenerative disease that kills 7000 Americans annually. |
| National Amyotrophic Lateral Sclerosis Registry | Committee, Work group, Advisory group, or Task Force | ATSDR, CDC | NINDS | The National ALS Registry is a congressionally mandated registry for persons in the US with ALS. It is the only population-based registry in the US that collects information to help scientists learn more about who gets ALS and its causes. https://www.cdc.gov/als/Default.html |
| National Biodefense Strategy (NBS) Therapeutics Joint Capabilities Plan Writing Group | Committee, Work group, Advisory group, or Task Force | ASPR, CDC, FDA | NIAID | The Joint Capabilities Plans outline how the USG will achieve the specific outcomes related to the topic areas included in the 2022 National Biodefense Strategy and Implementation Plan, which provides a framework that organizes how the USG manages its activities to more effectively assess, prevent, prepare for, respond to, and recover from biological threats. The JCPs will be finalized by the Writing Group in 2023 with semi-annual reporting requirements until 2027. |
| National Bioeconomy Board | Committee, Work group, Advisory group, or Task Force | ASPR | OD/OSP | NBB leads implementation of the government-wide bioeconomy efforts; serves as the governance body for the National Biotechnology and Biomanufacturing Initiative (NBBI); and serves as a forum to discuss, but not develop, federal policies relating to the bioeconomy at large. |
| National Clinical Cohort Collaborative (N3C) | Resource Development | ARPA-H, ASPE, ASPR, CDC, CMS, FDA | NCATS, NCI, NIDDK, NIGMS | The N3C is an NCATS-led initiative, in collaboration with NCI, NIDDK, ASPE, the NCATS-supported Clinical and Translational Science Awards (CTSA) Program hubs, and NIGMS-supported Institutional Development Award Networks for Clinical and Translational Research (IDeA-CTR). It leverages a secure, scalable data repository which houses multiple virtual domain-specific research tenants, covering the education, COVID, cancer, and renal domains. With over 23 million patients represented, N3C demonstrates that large-scale, harmonized clinical data sharing across diverse modalities is achievable, enabling high-impact translational research and precision medicine studies. Core objectives include: maintaining a secure and privacy-preserving infrastructure for clinical research; receiving longitudinal electronic health record (EHR) data from participating healthcare organizations; linking data from multiple sources such as claims and disease-specific registries; providing operational and analytic support to researchers working within the N3C platform; and ensuring rigorous adherence to governance frameworks and data agreements to protect patient privacy and integrity while facilitating groundbreaking clinical discoveries. |
| National Coalition for Oversight of Assisted Reproductive Technologies | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NICHD | The National Coalition for Oversight of Assisted Reproductive Technologies (NCOART) has become a successful forum for discussion of issues by organizations involved in the assisted reproductive technologies (ART) in the United States. |
| National Collaborative on Childhood Obesity Research (NCCOR) | Research Initiative | CDC | FIC, NCI, NHLBI, NIAMS, NICHD, NIDDK, NIEHS, NIMHD, NINR, OD/DPCPSI/OBSSR, OD/DPCPSI/ODP, OD/DPCPSI/ODS, OD/DPCPSI/ONR, OD/ECHO | NCCOR is a collaborative public private partnership between RWJF, USDA, CDC and NIH. This consortium aims to explore the contribution of genetics to variation in intentional weight loss and weight maintenance. The steering committee includes representatives from all 4 organizations, including David Berrigan of DCCPS/NCI and Andrew Bremer from NICHD. Drs. Berrigan and Bremer consult with IC leads from other member ICs on priorities and goals. Staff from all member ICs participate in meetings, projects, workgroups, and discussions. In addition to serving on the steering committee, Dr. Berrigan led the most recent contract competition for the NCCOR Coordinating center and serves as the COR. Many NCI staff play important roles in NCCOR activities. NCI is playing a leading role, but NCI co-leads this initiative, along with NICHD and representatives from other member ICs. No one IC is considered the "leader." Notable products include a suite of Measurement and data related tools (https://www.nccor.org/nccor-tools/mrresourcesuite/), the Youth Compendium of Physical Activities (https://www.nccor.org/nccor-tools/youthcompendium/), and an extensive library of webinars (https://www.nccor.org/webinars/). In 2024, NCCOR has held a variety of workshops, published peer reviewed articles, updated the catalog of surveillance systems, and generated new tools and guides. Most notably, NCCOR hosted two workshops addressing obesity at multiple levels (OPUS 1 and 2). Details are available at the website. |
| National Database for Antibiotic Resistant Organisms (NDARO) | Resource Development | CDC, FDA | FIC, NCATS, NCI, NHLBI, NIA, NIAAA, NIAID | The objective of this collaboration is to produce a collection of high-quality genome sequences from antibiotic-resistant strains and to create and maintain a publicly accessible database -- National Database for antibiotic resistance (AR), developed and housed at the National Center for Biotechnology Information of the National Library of Medicine (NLM). |
| National Death Index Linkage Access for NIH-Supported Investigators | Resource Development | CDC | OD/DPCPSI/OBSSR, OD/IMOD | As an agreement between the National Institutes of Health (NIH) and the Centers for Disease Control (CDC) National Center for Health Statistics, (NCHS), NIH will reimburse the NCHS National Death Index (NDI) for the costs of NIH-supported investigators to link their research databases with the NDI for the research aims supported by the NIH. |
| National Death Index Working Group | Committee, Work group, Advisory group, or Task Force | CDC | CC, NCI, NHLBI, NIA, NIAID, NIDA, OD/DPCPSI/OBSSR | The National Death Index (NDI) is a centralized database of death record information on file in state vital statistics offices. Working with these state offices, the National Center for Health Statistics (NCHS) established the NDI as a resource to aid epidemiologists and other health and medical investigators with their mortality ascertainment activities. The National Death Index Working Group brings together federal and non-federal demographic experts to improve the quality, comprehensiveness, and utility of the National Death Index. |
| National Ending the HIV Epidemic (EHE) Meeting | Meeting/ Workshop | CDC, HRSA, OASH | NIAID, NIMH, OD/DPCPSI/OAR | On September 15, 2022, 350 researchers, government leaders, public health partners, and community members from throughout the U.S. participated in the hybrid "2nd National Meeting for Research and Community Collaboration towards Ending the HIV Epidemic (EHE) in the U.S. Meeting" hosted by the NIH and the UAB CFAR. The meeting featured presentations by academic investigators and their implementation and community partners funded through NIH EHE awards and promoted the sharing of best practices and generalizable findings. |
| National Health Interview Survey | Health Survey | CDC | NEI | The National Health Interview Survey (NHIS) monitors the health of the nation. NHIS data on a broad range of health topics are collected through personal household interviews. NEI is funding vision supplements, with data to be expected in 2024. |
| National Health Interview Survey (NIHS) Cancer Control Supplement | Health Survey | CDC | NCI | The National Health Interview Survey (NHIS) - started in 1957 - is a continuous, nationwide in-person survey of the U.S. civilian non-institutionalized population. An estimated 27,000 sample adult and 9,000 sample child interviews are expected to be completed annually. NCI sponsors an annual Cancer Control Supplement (CCS) to the NHIS, which is administered to the sample adult in the selected household. The CCS focuses on the surveillance of cancer screening use, cancer risk assessment practices, and cancer-related health behaviors in the U.S. |
| National HIV/AIDS Strategy Steering Committee | Committee, Work group, Advisory group, or Task Force | CDC, FDA, HRSA, IHS, OASH, SAMHSA | NIAID, NIMH, OD/DPCPSI/OAR | This multi-agency steering committee is led by the White House's Office of National AIDS Policy. The Committee provided input to update the National HIV/AIDS Strategy (NHAS) which includes strategies to address social determinants of health. The committee was expanded to engage other departments and programs (Labor, Education, Housing, Agriculture, Transportation) to create a whole-of-government approach. The revised NHAS was released in December 2021. |
| National Institute of Occupational Safety & Health (NIOSH) SGM Equity Working Group | Committee, Work group, Advisory group, or Task Force | CDC | OD/DPCPSI/SGMRO | The National Institute for Occupational Safety & Health, part of CDC, organized a SGM work group in 2021 to advance inclusion of SGM populations in data collection and work related to occupational health and safety. There are not good demographic data available about experiences and differences in LGBTQI+ folks' experience at work or ways to look for systematic barriers or disparities for these populations in workforce settings, and this group seeks to address this gap. |
| National Institute on Deafness and Other Communication Disorders (NIDCD) Directory of Organizations | Resource Development | AHRQ, CDC, CMS | NIDCD | The National Institute on Deafness and Other Communication Disorders (NIDCD) Directory of Organizations is designed to help patients, health consumers, providers, and others find agencies and organizations with an interest in the diseases and disorders of human communication. The directory is maintained as an online database accessible to the public from the NIDCD website. Several US Department of Health and Human Services agencies are included. |
| National Integrated Heat Health Information System/IWG | Committee, Work group, Advisory group, or Task Force | OASH, ASPR | NIEHS | NIHHIS builds societal understanding of heat risks, develops science-based solutions, improves capacity, communication, and decision-making to reduce heat-related illness and death. |
| National Interagency Confederation for Biological Research (NICBR) | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NCI, NIAID | The National Interagency Confederation for Biological Research (NICBR) is a consortium of eight agencies with a common vision of Federal research partners working in synergy to achieve a healthier and more secure nation. It serves as a framework for facilitating and encouraging interaction among the NICBR member organizations where there are areas of mutual interest. Members collaborate and share technical expertise and scientific services. This multiagency confederation operates by consensus to ensure a balanced direction and focus. The eight members include elements of the Department of Defense, Health and Human Services, Agriculture, and Homeland Security. The mission of NICBR is to develop unique knowledge, tools, and products by leveraging advanced technologies and innovative discoveries to secure and defend the health of the American people. |
| National Interagency Confederation for Biological Research (NICBR) - Safety and Occupational Health Subcommittee | Committee, Work group, Advisory group, or Task Force | FDA | OD/OM, OD/OM/ORS | The purpose of the NICBR SOH Subcommittee is to identify, develop, communicate, and encourage the use of the best practices to optimize resources among the NICBR partners and foster a culture of safety and communication throughout the NICBR. The SOH facilitates interagency coordination by identifying opportunities as well as resolutions to problems and providing in-depth technical and/or regulatory information as necessary for FDICC decision making. |
| National Neurological Conditions Surveillance System | Research Initiative | CDC | NINDS | The National Neurological Conditions Surveillance System (NNCSS) is a congressionally mandated program of the Centers for Disease Control and Prevention (CDC). The authorizing legislation requires CDC to "enhance and expand infrastructure and activities to track the epidemiology of neurological diseases and incorporate information obtained through such activities into an integrated surveillance system, which may consist of or include a registry, to be known as the National Neurological Conditions Surveillance System." |
| National Prevention Week | Public Education Campaign | SAMHSA | NIDA | Each Year, National Prevention Week Includes:Involving communities in raising awareness of substance misuse and mental health issues, implementing prevention strategies, and showcasing the effectiveness of evidence-based prevention programs.Fostering partnerships and collaborations with federal agencies and national organizations dedicated to improving public health.Promoting and disseminating quality substance use prevention and mental health promotion resources and publications. |
| National Response Team | Committee, Work group, Advisory group, or Task Force | ASPR | NIEHS | The U.S. National Response Team (NRT) provides technical assistance, resources and coordination on preparedness, planning, response and recovery activities for emergencies involving hazardous substances, pollutants and contaminants, oil, and weapons of mass destruction in natural and technological disasters and other environmental incidents of national significance. |
| National Robotics Initiative | Committee, Work group, Advisory group, or Task Force | CDC | NCATS, NEI, NIA, NIBIB, NICHD, NINR | The National Robotics Initiative 3.0: Innovations in Integration of Robotics (NRI-3.0) program was launched by NSF in February of 2021. It builds upon the preceding NRI programs to support research that promotes integration of robots to the benefit of humans including human safety and human independence. |
| National Science Advisory Board for Biosecurity | Committee, Work group, Advisory group, or Task Force | ASPR, CDC, FDA | NIAID, OD/OSP | The NSABB is a federal advisory committee that addresses issues related to biosecurity and dual use research at the request of the United States Government. This is a FACA committee made up of external SGEs, but also includes ex officios from USG agencies |
| National Sewage Surveillance Interagency Leadership committee | Committee, Work group, Advisory group, or Task Force | CDC | NIDA, NIEHS, NLM | This collaboration brings together representatives across federal agencies to discuss ongoing work, priorities, and challenges in wastewater surveillance. To facilitate federal coordination, the US Department of Health and Human Services (HHS) and CDC have convened the National Sewage Surveillance Interagency Leadership (NSSIL) Committee. NSSIL member agencies support CDC in developing and implementing the National Wastewater Surveillance System (NWSS) to collect, analyze, and integrate wastewater-based data with case and syndromic data to assist state and local partners to make response decisions. |
| National Sexually Transmitted Infections (STI) Strategic Plan | Committee, Work group, Advisory group, or Task Force | OASH, ACF, ACL, CDC, CMS, FDA, HRSA, IHS, SAMHSA | NIAID | Plan sets national goals, objectives, and strategies to respond to the STI epidemic. The plan will serve as a roadmap to help federal and non-federal stakeholders at all levels and in all sectors reverse the sharp upward trends in STI rates. |
| National Strategy for Suicide Prevention Interagency Work Group | Committee, Work group, Advisory group, or Task Force | SAMHSA, ASPE, CDC | NIMH | The federal Interagency Work Group (IWG) helped develop the new National Strategy for Suicide Prevention. This IWG is comprised of over 20 agencies in 10 federal departments across the government, with support from the Suicide Prevention Resource Center (SPRC), the National Action Alliance for Suicide Prevention (Action Alliance), and a project management team co-led by officials at the Substance Abuse and Mental Health Services Administration (SAMHSA) and the Centers for Disease Control and Prevention (CDC), alongside the National Institute of Mental Health (NIMH) and the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Planning and Evaluation (ASPE/HHS). |
| National Survey of Family Growth | Health Survey | ACF, CDC | NICHD | The National Survey of Family Growth (NSFG) gathers information on family life, marriage and divorce, pregnancy, infertility, use of contraception, and men’s and women’s health. The survey results are used by the US Department of Health and Human Services and others to plan health services and health education programs and to do statistical studies of families, fertility, and health. The NSFG is used by: scholars in the behavioral sciences (e.g., sociology, demography, and economics) to study marriage, divorce, fertility, and family life; scholars in public health to study reproductive, maternal and infant health topics; agencies of the US Department of Health and Human Services to brief senior officials and to inform program decision-making; in research programs and in health and social service programs; state and local governments to plan health and social service programs; and the press, to prepare articles on a number of topics related to health and family life. https://www.cdc.gov/nchs/nsfg/index.htm |
| National Syphilis and Congenital Syphilis Syndemic (NSCSS) Federal Task Force | Committee, Work group, Advisory group, or Task Force | OASH, CDC, HRSA, IHS, SAMHSA | OD/DPCPSI/OAR | HHS established the National Syphilis and Congenital Syphilis Syndemic (NSCSS) Federal Task Force to leverage the resources and expertise within HHS agencies and partnership networks to respond to the U.S. syphilis and congenital syphilis epidemic. Since then, the task force has coordinated efforts across the federal government to address the surge in syphilis infections, including expanding access to syphilis testing and treatment and increasing providers' awareness and education, among other efforts. |
| National Teen Mental Health Essay Contest | Other | AHRQ, CDC, FDA, HRSA, SAMHSA, USPHS | NIMHD | The essay contest challenges high school students ages 16-18 to raise awareness of mental health. The contest gives students a platform to share ways to eliminate and/or reduce mental health stigma faced by young people, especially in diverse communities. |
| National Toxicology Board of Scientific Counselors | Committee, Work group, Advisory group, or Task Force | OASH, CDC, FDA | NIEHS | A federally chartered external advisory committee whose members are appointed by the Secretary of Health and Human Services |
| National Toxicology Program Executive Committee | Committee, Work group, Advisory group, or Task Force | ATSDR, CDC, FDA | NCI, NIEHS | An internal government group comprised of heads (or designees) of HHS (NCEH/ATSDR, FDA, NCI, NIEHS, NIOSH) and non-HHS (CPSC, DoD, EPA, OSHA) agencies |
| National Toxicology Program Steering Committee | Committee, Work group, Advisory group, or Task Force | ATSDR, CDC, FDA | NIEHS | An internal government group comprised of the principal agencies of the National Toxicology Program |
| National Vaccine Advisory Committee (NVAC) | Committee, Work group, Advisory group, or Task Force | OASH | NIAID | The National Vaccine Advisory Committee (NVAC) recommends ways to achieve optimal prevention of human infectious diseases through vaccine development and provides direction to prevent adverse reactions to vaccines. This advice is presented to the Assistant Secretary for Health who serves as the Director of National Vaccine Program on matters related to program responsibilities. |
| Natural History Studies and Registries in the Development of Rare Disease Treatments Workshop | Meeting/ Workshop | FDA | NCATS | NCATS worked with the FDA and the Reagan-Udall Foundation for the FDA to host a hybrid public workshop on May 13, 2024, to bring together rare disease patient advocates, academic researchers, regulated industry, and other key communities to discuss considerations for the use of natural history studies and registry data in rare disease drug development programs. This workshop addresses the role and design of registries and natural history studies to inform the development of rare disease treatments, including aspects of clinical trial design; collecting registry and natural history data that are fit for regulatory purposes; and the use of registries and natural history studies to inform regulatory decision-making. |
| Naval Research Laboratories XRAY Crystallography | Committee, Work group, Advisory group, or Task Force | FDA | NIDA | The Crystallographic Studies Group at the Naval Research Laboratories provides definitive, three-dimensional structural parameters of compound samples submitted by NIDA grantees, contractors and researchers in drug abuse. Data derived from X-ray crystallographic analysis is used to confirm complex structures in drug development. Researchers use this data for publications, grant applications and patent submissions. |
| NBS Implementation Plans Joint Capabilities Plans-Clinical Research Capacity | Committee, Work group, Advisory group, or Task Force | ASPR, FDA | NIAID | Several JCP WG to inform implementation |
| NCATS Toolkit for Patient-focused Therapy Development | Resource Development | FDA | NCATS | NCATS is dedicated to engaging the patient community throughout the translational science process. The NCATS Toolkit for Patient-Focused Therapy Development (Toolkit) was created to provide a collection of online resources that can help patient groups advance through the process of therapy development and provide them with the tools they need to advance medical research. Launched in September 2017, the Toolkit includes resources that have been developed primarily for the rare diseases community to facilitate therapeutics research and development. |
| NCI Cancer Data Standards Repository and Registry (caDSR) | Committee, Work group, Advisory group, or Task Force | ASPE, FDA | CIT, NCATS, NCI, NEI, NHLBI, NIAMS, NIBIB, NIDCD, NIMH, NINDS, NLM | Also Collaboration Type: Resource DevelopmentThe National Cancer Institute (NCI) is collaborating with other NIH institutes to develop and harmonize data standards across NCI and others NIH institutes for basic, translational and clinical research, clinical care, epidemiology, public health, administration, and public information. NCI caDSR provides services to meet NCI needs, and works with other NIH institutes to reuse/share existing content. |
| NCI Cervical Cancer "Last Mile" Initiative | Research Initiative | CDC, FDA, HRSA | NCI | The National Cancer Institute (NCI) Cervical Cancer ‘Last Mile’ Initiative is a public-private partnership bringing together federal agencies, industry partners, and professional societies to contribute evidence about the accuracy and clinical effectiveness of self-collection-based HPV testing for cervical cancer screening. The initiative is supporting the "Self-collection for HPV testing to Improve Cervical Cancer Prevention" ("SHIP") Trial, a nationwide multicenter clinical trial focused on an independent non-competetive evaluation of multiple self-collection devices and HPV assays for developing key scientific evidence to facilitate approvals of home-based HPV self-collection. |
| NCI Clinical Trials and Translational Research Advisory Committee (CTAC) | Committee, Work group, Advisory group, or Task Force | CMS, FDA | NCI | The Clinical Trials and Translational Research Advisory Committee makes recommendations on the National Cancer Institute-supported national clinical trials enterprise to build a strong scientific infrastructure by bringing together a broadly developed and engaged coalition of stakeholders involved in the clinical trial process. The Committee will provide advice on matters related to the conduct, oversight, and implementation of clinical trials and translational research across the Institute. |
| NCI Multi-Cancer Dectection (MCD) Trial Team | Research Initiative | CMS, FDA | NCI | Scientific development for the evaluation of Multi-Cancer Detection (MCD) assays for the purpose of cancer screening. This group is also known internally as the Tiger Team |
| NCI Scientific Steering Committees (SSCs) | Committee, Work group, Advisory group, or Task Force | FDA | NCI | Scientific Steering Committees (SSCs) are composed of leading cancer experts and advocates from outside the Institute as well as NCI senior investigators who meet regularly to: (1) increase the transparency and openness of the trial design and prioritization process; (2) enhance patient advocate and community oncologist involvement in clinical trial design and prioritization; (3) convene Clinical Trial Planning Meetings to identify critical questions, unmet needs, and prioritize key strategies. |
| NCI-FDA Joint Fellowship Program (IOTF) | Training Initiative | FDA | NCI | The objective of the NCI-FDA Joint Fellowship Training Program is to train a cadre of scientists in research and research-related regulatory review, policies, and regulations so that they develop a skill set bridging the two disparate processes. Fellows learn to build awareness of regulatory requirements into the early stages of the medical product development process and develop strategies to improve planning throughout research and regulatory review. There are four different programs tracks within the program. For example, the Clinical Investigator Program track trains physicians in aspects of clinical trials methodology and analysis, epidemiology, clinical aspects of medical product development, and regulation to facilitate the movement of drugs, biologics, and devices from the basic bench science to commercialization. This allows the FDA to gain an academic oncologist with disease-specific expertise who is actively involved and understands critical nuances of the field, NCI gains a clinical investigator and leader who understands regulatory considerations in drug development, and the oncologic community gains a regulator/academic who will provide a leadership voice to help design trials with regulatory endpoints in mind. |
| NCI/FDA Memorandum of Understanding for Proteomics | Research Initiative | FDA | NCI | This Memorandum of Understanding (MOU), signed in 2007, renewed in 2012, 2017, and 2022 establishes an official relationship in clinical proteomic regulatory science between NCI's Office of Cancer Clinical Proteomics Research and the FDA. Active areas of research collaboration include sample collection, preparation, storage and processing; bioinformatics and data analysis; discovery and validation of biomarkers; and surrogate biomarkers of cancer development and drug response, including standardization among technology platforms and assay standards development. |
| Necrotizing Enterocolitis (NEC) in Preterm Infants Working Group of the National Advisory Council of Child Health and Human Development (NACHHD) | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NIAID, NICHD | A subgroup of NICHD’s National Advisory Child Health and Human Development Council, in response to a U.S. Department of Health and Human Services (HHS) request to evaluate the current state of the science on enteral nutrition and NEC in preterm infants. |
| NEHEP Partnership Summit | Committee, Work group, Advisory group, or Task Force | OASH | NEI | NEHEP was joined by the Office of Disease Prevention and Health Promotion in a partnership summit in 2023 to connect NEI and NEHEP’s work to the Healthy People 2030 vision objectives. The next NEHEP Partnership Summit is planned for October 2025. |
| NEI-FDA-ONC Joint Partnership on Promoting Adoption of Ocular Imaging Standards | Research Initiative | FDA, ONC | NEI | This virtual NEI, FDA, and ONC hosted workshop focused on delineating the state of the science and improving interoperability among ocular imaging modalities and devices to improve biomedical research and patient care. This meeting consisted of a day of discussion identifying the gaps in knowledge, barriers to progress, and potential strategies for overcoming them in the context of addressing the goal of Promoting the Adoption of Ocular Imaging Standards. This was an open workshop to the general public, attended by researchers from academia, industry, non-profits, other government agencies, patients and care partners. The white paper from this workshop, Accelerating Care: A Roadmap to Interoperable Ophthalmic Imaging Standards in the United States, was published in January 2024. As a follow up to the workshop, NEI published the Standardized Ocular Imaging Expectations for Clinical and Nonclinical Research Funded by NEI notice in May 2024. This notice strongly encourages applicants to use common formats for files and metadata standards when incorporating ocular imaging in their research proposals. This applies to both clinical and nonclinical research applications submitted in response to NOFOs where NEI is the issuing or participating organization. Investigators are strongly encouraged to adopt common formats for files and metadata standards in their research involving ocular imaging. For instance, the Digital Imaging and Communications in Medicine (DICOM) standard, widely used for medical imaging devices, defines formats and accompanying data. Applicants may propose alternative standards provided they meet the necessary requirements for data interoperability, accessibility, and sharing. The widespread adoption of standardized imaging formats will significantly advance the field by: Enabling streamlined digital workflows.Facilitating interoperability of large datasets.Creating extensive training sets for artificial intelligence-based research.By promoting these standards, we aim to foster an environment where data can be seamlessly integrated and analyzed across different studies, enhancing the overall impact of vision research.This partnership successfully concluded in 2024 after each agency fulfilled the commitments outlined in the white paper references above. While this specific collaboration has ended, our work in this space is far from over. These efforts have laid the foundation for increased interoperability, improved data sharing, and expanded opportunities for AI-driven research in vision science. Moving forward, we remain committed to fostering adoption of imaging standards and supporting the research community in leveraging these advancements to enhance patient care and scientific discovery. One such follow-on activity is the following whitepaper: Ocular Imaging Challenges, Current State, and a Path to Interoperability: A HIMSS-SIIM Enterprise Imaging Community Whitepaper |
| New diagnostic methods for identification of Trypanosoma cruzi | Research Initiative | CDC | CC | Collaborate with experts from other institutes outside NIH to develop new diagnostic methods for identification of Trypanosoma cruzi, a parasitic protozoan that is the causative agent of Chagas disease (American trypanosomiasis). Outside collaborators include: Sue Montgommery, CDC, United States and Adrienne Showler,, George washington University, United States. |
| Newborn Screening Coding and Terminology Guide | Resource Development | AHRQ, CDC, FDA, HRSA, IOS | NHGRI, NHLBI, NICHD, NLM | This ongoing collaboration develops, supplements, and promotes a free online resource that provides guidance for the efficient electronic exchange of standardized newborn screening data. Related efforts include examining the screening process for diseases including severe combined immunodeficiency (SCID), lysosomal storage disorders (LSDs), and critical congenital heart disease (CCHD). Additionally, they involve developing standard codes for ordering and reporting the results of newborn screening for SCID, CCHD, and other conditions added to the Recommended Uniform Screening Panel of the Secretary’s Advisory Committee on Heritable Disorders in Newborns and Children. https://lhncbc.nlm.nih.gov/newbornscreeningcodes/ |
| Newborn Screening Federal Partners Committee | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, HRSA | NHGRI, NICHD, NLM | The federal members of the Advisory Committee on Heritable Disorders in Newborns and Children meet monthly to share information about newborn screening activities. |
| NGSP (formerly the National Glycohemoglobin Standardization Program) | Research Initiative | CDC | NIDDK | The purpose of the NGSP (formerly the National Glycohemoglobin Standardization Program) is to standardize Hemoglobin A1c test results to those of the Diabetes Control and Complications Trial (DCCT) and the United Kingdom Prospective Diabetes Study (UKPDS), which established the direct relationships between HbA1c levels and outcome risks in patients with diabetes. NIDDK has provided funding for NGSP research initiatives, and NIDDK Extramural Program staff have served on committees. |
| NHAS Quality of Life Indicators Subcommittee | Committee, Work group, Advisory group, or Task Force | ACL, CDC, HRSA, SAMHSA | NIAID, NIMH, OD/DPCPSI/OAR | A working group of representatives from six federal agencies involved in developing and implementing the NHAS was tasked with carefully listening to community input and evaluating options for possible quality of life measures, data sources, and targets that could be adopted and implemented. As a result of their work and community input, the Office of National AIDS Policy ultimately adopted five indicators that reflect the multi-dimensional nature of quality of life among people with HIV. Indicators address self-rated health status, mental health, food insecurity, employment status, and unstable housing or homelessness. |
| NIAID/BARDA Biannual Meeting for Radiation Medical Countermeasures and Biodosimetry Research Shared Portfolio Discussions | Committee, Work group, Advisory group, or Task Force | BARDA | NIAID | NIAID and BARDA upate each other regarding status of programs to discuss areas of common interest and possible BARDA handoffs in the radiation medical countermeasures and biodosimetry research space. |
| NIAID/CDC Dual Use Research of Concern (DURC) Risk Mitigation Reviews | Committee, Work group, Advisory group, or Task Force | CDC | NIAID | The Centers for Disease Control and Prevention (CDC) Division of Select Agents and Toxins Division will provide technical assistance in evaluating the sufficiency of the biosecurity and/or biosafety measures incorporated into risk mitigation plans received from institutions, and cross-check risk mitigation plans and research conducted using select agents and toxins against information in the Federal Select Agent Program (FSAP) database. |
| NIAID/FDA Action Team Collaborative for Radiation Research | Committee, Work group, Advisory group, or Task Force | FDA | NIAID | NIAID works with the FDA Office of Commissioner to provide ground-truth research eing carried out in the field of radiation medical countermeasures development, and the FDA shares planned directions and guidance for Animal Rule licensure of these approaches. CBER, CDER, and CDRH all participate in these meetings. |
| NIAID/HESI Workshop: Regulatory T Cell Therapies to Treat Autoimmune and Autoinflammatory Diseases - Challenges and Opportunities | Meeting/ Workshop | FDA | NIAID | Organizing committee for a workshop to be held November 2024 to bring together industry, academic and governmental scientists to assess key concepts in engineered regulatory T cell therapies. The workshop will address clinical development challenges and opportunities including pharmacological, toxicological, manufacturing, and regulatory considerations. |
| NIDA/ABCD | Other | CDC | OD/All of Us | collaborating with programs to leverage cross enrollment and data linkage between programs. Collaboration Type- cross program communication and collaborations |
| NIDCR-CDRH/FDA Collaborative Agreement | Committee, Work group, Advisory group, or Task Force | FDA | NIDCR | Interagency Collaboration MOU serving as framework for coordination and collaborative efforts |
| NIH Asian American Pacific Islander Health Scientific Interest Group | Committee, Work group, Advisory group, or Task Force | CDC, HRSA | NCI | *All NIH ICOs participate AAPI-HSIG BackgroundIn 1999, White House established a first Initiative on Asian Americans and Pacific Islanders (AAPI) to improve their quality of life and opportunities to participate in federal programs (https://www.govinfo.gov/content/pkg/FR-1999-06-10/pdf/99-14901.pdf (PDF File)). In 2021, the NIH Asian American Pacific Islander Health Scientific Interest Group (AAPI-HSIG) was formed. It is open to all in the intramural and extramural NIH community, as well as HHS staff, with an interest in research relating to the health of Asian Americans and Pacific Islanders (including Native Hawaii) populations. The group provides a forum to foster scientific communications, share and disseminate information, facilitate collaborations, provide education, assess research needs, and make recommendations to NIH leadership aiming to stimulate research and to improve the health and well-being of AAPI populations. Regular activities include a monthly meeting with research and education seminars, virtual or in-person on NIH campus. Other activities can be both inside and outside the NIH, such as potential conferences and lectures in collaborations with NIH ICOs or other NIH SIG groups and other Federal and Non-Federal entities. |
| NIH Dissemination and Implementation Working Group | Meeting/ Workshop | AHRQ, CDC | FIC, NCI, NHGRI, NHLBI, NIAAA, NIDA, NIDDK, NIEHS, NIMH, NIMHD, NINR, OD/DPCPSI/ODP | Annual Conference on the Science of Dissemination and Implementation is a forum for discussing the science of dissemination and implementation and aims to grow the research base by bridging the gap between evidence, practice, and policy in health and medicine. Researchers, evaluators, and implementers who are interested in identifying opportunities, challenges, and strategies for disseminating the findings and implementation of research to key stakeholders are encouraged to attend. Discuss, debate, and explore in-depth approaches to advance dissemination and implementation science. |
| NIH Guide for Grants and Contracts | Resource Development | AHRQ, CDC, FDA | CIT, CSR, FIC, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI, OD/OER | The National Institutes of Health (NIH) Guide for Grants and Contracts is the official publication for NIH medical and behavioral grant policies, guidelines, and funding opportunities. Other US Department of Health and Human Services agencies also use the Guide to disseminate Funding Opportunity Announcements to its 60,000 subscribers. |
| NIH Helping to End Addiction Long Term (HEAL) Initiative | Research Initiative | AHRQ, CDC, CMS, FDA, HRSA, OS, SAMHSA | NCATS, NCCIH, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDDK, NIMH, NINDS, NINR, OD/DPCPSI/OBSSR | In April 2018, the National Institutes of Health (NIH) launched the HEAL (Helping to End Addiction Long-term) Initiative, an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis. This Initiative will build on extensive, well-established NIH research, including basic science of the complex neurological pathways involved in pain and addiction, implementation science to develop and test treatment models, and research to integrate behavioral interventions with medications for opioid use disorder (OUD) The NIH HEAL Initiative will bolster research across NIH to improve treatments for opioid misuse and addiction and enhance pain management. The NIH HEAL Initiative forges collaborations among research programs across NIH, the U.S. Department of Health and Human Services, and the private sector. |
| NIH IC U.S. Preventive Services Task Force (IC USPSTF) | Committee, Work group, Advisory group, or Task Force | AHRQ | NIA, NIAID, NICHD, NIDA, NIMHD, NINR, OD/DPCPSI/OAR, OD/DPCPSI/OBSSR, OD/DPCPSI/ODS, OD/DPCPSI/ORWH | The USPSTF NIH Institutes, Centers, and Offices (ICOs) Liaison Workgroup is made up of IC representatives who work with AHRQ to identify research needs related to the fields of preventive medicine and primary care, including internal medicine, family medicine, pediatrics, behavioral health, obstetrics/gynecology, and nursing. |
| NIH Metabolomics Scientific Interest Group | Other | FDA | NCATS, NCI | Collaboration type: Scientific Interest Group The Metabolomics Scientific Interest Group was created to help stimulate more interest in the field and aims to bring interested NIH program officials, intramural investigators and others together. The group will have periodic webinars and seminars that highlight recent work in the field. Additionally, the listserv will be used to communicate information on upcoming metabolomics-related seminars, funding opportunities, and other NIH activities and initiatives.This SIG was previously advised by a trans-agency working group that was sunset in 2021. Since then, NCI has planned webinars for the SIG with no collaborative partners. We are planning to resume SIG activities in collaboration with NCATS intramural in 2024. |
| NIH Organizational Health and Reporting to HHS | Committee, Work group, Advisory group, or Task Force | ASFR | OD/OER, OD/OIR, OD/OM, OD/OM/OALM, OD/OM/OSPMO | OSPMO coordinates with multiple OD offices to compile quarterly data on key organizational health and performance measures that were prioritized by NIH in response to the OMB 23-15 memo. |
| NIH Pathways to Prevention Workshop Program - Management of Menopausal Symptoms | Meeting/ Workshop | AHRQ | NCI, NHLBI, NIA, NICHD, NIMH, OD/DPCPSI/ODP, OD/DPCPSI/ORWH | The NIH Office of Disease Prevention is planning a Pathways to Prevention (P2P) workshop to identify research gaps in menopause and menopausal transition. The workshop is tentatively scheduled to take place in late 2025. The Pathways to Prevention (P2P) program is a workshop series hosted by the Office of Disease Prevention (ODP) to identify research gaps in a selected scientific area, identify methodological and scientific weaknesses in that scientific area, suggest research needs, and move the field forward through an unbiased, evidence-based assessment of a complex public health issue. P2P workshops are designed for topics that have incomplete or underdeveloped research and for which there is a need for a systematic evidence review that synthesizes the published literature. After each workshop, ODP also organizes a meeting of all Federal Partners who have an interest in or activities related to the workshop topic to discuss ways that the Federal Partners might collaborate to implement workshop recommendations. |
| NIH RECOVER (Long COVID) Program | Committee, Work group, Advisory group, or Task Force | OASH | NHLBI, NIAID, NINDS | The purpose of this working group is to work together across NIH to develop a program to understand, predict, treat, and prevent PASC/Long COVID |
| NIH Research Advancing Hepatitis Elimination - Leaving No One Behind | Committee, Work group, Advisory group, or Task Force | ASFR, CDC | NCI, NIAID, NIDDK, NIMHD | Webinar Series was launched to bring together the research and implement strategies to improve hepatitis prevention, testing, and treatment. |
| NIH World AIDS Day | Other | OASH | NCI, NHLBI, NIAAA, NIAID, NICHD, NIDA, NIMH, NINDS, NLM, OD/DPCPSI/OAR | This is an event organizing committee. OAR led coordination and planning for the annual NIH World AIDS Day event, which involved a panel discussion followed by a public Q&A session. |
| NIH-BMGF--CEPI epidemic preparedness working group | Committee, Work group, Advisory group, or Task Force | ARPA-H, ASPR, BARDA | FIC, NCATS, NIAID | Working group meets quarterly to discuss collaboration, communication, and coordination on epidemic preparedness programs supported by each entity. 10 sub working groups tackle specific issues in more depth, including preparedness vaccines, antivirals, and pathogen and immune sequencing. |
| NIH-CMS Opioid Working Group | Committee, Work group, Advisory group, or Task Force | CMS | NIDA | The NIH-CMS Opioid Working Group is a collaborative effort between the National Institutes of Health (NIH) and the Centers for Medicare & Medicaid Services (CMS) to address the opioid crisis |
| NIH-FDA Biomarkers Working Group | Committee, Work group, Advisory group, or Task Force | FDA | CC, CIT, CSR, FIC, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM | The mission of the NIH-FDA Biomarker Working Group is to: promote communication across NIH and FDA on scientific issues related to biomarker development and regulatory acceptance; identify process and policy enhancements that may help address challenges; and coordinate activities and leverage resources that have an impact on NIH-FDA ICs. |
| NIH-FDA Medical Device Research Interest Group | Committee, Work group, Advisory group, or Task Force | FDA, CMS | NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDCD, NIDDK, NIEHS, NIGMS, NINR, NLM, OD/DPCPSI/ORIP | MDRIG meets quarterly to share information and ideas on supporting research throughout the device development pipeline. Recent topics of interest included clinical innovation and translation efforts, artificial intelligence and machine learning in imaging, digital twins, and early feasibility supplements for the Small Business Innovation Research (SBIR) grantees that would facilitate grantee Food and Drug Administration (FDA) meetings and communication in the formative years to increase appropriate planning during the development of their technologies toward eventual FDA approval. Recently, a successful pilot program was launched through collaboration between the NCI and FDA. Scalability to other institutes was discussed. Supported by NIBIB, MDRIG continues to meet four times per year. In 2018, NIBIB hosted a trans-NIH workshop on gadolinium retention in patients after magnetic resonance imaging. Collaborators included the extramural medical imaging community. A subsequent widely referenced white paper identified gaps in knowledge and future areas for research. This workshop included FDA participation. |
| NIH/BARDA Antimicrobial Resistance (AMR) Diagnostic Challenge Working Group | Research Initiative | ASPR, CDC, FDA | NIAID | The Working Group designed, launched, and managed the largest USG Challenge competition of $20M through each of the three stages during the 5 years of the competition. The goal was to support the development of novel, innovative, rapid, point-of-need diagnostic in vitro assays to improve antibiotic stewardship and decrease the rapidly expanding AMR pandemic. |
| NIMH Ask Suicide-Screening Questions (ASQ) Research Team Collaboration with Indian Health Service | Research Initiative | IHS | NIMH | The NIMH ASQ research team has been helping the Indian Health Service implement suicide risk screening since 2017, piloting ASQ as their suicide risk screening tool, helping with training, and devising local clinical pathways. |
| NIMH-SAMHSA Collaboration to Support the Delivery of Evidence-Based Practices in Certified Community Behavior Health Clinic-Expansion (CCBHC-E) Awardees | Research Initiative | SAMHSA | NIDA, NIMH | The goal of this collaboration is to identify mutual National Institute of Mental Health (NIHMH) and Substance Abuse and Mental Health Services Administration (SAMHSA) priority areas of interest and to develop relevant funding initiatives that will invest in mental health services and implementation science research to support the adoption and sustained fidelity of evidence-based practices in Certified Community Behavioral Health Clinic-Expansion awardees. |
| NINDS Common Data Elements Program | Resource Development | CDC, FDA | CIT, NCATS, NEI, NHGRI, NHLBI, NIA, NIBIB, NIDDK, NIEHS, NIGMS, NIMH, NINDS, NINR | NINDS works closely with the research community (academia and industry), patient advocates, and other federal agencies to develop and maintain data standards called common data elements (CDEs). Data standards facilitate data collection and data sharing in clinical research. Through the efforts of several working groups, CDEs have been developed for use in adult and pediatric research studies of many neurological disorders, including ALS, cerebral palsy, Chiari I malformation, epilepsy, Friedreich’s ataxia, headache, Huntington’s disease, mitochondrial disease, multiple sclerosis, ME/CFS, several neuromuscular diseases, Parkinson’s, spinal cord injury, stroke, and TBI. |
| Nipah viral replicon particle vaccine safety & efficacy evaluation in NHP model | Research Initiative | CDC | NIAID | Testing in nonhuman primates of a newly developed vaccine for protection against Nipah virus infection. |
| NITRD Digital Twins Fast-Track Action Committee (FTAC) | Committee, Work group, Advisory group, or Task Force | ACL, AHRQ, AoA, ASA, ASFR, ASPA, ASPE, ASPR, ATSDR, BARDA, CFBNP, CDC, CMS, CTO, FDA, GDM, HRSA, IEA, IHS, IOS, IOS/ODPHP, OASH, OCIIO, OCR, OGC, OGA, OIDP, OIG, ONC, ONS, OPHS, ORAC, OS, OSG, OSTP, PHSSEF, PSC, SAMHSA, USPHS | NCI, NIDCR | Digital Twins was an area of interest for OSTP, and there was a foundational need for a Strategic Plan. The duration of this FTAC is 1 year with the exception of developing into an interagency working group (WG). The purpose of the DT FTAC is to develop a cohesive strategic plan to advance the foundational research gaps, development, and future directions for Digital Twins based on the 2024 NASEM Digital Twin Report. |
| NOFO 22-049 'Integrating Biospecimen Science Approaches into Clinical Assay Development' Steering Committee Collaboration | Research Initiative | FDA | NCI | As part of a U01 grants program/network, the Steering Committee provides an opportunity to improve the quality of funded research and potentially amplify the impact of the grants program through collaborative activities. The Steering Committee reviews research progress and develops collaborative activities that may include, among other activities, specific working groups and joint research projects. The Steering Committee also advocates for the sharing of data and biospecimens within the network and promotes best practices in biospecimen handling in related research areas. |
| Norm Coleman Special Issue on Radiation Preparedness in Disaster Medicine and Public Health Preparedness | Committee, Work group, Advisory group, or Task Force | ASPR, BARDA | NIAID | NIAID leads effort to publish a series of radiation emergency preparedness and commemorate the legacy and contributions of Dr. Norman Coleman. |
| Notice of Special Interest (NOSI) and Notice of Funding Opportunity (NOFO): Priority Research Opportunities in Crisis Response Services | Research Initiative | SAMHSA | NIMH | The National Institute of Mental Health (NIMH) collaborated with the Substance Abuse and Mental Health Services Administration (SAMHSA) to develop a Notice of Special Interest (NOT-MH-23-140) that communicates priority research opportunities in crisis response services. This includes research on 1) treatment and services interventions; 2) triage, dispatch, and other forms of decision support; and 3) strategies to promote service engagement/continuity and quality of care. |
| NSF 24-561: Foundations for Digital Twins as Catalyzers of Biomedical Technological Innovation (cross Agency NSF-FDA-NIH initiative) | Other | FDA | NCI, NHLBI, NIBIB, NIDCR, NLM | The Foundations for Digital Twins as Catalyzers of Biomedical Technological Innovation (FDT-BioTech) program supports inherently interdisciplinary research projects that underpin the mathematical and engineering foundations behind the development and use of digital twins and synthetic data in biomedical and healthcare applications, with a particular focus on digital, in silico models used in the evaluation of medical devices and the relevance of the developed models in addressing current and emerging challenges affecting the development and assessment of biomedical technologies. The goal of the FDT-BioTech initiative is to catalyze biomedical technological innovation through new foundational development of methods and algorithms relevant to digital twins and synthetic humans. |
| NSTC Committee on Science, Subcommittee on Scientific Integrity | Committee, Work group, Advisory group, or Task Force | ASPE, CDC, FDA | NIAAA, NIEHS, NIMHD, OD/DPCPSI/ORWH, OD/OER, OD/OIR, OD/OSP | Established to coordinate, assess, and communicate on matters of federal scientific integrity. Assists OSTP in assessment and iterative improvement of agency and EOP component scientific integrity policies, practices, and culture; provides advisory responses to agency requests for another agency to review their internal scientific integrity policies and processes, such as inquiries related to senior-level officials, political appointees, or scientific integrity officials; and serves as a community of practice for Federal agency scientific integrity officials and staff. |
| NSTC Subcommittee on Biological Sciences -Interagency Synthetic Biology Working Group (BSSC-SBWG) | Committee, Work group, Advisory group, or Task Force | ASPR, CDC | OD/OSP | Provides coordination and strategic planning to help ensure responsible innovation and significant advances in research in synthetic biology. |
| NSTC Subcommittee on Environmental Justice | Committee, Work group, Advisory group, or Task Force | ATSDR, CDC | NCI, NIEHS, NIMHD | Convened to develop an Environmental Justice Science, Data, and Research Plan |
| NSTC Subcommittee on Open Science | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, ASPR, CDC, CMS, FDA | NLM, OD/DPCPSI/ODSS, OD/OSP | The National Science and Technology Council (NSTC) Subcommittee on Open Science (SOS) advances federal efforts to support open science by increasing access to, and use of, the results of federally funded research and development including, but not limited to, scholarly publications and digital data. Among its responsibilities, the SOS aims to improve the implementation of policies that increase access to the results of federally funded scientific research and to identify additional steps that federal departments and agencies can take to enhance the preservation, discoverability, accessibility, quality, and utility of research outputs. The SOS meets monthly to coordinate government-wide efforts to advance open science and improve access to and use of publications, data, and other outputs of federally funded research. |
| NSTC Subcommittee on Open Science, Infrastructure Working Group | Committee, Work group, Advisory group, or Task Force | ACL, AHRQ, ASPR, CDC, FDA | NINDS, OD/DPCPSI/ODSS, OD/OER, OD/OSP | The Open Science Infrastructure Working Group of the Subcommittee on Open Science of the National Science and Technology Council (NSTC) works to enhance the federal government's understanding of infrastructure that supports open science and promotes best practices across agencies. |
| NSTC Subcommittee on Open Science, Infrastructure Working Group, Effective Data Management Subgroup | Committee, Work group, Advisory group, or Task Force | ACF, ACL, ASPR, CDC | NLM, OD/OSP | The SOS Effective Data Management Subgroup (formerly the Data Management & Repository Standards Subgroup) was established to coordinate implementation of and ongoing support for federal agency policies on public access to scientific data. OSP co-chairs this group with NSF and ACL. |
| NSTC Subcommittee on Open Science, Security/Risk Management Subgroup | Committee, Work group, Advisory group, or Task Force | CDC, OASH | OD/OSP | The Security/Risk Management Subgroup of the Subcommittee on Open Science (SOS) of the National Science and Technology Council (NSTC) is investigating methodologies for a coordinated, cross-agency approach to raising agency awareness of the benefits and risks of public access to the results of federally funded research. A consistent risk management program is a critical component within the research data lifecycle and can lead to an increase in public release determinations. When potential adverse disclosure risks are evaluated by expert reviewers, the data may be released intact or after mitigations that lower disclosure risk are implemented. The overarching goal is to suggest a robust risk management regime which sustains integrity of federal research objects and promotes public confidence and trust in federal science programs. Efforts will focus on statutory, regulatory, and federal agency policy; technical risk factors that affect pre-lease, release, and post-release stages of the research data lifecycle; and controlled access to results of federally funded research. In July 22, 2018, Federal agencies held a workshop at NIH on the risks of unintended disclosures from public access to scientific data; in March 2020, the SOS established a Risk Workgroup. |
| NSTC Subcommittee on Open Science, Subgroup on Engagement (previously Year of Open Science Subgroup) | Committee, Work group, Advisory group, or Task Force | CDC | NLM | The White House Office of Science and Technology Policy (OSTP) launched a Year of Open Science in 2023. Throughout the year, participating agencies formed a subcommittee of the OSTP’s Subcommittee on Open Science and hosted events to promote open science, communicate the value of making research outputs open, and collaborate on activities to advance open science. A central website, open.science.gov, was created to showcase agency efforts. The Subgroup on Engagement (previously Year of Open Science Subgroup), of the Subcommittee on Open Science of the National Science and Technology Council, continues this work. open.science.gov |
| NSTC Subcommittee on Social and Behavioral Sciences | Committee, Work group, Advisory group, or Task Force | ACF | NCI, OD/DPCPSI/OBSSR | The SBS is rechartered to prioritize and expand the scope of evidence-based methods in support of Federal policymaking—particularly to advance equity. The SBS provides executive departments and agencies a forum for discussing the use of social and behavioral science methods and evidence to promote these goals in light of these disciplines' unique role in describing, understanding, and addressing societal challenges and assessing and evaluating initiatives, programs, and policies promulgated by the Federal government. The SBS will carry out short term, high-priority tasks associated with elevating best practices regarding the creation and use of social and behavioral science evidence in Federal practices and policies, and then will lay the groundwork for longer-term coordination of agency efforts related to these topics. |
| NSTC: Subcommittee on Scientific Integrity (SOSI) Implementation and Evaluation Working Group | Committee, Work group, Advisory group, or Task Force | ASPE, ASPE, CDC | OD/DPCPSI/OEPR | This working group was convened to support SOSI in implementing and assessing agency scientific integrity policies, practices and culture using the Framework’s critical metrics for assessment as outlined in the 2022 Scientific Integrity Framework Interagency Working Group report entitled A Framework for Federal Scientific Integrity Policy and Practice. |
| Nutrition Research Coordinating Committee (NRCC) | Committee, Work group, Advisory group, or Task Force | ACL, AHRQ, CDC, FDA, HRSA, IOS/ODPHP, OASH | CSR, FIC, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI, OD/DPCPSI/OAR, OD/DPCPSI/OBSSR, OD/DPCPSI/ODP, OD/DPCPSI/ODS, OD/DPCPSI/ODSS, OD/DPCPSI/ONR, OD/DPCPSI/ORWH, OD/DPCPSI/OSC, OD/ECHO | The Nutrition Research Coordinating Committee (NRCC) was established by the National Institutes of Health (NIH) Office of the Director in 1975 to improve communication and research coordination of nutrition activities within the NIH and across the federal government. Today it provides an open forum for members to discuss current and future nutrition research challenges and opportunities. The NRCC has broad representation from the NIH institutes and centers. In addition, liaisons from other federal offices and agencies also participate. The NRCC meets monthly, alternating between intra-NIH and interagency meetings. NRCC membership is open to any federal staff member interested in carrying out any trans-NIH or trans-agency nutrition research efforts. |
| OA/ABSD - HHS IAE Systems Forum (formerly DCIS User's Group Meeting) | Meeting/ Workshop | PSC, ARPA-H, AHRQ, CMS, HRSA, IHS | OD/OM, OD/OM/OALM | To open the lines of communication among the Office of Acquisition (OA), Acquisition Business Systems Division (ABSD) and its customers; this is a forum to share announcements, status reports on current and upcoming activities, and hold open discussion on the HHS Integrated Award Environment (IAE) systems. |
| Observational Cohort to Assess Therapeutic Efficacy and Emergence of HIV Drug Resistance following Initiation of Tenofovir-Lamivudine-Dolutegravir (TLD) | Research Initiative | CDC | NIAID | This is a study of the safety, adherence, and efficacy of a fixed-dose combination of drug tenofovir/lamivudine/dolutegravir (TLD) among HIV patients, including those co-infected with tuberculosis, receiving care at PEPFAR (President’s Emergency Plan for AIDS Relief) funded sites in resource limited countries. |
| Obstetrics, Reproductive and Urologic Drugs Advisory Committee (ORUDAC) | Committee, Work group, Advisory group, or Task Force | FDA | NICHD | The Committee reviews and evaluates data on the safety and effectiveness of marketed and investigational human drug products for use in the practice of osteoporosis and metabolic bone disease, obstetrics, gynecology, urology and related specialties, and makes appropriate recommendations to the Commissioner of Food and Drugs. https://www.fda.gov/advisory-committees/human-drug-advisory-committees/… |
| Occupational Exposure Assessment of a-Pinene and related Monoterpenes | Research Initiative | CDC, FDA | NIEHS | This research will define the range of exposures present across several industries that routinely handle monoterpene compounds, to determine which working populations are most at risk of elevated exposures to monoterpenes. |
| Occupational Exposure Assessment of Emerging Per- and Polyfluoroalkyl Substances (PFAS) | Research Initiative | CDC | NIEHS | The primary objectives of this study are to identify PFAS compounds currently in use in commerce or industry and the companies, industries, and worker populations who are manufacturing, processing, or using PFAS products and to conduct targeted occupational exposure assessments in high- and moderate-PFAS volume industries. Based on the results of the exposure assessment, secondary objectives of this study are to assess health effects associated with PFAS exposure. |
| ODP Prevention Scientific Interest Groups (SIGs) | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, OASH | NCI, NHLBI, NICHD, NIDDK, NIEHS, NIMHD, NINR, OD/DPCPSI/OBSSR, OD/DPCPSI/ODP | The Office of Disease Prevention (ODP) Prevention Scientific Interest Groups (SIGs) develop collaborative research initiatives to address unmet prevention research needs. To avoid overlap with other collaborative research planning groups, they focus on areas where there are no existing collaborative NIH-wide or federal groups. |
| Office of AIDS Research Advisory Council | Committee, Work group, Advisory group, or Task Force | CDC | NIAID, OD/DPCPSI, OD/DPCPSI/OAR | The Office of AIDS Research Advisory Council (OARAC) provides advice to the Office of AIDS Research (OAR) Director on the planning, coordination, and evaluation of research and other HIV/AIDS activities conducted or supported by the National Institutes of Health (NIH). The OARAC advises the Secretary of Health and Human Services, the Assistant Secretary for Health, the Director of NIH, and the Director of OAR on HIV/AIDS research programs and the development and annual review of the comprehensive NIH Strategic Plan for HIV and HIV-Related Research. |
| Office of the Secretary Patient-Centered Outcomes Research Trust Fund Strategic Plan Implementation | Committee, Work group, Advisory group, or Task Force | ASPE | NCCIH, NICHD, NIDA | This group focuses on developing and overseeing implementation activities for the OS-PCORTF Strategic Plan. https://aspe.hhs.gov/os-pcortf-strategic-plan-2020-2029 |
| OJP/CDC MDI-IWG | Committee, Work group, Advisory group, or Task Force | CDC, FDA, HRSA, SAMHSA | NCI, NIDA | Medicolegal death investigation workgroups with CDC and DOJ leads. |
| Older Individuals Collaborative on Nutrition | Meeting/ Workshop | ACL, AHRQ, CDC, CMS, FDA, HRSA, IHS, IOS, IOS/ODPHP, OASH, OS, SAMHSA | NIA, OD/DPCPSI/ODP, OD/DPCPSI/ODS, OD/DPCPSI/ONR | The Older Individuals Collaborative on Nutrition (OICN) is a network of nutrition experts and other health professionals across the federal government whose areas of expertise “touch the lives of older adults. Nutritionists, communications professionals, and service providers from across the government discuss programs and materials development, as well as research news. |
| ONC Health Information Technology Advisory Committee (HITAC) | Committee, Work group, Advisory group, or Task Force | ONC, CDC, CMS, FDA | NEI | The Health Information Technology Advisory Committee (HITAC) was established by the 21st Century Cures Act (P.L. 114-255) and is governed by the provisions of the Federal Advisory Committee Act (FACA), P.L. 92-463, as amended, 5 U.S.C. App. 2, which sets forth standards for the formation and use of federal advisory committees. The HITAC will recommend to the National Coordinator for Health Information Technology policies, standards, implementation specifications, and certification criteria relating to the implementation of a health information technology infrastructure, nationally and locally, that advances the electronic access, exchange, and use of health information. HITAC unifies the roles of, and replaces, the Health Information Technology Policy Committee and the Health Information Technology Standards Committee that were in existence before the date of the enactment of the 21st Century Cures Act. |
| ONC Health Information Technology Research and Development (HITRD) Interagency Working Group | Committee, Work group, Advisory group, or Task Force | ONC, OSTP | OD/All of Us | Federal agency members of the Health Information Technology Research and Development Interagency Working Group (HITRD IWG) advance information technology (IT) research and development (R&D) for improving health by coordinating Federal health IT R&D plans and activities, providing a forum for sharing information about Federal health IT R&D programs, promoting synergies across Federal health IT investments, and articulating health IT R&D needs to policy-makers and decision-makers. The HITRD IWG reports to the NSTC Committee on Technology’s Subcommittee on Networking and Information Technology. |
| ONDCP Harm Reduction Interagency Working Group - Reimbursement Subgroup | Committee, Work group, Advisory group, or Task Force | ASPE, CDC, CMS, HRSA | NIDA | This interagency working group (IWG) will help drive action in support of the Biden-Harris Administration goal of increasing access to evidence-based harm reduction services through expanded Medicaid reimbursement, comprehensive federal grant funding, research, and workforce training. Specifically, the IWG will focus on integrating harm reduction services with traditional health care infrastructure by developing sustainable funding streams needed to expand the availability of syringe services programs, naloxone, fentanyl test strips, and low-threshold medication treatment for opioid use disorder at harm reduction programs, as outlined in the 2022 National Drug Control Strategy. |
| ONDCP Harm Reduction Interagency Working Group - Research Subgroup | Committee, Work group, Advisory group, or Task Force | ASPE, CDC, CMS, HRSA, SAMHSA | NIDA | This interagency working group (IWG) will help drive action in support of the Biden-Harris Administration goal of increasing access to evidence-based harm reduction services through expanded Medicaid reimbursement, comprehensive federal grant funding, research, and workforce training. Specifically, the IWG will focus on integrating harm reduction services with traditional health care infrastructure by developing sustainable funding streams needed to expand the availability of syringe services programs, naloxone, fentanyl test strips, and low-threshold medication treatment for opioid use disorder at harm reduction programs, as outlined in the 2022 National Drug Control Strategy. |
| ONDCP Recovery Research Interagency Working Group | Committee, Work group, Advisory group, or Task Force | AHRQ, ASPE, CDC, CMS, IHS, IOS, SAMHSA | NIAAA, NIDA | To develop, prioritize, and coordinate the implementation of a federal recovery research agenda across agencies. Through this IWG, which is called for in the President’s National Drug Control Strategy (NDCS), we will assess the current scientific knowledge of recovery from SUD, review federally funded research, evaluation, and data collection portfolios/strategies, and identify areas where additional research and evaluation efforts should be prioritized to support science-based policy. |
| One Health Coordination Unit | Committee, Work group, Advisory group, or Task Force | ASPR, CDC, FDA | NIAID | A multisectoral coordination mechanism to strengthen One Health collaboration related to prevention, detection, control, and response for zoonotic diseases and related One Health work across the federal government. |
| ONR Microbiomes, Diet, and Health Working Group | Committee, Work group, Advisory group, or Task Force | CDC, HRSA, SAMHSA | NIA | The main goal of this Working Group is to coordinate and promote research on diet-microbiome-host interactions. This working group is represented by intramural, extramural NIH scientists and representatives from other agencies with interest in microbiome-host interactions across the lifespan and in relation to disease and treatment. This group aspires to advance a nutrition research agenda by better defining diet-microbiome host interrelationships. |
| OPTN Heart Transplantation Committee Member | Committee, Work group, Advisory group, or Task Force | HRSA | NIAID | Organ Procurement and Transplantation Network (OPTN): Heart Transplant Committee Member, UNOS Region 2 representative |
| OPTN-D-TAC HIV Positive vs. HIV Infected Work Group | Committee, Work group, Advisory group, or Task Force | HRSA | Develop an algorithm/method for HIV+ vs. HIV-infected terms for the US Transplantation system | |
| Oral Health & Aging: Information for Caregivers | Public Education Campaign | ACL, HRSA, OASH | NIA, NIDCR | Fact sheets designed to provide caregivers with information they need to assist older adults with oral hygiene. There are four fact sheets in the series: Brushing, Flossing, Dry Mouth, and Finding Low-Cost Dental Care. |
| Oral Health in America: Advances and Challenges | Resource Development | CDC, CMS, FDA, HRSA, IHS, OASH, SAMHSA | NCATS, NIAID, NIDA, NIDCR | This report was a federally supported, multi-agency public-private-partner effort to examine the nation's oral health, highlighting advances and challenges, over the 20 years since the publication of the first U.S. Surgeon General's Report on oral health, published in 2000. The report continues to be disseminated and serves as a call to action for coordinated efforts among engaged communities including clinicians, scientists, professional and patient organizations, and local, state, and federal government agencies. |
| Organ Transplantation Affinity Group (OTAG) | Committee, Work group, Advisory group, or Task Force | CMS, HRSA | NHLBI, NIAID, NIDDK | Collaborative working group sponsored by CMS and HRSA on behalf of DHHS to ensure a strategic and comprehensive approach by the federal government to improve the US transplantation system |
| Overdose Prevention/ Polysubstance use Intra-agency Working Group | Committee, Work group, Advisory group, or Task Force | ASPE, CDC, FDA, SAMHSA | NIDA | To identify opportunities for collaboration across HHS agencies. |
| P2.2 WH Task Force sub-meeting | Committee, Work group, Advisory group, or Task Force | FDA | NCI | Unknown |
| Pain Assessments Web-Based Tool | Resource Development | FDA | NCATS, NCCIH, NCI, NEI, NHLBI, NIA, NIAAA, NIAMS, NIBIB, NIDCD, NIDDK, NIGMS, NIMH, NIMHD, NINDS, NINR | The NIH Pain Consortium and CMS pain assessments tool provides health care practitioners with relevant and validated pain assessment tools that are appropriate to their patient population and easily embedded into their practices. The goal is to provide access to measures across biopsychosocial pain domains to facilitate discussions between clinicians and patients to develop a treatment plan and monitor progress. The website lists and describes validated, commonly used measures across pain domains and collections of additional measures. |
| Pandemic Response Team | Other | ASPR, CDC | NIAID | Ongoing work and collaboration since the COVID-19 pandemic for COVID-19 vaccines allocation approvals for the use in NIH clinical trials and preclinical studies. |
| Partnership for Research on Vaccines and Infectious Diseases in Liberia | Research Initiative | CDC | NIAID | The PREVAIL partnership was established between the governments of Liberia and the United States. The Government of Liberia is represented through the Ministry of Health (MOH) and three autonomous agencies, the United States government is represented through NIAID and the Centers for Disease Control (CDC). The purpose of this partnership is to conduct collaborative biomedical and public health research to advance science, strengthen health policy and practice, and improve the health of Liberians and people worldwide while enhancing Liberian preparedness and agility to rapidly respond during any future infectious disease outbreaks. |
| Partnership of FDA Centers of Excellence in Regulatory Science and Innovation (CERSI) and NIH Clinical and Translational Science Award (CTSA) Programs | Research Initiative | FDA | NCATS | This activity aims to collaborate and foster partnership between the CTSA Program and CERSI Program to advance regulatory science by leveraging the resources and expertise from both programs. The respective shared goals of regulatory science and translational science provide opportunities to tackle high-impact concepts across all stages of the translational science spectrum. Collaborative groups from the CTSA Program and CERSI Program eligible organizations are invited to develop multi-site research projects to address roadblocks in translational research with innovative solutions. |
| Pathogen Detection Project and Interagency Collaboration on Genomics for Food and Feed Safety (Gen-FS) | Committee, Work group, Advisory group, or Task Force | CDC, CDC, FDA | NLM | The Pathogen Detection Project is a multi-agency collaboration that combines pathogen outbreak data with other information to determine the major source of contamination. Collaborating agencies include NLM, FDA, CDC, USDA-Food Safety and Inspection Service, and Public Health England. The U.S. agencies formalized their collaboration in a charter document, Interagency Collaboration on Genomics for Food and Feed Safety (Gen-FS), which outlines their coordinated efforts on antimicrobial resistance. http://www.ncbi.nlm.nih.gov/pathogens/ |
| Pathways to Prevention on Postpartum Health | Meeting/ Workshop | AHRQ, CDC, CMS, HRSA, IHS, OASH, SAMHSA | NHLBI, NICHD, NIMH, OD/DPCPSI/ODP, OD/DPCPSI/ORWH | ORWH initiated the development and submission of a P2P proposal on postpartum health with coordinated through ODP and with NIMHD, NHLBI and NICHD. In 2022 NIH worked with the AHRQ to develop a systematic evidence review on the topic to inform the P2P, conducted a cross-government portfolio analysis and held the P2P workshop November 29th-December 1, 2022. The Federal Partner’s meeting to be held Octber 23 and 25, 2023. The final report form the P2P and also the Federal Partner's report came out in 2024. The formal collaboration on this P2P ended in October 2024. Materials are at: https://prevention.nih.gov/research-priorities/research-needs-and-gaps/… |
| Patient Safety Chart Book | Committee, Work group, Advisory group, or Task Force | AHRQ | NIA, NIMH, NIMHD | review of chart book publication |
| PCOR Advisory Committee | Committee, Work group, Advisory group, or Task Force | ASPE, ACF, ACL, AHRQ, ASPR, CDC, CMS, FDA, HRSA, IHS, OASH, ONC, SAMHSA | NICHD, OD/OSP | Guide and support efforts under the OS- Patient Centered Outcomes Reseach Trust Fund, and coordinate agency participation and interactions |
| PCORTF Frailty & Functional Disabilities Project Working Group | Committee, Work group, Advisory group, or Task Force | AHRQ, ASPE, CDC, CMS | NIA | Validate and Expand Claims-Based Algorithms, Identifying Patients with Frailty and Functional Disabilities across Payer and Patient Populations |
| Pediatric COVID-19/MIS-C Interagency Team | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OASH | NHLBI, NIAID | To coordinate and plan research interests across the country involving MIS-C (Multi system Inflammatory Syndrome in Children) related to COVID-19. |
| Pediatric Medical Device Public Private Partnership | Resource Development | BARDA, FDA | NCI, NIAMS, NIBIB, NICHD, NIMH, NINDS | Despite numerous legislative, regulatory, and scientific efforts in the recent past, innovative pediatric medical devices (PMDs) have yet to be made timely available at the same rate as adult medical devices. In many cases, the cause of this disparity is not a lack of technologies but rather a lack of incentives for the industry to become involved in PMD R&D. Furthermore, many innovative medical devices approved for adult use have not been approved for pediatric use; when used “off-label” in children, it exposes children to a benefit/risk profile that has not been evaluated by the FDA, deepening the health inequities between these two populations. Over the past 13 years, the FDA Center for Devices and Radiological Health (CDRH) developed multiple programs for accelerating the innovation of PMDs. Nevertheless, medical device development for pediatrics has remained relatively stagnant, as evidenced by premarket approvals (PMAs) and humanitarian device exemptions (HDEs) with labeling for pediatric usage. During this period, at CDRH, approvals of PMAs and HDEs labeled only for adults increased at about twice the rate of devices labeled for both adult and pediatric use and about 21 times the rate of devices labeled solely for pediatric use. These data point to the persisting lack of availability, and subsequent access, to medical device options designed and approved for the pediatric population, which is even more dramatic for the youngest patients. This is a long-standing and significant public health problem.To address this inequality in our healthcare system, from 2023-2025, the FNIH will lead the design of a full-scale public-private partnership (PPP), bringing together the resources of multiple U.S. government agencies and private sector organizations, including industry and non-profits. The Design Phase of the PMD project will assemble a governance structure incorporating and building on foundational elements developed during the System of Hospitals for Innovation in Pediatrics – Medical Devices (SHIP-MD) 2021 pre-consortium workshop and convening a series of meetings for up to six integrated workstreams (i.e., Navigation, Hospitals, Regulatory, Finance, Decentralized Health Innovation, and Reimbursement). Additionally, this phase will produce a white paper with a detailed plan to build and launch a multi-year PPP. The focus is on the critical primary processes of building the national pediatric medical device ecosystem, as proposed in the SHIP-MD framework, which would include a network of hospitals, as well as associated but decentralized elements, optimizing public and private financing and reimbursement for R&D of pediatric medical devices, and ultimately creating a self-sustaining entity that will administer and manage the partnership over the long-term to benefit pediatric patients.With the goal of launching a full-scale PMD-PPP in 2025, the project aims to consolidate a national ecosystem that optimizes the translation of technological advancements in medical device design, evaluation, and approval for pediatric populations. The project will de-risk and streamline processes enabling the translation of medical advances from bench-to-bedside for medical devices for children. The PMD-PPP project will strive to develop a sustainable infrastructure for the successful development and commercialization of pediatric medical devices. Additionally, the project will integrate existing frameworks and the expertise and resources of the public and private sectors into a strategic and actionable plan. Ultimately this PPP will address the lack of access to medical device options designed and approved for the pediatric population. The PPP also will allow new, impactful synergies with other key players in the emerging national ecosystem, shaping and contributing to the success of the ongoing and new activities. |
| Pediatric Radiation Medical Countermeasures Working Group | Committee, Work group, Advisory group, or Task Force | BARDA, FDA | NIAID | This group was established in an effort to harmonize efforts in the pediatric space and to push ahead pediatric radiation and multi-utility (Chem/Rad) products. The plan is to critically evaluate the status of pediatric drug development against radiation injury. Identify resources and cross-cutting efforts in this area to ensure a clear pathway is established to advance radiation products with a pediatric indication |
| PHEMCE Broad Spectrum Antibiotic Working Group | Committee, Work group, Advisory group, or Task Force | ASPR, CDC, FDA | NIAID | Working group on broad spectrum antibiotics. |
| PHS Technology Transfer Policy Board | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NIAID | The purpose of the PHS Technology Transfer Policy Board (TTPB) is to serve as the principal advisory board to the National Institutes of Health (NIH) as lead agency in the PHS technology transfer program, the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA), in establishing PHS technology transfer policies and modifying existing policies, as applicable. |
| Physical Activity Guidelines Advisory Committee | Committee, Work group, Advisory group, or Task Force | OASH, CDC | NCI, NIAMS | The Physical Activity Guidelines is an essential resource for health professionals and policy makers. It includes recommendations for Americans ages 3 years and over — including people at increased risk of chronic disease — and provides evidence-based advice on how physical activity can help promote health and reduce the risk of chronic disease.The Guidelines serves as the primary, authoritative voice of the federal government for evidence-based guidance on physical activity, fitness, and health for Americans. ODPHP leads the development of the Guidelines in collaboration with the Centers for Disease Control and Prevention, the National Institutes of Health, and the President’s Council on Sports, Fitness & Nutrition. |
| Physical Activity Guidelines Executive Committee | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, OASH | OD/DPCPSI/ODS | The Executive Committee will support the 2028 Physical Activity Guidelines Advisory Committee and the 2028 U.S. Physical Activity Guidelines. |
| Population Assessment of Tobacco and Health (PATH) Study | Health Survey | FDA | NIDA | The PATH Study is a national longitudinal cohort study that will follow an estimated 59,000 US household residents ages 12 years and older for at least three years. |
| PRAMS Interagency Workgroup | Committee, Work group, Advisory group, or Task Force | CDC, CMS, HRSA | NICHD | Support team of PRAMS users as they build their internal capacity to link MCH data sets and inform their future programming. |
| PRAMS Multi-Jurisdiction Data Linkage Learning Community | Committee, Work group, Advisory group, or Task Force | CDC, CMS, HRSA | NICHD | Support teams of PRAMS users building their internal capacity to link MCH data sets and inform their future programming. |
| Precision Oncology Interest Group | Committee, Work group, Advisory group, or Task Force | FDA | NCATS, NCI, NHLBI, NIAID, NIAMS, NIBIB, NIDDK, NINDS, OD | The POIG, and its attendant listserv will aim to foster effective communication across the basic and clinical research oncology communities, to harness the translational powers of the NIH to advance precision therapy across cancers. The goals of the POIG are to discuss, plan, implement and execute the current CCR initiative to perform standardized genomic analyses (RNA-SEQ, exome-SEQ, methylation analysis) on a large cohort of NCI patients, with the goal of using these data to drive collaborative predictive and prognostic biomarker discovery and precision therapy strategies for improving patient outcomes, to discuss and implement best sample acquisition and management practices to learn the most from any precious patient material, to discuss and implement the best technologies and informatics to help us discover candidates for targeted therapies with the goal of maximizing favorable outcomes for oncology patients, and to rationally design clinical trials in oncology with a focus on precise therapies that have the potential to maximize benefit and minimize side effects. |
| Preclinical Assessment of Phage Therapy for Pathogen Decolonization | Research Initiative | FDA | NIAID | This project addresses key regulatory considerations relevant to using bacteriophages for decolonization of the drug-resistant nosocomial pathogens, vancomycin-resistant enterococci (VRE) and methicillin-resistant Staphylococcus aureus (MRSA). These include characterizing pathogen resistance to phage, defining phage mixtures ("cocktails") to circumvent resistance, optimizing mouse models to evaluate pathogen decolonization, and identifying endpoints that support claims for clinical benefit (e.g., reduced risk of disease transmission). |
| Pregnancy and Birth to 24 months (P/B-24) Project | Committee, Work group, Advisory group, or Task Force | CDC, FDA, HRSA, OS | NCI, NHLBI, NICHD, NIEHS, NINR | In 2012, the US Department of Agriculture (USDA) and Department of Health and Human Services (HHS) initiated a project informally called the “B-24 project.” This multi-phase project was originally intended to conclude in 2018 with information that could help the Departments develop dietary recommendations for infants and toddlers for release separate from the Dietary Guidelines. The first phase was completed in 2012-2013. In February 2014, Congress passed the Agricultural Act of 2014, also known as the Farm Bill, mandating that the Dietary Guidelines expand to include dietary guidance for infants and toddlers (from birth to age 24 months), as well as women who are pregnant, beginning with the 2020-2025 edition. Thus, USDA and HHS adjusted the purpose, timeline, and scope of the project. Now called the “Pregnancy and Birth to 24 Months project” or “P/B-24 project” to reflect the addition of pregnant women, this project is a joint initiative led by USDA and HHS in collaboration with programmatic and scientific experts. Rather than concluding in 2018 with dietary recommendations, the goal of the current project is to begin examining topics of public health importance for women who are pregnant and infants and toddlers from birth to 24 months of age. The findings from this work will be made publicly available at the completion of the project. https://www.fns.usda.gov/resource/pregnancy-and-birth-24-months |
| President's Advisory Council for HIV/AIDS | Committee, Work group, Advisory group, or Task Force | CDC, HRSA, IHS, OASH, SAMHSA | OD/DPCPSI/OAR | The Presidential Advisory Council on HIV/AIDS (PACHA) provides advice, information, and recommendations to the Secretary of Health Human Services regarding programs, policies, and research to promote effective treatment, prevention, and cure of HIV, including considering common co-morbidities of those with HIV as needed to promote effective HIV prevention and treatment and quality services to persons living with HIV. |
| President's Emergency Plan for AIDS Relief (PEPFAR) Cervical Cancer Prevention Expert Task Force | Committee, Work group, Advisory group, or Task Force | CDC | NCI, NIAID | NCI participates with other US government agencies (Department of State, CDC, USAID, and others) on an expert task force to inform the development and oversight of cervical cancer prevention programs within the US President’s Emergency Plan for AIDS Relief (PEPFAR) initiative. The Department of State-convenes an Expert Task Force from experts from the CDC, NIH (NCI), and other US government agencies including Department of State, US Agency for International Development (USAID), Department of Defense, and Peace Corps to inform the development and oversight of cervical cancer prevention programs within the US President’s Emergency Plan for AIDS Relief (PEPFAR) initiative. The task force meets periodically to review progress and updates from focus countries in the PEPFAR cervical cancer prevention efforts, refines and updates guidance for screening and precancer treatment for implementing partners in target countries, and provides recommendations for procedures for quality assurance and adverse event monitoring and reporting. |
| President's Task Force on Environmental Health Risks and Safety Risks to Children | Committee, Work group, Advisory group, or Task Force | OASH, ACF, ASPR, ATSDR, CDC, FDA, SAMHSA | NHLBI, NICHD, NIEHS, NIMH, NIMHD, OD/ECHO | In 1997, President Clinton issued Executive Order 13045, calling for each federal agency to ensure that its policies, programs, activities, and standards address disproportionate risks to children that result from environmental health risks or safety risks.” EO13045 established the President’s Task Force on Environmental Health Risks and Safety Risks to Children (Task Force).The Task Force has addressed issues such as childhood asthma, unintentional injuries, lead poisoning, developmental disorders, childhood cancer, and climate change. The Task Force also recommended the initiation of a prospective cohort study, from birth to adulthood, to evaluate the effects of both environmental exposures on child health and human development. An interdepartmental working group of senior staff was established to support the work of the Task Force—the Senior Staff Steering Committee (Steering Committee). It is co-chaired by the U.S. Environmental Protection Agency (EPA) and the Department of Health and Human Services (HHS). Working together through the Task Force, the federal government can continue to protect current and future generations by understanding and preventing negative environmental health impacts and helping to ensure opportunities for the development of healthy, more resilient children. |
| President's Task Force on Environmental Health Risks and Safety Risks to Children, Subcommittee on Climate, Emergencies, and Disasters | Committee, Work group, Advisory group, or Task Force | ACF, ASPR, CDC, HRSA, OASH | NHLBI, NICHD, NIEHS | In 1997, President Clinton issued Executive Order 13045, calling for each federal agency to “ensure that its policies, programs, activities, and standards address disproportionate risks to children that result from environmental health risks or safety risks.” EO13045 established the President’s Task Force on Environmental Health Risks and Safety Risks to Children (Task Force). Subcommittee on Climate, Emergencies, and Disasters. The new Subcommittee on Climate, Emergencies, and Disasters within the PTFCEH aims to address current gaps in health protection, promotion and research related to children resulting or arising from climate change, public health emergencies, and disasters. Dr. Dixon is a Co-Chair. https://ptfceh.niehs.nih.gov/ |
| Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria | Committee, Work group, Advisory group, or Task Force | ASPR | NIAID | In March 2015, the Department of Health and Human Services (HHS) announced the establishment of the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB). This Federal Advisory Committee (FACA) includes public voting members, non-voting liaison representatives from organizations and/or interest groups, and non-voting federal ex-officio members. PACCARB provides advice, information, and recommendations to the Secretary regarding programs and policies intended to support and evaluate the implementation of Executive Order 13676, including the National Strategy for CARB and the National Action Plan for CARB. PACCARB has been reauthorized until January 18, 2019 (based on its charter), through Executive Order 13811 on September 29, 2017. |
| President’s Task Force for Environmental Health and Safety Risks to Children | Committee, Work group, Advisory group, or Task Force | ASPR, ACF, CDC, HRSA, OASH, SAMHSA | NIA, NIAID, NICHD, NIEHS, NIMHD, OD | The President’s Task Force on Environmental Health Risks and Safety Risks to Children is the focal point for coordinating federal government efforts to explore, understand, and act together to improve children’s environmental health and safety. |
| Prevention Research Coordinating Committee | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, OASH, OS | CC, FIC, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI/OAR, OD/DPCPSI/OBSSR, OD/DPCPSI/ODP, OD/DPCPSI/ODS, OD/DPCPSI/ORWH, OD/OLPA | The NIH Prevention Research Coordinating Committee (PRCC) serves as a venue for exchanging information on recent scientific advances in disease prevention; examining the impact of new policies on research; planning new or discussing ongoing initiatives; and highlighting program accomplishments. As a trans-NIH, trans-agency committee, the PRCC provides a broad perspective on the current state-of-the-science and actively disseminates information about prevention-related activities sponsored by federal and non-federal organizations to the NIH Institutes and Centers. |
| Prioritization of compounds to be submitted for international scheduling at the WHO expert committee on drug dependence | Committee, Work group, Advisory group, or Task Force | FDA, SAMHSA | NIDA | Collaboration description: This group (representing NIDA, CDC, DEA, FDA, ONDCP, SAMHSA, and the State Department) meets once per year ahead of the World Health Organization’s Expert Committee on Drug Dependence (ECDD). This effort is headed by the FDA and seeks input from the other representatives on inclusion/exclusion of specific drugs to be recommended by the USA to the WHO for International Scheduling. The drugs recommended to the WHO would be considered the deliverables in this case. |
| Privacy Enhancing Technologies (PET) SubIPC | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NCI | Working Group created for the development of Privacy-Enhancing Technologies |
| Probiotic and Prebiotic Working Group | Committee, Work group, Advisory group, or Task Force | FDA | CC, CIT, CSR, FIC, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM | The Probiotic and Prebiotic Working Group (PPWG) is a trans-NIH effort formed in 2006 to identify gaps and challenges in prebiotic and probiotic research. Their goals include (1) facilitating interactions and collaborations among research scientists in the field of probiotics and prebiotics, (2) advancing prebiotic and probiotic research, and (3) understanding the role of gut microbiota and use of prebiotics and probiotics in health and disease. The working group strives to promote constructive interactions across NIH Institutes, Centers, and Offices, by disseminating real-time information and keeping PPWG members abreast of current and future activities occurring in the fields of probiotics and prebiotics. The group meets quarterly to form allied partnerships and collaborate on various pre- and probiotic activities. 2024 update: Trans - NIH workshop "Oral Microbiome in Health and Systemic Diseases" June 25, 2024. Workshop is led by DCP/NCIA paperhttps://events.cancer.gov/nci/oral-microbiome |
| Programmatic Interagency EHE | Committee, Work group, Advisory group, or Task Force | CDC, HRSA | NIAID | The Programmatic Interagency EHE (PIE) Group was formed to facilitate knowledge sharing and capacity building across EHE implementing agencies, identify opportunities for innovation and coordination, build a shared repertoire of resources and ideas, and connect with other federal colleagues working on EHE activities across the various agencies. |
| Proteomics Scientific Interest Group | Committee, Work group, Advisory group, or Task Force | FDA | NCI, NHLBI, NIAID, NIDA, NIDCR | ProtIG is an NIH Special Interest Group (SIG) that organizes seminars and workshops in relevant areas of proteomics, including talks on separation and protein identification methods, determination of post-translational modifications, protein-protein interactions, and bioinformatics and data management. A monthly seminar series is usually held at 12 pm on the Second Thursday of each month. |
| Public Health and Emergency Medical Countermeasures Enterprise (PHEMCE) Advisory Council | Committee, Work group, Advisory group, or Task Force | ASPR | NIAID, OD/IMOD | Replaces the old PHEMCE Executive Steering Committee (ESC). Comprised of directors of each PHEMCE agency that are convened by the ASPR to provide council/advise on enterprise issues to include requirements and the SNS, etc. |
| Public Health and Emergency Medical Countermeasures Enterprise (PHEMCE) Equity Executives Committee | Committee, Work group, Advisory group, or Task Force | ASPR | NIAID | Replaced the old PHEMCE Executive Enterprise Committee (EEC). comprised of senior executives within each PHEMCE agency that convene to coordinate MCM development across the USG. |
| Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) | Committee, Work group, Advisory group, or Task Force | ASPR | NIAID, NIAMS, NINDS, NLM, OD/IMOD | The Public Health and Emergency Medical Countermeasures Enterprise (PHEMCE) advances national preparedness for natural, accidental, and intentional threats by coordinating medical countermeasure-related efforts within HHS and in cooperation with PHEMCE interagency partners. NIAID has representatives on many groups within PHEMCE. |
| Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Personal Protective Equipment (PPE) Working Group (WG) | Committee, Work group, Advisory group, or Task Force | ASPR, CDC, FDA | OD/OM, OD/OM/ORS | This WG is a consolidation of the Gowns/gloves and Respiratory Protective Device (RPD) WGs into a single PPE WG that will address a broader set of topics. The primary purpose of the PPE WG is to analyze, strategize, and provide recommendations on matters pertinent to PPE within the context of public health emergencies. The PPE WG shall aid in developing strategies to address key cross-cutting policy and acquisition issues related to the research, development, acquisition, deployment, utilization, monitoring, and evaluation of PPE in consideration of available programmatic resources at the Federal, State, local, tribal and territorial levels. |
| Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Preparedness Against Chemical Threats (PACT) Working Group | Committee, Work group, Advisory group, or Task Force | ASPR | NIAID, NINDS | The US Department of Health and Human Services (HHS) Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) leads the mission to develop and acquire medical countermeasures that will improve public health emergency preparedness as well as prevent and mitigate the adverse health consequences associated with chemical, biological, radiological and nuclear (CBRN), and naturally occurring threats.https://www.medicalcountermeasures.gov/ |
| Public Health Service Technology Transfer Policy Board | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NCATS, NCI, NIAID, NIDA, OD/OER, OD/OIR, OD/OSP, OD/OTT | The purpose of the Public Health Service (PHS) Technology Transfer Policy Board (TTPB) is to serve as the principal advisory board for establishing PHS technology transfer policies and modifying existing policies, as applicable. Membership is drawn from the National Institutes of Health (NIH) as lead agency in the PHS technology transfer program, the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA). |
| Public Wastewater Surveillance Consortium | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NIAID, NIBIB, NIDA, NLM | The Public Wastewater Surveillance Consortium provides an interagency platform to enhance the use of wastewater and other environmental data for public health bio-surveillance. The group will identify key topic areas, foster discussion among stakeholders, and develop standards and best practices for analyzing and sharing environmental bio-surveillance data. |
| Quantum Barcoding for analysis of Ebola infection | Other | FDA | NIAID | Viral MIBI and Quantum barcoding: These projects are part of a Food and Drug Administration (FDA) contract with Dr. Gary Nolan's group at Stanford. The first project will develop and validate an assay for nucleic acid-based method for viral detection on the MIBI, compatible with Formalin-Fixed Paraffin-Embedded tissue, and then apply to Ebola samples. The second will use quantum barcoding to develop anti-human and anti-macaque antibody reagents, to hep develop a system that will replace multiplexing technologies such as high parameter FACS and CyTOF with a platform based on sequence tags (rather than fluorophores or mass tags) that uses decontaminated and ambient temperature-stable samples. This will be applied to BSL-3/4 samples. |
| R&D Community of Practices (CoP) Meeting | Meeting/ Workshop | ACF, BARDA, CDC, CMS, FDA | OD/OM, OD/OM/OALM | The R&D Community of Practices allows agencies to work together to exchange problems and solutions for reporting requirements associated with R&D and to provide feedback to both OMB and NSF-NCSES on ways to improve the process of reporting. |
| Racial/Ethnic Variation of HPV Type Distribution in High-Grade Cervical Precancers and Invasive Cancers in the United States | Research Initiative | CDC | NCI | The National Cancer Institute (NCI) and Centers for Disease Control and Prevention (CDC) are collaborating in pooled anlaysis of seven U.S. studies conducted between 1997-2015 to examine HPV genotype attribution for cervical precancer and cancer by race/ethnicity. |
| Radiation and Chemical Defense Working Group | Committee, Work group, Advisory group, or Task Force | BARDA, FDA, ASPR | NIAID, NIAMS, NIEHS | This group identifies scientific overlap between the chemical radiation defense missions ensures they are leveraged to advance the missions of both research areas. Goals are to understand areas of synergy in chemical and radiological insults, identify key pathways, foci of intervention, drug development. Team includes staff from across the NIH, FDA and ASPR. A scientific Zoom conference was held January 2022 and a Special Journal Issue resulting from the presentations and meeting report is nearly complete. A follow-on NOSI is in preparation to provide supplements to cross-pollinate the rad and chem research areas. |
| Radiation Biodosimetry Interagency Working Group | Committee, Work group, Advisory group, or Task Force | FDA | NIAID | NIAID provides expertise on radiation biodosimetry topics and updates for the FDA / CDRH. |
| Radiation Biodosimetry Working Group | Committee, Work group, Advisory group, or Task Force | FDA | NIAID | This working group is focused on regulatory and scientific issues regarding technologies and devices for radiation biodosimetry. The working group assisted in drafting the new Food and Drug Administration (FDA) Center for Device and Radiological Health (CDRH) guidance for industry. |
| Radiobiology Bioterrorism Research and Training Group (RABRAT) | Committee, Work group, Advisory group, or Task Force | ASPR, FDA | NCI, NIAID | This activity involves monthly meetings to discuss research initiatives, funding opportunities, training, conferences, publications, and other events and information related to preparing the US Government to respond to nuclear terrorism. |
| Rapid Acceleration of Diagnostics Tech Program | Research Initiative | ASPR, ASPR, BARDA, CDC, CMS, FDA | NCI, NHLBI, NIAID, NIBIB, OD/DPCPSI/IMOD | To help address the COVID-19 pandemic, National Institute of Biomedical Imaging and Bioengineering (NIBIB) received $651 million (in FY2021) to support the development of new SARS-CoV-2 virus testing technologies. The Rapid Acceleration of Diagnostics (RADx®) Tech program is leveraging NIBIB's existing Point-of-Care Technologies Research Network (POCTRN) to accelerate the development, validation, and commercialization of innovative POC and home-based tests, as well as improvements to existing clinical laboratory methods. RADx Tech is supporting the full range of product development including technology validation, clinical translation, commercialization, and product distribution. RADx Tech also established the Independent Test Assessment Program (ITAP) in order to accelerate regulatory review and availability of high-quality, accurate, and reliable over-the-counter COVID-19 tests to the public. |
| Rare Disease Day at NIH | Meeting/ Workshop | FDA | NCATS, NCI, NHLBI, NIAAA, NINDS | Rare Disease Day takes place worldwide, typically on or near the last day of February each year, to raise awareness among policymakers and the public about rare diseases and their impact on patients' lives. Each year, the National Center for Advancing Translational Sciences (NCATS) and the National Institutes of Health (NIH) Clinical Center sponsor Rare Disease Day at NIH as part of this global observance. Rare Disease Day at NIH aims to raise awareness about rare diseases, the people they affect, and NIH collaborations that address scientific challenges and advance research for new treatments. The goals of Rare Disease Day at NIH are to: demonstrate the NIH commitment to helping people with rare diseases through research; highlight NIH-supported rare diseases research and the development of diagnostics and treatments; initiate a mutually beneficial dialogue among the rare disease community; exchange the latest rare diseases information with stakeholders to advance research and therapeutic efforts; shine a spotlight on stories told by people living with a rare disease, their families, and their communities. |
| Rare Diseases Registry Program (RaDaR) | Resource Development | FDA | NCATS | NCATS launched the Rare Diseases Registry Program (RaDaR) website to provide the rare diseases community with easily accessible guidance on how to set up and maintain high-quality registries that are based on best practices and data standards. The goal is to enable rare diseases patient organizations to better promote and support patient-focused research and the collection of patient data that can be used in developing treatments for rare diseases. |
| Recognize, Assist, Include, Support and Engage (RAISE) Family Caregiving Advisory Council | Committee, Work group, Advisory group, or Task Force | ACL, ACF, ASPE, CDC, CMS, FDA, HRSA, IHS, OASH, SAMHSA | NIA | Federal and non-federal advisory council is charged with providing recommendations to the Secretary of Health and Human Services on effective models of both family caregiving and support to family caregivers, as well as improving coordination across federal government programs, as mandated by the Recognize, Assist, Include, Support, and Engage (RAISE) Family Caregivers Act of 2017. |
| Recovery Month | Public Education Campaign | SAMHSA | NIDA | The Substance Abuse and Mental Health Services Administration (SAMHSA) holds an annual public health observance for people in recovery from substance abuse. The National Institute on Drug Abuse (NIDA) is part of SAMHSA's inter-agency planning committee and a promotional partner. |
| Regenerative Medicine Innovation Project (RMIP) | Committee, Work group, Advisory group, or Task Force | FDA | NIA, NIAMS | NIAMS assumed the lead IC role in the Regenerative Medicine Innovation Project (RMIP) in 2023. The RMIP was established by the 21st Century Cures Act to accelerate progress in the field by supporting clinical research on adult stem cells, while promoting scientific rigor and protecting patient safety. This initiative is a trans-NIH effort, in coordination with the Food and Drug Administration (FDA). |
| Regenerative Medicine Innovation Project (RMIP) In-Depth Cell Characterization Hub (IDCCH) Scientific Oversight Subcommittee (SOS) | Committee, Work group, Advisory group, or Task Force | FDA, HRSA | NCATS, NEI, NHLBI, NIA, NIAMS, NIDCD, NIDCR, NIDDK, NINDS | The Regenerative Medicine Innovation Project was established by the 21st Century Cures Act to accelerate progress in the field by supporting clinical research on adult stem cells, while promoting scientific rigor and protecting patient safety. This initiative is a trans-NIH effort, in coordination with the Food and Drug Administration (FDA). |
| Regenerative Medicine Innovation Project (RMIP) Senior Oversight Committee | Committee, Work group, Advisory group, or Task Force | FDA, HRSA | NCATS, NEI, NHLBI, NIA, NIAID, NIAMS, NIDCD, NIDCR, NIDDK, NINDS | The Regenerative Medicine Innovation Project was established by the 21st Century Cures Act to accelerate progress in the field by supporting clinical research on adult stem cells, while promoting scientific rigor and protecting patient safety. This initiative is a trans-NIH effort, in coordination with the Food and Drug Administration (FDA). |
| Registry-based studies of hematologic malignancy incidence and survivorship | Research Initiative | FDA | NCI | NCI and FDA investigators are collaborating to utilize registry-based data to describe incidence trends of hematologic malignancies as well as second cancer risk and mortality patterns among hematologic malignancy survivors. |
| Research in Diabetes Mellitus, Its Complications, and Obesity | Research Initiative | IHS | NIDDK | The objectives are to identify the determinants and understand the progression of type 2 diabetes, obesity, and other chronic diseases in Native American and related populations. |
| Review Policy Committee (RPC) | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC | CSR, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/OER | The Review Policy Committee (RPC) is the principal forum for the development, implementation, and evaluation of review policies and procedures for all types of research, training, and development awards submitted to the NIH. RPC membership includes one senior extramural review official from each NIH Institute and Center that has extramural review functions. The RPC has designated liaisons from other HHS agencies including Agency for Healthcare Research and Quality (AHRQ) and Centers for Disease Control and Prevention (CDC). From SLC: This description is still accurate. |
| Rheumatic and Autoimmune Diseases in Minority Communities | Research Initiative | FDA | NHGRI | This project studies the clinical presentation of rheumatic diseases in an underserved, largely ethnic minority community in the Washington, D.C. metropolitan area. Through the NIAMS Community Health Center, subjects with rheumatic complaints are evaluated and provide clinicians with first-hand experience in understanding ethnic differences in autoimmune disease phenotypes as well as barriers to care. https://reporter.nih.gov/search/TjYJobq_NUuCDBdx6gb8qA/project-details/… |
| Role of Gs-alpha in pancreatic islet cell growth and function | Research Initiative | FDA | NIDDK | Role of Gs-alpha in pancreatic islet cell growth and function |
| Rural Opioid Initiative | Research Initiative | AHRQ, CDC, SAMHSA | NIDA | The ROI consists of eight research teams centrally located in rural areas whose overarching aim is to help communities develop comprehensive approaches to prevent and treat outcomes related to substance use. |
| Ruth L. Kirschstein National Research Service Award Program | Training Initiative | AHRQ, HRSA | OD/OER | The National Institutes of Health (NIH) Ruth L. Kirschstein National Research Service Award program provides predoctoral and postdoctoral training to meet the nation’s need for investigators in biomedical, behavioral, and clinical research. In accordance with the Public Health Service Act and annual appropriations acts, NIH annually transfers a portion of these funds to the Agency for Healthcare Research and Quality and Health Resources and Services Administration to foster the training of health services and primary care researchers. |
| RxNorm | Resource Development | FDA | NLM | RxNorm provides normalized names for generic and branded drugs and links its names to many of the drug vocabularies commonly used in pharmacy management and drug interaction software. By providing links between these vocabularies, RxNorm can facilitate communication between systems that use different software and vocabulary. http://www.nlm.nih.gov/research/umls/rxnorm/ |
| SARS CoV-2 Risk Group and Biosafety Level Working Group | Committee, Work group, Advisory group, or Task Force | CDC | OD/OM, OD/OM/ORS | Discussed and made recommendation on risk level and biosafety level for SARS-CoV-2 |
| SARS-CoV-2 Assay Development, Training, and Standardization | Committee, Work group, Advisory group, or Task Force | FDA | NIAID | SARS-CoV-2 Assay Development, Training, and Standardization in BSL4 lab at Integrated Research Facility, Fort Dietrick |
| SARS-CoV-2 Assessment of Viral Evolution Program | Committee, Work group, Advisory group, or Task Force | ASPR, CDC, FDA | NIAID | SAVE provides a comprehensive real-time risk assessment of emerging mutations in SARS-CoV-2 that could impact transmissibility, virulence, and susceptibility to infection- or vaccine-induced immunity. The goals of the SAVE program are to understand emerging changes in the virus that could impact transmissibility, virulence, susceptibility to convalescent and vaccine-induced immunity and diagnostic testing. |
| SARS-CoV-2 Interagency Group on Diagnostics | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NIAID | SARS-CoV-2 interagency Working Group aimed at evaluating the impact of SARS-CoV-2 variants on COVID-19 diagnostics |
| SARS-CoV-2 Sequencing for Public Health Emergency Response, Epidemiology, and Surveillance | Committee, Work group, Advisory group, or Task Force | CDC | NIAID | A new national genomics consortium to coordinate SARS-CoV-2 sequencing across the United States |
| Scientific Registry of Transplant Recipients (SRTR) Visiting Committee | Committee, Work group, Advisory group, or Task Force | HRSA | The SRTR Visiting Committee advises the SRTR on:(1) analytic methodologies to support the Organ Procurement and Transplantation Network policy development and evaluation; (2) objectives, study designs, and statistical methods for research projects performed by SRTR, including risk-adjusted analyses of organ procurement organization and transplant program performance; (3) methods used in simulated allocation models; (4) new areas of research and innovative advances in analytical methodologies that might improve the effectiveness of SRTR. | |
| Secretary’s Initiative on Protecting Farmworkers from Extreme Heat and Wildfire Smoke | Other | CDC, HRSA, SAMHSA | NIEHS, NIMHD, NINR | Proposed by the HHS Secretary. It intends to facilitate communication and collaboration across HHS agencies on research, policy, and healthcare services to protect farmworkers from extreme heat and wildfire smoke (the latter related to more recent climate events in various states. |
| Secretary's Advisory Committee on Human Research Protections | Committee, Work group, Advisory group, or Task Force | OASH, AHRQ, CDC, FDA, HRSA, IHS, OCR, ONC | OD/OSP | The Secretary’s Advisory Committee on Human Research Protections (SACHRP) provides expert advice and recommendations to the Secretary of HHS on issues pertaining to the protection of human subjects in research. |
| Secretary's Advisory Committee on Infant Mortality | Committee, Work group, Advisory group, or Task Force | CDC, HRSA | NICHD | The Secretary’s Advisory Committee on Infant Mortality (SACIM) was formed in 1991 to advise the Secretary on Department of Health and Human Services’ programs that are directed at reducing infant mortality and improving the health status of pregnant women and infants. https://www.hrsa.gov/advisory-committees/infant-mortality/index.html |
| Secretary's Tribal Advisory Committee (STAC) | Committee, Work group, Advisory group, or Task Force | IOS | OD/IMOD | The Secretary’s Tribal Advisory Committee signals a new level of attention to Government-to-Government relationship between HHS and Indian Tribal Governments.The STAC’s primary purpose is to seek consensus, exchange views, share information, provide advice and/or recommendations; or facilitate any other interaction related to intergovernmental responsibilities or administration of HHS programs, including those that arise explicitly or implicitly under statute, regulation or Executive Order. This purpose will be accomplished through forums, meetings and conversations between Federal officials and elected Tribal leaders in their official capacity (or their designated employees or national associations with authority to act on their behalf). |
| Sepsis Interagency Meeting | Committee, Work group, Advisory group, or Task Force | AHRQ, BARDA, CDC, CMS | NHLBI, NIAID, NICHD, NIGMS | Discuss Sepsis Priority Areas identified in Biomedical Advanced Research and Development (BARDA) market research: Unifying definitions of Sepsis across the patient continuum, Harmonizing Data for Access and Interoperability, Optimizing Health Outcomes and Reducing Economic Burden, Improving Evaluation and Catalyzing Adoption of Critical Technologies. |
| Sequencing for Public Health Emergency Response, Epidemiology and Surveillance | Other | CDC | NIA, NIAID, NLM | To accelerate the use of near-real-time pathogen genomic data during the SARS-CoV-2 pandemic and future public health events, the CDC established the Sequencing for Public Health Emergency Response, Epidemiology, and Surveillance (SPHERES) consortium. The consortium works to improve communication and knowledge-sharing among U.S. laboratories, develop consensus guidance on data and metadata standards, reduce barriers to bioinformatics analysis and data sharing, and better align sequencing requirements and resource needs with available sources of funding, technology, expertise, and other resources. https://www.cdc.gov/advanced-molecular-detection/php/spheres/ |
| Sequencing Quality Control Phase 2 (SEQC2) | Resource Development | FDA, FDA | CIT, NCI, NHLBI, NIEHS, NLM | The Sequencing Quality Control (SEQC) consortium is an FDA-led community-wide effort. SEQC Phase 2 (SEQC2) is a project within the consortium. The goals of SEQC2 are to: (1) develop quality metrics for reproducible next-generation sequencing (NGS) results from both whole genome sequencing (WGS) and targeted gene sequencing (TGS); (2) benchmark bioinformatics methods for WGS and TGS towards the development of standard data analysis protocols; and (3) assess the joint effects of key parameters affecting NGS results and interpretation for clinical application. NLM provides a data portal and supports the effort with data analysis. https://www.fda.gov/science-research/bioinformatics-tools/microarrayseq…; https://ftp.ncbi.nlm.nih.gov/ReferenceSamples/seqc/Somatic_Mutation_WG/ |
| Serum concentrations of per- and polyfluoroalkyl substances and breast cancer risk among postmenopausal women: A nested case-control study in the Women’s Health Initiative (WHI) | Research Initiative | CDC | NCI | To clarify the potential role of PFAS in the development of breast cancer overall and for specific hormone receptor subtypes, the National Cancer Institute (NCI) and Centers for Disease Control and Prevention (CDC) are collaborating on measurements of serum concentrations of per- and polyfluoroalkyl substances (PFAS) for a nested case-control study of breast cancer among postmenopausal women in the Women’s Health Initiative (WHI) Observational Study. |
| Serum organochlorine/PCB concentrations and risk of prostate cancer in men from Ghana | Research Initiative | CDC | NCI | National Cancer Institute (NCI) and Centers for Disease Control and Prevention (CDC) are collaborating to measure serum levels of persistent organic pollutants for a case-control study of prostate cancer in the Ghana Prostate Study. |
| Serum PFAS concentrations and risk of renal cell carcinoma in the Multiethnic Cohort | Research Initiative | CDC | NCI | National Cancer Institute (NCI) and Centers for Disease Control and Prevention (CDC) are collaborating to measure serum levels of per- and polyfluoroalkyl substances (PFAS) for a nested case-control study of renal cell carcinoma (RCC) in the Multiethnic Cohort. |
| SHIELD: Standardization of Lab Data to Enhance Outcomes Research and Value Based Care | Committee, Work group, Advisory group, or Task Force | FDA, CDC, FDA | NLM | This project will expand the collaborative efforts of the FDA and other stakeholders involved in the SHIELD (Systemic Harmonization and Interoperability Enhancement for Laboratory Data) initiative to ensure laboratory information interoperability, such that the same type of device is described the same way across electronic health records systems. To achieve this, the project will develop code mapping manuals to consistently map the same LOINC (Logical Observations Identifiers Names and Codes) to the same type of in vitro diagnostic (IVD) devices. This is important because, without specific guidance, manufacturers of IVD devices and laboratories often assign different (and frequently incorrect) LOINC codes for the same type of device. Additionally, the project will pilot the implementation of SHIELD standard digital formats to update infrastructure in active healthcare provider laboratories. This will facilitate the seamless distribution of LOINC and SNOMED-CT (Systematized Nomenclature of Medicine—Clinical Terms) coding to those provider institutions and registries. https://aspe.hhs.gov/shield-standardization-lab-data-enhance-patient-ce… |
| Sickle Cell Disease Federal Interagency Work Group (SCD FIWG) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, HRSA, OASH | NHGRI, NHLBI | The Sickle Cell Disease Federal Interagency Work Group (FIWG) fosters a community of partners engaged in achieving the vision of long, healthy, productive lives for those living with Sickle Cell Disease (SCD) and those with Sickle Cell Trait (SCT)." This involves building the capacity to address the recommendations shared in the NASEM Sickle Cell Disease Strategic Plan and Blueprint for action. |
| Small Business Procurement Advisory Counsel (SBPAC) | Committee, Work group, Advisory group, or Task Force | HRSA, CDC, CMS, FDA | OD/OM, OD/OM/OALM | Particpate with the Small Business Adminstration and other federal agencies on small business procurement concerns, regulations, and policies. |
| Small Business Program Managers Committee | Meeting/ Workshop | CDC, FDA | OD/DPCPSI/ORIP | Monthly meetings organized by the Small Business Education and Entrepreneurial Development (SEED) at OER, OD. Attendance includes all Small Business Program Managers of the NIH-ICOs, CDC and FDA. Venue to discuss program updates, presentations , challenges and new initiatives amongst ICOs SB managers. |
| Smallpox Working Group | Committee, Work group, Advisory group, or Task Force | ASFR, CDC, FDA | NIAID | Working group on smallpox. |
| Smokefree.gov Initiative | Resource Development | CDC, FDA, IHS | NCI | The Smokefree.gov Initiative (SFGI) provides tobacco users who want to quit with free, evidence-based cessation information and on-demand support. SFGI includes 5 mobile-optimized websites, 10 SMS text programs, a smartphone app, and 6 social media platforms. Tailored content is provided for special populations including women, teens, Spanish speakers, and veterans. |
| Social Determinants of Health Research Coordinating Committee | Committee, Work group, Advisory group, or Task Force | SAMHSA | FIC, NCATS, NCCIH, NCI, NIA, NIAMS, NIEHS, NIMHD, NINR, OD/DPCPSI/OBSSR, OD/DPCPSI/ODP, OD/DPCPSI/ORWH | The overall goal of the Research Coordinating Committee (RCC) is to accelerate NIH-wide SDOH research across diseases and conditions, populations, stages of the life course, and SDOH domains, domestically and globally. |
| Society for Prevention Research Annual Conference | Meeting/ Workshop | ACF, CDC | NCCIH, NCI, NIAAA, NINR | This annual conference is funded by an R13 award and is co-funded by several other NIH Institutes as well as the ACF and the CDC. |
| Somatic Cell Genome Editing | Research Initiative | FDA | NCATS, NCI, NEI, NHGRI, NHLBI, NIAID, NIAMS, NIBIB, NICHD, NIDDK, NIEHS, NIMH, NINDS, OD/DPCPSI/ORIP, OD/DPCPSI/OSC | The Somatic Cell Genome Editing (SCGE) program aims to develop quality tools to perform effective and safe genome editing in human patients. These research tools will be made widely available to the research community to reduce the time and cost required to develop new therapies. Representatives from Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) attend SCGE Consortium meetings with NIH and Prinicpal Investigators that covers emerging science and opportunities as well as progress of SCGE awardees. The NIH is also establishing a Memorandum of Understanding (MOU) with the FDA for direct NIH/FDA communications on general regulatory issues around genome editing that may inform how NIH manages the SCGE program. The SCGE program is a member of the National Institute of Standards and Technology (NIST) Gene Editing Consortium. |
| Somatic Cell Genome Editing (SCGE)-related Memorandum of Understanding (MOU) | Other | FDA | NCATS, NINDS, OD/DPCPSI/OSC | The SCGE-related MOU provides the principles and procedures for information sharing between FDA/CBER and NIH. |
| Special Populations Research Forum, Clinical Research Recommendations Subcommittee | Committee, Work group, Advisory group, or Task Force | SAMHSA | NCI, NHLBI, NINDS, OD/DPCPSI/SGMRO | The Special Populations Research Forum (SPRF) provides a resource for NIH and HHS staff to share best practices and lessons learned in promoting diversity, equity, and inclusion (DEI) in intramural and extramural training and research. |
| State Cancer Profiles | Resource Development | CDC | NCI | State Cancer Profiles is an interactive mapping engine produced in collaboration between the National Cancer Institute and Centers for Disease Control and Prevention. It was developed with the idea to provide a geographic profile of cancer burden in the United States and reveal geographic disparities in cancer incidence, mortality, risk factors for cancer, and cancer screening across different population subgroups. The target audiences are health planners, policy makers, and cancer information providers who need quick and easy access to cancer related data and maps to inform and prioritize investments in cancer control. Other collaborative activity: database |
| State of the Science in Transfusion Medicine Symposium | Committee, Work group, Advisory group, or Task Force | OASH | NHLBI | On August 29-30, 2022, the National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), and the Office of the Assistant Secretary for Health (OASH), Department of Health and Human Services (DHHS) held a virtual transfusion medicine (TM) research symposium. In advance of the symposium, six multidisciplinary working groups (WG) convened to define research priorities in the following topic areas: blood donors and the supply, optimizing transfusion outcomes for recipients, emerging infections, mechanistic aspects of components and transfusion, new computational methods in transfusion science, and the impact of health disparities on donors and recipients. The objective was to identify key basic, translational, and clinical research questions, that if addressed over the next decade, will increase and diversify the volunteer blood donor pool, help ensure safe and effective transfusion strategies for all blood recipients, and identify which blood products from which donors best meet the clinical needs of specific recipient populations. |
| Steering Committee of the Scientific Interest Group in Glycobiology | Committee, Work group, Advisory group, or Task Force | FDA | NCI, NHGRI, NHLBI, NIAID, NIDCR, NIDDK | The Steering Committee of the Scientific Interest Group in Glycobiology (GlycoSIG) is comprised of National Institutes of Health (NIH) intramural scientists and program staff as well researchers from the Food and Drug Administration (FDA) and the National Institute of Standards and Technology (NIST). The committee organizes a seminar series; an annual NIH/FDA Glycosciences Research Day Meeting (averaging 250 people in attendance); and a Mentoring & Networking Luncheon for graduate students and postdoctoral fellows to meet with staff from federal agencies and learn about NIH extramural programs. The Committee also offers a Special Topics in the Glycosciences Course every other year. In addition, the GlycoSIG maintains an email list serve to distribute information on meetings, jobs, funding opportunities, and seminars. The SIG cross posts with other NIH SIG’s that share interests. |
| Substance-exposed Pregnancies workgroup | Committee, Work group, Advisory group, or Task Force | ASPE, ACF, ACL, AHRQ, CDC, FDA, HRSA, SAMHSA | NIDA, OD/ECHO | Share information re: Substance use disorders, illness in children, current research, and future plans. |
| Sudden Unexpected Infant Death and Sudden Death in the Young Case Registry | Research Initiative | CDC | NHLBI, NINDS | Sudden Death in the Young (SDY), those under 20 years of age, is a tragic event with longstanding impact on families and communities. Although the causes of SDY are myriad, sudden unexpected infant death (SUID), sudden cardiac death and sudden unexpected death in epilepsy (SUDEP) are three examples that have inspired public health efforts at prevention. The Sudden Unexpected Infant Death (SUID) and SDY Case Registry is a collaboration between the National Institutes of Health (NHLBI and NINDS) and the Centers for Disease Control and Prevention. |
| Supply Chain Risk Management (SCRM) Program | Committee, Work group, Advisory group, or Task Force | ASPR, ONS, CDC, CMS, FDA | OD/OM, OD/OM/OALM | HHS E-SCRM protects the Department's internal supply chain concerning threats posed towards the lifecycle of mission-critical products, materials, services used by the OPDIVS and STAFFDIVS through the identification, assessment, and mitigation of threats. OD/OM/OALM collaborates with HHS/ASPR/OSVP to conduct classified and unclassified analyses of threats and vulnerabilities called SCARs and HHS/ONS for the FOCI touchpoints. |
| Support for Implementation of Agency Public Access Policies | Resource Development | ACL, AHRQ, ASPR, CDC, FDA | NLM, OD/OSP | The National Library of Medicine (NLM) collaborates with other federal agencies to provide free public access through NLM’s PubMed Central digital archive to peer-reviewed publications resulting from agency-funded research. These agencies include five divisions and offices in HHS and four agencies outside HHS. Interagency agreements (IAAs) have been signed with the Agency for Healthcare Research and Quality (AHRQ), Administration for Strategic Preparedness and Response, CDC, FDA, and Administration for Community Living within HHS, as well as with the National Institute of Standards and Technology, Department of Veterans Affairs (VA), EPA, and Department of Homeland Security. IAAs with VA and AHRQ have also been extended to support the inclusion of non-journal literature in NLM’s Bookshelf resource. NLM has also agreed to manuscript redistribution terms with the National Oceanic and Atmospheric Administration and Department of Defense to streamline public access compliance across the federal government. https://www.ncbi.nlm.nih.gov/pmc/about/public-access-info |
| Supporting Early Psychosis Research and Implementation and Other Cross-Agency Common Interests | Research Initiative | ASPE, OS | NIMH | The National Institute of Mental Health (NIMH) supports research on the delivery of evidence-based early psychosis care, including facilitating the implementation of evidence-based coordinated specialty care (CSC) for early psychosis. Collaborators from NIMH and the Department of Health and Human Services (HHS) Office of the Secretary (OS) and the Office of the Assistant Secretary for Planning and Evaluation (ASPE) meet on a regular basis to inform each other's research agenda on early psychosis care generally and CSC specifically, identify synergies in research initiatives and formulate new research initiatives, and share related draft reports and funding opportunity announcements for comment. |
| Surveillance, Epidemiology, and End Results (SEER) Program | Resource Development | CDC | NCI | The Surveillance, Epidemiology, and End Results (SEER) program is the premier source for cancer statistics in the US. It collects information on incidence, prevalence, and survival from specific geographic areas representing 48 percent of the US population. Through SEER, NCI develops reports on all of these information areas plus cancer mortality for the entire country. The site is intended for anyone interested in US cancer statistics or cancer surveillance methods. |
| Sustainability and the Dietary Guidelines for Americans Subcommittee (ICHNR) | Committee, Work group, Advisory group, or Task Force | IOS/ODPHP | OD/DPCPSI/ONR | This subcommittee of the ICHNR focuses on the incorporation of sustainable practices (including agriculture and climate change) in the development process for the Dietary Guidelines for Americans (DGA). This group will develop an RFI in order to obtain public input on these practices for including sustainability in the review process for the DGA. |
| Systematic Evidence Review of Trauma Informed Care (TIC) | Research Initiative | AHRQ | NIMH | This project, a collaboration between the National Institute of Mental Health (NIMH) and the Agency for Healthcare Research and Quality (AHRQ) will aim to review the effectiveness of trauma-informed care in improving patient care and outcomes. |
| Systematized Nomenclature of Medicine-Clinical Terms (SNOMED CT) | Resource Development | OS, AHRQ, CDC, CMS, FDA, HRSA, IHS, IOS, SAMHSA | NLM | SNOMED CT (Systematized Nomenclature of Medicine - Clinical Terms), the standard nomenclature of medicine, is a comprehensive, precise, and multilingual health terminology system. It assists with the electronic exchange of clinical health information, can be mapped to other coding systems, and serves as a resource with extensive, scientifically validated clinical content. NLM serves as the United States National Release Center, is a member of SNOMED International, and is responsible for creating and distributing the US Edition of SNOMED CT. NLM also accepts content requests for inclusion in the US Edition of SNOMED CT. Collaborators, including the Department of Veterans Affairs, National Cancer Institute, Agency for Healthcare Research and Quality, CDC, Centers for Medicare & Medicaid Services, and FDA, have integrated SNOMED CT into their resources and submitted content requests for inclusion in the US Edition of SNOMED CT. https://www.nlm.nih.gov/healthit/snomedct/index.html |
| Task Force for Combating Antibiotic-Resistant Bacteria (CARB) | Committee, Work group, Advisory group, or Task Force | AHRQ, ASPR, CDC, CMS, FDA, HRSA | NIAID | Established by Executive Order 13676, the Task Force facilitates implementation of the CARB Action Plan and provides progress reports and quarterly updates describing key achievements. The Task Force is an internal government committee comprised of federal representatives and co-chaired by the Secretaries of Defense, Agriculture, and HHS. |
| Task Force on Maternal Mental Health | Committee, Work group, Advisory group, or Task Force | SAMHSA, ACF, ACL, AHRQ, ASPE, CDC, CMS, HRSA, IEA, IHS, OASH | NICHD, NIMH | The Task Force on Maternal Mental Health, co-led by the Office on Women’s Health and the Substance Abuse and Mental Health Services Administration (SAMHSA), will identify, evaluate, and make recommendations to coordinate and improve activities related to addressing maternal mental health conditions and co-occurring substance use disorders. There will be a focus on mental health equity as well as trauma-informed practices.Areas of FocusData, Research, Quality Improvement and Health EquityPrevention, Screening, and DiagnosisEvidence-based Intervention and TreatmentEvidence-based Community PracticesCommunications and Community Engagement |
| Technical Expert Panel on the Development of Evidence-Based Practice Guide on the Treatment of Serious Mental Illness (SMI) in Older Adults | Meeting/ Workshop | SAMHSA | NIMH | Substance Abuse and Mental Health Services Administration (SAMHSA) convened a technical expert panel to provide guidance on the development of an evidence-based practice guide on the treatment of serious mental illness in older adults. The guide is an important part of the 21st Century Cures Act's charge at SAMHSA to disseminate information on evidence-based practices and will address best practices for older adults. |
| Testing Risks of Artificial Intelligence for National Security (TRAINS) Taskforce | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, IHS, SAMHSA | OD/OCIO | Identify, measure, and manage the emerging national security and public safety implications of rapidly evolving AI technology |
| The Administration for Strategic Preparedness and Response (ASPR)'s chemical, biological, radiological and nuclear defense subject matter expert team | Committee, Work group, Advisory group, or Task Force | ASPR | NCI, NIAID | NCI and NIAID participate in Assistant Secretary for Preparedness and Response (ASPR)'s chemical, biological, radiological and nuclear defense team. Both NCI and NIAID provide expertise on radiation topics and for the Biomedical Advanced Research and Development Authority (BARDA), within the Office of ASPR in the U.S. |
| The Agricultural Health Study | Research Initiative | CDC | NIEHS | The Agricultural Health Study (AHS) is a prospective study of cancer and other health outcomes in a cohort of licensed pesticide applicators and their spouses from Iowa and North Carolina. The AHS began in 1993 with the goal of answering important questions about how agricultural, lifestyle and genetic factors affect the health of farming populations. |
| The Cancer Cabinet Task Force for Prevention and Screening | Committee, Work group, Advisory group, or Task Force | CDC, CMS, FDA | NCI | In February 2022, President Biden kickstarted the next phase of the Cancer Moonshot with bold new goals: to reduce the cancer death rate by half within 25 years and improve the lives of people with cancer and cancer survivors. The following month, the White House convened the Cancer Cabinet, bringing together departments and agencies from across the federal government to establish a prioritized agenda across government, including the development of new interagency programs and collaborations. The Cancer Cabinet includes members from 20 executive branch departments, agencies, and offices. Priority Actions for the Cancer Cabinet:Close the Screening Gap: Americans missed nearly 10 million cancer screenings as compared to prior years due to the COVID-19 pandemic. Through targeted and coordinated programs, we should cut that deficit by providing access to more cancer screening opportunities and expand equitable access to cancer early detection.Decrease the Impact of Preventable Cancers: Thanks to scientific advancements, there are more tools today than ever before to prevent cancer. There are also healthy lifestyle choices like nutrition, tobacco cessation, others as well as tools such as the HPV vaccine and Hepatitis C antivirals that can prevent cervical, head and neck, and liver cancer, respectively. Additionally, advances in colonoscopy technology enable detection and removal of pre-cancerous growths to prevent the development of colon cancer in more individuals. Additional efforts are needed to expand access to these cancer-prevention approaches along with public health campaigns and community health efforts to ensure these preventative tools are reaching all populations. In doing so, there is opportunity to nearly or wholly eliminate certain cancer types. |
| The Environmental Determinants of Diabetes in the Young (TEDDY) | Research Initiative | CDC | NIAID, NICHD, NIDDK, NIEHS | This consortium, established and funded by NIDDK, is organizing international efforts to identify infectious agents, dietary factors, or other environmental factors that trigger type 1 diabetes in genetically susceptible people. The study enrolled over 8,000 newborns and is following them for 15 years to identify environmental triggers of type 1 diabetes. |
| The Epidemiology of Burkitt Lymphoma in East-African Children and Minors (EMBLEM) | Research Initiative | CDC, FDA | NCI, NHGRI, NHLBI, NIA, NIAID, NIEHS | The Epidemiology of Burkitt Lymphoma in East-African Children and Minors (EMBLEM) initiative provides a unique infrastructure to obtain valuable data and samples to study Burkitt’s lymphoma (BL) epidemiology. Study data will help characterize or investigate: (1) The association of malaria-resistance genes with endemic BL. (2) Host genetic polymorphisms associated with BL using genome-wide association methods. (3) The role of the Epstein-Barr virus (EBV) genetic variants in endemic BL. (4) The role of malaria immunology and phenotype of inflammation in BL. (5) The complexity of coinfection with different P. falciparum malaria genotypes in BL. (6) The interaction between helminthic parasites, HIV, malaria, and EBV in BL. (7) The immunohistochemistry and molecular pathology of BL. (8) The impact of malaria, helminthic parasites, and HIV on childhood BL. |
| The Federal Asian Pacific American Council (FAPAC) NIH Chapter | Other | AHRQ, CDC, FDA, HRSA, SAMHSA, USPHS | NIMHD | The goals of FAPAC NIH are to: 1) assist NIH in promoting, establishing, and maintaining an effective and equitable participation of AA&NHPI in the workforce; 2) promote overall awareness of the impact of AA&NHPI culture, contribution, work ethics, and behavior as related to government employment; 3) promote a better understanding of and potential solutions to address equal employment opportunity, racial equality, and health disparities of the AA&NHPI community; 4) collaborate with the AA&NHPI with Employee Resource Groups and FAPAC chapters of other HHS Agencies; and 5) recognize AA&NHPI leaders, promote leadership development and career advancement of AA&NHPI employees at NIH and their families. |
| The Golestan Cohort Study of Esophageal Cancer | Research Initiative | CDC | NCI | NCI and the CDC are collaborating on a pilot study to measure nitrate in urine. The aim of the pilot is to determine if drinking water sources in high and low nitrate regions of Golestan province are associated with higher urinary nitrate concentrations (a biomarker of ingestion) after accounting for dietary intake. |
| The Impact of Tobacco Use on Oral Health and the Oral Microbiome | Research Initiative | FDA, CDC | NCI | The US Food and Drug Administration Intramural Center of Tobacco Regulatory Science Award Program funded a project examining how tobacco affects oral health and the oral microbiome in the National Health and Nutrition Examination Survey (NHANES) study. |
| The Incidence of Breast and Other Cancers Among Female Flight Attendants | Research Initiative | CDC | NCI | A cohort study of approximately 10,000 Pan Am flight attendants to determine cancer incidence (primarily breast cancer) associated with cosmic radiation and circadian disruption from their work. |
| The Interagency Work Group on Drinking and Drug Use in Women and Girls | Committee, Work group, Advisory group, or Task Force | ACF, ACL, ASPE, ASPR, ATSDR, CDC, CMS, HRSA, IHS, SAMHSA | NIAAA, NIMH | Members of IWG work collaboratively to develop and implement joint initiatives to improve the quantity, range, and quality of prevention, treatment, and recovery services for mental health and SUDs among women and girls across the lifespan. |
| The NSTC Nanoscale Science, Engineering, and Technology (NSET) Subcommittee | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NCI, NIBIB, NIDCR | This subcommittee of the National Science and Technology Council's Committee on Technology is responsible for coordinating the National Nanotechnology Initiative (NNI). The NNI, established in 2001, is a U.S. Government research and development (R&D) initiative. Over thirty Federal departments, independent agencies, and commissions work together toward the shared vision of a future in which the ability to understand and control matter at the nanoscale leads to ongoing revolutions in technology and industry that benefit society. The NSET Subcommittee is co-chaired by representatives from two agencies and from the Office of Science and Technology Policy (OSTP). NSET participants work together to develop shared goals and priorities for the NNI and to develop a comprehensive nanotechnology R&D program that leverages individual agency resources and investments. |
| Tickborne Disease Working Group (HHS) | Committee, Work group, Advisory group, or Task Force | CDC, CMS, FDA, OS | NIAID | The Tick-Borne Disease Working Group was established by Congress in 2016 as part of the 21st Century Cures Act to provide subject matter expertise and to review federal efforts related to all tick-borne diseases, to help ensure interagency coordination and minimize overlap, and to examine research priorities. The focus of this effort is the development of a report to the Secretary of Health and Human Services and Congress on the findings and any recommendations of the Working Group for the federal response to tick-borne disease prevention, treatment, and research, as well as how to address gaps in these areas. |
| Tobacco and Nicotine Research Interest Group (TANRIG) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, SAMHSA | CSR, FIC, NCCIH, NCI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIDA, NIDCR, NIEHS, NIGMS, NIMH, NIMHD, NLM, OD/DPCPSI/ODP, OD/DPCPSI/ODS | The Tobacco and Nicotine Research Interest Group (TANRIG) was formed in January 2003 with the goal of increasing collaboration, coordination, and communication of tobacco- and nicotine-related research among National Institutes of Health Institutes and Centers, as well as with other relevant US Department of Health and Human Services agencies. |
| Tobacco Longitudinal Mortality Study (TLMS) Steering Committee | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NCI, NHGRI, NIA | The Steering Committee oversees the operation and coordinates the research efforts of the TLMS study |
| Tobacco Product Disease Risks | Research Initiative | FDA | NCI | The NCI and the FDA-Center for Tobacco Products, in collaboration with the US Census Bureau, co-lead this study, which harmonizes data on cigarette, cigar, and pipe use from various Tobacco Use Supplements that have been administered over the years as part of the Current Population Survey. The participants in these surveys have been followed for mortality by linkage to the National Death Index. These data are used to provide contemporary estimates of the mortality risks of daily and non-daily use of cigarettes, pipes, and cigars. |
| Tobacco Regulatory Science Program | Research Initiative | FDA | NCI, NHLBI, NIDA, NIEHS, OD/DPCPSI/ODP | Located in the National Institutes of Health (NIH) Office of Disease Prevention, the Tobacco Regulatory Science Program (TRSP) coordinates the trans-NIH collaborative effort with the US Food and Drug Administration’s (FDA) Center for Tobacco Products (CTP) to conduct research to support its regulatory activities over tobacco products. Within the framework of the Tobacco Control Act, the NIH and FDA formed an interagency partnership to foster tobacco regulatory research. The NIH has the infrastructure for the solicitation, review, and management of research. The FDA has expertise in tobacco regulatory science and the authority and resources to support research responsive to FDA’s regulatory authority. Support from FDA was used to fund grants and to provide administrative support and oversight to manage Funding Opportunity Announcements (FOA), application review, policy implementation and oversight, and communicating and reporting to a variety of sources. (language updated by ODP TRSP) The Tobacco Regulatory Science Program (TRSP) is an interagency partnership between the National Institutes of Health and the Food and Drug Administration (FDA) Center for Tobacco Products to foster tobacco regulatory research. With funds from the FDA, NIH can provide new funding opportunities in tobacco regulatory science that complement existing NIH tobacco research activities. TRSP awards R01, K01, K99/R00, and U54s. Activities include research awards, annual meetings, manufacture and distribution of nicotine research cigarettes, online resources, and data sharing. |
| Tobacco Regulatory Science Program (TRSP) | Committee, Work group, Advisory group, or Task Force | FDA | NCI | With the passage of the 2009 Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act), the FDA acquired the authority to regulate the manufacture, marketing, and distribution of tobacco products in order to protect public health. To better inform FDA’s regulatory authorities, the NIH and FDA formed an interagency partnership to foster tobacco regulatory research, capitalizing on NIH’s infrastructure to support tobacco-related research and funding from FDA. |
| Tobacco Use Supplement to the Current Population Survey | Health Survey | CDC, FDA | NCI, NIMHD | The Tobacco Use Supplement to the Current Population Survey (TUS-CPS) is an NCI-sponsored survey of tobacco use that has been administered as part of the U.S. Census Bureau's Current Population Survey approximately every 3-4 years since 1992-93. |
| Toxic Exposure Research Work Group | Committee, Work group, Advisory group, or Task Force | CDC | NIEHS | The Toxic Exposure Research Working Group was established under Section 501 of the Honoring our PACT Act in 2023. Under 38 USC § 501, a multi-agency federal working group called the Toxic Exposure Research Working Group will identify collaborative toxic exposure research studies and develop a 5-year strategic plan. |
| Toxicology in the 21st Century (Tox 21) | Resource Development | FDA | NCATS, NIEHS | The Toxicology in the 21st Century (Tox21) program is a federal collaboration among NIH's National Center for Advancing Translational Science (NCATS) and the National Toxicology Program (now called Division of Translational Toxicology, NIEHS; the Environmental Protection Agency; and the Food and Drug Administration. Tox21 researchers aim to develop better toxicity assessment methods to quickly and efficiently test whether certain chemical compounds have the potential to disrupt processes in the human body that may lead to negative health effects. |
| Toxin Working Group of the Intragovernmental Select Agents and Toxins Technical Advisory Committee | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NIAID | The workgroup holds biweekly meetings to discuss the following: point of regulation of select toxins (Botulinum neurotoxins, Staphylococcal enterotoxins, Abrin, Ricin, Conotoxins, Saxitoxin, Tetrodotoxin, Diacetoxyscirpenol, T-2 toxin), natural environment, toxin exclusion limits, space decontamination, and potential updates to the Centers for Disease Control and Prevention (CDC) manual “Biosafety in Microbiological and Biomedical Laboratories.” |
| Toxins Assessment Working Group | Committee, Work group, Advisory group, or Task Force | ASPR, CDC, FDA | NIAID | Biological (not engineered) toxins with specific effects on the nervous system, focusing on neurotoxins, applications in medical research and historical consideration as bioweapons |
| Training Advisory Committee | Committee, Work group, Advisory group, or Task Force | AHRQ | CSR, FIC, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI/ORIP, OD/OER | The Training Advisory Committee (TAC) advises on programmatic, review, and management issues related to extramural research training, research education, career development programs and the Loan Repayment Programs (LRP), and evaluation of these programs. TAC provides an NIH-wide forum to identify and discuss issues related to these programs and recommend solutions. |
| Training Institute for Dissemination and Implementation in Genomics and Precision Public Health (TIDIR-GPPH) | Training Initiative | CDC | NCI, NHGRI, NHLBI | This training course is intended to provide investigators at any career stage with a thorough grounding in conducting dissemination and implementation (D&I) research with a focus on genomics and precision public health. TIDIR-GPPH will be a hybrid course including training through open access online modules with assigned reading material, office hours, and culminating with a 2-day in-person event on September 5-6, 2024. (Please note: The online material is not cancer-specific, and applicable to all focus areas). |
| Trans-Agency (Medical) Imaging Phantom (TAIP) Workgroup | Committee, Work group, Advisory group, or Task Force | FDA | NCI, NIBIB | A common set of scientifically validated medical phantoms that have long term curation, convenient dissemination, associated measurement protocols and analysis software will be of great benefit to the FDA, NIH, NIST and to the scientific community they serve. This working group is created to enhance collaboration between FDA, NIST, and NIH to cooperate, where possible, on the development, validation, and dissemination of these medical calibration objects and to establish and maintain a library of these medical phantoms for use by the larger medical community. |
| Trans-Atlantic Task Force on Antimicrobial Resistance | Committee, Work group, Advisory group, or Task Force | ASPR, CDC, FDA | NIAID | The presidential declaration issued at the 2009 EU-US summit called for the creation of “a transatlantic task force on urgent antimicrobial resistance issues focused on appropriate therapeutic use of antimicrobial drugs in the medical and veterinary communities, prevention of both healthcare- and community-associated drug-resistant infections, and strategies for improving the pipeline of new antimicrobial drugs, which could be better addressed by intensified cooperation between us.” The objectives of the Trans-Atlantic Task Force on Antimicrobial Resistance (TATFAR) are to increase the mutual understanding of US and EU activities and programs relevant to the antimicrobial resistance issues identified in the declaration in order to deepen the transatlantic dialogue, provide opportunities to learn from each other, and promote information exchange, coordination, and cooperation. |
| Trans-NIH Biomedical Technology and Engineering Collective Meeting (bTEC) | Committee, Work group, Advisory group, or Task Force | ARPA-H | CSR, FIC, NCATS, NCI, NEI, NHLBI, NIA, NIAID, NIDCD, NIDDK, NIEHS, NIGMS, NIMH, NINDS | The Trans-NIH Biomedical Technology and Engineering Collective (bTEC) is a collective (or working group) concentrating on areas of common interests and concerns within Extramural Engineering programs at NIH |
| Trans-NIH Liver Cancer Working Group | Committee, Work group, Advisory group, or Task Force | CDC | NCI, NIAAA, NIAID, NIDDK | The charge of this working group is to develop an integrated NIH-wide plan for research in liver cancer that addresses basic, behavioral, translational, and clinical aspects of liver cancer aimed at understanding the basic mechanisms, the prevention, and cure of the disease. Additionally, the working group is interested in global health and health disparities research on liver disease. Other collaborative activities: meeting/workshop, public education campaign |
| Trans-NIH Mitochondrial Disorders Working Group | Committee, Work group, Advisory group, or Task Force | FDA | NCATS, NCI, NEI, NHLBI, NIA, NIAMS, NICHD, NIDDK, NIEHS, NIGMS, NIMH, NINDS | The Trans-NIH Mitochondrial Disorders Working Group meets every 2-3 years to discuss and share information about ongoing funded research related to mitochondrial disorders including mechanisms and therapies. |
| Trans-NIH Regenerative Medicine Working Group | Committee, Work group, Advisory group, or Task Force | FDA | NEI, NIAMS | Building new Accelerated Medicine Partnership (AMP) program in cell-based therapies. |
| Transboundary Animal Disease Threats Interagency Working Group | Committee, Work group, Advisory group, or Task Force | CDC | NIAID | interagency working group under the HST subcommittee to continue its work to address agricultural research and development gaps as they pertain to transboundary animal disease threats to U.S. livestock and emerging diseases in animals that may impact public health. |
| Transcatheter Valve Therapy (TVT) Registry | Meeting/ Workshop | FDA, CMS | NHLBI | Promote scientific meetings, workshops, and education for TVT. |
| Translational Science Interagency Fellowship (TSIF) | Training Initiative | FDA | NCATS | The Translational Science Interagency Fellowship (TSIF) program is a three-year postdoctoral fellowship opportunity jointly sponsored by the National Center for Advancing Translational Science (NCATS) and the U.S. Food and Drug Administration (FDA). The program aims to provide training in both translational science and regulatory science. The common goal of NCATS and the FDA is to bring safe and effective drugs, regimens, and devices from bench-to-bedside as quickly and efficiently as possible. To that end, fellows are trained in preclinical translational science, technology development, and regulatory research and review. By combining training in translational science and research-related regulatory review, the program enables fellows to build awareness of regulatory requirements into the early stages of medical product development thereby improving efficiencies in both the development and review processes. Fellows in this program will develop valuable skills for future careers in academia, the pharmaceutical industry, and government. |
| Transplant Cancer Match Study | Research Initiative | HRSA | NCI | A study linking databases of US transplant recipients, donors, and waitlist candidates to multiple US cancer registries to evaluate the spectrum of cancer risk and outcomes in the transplant population. |
| Trial to Assess Chelation Therapy 2 | Research Initiative | CDC | NCCIH, NHLBI, NIDDK, NIEHS | TACT2 is a clinical trial to determine whether intravenous 2EDTA chelation therapy in combinations with oral multivitamins or alone will reduce the risk of major cardiovascular events (such as stroke and heart attack) in patients who have already had a heart attack and who also have type 2 diabetes. NIDDK has funded trials within this research initiative. |
| Trial Transparency via Registration and Results Reporting at NIH ClinicalTrials.gov | Resource Development | FDA | NLM, OD/OSP | The purpose of this trans-NIH, inter-agency collaboration is to implement legal and policy requirements related to disseminating clinical trial information and promote understanding of these requirements through engagement with and the development of resources for stakeholders. NLM collaborates with FDA, OD/OSP, OD/OER, OGC, and other parts of NIH to improve transparency of clinical trials via registration and results reporting at NLM's ClinicalTrials.gov through implementing regulatory requirements and NIH trial transparency policies, including the 2016 NIH Policy on the Dissemination of NIH-funded Clinical Trial Information. NLM also provides technical assistance on reporting policy-related issues and NIH and FDA monitoring of compliance. NLM has also collaborated with OD/OBSSR to develop resources for the behavioral and social science community to support submitting study information to ClinicalTrials.gov and with OD/OBSSR, OD/OSP, OER, OLPA, and OCPL to engage the basic science community and understand their concerns about reporting NIH-funded basic experimental studies with humans to ClinicalTrials.gov. |
| Tribal Epidemiology Centers Program | Research Initiative | CDC, IHS | NIMHD, OD/DPCPSI/THRO | The Tribal Epidemiology Centers Program develops Epidemiology Centers for ongoing disease surveillance and public health infrastructure for American Indian and Alaska Native communities. NIMHD issued a funding opportunity announcement, the Collaborative Minority Health, and Health Disparities Research with Tribal Epidemiology Centers (R01 and R21 Clinical Trials Not Allowed). PAR-17-484 and PAR-17-48. In addition, in 2022 NIMHD with support from the NIH Office of Data Science Strategy (ODSS) established a Resource Center for Tribal Epidemiology Centers (RC-TEC). |
| Trusted Exchange Framework and Common Agreement (TEFCA) | Committee, Work group, Advisory group, or Task Force | ONC, CDC, CMS, FDA | OD/DPCPSI/ODSS | To discuss developing research use case for TEFCA. |
| U.S. Global Change Research Program Interagency Crosscutting Group on Climate Change and Human Health | Committee, Work group, Advisory group, or Task Force | CDC, ACF, ASPR, OASH | FIC, NCI, NHLBI, NIEHS, OD/DPCPSI/ODS | The Interagency Crosscutting Group on Climate Change and Human Health (CCHHG) coordinates, implements, evaluates, and communicates federal research and scientific activities related to the human health impacts of global climate change. With health recently identified as one of USGCRP’s Focus Areas, the CCHHG works to address key gaps related to human health aspects of global change. CCHHG develops data-driven scientific products, such as tools, indicators, and assessments, including the 2016 Impacts of Climate Change on Human Health: A Scientific Assessment. The group also facilitates multi-directional communication among relevant stakeholders to help provide end-user input into federal research efforts. In addition to its U.S.-focused activities, the CCHHG supports USGCRP and its member agencies, including the U.S. Department of State and USAID, by bringing health expertise to international negotiations, collaborative projects, and capacity-building activities. |
| U.S. Government Global Nutrition Coordination Plan | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OGA | FIC, NICHD, OD/DPCPSI/ONR | The U.S. Government Global Nutrition Coordination Plan is an interagency effort to strengthen the impact of the many diverse nutrition investments across the U.S. Government through better communication and collaboration and by linking research to program implementation. Through coordination mechanisms, the U.S. Government is working to maximize its support to country-led programs, continue its global leadership and partnerships, and generate, share, and apply knowledge and evidence in the nutrition sector in order to accelerate progress toward shared nutrition goals. At the forefront of the Coordination Plan is the recognition that, as stewards of American investments, U.S. Government agencies must ensure that these investments are used in the most efficient and impactful way possible.https://www.usaid.gov/global-health/health-areas/nutrition/usgplan |
| U.S. Government ORCID Consortium | Committee, Work group, Advisory group, or Task Force | CDC, FDA | OD/OER | The Consortium was created to provide a community of practice to share best practices, facilitate ORCID integrations, and identify and resolve issues, while decreasing costs and streamlining administrative processes and technical support. The Consortium provides and facilitates the Consortium Community of Practice. The Community of Practice is open to all Consortium members interested in participating. It is a place to share best practices and use cases, discuss challenges, raise ORCID awareness, share ORCID integration ideas, identify cross facility/office collaborations, and offer benchmarking to Consortium members. |
| U.S. Preventive Services Task Force | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, IHS, OASH, SAMHSA | NCI, NHLBI, NIA, NIAID, NIAMS, NICHD, NIDDK, NIMHD, NINR, OD/DPCPSI/OAR, OD/DPCPSI/ODP, OD/DPCPSI/ODS | The US Preventive Services Task Force (USPSTF) is an independent panel of non-Federal experts in prevention and evidence-based medicine. The USPSTF uses information from systematic evidence reviews to make recommendations for a broad range of clinical preventive health care services (such as screening, counseling, and preventive medications) that are delivered in or referred from primary care practice. USPSTF recommendations are developed for primary care clinicians, health systems, and policy-makers, and published in the form of "Recommendation Statements." The Agency for Healthcare Research and Quality (AHRQ) has been authorized by the US Congress to convene the Task Force and to provide ongoing scientific, administrative, and dissemination support to the Task Force. The NIH Office of Disease Prevention (ODP) works closely with AHRQ and the USPSTF to provide scientific input from NIH Institutes and Centers on draft research plans, draft evidence reviews, and draft recommendation statements. The ODP also disseminates information to NIH Institutes and Centers about high-priority evidence gaps for clinical preventive services that have been identified by the USPSTF. |
| U.S. Renal Data System | Resource Development | CMS, HRSA | NIDDK | The United States Renal Data System (USRDS), supported and hosted by NIDDK, is a national data system that collects, analyzes, and distributes information about chronic kidney disease and end-stage renal disease (ESRD) in the United States. The missions of USRDS are: (1) To characterize the total renal patient population and describe the distribution of patients by socio-demographic variables across treatment modalities; (2) To report on the incidence, prevalence, mortality rates, and trends over time of renal disease by primary diagnosis, treatment modality and other variables; (3) To develop and analyze data on the effect of various modalities of treatment by disease and patient group categories; (4) To identify problems and opportunities for more focused special studies of renal research issues; (5) To conduct cost effectiveness studies and other economic studies of ESRD; and (6) To make the data available to investigators, and by supporting investigator-initiated projects, to conduct biomedical and economic analyses of ESRD patients. |
| Unified Coordination Group for HPAI H5N1 outbreak | Committee, Work group, Advisory group, or Task Force | ASPR, CDC, FDA | NIAID | A series of working groups meant to cover USG responses to the HPAI H5N1 outbreak in dairy cattle |
| Unified Medical Language System Metathesaurus (UMLS) | Resource Development | AHRQ, CDC, CMS, FDA | NLM | The NLM Unified Medical Language System (UMLS) integrates and distributes key terminology, classification and coding standards, and related resources to support the development of more effective and interoperable biomedical information systems and services, including electronic health records. NLM ingests over 200 different medical vocabulary sources, facilitates the mapping of vocabularies into a unified terminology set, and provides access to the native versions of these terminologies to enhance interoperability among researchers, health professionals, and health data systems. Collaborators such as the National Cancer Institute, Agency for Healthcare Research and Quality, CDC, Centers for Medicare & Medicaid Services, and FDA have provided vocabularies for inclusion and provide input on UMLS development and enhancements. https://www.nlm.nih.gov/research/umls/index.html |
| Union for International Cancer Control (UICC) | Other | OGA | NCI | The Union for International Cancer Control (UICC) is the largest and oldest international cancer-fighting organisation. Founded in Geneva in 1933, UICC has over 1,200 members in 173 countries, enjoys consultative status with the United Nations (ECOSOC) and has official relations with the following institutions: WHO, IARC, IAEA, UNODC. UICC has over 60 partners, including associations working to fight cancer, as well as companies and foundations. UICC is a founding member of the NCD Alliance, McCabe Centre and ICCP. UICC’s mission is to unite and support the cancer community to reduce the global cancer burden, to promote greater equality and to ensure that the cancer control continues to be a priority in the world health and development agenda. Its main areas of activity focus on convening the world's leaders for innovative, wide-reaching, cancer-control events and initiatives; building capacity to meet regional needs; and developing awareness campaigns. The purpose of the Memorandum of Understanding (MOU) with NCI/CGH is to serve as a framework for collaboration between NCI/CGH and UICC to develop and implement joint activities to support global cancer control, leveraging each other’s expertise and experience for greater impact. The focus areas of the Collaboration:• Convening meetings and other events, such as the World Cancer Congress;• Capacity building, such as the UICC Technical Fellowships, and the UICC-led replication of the Project ECHO for Knowledge Summaries for Comprehensive Breast Cancer Control;• Knowledge, advocacy and policy, such as scientific collaboration on the TNM cancer staging system and tobacco control, and the International Cancer Control Partnership (ICCP); and• Additional areas mutually identified by the Participants. Type of collaborative activity: partnership |
| United States Core Data for Interoperability (USCDI+) | Committee, Work group, Advisory group, or Task Force | ONC, CDC, CMS, FDA | NCI, OD/DPCPSI/ODSS | The USCDI+ initiative supports the identification and establishment of domain or program-specific data element lists that operate as extensions to the existing USCDI. USCDI+ is a service ONC provides to federal and industry partners to establish, harmonize, and advance the use of interoperable data element lists that extend beyond the core data in the USCDI in order to meet specific programmatic and/or use case requirements. This approach allows HHS to assure that USCDI+ extensions are built from the same core USCDI foundation, align to harmonized data standards and taxonomies, and create the opportunity for aligning similar data needs across programs and use cases. |
| United States Core Data for Interoperability Plus (USCDI+) Sickle Cell Disease Technical Expert Panel | Committee, Work group, Advisory group, or Task Force | OASH, CDC, CMS, FDA, HRSA | NHLBI | USCDI+ is a framework that aims to establish a baseline version of the United States Core Data for Interoperability. The expert panel is designed to facilitate the exchange of health information relevant to Sickle Cell Disease. |
| United States Digital Corps Fellowship Program | Other | ACF, ASA, CDC, CMS, HRSA | OD/DPCPSI/ODSS | To recruit early career technologist to the federal government and enhance the federal data science workforce |
| United States Government Children in Adversity Working Group | Committee, Work group, Advisory group, or Task Force | ACF, CDC | FIC, NICHD, NIEHS, NIMH | The United States Government (USG) Children in Adversity Working Group (WG) is a United States Agency for International Development (USAID)-led, USG-wide working group aimed at coordinating USG activities focused on at-risk children globally in accordance with Public Law 109-95. https://www.childreninadversity.gov/home |
| United States Government Coronavirus Risk Management Meeting | Committee, Work group, Advisory group, or Task Force | CDC | NIAID, NLM | Previously known as the United States Government SARS-CoV-2 Interagency Group, the United States Government Coronavirus Risk Management Meeting serves as a forum for identifying and addressing risk management issues in the development, acquisition, deployment, and use of medical and public health countermeasures for coronavirus. |
| Urine biomarkers and risk of lung cancer in the Sisters Study | Research Initiative | CDC, FDA | NCI | The National Cancer Institute (NCI) is using urine samples from the Sisters study cohort National Institute of Environmental Health Sciences (NIEHS) and the laboratory resources of the Centers for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA) funding to examine urine biomarkers of tobacco exposure and risk of lung cancer in a prospective study. |
| Urine biomarkers of tobacco and opium and risk of cancers and heart disease | Research Initiative | CDC, FDA | NCI | The National Cancer Institute (NCI) is using urine samples from the Golestan Cohort Study and the laboratory resources of the Centers for Disease Control and Prevention (CDC) and partial Food and Drug Administration (FDA) funding to examine urine biomarkers of tobacco and opium exposure and risk of several cancers, heart disease, and lung disease. |
| US Global Change Research Program Subcommittee for Global Change Research (SGCR) | Committee, Work group, Advisory group, or Task Force | CDC | NIEHS | The U.S. Global Change Research Program (USGCRP) was established by Congress in 1990 to coordinate federal research and investments in understanding the forces shaping the global environment, both human and natural, and their impacts on society. USGCRP facilitates collaboration and cooperation across 15 federal member agencies to advance understanding of the changing Earth system. Research supported by USGCRP informs the Nation in navigating the challenges of a changing environment and identifying opportunities for a more resilient future.Together, USGCRP and its member agencies provide a gateway to authoritative science, tools, and resources to help people and organizations across the country manage risks and respond to changing environmental conditions. |
| US Interagency Joint External Evaluation Tool / SPAR | Committee, Work group, Advisory group, or Task Force | CDC | OD/OM, OD/OM/ORS | The JEE is a voluntary, collaborative, multisectoral process that is coordinated by the WHO to assess country capacities to prevent, detect, and rapidly respond to public health risks and is intended to augment annual self-assessments like the States Parties Annual Reporting (SPAR). The first phase of the JEE (self-evaluation) will take place from April to June 2024. The second phase, a week-long visit to the USA by a WHO external evaluation team, is anticipated to occur in late September 2024. |
| US Joint External Evaluation for Zoonotic Diseases | Committee, Work group, Advisory group, or Task Force | ASPR, CDC, FDA, HRSA, OS | NIAID | A Joint External Evaluation (JEE) is a voluntary, collaborative, multisectoral process to assess country capacities to prevent, detect and rapidly respond to public health risks whether occurring naturally or due to deliberate or accidental events. |
| US-Canada: Interagency Coordination on Wildfire Smoke and Health Research | Committee, Work group, Advisory group, or Task Force | CDC | NIEHS | Description to be updated |
| US-EU Bilateral Health Focus Group Meeting | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NCI | This group addresses new challenges around cancer, global health threats and strengthening the global health infrastructure |
| US-Israel White House-HHS Taskforce on Pandemic Preparedness and Innovation | Committee, Work group, Advisory group, or Task Force | ASPR, CDC | NIBIB | A partnership between the US and Israel on critical and emerging technologies to bring the cooperation between the countries to new heights including innovations for pandemic preparedness. |
| USCDI + Cancer | Committee, Work group, Advisory group, or Task Force | ONC, CDC, CMS, FDA, IHS | NCI, OD/DPCPSI/ODSS | This collaboration is designed to identify a core set of data elements that clinicians and researchers could use to (1) match patients to clinical trials; (2) document patients in cancer registries; and (3) identify patients who have experienced an immune-related adverse event. Additionally, this collaboration is designed to identify and mitigate the barriers clinical sites, EHR vendors, patients, etc. face when trying to implement this core set of data elements. We plan to release a draft set of data elements for public comment in July, 2024. |
| USCDI+ Cancer Trans-HHS Initiatives | Committee, Work group, Advisory group, or Task Force | CDC, CMS, FDA, ONC | NCI, OD/DPCPSI/ODSS | Also Collaboration Type: Resource DevelopmentThis trans-HHS collaboration began in 2024. In 2024, we finalized a core set of data elements that clinicians and researchers could use to document patients in cancer registries. The trans-HHS Team is developed a draft set of core data elements that clinicians and researchers could us to match patients to clinical trials and identify patients who have experienced an immune-related adverse event. This collaboration continues to identify and mitigate the barriers clinical sites, EHR vendors, patients, etc. face when trying to implement this core set of data elements. We plan to release a draft set of clinical trial matching and immune-related adverse event data elements for public comment in the Spring of 2025. |
| USG Interagency Cookstoves/Household Energy Meeting | Committee, Work group, Advisory group, or Task Force | CDC | NIEHS | Description will be updated |
| USG pandemic preparedness portfolio sharing group | Committee, Work group, Advisory group, or Task Force | ARPA-H, ASPR, BARDA | NIAID | Working group meetings bi-monthly to share portfolios and activities on vaccine and monoclonal antibody development for viruses with pandemic preparedness. |
| Using Real-time Prescription and Insurance Claims Data to Support the HIV Care Continuum | Research Initiative | CDC | NIMH | The Centers for Disease Control and Prevention (CDC) and the National Institute of Mental Health (NIMH) have established a cooperative agreement titled “Using Real-time Prescription and Insurance Claims Data to Support the HIV Care Continuum (CDC RFA-PS-19-003).” The purpose of the cooperative agreement is to develop, implement, and evaluate a “insurance-based data-to-care (D2C)” model. The insurance-based D2C model will start with Medicaid claims (diagnosis and procedure) to identify persons with diagnosed HIV, and then use real-time Medicaid claims data to determine whether these individuals have current antiretroviral (ARV) prescriptions. Persons with HIV who show lapsed ARV medications will receive a set of escalating adherence, retention, and re-linkage interventions. The research study will test the effectiveness of the approach (on viral suppression) as well as the cost-effectiveness of the approach. |
| Vaccines and Related Biological Products Advisory Committee (VRBPAC) | Committee, Work group, Advisory group, or Task Force | FDA | NIAID, OD/OSP | VRBPAC reviews and evaluates data concerning the safety, effectiveness, and appropriate use of vaccines and related biological products which are intended for use in the prevention, treatment, or diagnosis of human diseases, and, as required, any other products for which the Food and Drug Administration has regulatory responsibility. |
| Value Set Authority Center (VSAC) | Resource Development | CMS, ONC | NLM | NLM maintains the Value Set Authority Center (VSAC), an online repository of value sets (code sets from standardized medical vocabularies) used for clinical quality measurement in the Centers for Medicare & Medicaid Services (CMS) Electronic Health Record Incentive Program, also known as “Meaningful Use”. The VSAC provides downloadable access to all official versions of vocabulary value sets contained in the electronic Clinical Quality Measures (eCQMs) from CMS and Consolidated Clinical Document Architecture (C-CDA) data from Health Level Seven International, or HL7. NLM works with CMS and the Assistant Secretary for Technology Policy/Office of the National Coordinator for Health Information Technology (ASTP/ONC) to publish the eCQM and C-CDA value sets in VSAC for public use in the United States. Each value set consists of the numerical values (codes) and human-readable names (terms) drawn from standard vocabularies such as SNOMED CT ®, RxNorm, LOINC ®, and ICD-10-CM, which are used to define clinical concepts used in clinical quality measures (e.g., patients with diabetes, clinical visits). NLM, CMS, and ASTP/ONC work together to provide technical features in VSAC that support the use of eCQM and C-CDA data. http://vsac.nlm.nih.govhttp://vsac.nlm.nih.gov |
| Veterans Affairs Science and Health Initiative to Combat Infectious and Emerging Life-threatening Diseases | Other | CDC | NIAID | Advancing rapid detection, therapy and prevention of emerging diseases aimed at improving the quality and safety of health care for Veterans. |
| Virology Interest Group | Committee, Work group, Advisory group, or Task Force | FDA | NCI, NHLBI, NIAID, NIDCR, NIDDK, NIMH, NINDS | The Virology Interest Group comprises researchers at NIH and in the local area who are interested in virology. The group organizes activities designed to promote interactions and exchange information. |
| Virology Quality Assurance Program | Other | CDC | NIAID | The Virology Quality Assurance Program (VQA) is a National Institute of Allergy and Infectious Diseases (NIAID)/National Institutes of Health (NIH) funded contract that is designed to provide quality assurance and proficiency testing for virologic-based assays for HIV and other viral pathogens that are conducted in NIAID-supported laboratories performing assays on samples from subjects enrolled in multisite clinical studies. In a partnership with the Center for Disease Control, VQA is currently supporting external quality assurance for virological assays performed through the CDC-supported laboratory in Zimbabwe. |
| Vivek H. Murthy Distinguished Lecture Series for Public Health Leadership: Fostering Social Connection to Enhance Health and Wellbeing | Meeting/ Workshop | OSG | NIMHD | This is an annual event held in collaboration with the NIH chapter of the Federal Asian and Pacific American Council (FAPAC) to commemorate Asian, Native Hawaiian and Pacific Islander month in May. Each year, Dr. Murthy recognizes a leader in the AA and NHPI community. During the May 2024 event, Dr. Murthy recognized Hahrie Han, Ph.D., Professor and Inaugural Director of the Stavros Niarchos Foundation Agora Institute at Johns Hopkins University, for her leadership in exploring social connections with health wellbeing. The event featured an introduction from NIH Leadership, followed by a conversation between Drs. Murthy and Han, moderated by NIMHD Deputy Director, Monica Webb Hooper, Ph.D. |
| Weighting methods for healthy worker survivor bias | Research Initiative | CDC | NCI | In collaboration with the National Institute of Occupational Safety and Health, we are developing new methods to address healthy worker survivor bias, a bias in occupational studies that can result in underestimates about the effects of occupational exposures on cancer outcomes. |
| Well-Being Workgroup | Committee, Work group, Advisory group, or Task Force | IOS/ODPHP, ACL, CDC, FDA, HRSA, SAMHSA | NCCIH, NIA, NIMHD, OD/DPCPSI/ODP | The Well-Being Workgroup is a cross-agency activity organized by the HHS Office of Disease Prevention and Health Promotion (ODPHP) to increase understanding of the various dimensions of well-being and leverage federal efforts to support Overall Health and Well-Being Measures within the Healthy People initiative. Workgroup goals include identifying definitions, terminology, frameworks, and metrics; creating a collaborative space for sharing information and resources; securing resources to fund data collection for well-being via nationally representative and reliable data sources (e.g., NHIS). The guiding principle for the WG is to “Understand federal efforts to address well-being to inform the Healthy People initiative, including implementation of its Overall Health and Well-being Measures (OHMs) and development of Healthy People 2040.” |
| White House Cancer Moonshot Data and Innovation Task Force | Committee, Work group, Advisory group, or Task Force | FDA | NCI | The Cancer Cabinet was convened by the White House, bringing together cabinet agencies and relevant departments, including multiple White House components to address progress against cancer in five priority actions.(1) close the screening gap, (2) understand and address environmental exposure, (3) decrease the impact of preventable cancers, (4) bring cutting edge research through the pipeline to patients and communities, and (5) support patients and caregivers. This WG is focused on different tasks related to cancer data and innovation, including support for innovative clinical trial design and development; work group focus areas include 1) decentralizing clinical trials 2) innovative clinical trial design. |
| White House Cancer Moonshot Data and Innovation Task Force - Data Standards and Interoperability Working Group | Committee, Work group, Advisory group, or Task Force | FDA, OSTP | NCI | Co-lead group developing standard data elements to facilitate clinical trial matching, immune-related adverse event reporting, cancer registry reporting, and AI. Work is aligned with HHS working group and USCDI+ |
| White House Conference on Hunger, Nutrition and Health | Committee, Work group, Advisory group, or Task Force | OASH | NCI | Support conference to address national hunger and malnutrition |
| White House Council on Native American Affairs (WHCNAA) | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, ASFR, ASPR, CDC, CMS, FDA, HRSA, IHS, IOS, OGC, SAMHSA | OD/DPCPSI/THRO | The White House Council on Native American Affairs (WHCNAA) has the responsibility for corrdinating acttivities and responses to issues related to Tribes and Native Americans across the federal agencies. The purpose of the WHCNAA is to improve coordination between federal agencies and tribal communities, working to meet the federal government's treaty and trust obligations to Native Americans and promote a government-to-government relationship. It aims to enhance the well-being and prosperity of Tribal nations by ensuring effective use of federal resources and promoting meaningful Tribal-Federal engagement. |
| White House Gender Policy Council, Science and Technology Interagency Working Group | Committee, Work group, Advisory group, or Task Force | FDA, OASH | NCI, NICHD | White House-led interagency group on gender policy in science and technology. https://www.whitehouse.gov/gpc/ |
| White House Initiative for Hispanics Inter-agency Workgroup | Committee, Work group, Advisory group, or Task Force | CDC, HRSA, OASH, SAMHSA | NIMHD | The White House Initiative on Advancing Educational Equity, Excellence, and Economic Opportunity for Hispanics seeks to advance equity in our Nation’s schools and to promote the economic opportunity that follows it. The Initiative advances educational equity and economic opportunity for Latino and Hispanic students, families, and communities by focusing on several policy goals. |
| White House Initiative on Black Americans Inter-agency Workgroup | Committee, Work group, Advisory group, or Task Force | CDC, HRSA, OASH, SAMHSA | NIMHD | The White House Initiative for Black Americans Inter-agency workgroup is led by the Department of Education and supports the agency’s work in implementing the goals of the White House Initiative on Advancing Educational Equity, Excellence, and Economic Opportunity for Black Americans. The IWG is comprised of representatives from all federal agencies and meets monthly to share updates and collaborate on activities across the federal government to advance the WHI for Black Americans. The WHI for Black Americans was created to strengthen the nation by improving educational outcomes for Black Americans of all ages and to help ensure that this population would receive an education that prepares them for college and productive careers to contribute to the wellbeing of society. |
| White House Initiative on Historically Black Colleges and Universities Inter-agency Workgroup | Committee, Work group, Advisory group, or Task Force | CDC, HRSA, OASH, SAMHSA | NIMHD, OD/OM/OALM | The White House Initiative on HBCU Inter-agency workgroup (WHI HBCU-IWG) is led by the Department of Education and supports the agency’s work in implementing the goals of the White House Initiative on Advancing Educational Equity, Excellence, and Economic Opportunity through Historically Black Colleges and Universities. The WHI Initiative on HBCUs is dedicated to a government-wide policymaking effort to eliminate barriers HBCUs face in providing the highest-quality education to a growing number of students. The IWG is comprised of representatives from all federal agencies and meets monthly to share updates and collaborate on activities across the federal government to advance the WHI HBCU. |
| White House Quantum Initiative Committee | Committee, Work group, Advisory group, or Task Force | FDA | NCATS | NIH ICs and other federal agencies such NIST, NSF, and DOE collaborate on advancing quantum sensing and quantum computing technologies for biomedical applications. |
| White House Task Force to Address Online Harassment and Abuse | Committee, Work group, Advisory group, or Task Force | CDC | NIA, NIAAA, NICHD, NIMH, OD/DPCPSI/ORWH, OD/DPCPSI/SGMRO | The Task Force is an interagency effort to address online harassment and abuse, specifically focused on technology-facilitated gender-based violence. In consultation with survivors, advocates, educators, experts from diverse fields, and the private sector, the Task Force will develop specific recommendations to improve prevention, response, and protection efforts through programs and policies in the United States and globally. https://www.whitehouse.gov/briefing-room/statements-releases/2022/06/16… |
| White House Womens Health Research Initiative | Research Initiative | OASH | CSR, NHLBI, NIA, NIAMS, NICHD, OD/DPCPSI/ORWH, OD/OER | The White House Initiative on Women’s Health Research, is an effort led by First Lady Jill Biden and the White House Gender Policy Council, aims to galvanize the Federal government and the private and philanthropic sectors to spur innovation, unleash transformative investment to close research gaps, and improve women’s health. Executive Order (EO) 14120 builds upon the White House Initiative on Women’s Health Research. The EO outlines strategies to improve women’s health research by integrating women’s health across the federal research portfolio, prioritizing funding, galvanizing new research on women’s midlife health, and assessing areas needing further support. Aligned with the EO, NIH announced the launch of a new enterprise-wide effort to fund $200 million of new, interdisciplinary women’s health research projects in Fiscal Year 2025. NIH is committed to closing gaps in women’s health research across the lifespan, including on issues that cut across the traditional mandates of the institutes and centers at NIH. |
| Workforce Engagement Plan (WEP) Reporting to HHS | Committee, Work group, Advisory group, or Task Force | ASA | CIT, OD/OM, OD/OM/OHR, OD/OM/ORS, OD/OM/OSPMO, OD/EDI | Coordination across several offices to provide data bi-weekly in response to HHS' Workforce Engagement Plan (WEP) data call. The data provided from these data calls informs Senior Leadership discussions on our progress with meaningful on-site presence. |
| Workforce Workgroup of the HHS Behavioral Health Coordinating Council | Committee, Work group, Advisory group, or Task Force | CMS, HRSA, IHS, SAMHSA | NIDA, OD/DPCPSI/OBSSR | To identify opportunities for collaboration across HHS agencies to advance programs and policies that will support integration of behavioral and physical health services |
| Workgroup on Timely and Strategic Action to Inform ICD-11 Policy | Committee, Work group, Advisory group, or Task Force | CDC | NLM | The purpose of the National Committee on Vital and Health Statistics (NCVHS) Workgroup on Timely and Strategic Action to Inform ICD-11 Policy is to gather information and provide recommendations to HHS regarding the adoption and implementation of the International Classification of Diseases, 11th Revision (ICD-11) as a Health Insurance Portability and Accountability Act (HIPAA) code set. NCVHS finds that immediate action is needed to prepare for a timely transition to ICD-11 and potentially avoid some of the challenges faced during the transition from ICD-9 to ICD-10. As an advisory committee to the Secretary, NCVHS intends for this project to support HHS in leading the U.S. in preparing for policy and implementation decisions regarding ICD-11. NLM contributes by researching the feasibility of replacing ICD-10-CM with ICD-11 for morbidity coding. Additionally, NLM provides subject matter expertise on ICD-11 and medical terminologies. |
| Working Group on Accessible and Affordable Hearing Health Care for Adults | Committee, Work group, Advisory group, or Task Force | FDA | NIA, NIDCD | In partnership with NIA and the FDA, NIDCD plans to revisit topics related to hearing health care access and affordability. The goal of this working group is to hear from subject matter experts and partners about hearing health care needs that remain, and about new work that should be conducted both in the context of OTC hearing aid availability and, more broadly, in the changing landscape of health care. |
| Workshop on Patient-Reported Outcomes and Vision Related Quality of Life Questionnaires | Meeting/ Workshop | FDA | NEI | NEI is partnering with the FDA to highlight the importance of patients’ perspectives, patient-reported outcomes (“PROs”), and questionnaires to measure visual function and vision-related quality of life (“VFQs”) in vision research and clinical care. The goal of the workshop was to identify future steps in the development of PROs and VFQs for a variety of ocular conditions and varying degrees of visual impairment. The workshop was open to the public and was attended by researchers from academia, industry, non-profits, other government agencies, patients, and care partners. |
| World Cancer Research Day, World No Tobacco Day, and World Cancer Day observances | Public Education Campaign | CDC, OGA | FIC, NCI | The NCI Office of Communications and Public Liaison and Center for Global Health collaborate with NCI Divisions, Offices, and Centers and the DHHS Assistant Secretary for Public Affairs Digital Media Office to coordinate public education campaigns featuring digital materials that highlight prevention promotion and wellness programs. These materials are shared across several HHS OPDIVs. |
| World Medical Association Revision of the Declaration of Helsinki | Resource Development | OGA, AHRQ, CDC, FDA | OD/OSP | The Declaration of Helsinki is an internationally recognized set of ethical principles for medical research involving human participants. Last updated in 2013, the World Medical Association (WMA) initiated a 30 month long collaborative process to revise and update the Declaration to ensure that it properly takes into consideration emerging technology, novel clinical trial designs, emergency research, research in resource-poor settings, community engagement, and research with individuals vulnerable to coercion or undue influence. |
An official website of the United States government
Here's how you know
Official websites use .gov
A .gov website belongs to an official government
organization in the United States.
A .gov website belongs to an official government
organization in the United States.
Secure .gov websites use HTTPS
A lock (🔒) or https:// means you've safely connected to the .gov website.
Share sensitive information only on official, secure websites.
A lock (🔒) or https:// means you've safely connected to the .gov website.
Share sensitive information only on official, secure websites.